

Arthritis & Rheumatism

An Official Journal of the American College of Rheumatology
www.arthritisrheum.org and www.interscience.wiley.com

VOLUME 56

JANUARY 2007

NO. 1

Special Articles

- Editorial: Sex and Rheumatoid Arthritis: Mouse Model Versus Human Disease
Maurizio Cutolo 1
- Editorial: Spondylarthritides and Related Entities: Entheses and Hypotheses
Lars C. Huber, Falk Moritz, and Steffen Gay 4
- Editorial: Treatment of Pulmonary Fibrosis in Systemic Sclerosis: Light at the End of the Tunnel?
Frank A. Wollheim 9

Rheumatoid Arthritis Clinical Studies

- Outcomes After Switching From One Anti-Tumor Necrosis Factor α Agent to a Second Anti-Tumor Necrosis Factor α Agent in Patients With Rheumatoid Arthritis: Results From a Large UK National Cohort Study
Kimme L. Hyrich, Mark Lunt, Kath D. Watson, Deborah P. M. Symmons, and Alan J. Silman, for the British Society for Rheumatology Biologics Register 13
- Genetically Determined High Serum Levels of Mannose-Binding Lectin and Agalactosyl IgG Are Associated With Ischemic Heart Disease in Rheumatoid Arthritis
Lone N. Troelsen, Peter Garred, Hans Ole Madsen, and Søren Jacobsen 21

Clinical Images

- Three-Dimensional Computed Tomography Imaging of Tophaceous Gout
Nicola Dalbeth, Barnaby Clark, Kate Gregory, Timothy Sheehan, and Fiona McQueen 29

Rheumatoid Arthritis Basic Science Studies

- Genetic Association Between the *PRKCH* Gene Encoding Protein Kinase C η Isozyme and Rheumatoid Arthritis in the Japanese Population
Yoichiro Takata, Daisuke Hamada, Katsutoshi Miyatake, Shunji Nakano, Fumio Shinomiya, Charles R. Scafe, Vincent M. Reeve, Dai Osabe, Maki Moritani, Kiyoshi Kunika, Naoyuki Kamatani, Hiroshi Inoue, Natsuo Yasui, and Mitsuo Itakura 30
- CD56-Expressing T Cells That Have Features of Senescence Are Expanded in Rheumatoid Arthritis
Joshua J. Michel, Carl Turesson, Bonnie Lemster, Sarah R. Atkins, Cristina Iclozan, Tim Bongartz, Mary Chester Wasko, Eric L. Matteson, and Abbe N. Vallejo 43
- Dissecting the Heterogeneity of Rheumatoid Arthritis Through Linkage Analysis of Quantitative Traits
Lindsey A. Criswell, Wei V. Chen, Damini Jawaheer, Raymond F. Lum, Mark H. Wener, Xiangjun Gu, Peter K. Gregersen, and Christopher I. Amos 58

Inflammation

- New Humanized HLA-DR4-Transgenic Mice That Mimic the Sex Bias of Rheumatoid Arthritis
Veena Taneja, Marshall Behrens, Ashutosh Mangalam, Marie M. Griffiths, Harvinder S. Luthra, and Chella S. David 69
- Tenosynovitis and Osteoclast Formation as the Initial Preclinical Changes in a Murine Model of Inflammatory Arthritis
Silvia Hayer, Kurt Redlich, Adelheid Korb, Sonja Hermann, Josef Smolen, and Georg Schett 79
- Interleukin-17 as a Molecular Target in Immune-Mediated Arthritis: Immunoregulatory Properties of Genetically Modified Murine Dendritic Cells That Secrete Interleukin-4
Sujata Sarkar, Laura A. Tesmer, Vindhya Hindnavis, Judith L. Endres, and David A. Fox 89
- Evaluation of Protease-Activated Receptor 2 in Murine Models of Arthritis
Nathalie Busso, Matthias Frasnelli, Roland Feifel, Bruno Cenni, Martin Steinhoff, Justin Hamilton, and Alexander So 101
- Reduced Expression and Proteolytic Susceptibility of Lubricin/Superficial Zone Protein May Explain Early Elevation in the Coefficient of Friction in the Joints of Rats With Antigen-Induced Arthritis
Khaled A. Elsaid, Gregory D. Jay, and Clinton O. Chichester 108
- Use of Molecular Imaging to Quantify Response to IKK-2 Inhibitor Treatment in Murine Arthritis
Elena S. Izmailova, Nancy Paz, Herlen Alencar, Miyoung Chun, Lisa Schopf, Michael Hepperle, Joan H. Lane, Geraldine Harriman, Yajun Xu, Timothy Ocain, Ralph Weissleder, Umar Mahmood, Aileen M. Healy, and Bruce Jaffee 117

Osteoarthritis Clinical Studies

- Low Levels of Vitamin D and Worsening of Knee Osteoarthritis: Results of Two Longitudinal Studies
David T. Felson, Jingbo Niu, Margaret Clancy, Piran Aliabadi, Burton Sack, Ali Guermazi, David J. Hunter, Shreyasee Amin, Gail Rogers, and Sarah L. Booth 129
- Sex and Ethnic Differences in the Association of *ASPN*, *CALM1*, *COL2A1*, *COMP*, and *FRZB* With Genetic Susceptibility to Osteoarthritis of the Knee
Ana M. Valdes, John Loughlin, Mark Van Oene, Kay Chapman, Gabriela L. Surdulescu, Michael Doherty, and Tim D. Spector 137

Osteoarthritis and Cartilage Biology Basic Science Studies

- Crucial Role of Macrophages in Matrix Metalloproteinase-Mediated Cartilage Destruction During Experimental Osteoarthritis: Involvement of Matrix Metalloproteinase 3
Arjen B. Blom, Peter L. van Lent, Sten Libregts, Astrid E. Holthuysen, Peter M. van der Kraan, Nico van Rooijen, and Wim B. van den Berg 147
- Restoration of the Extracellular Matrix in Human Osteoarthritic Articular Cartilage by Overexpression of the Transcription Factor *SOX9*
Magali Cucchiaroni, Tanja Thurn, Anja Weimer, Dieter Kohn, Ernest F. Terwilliger, and Henning Madry ... 158
- Isolation and Chondroinduction of a Dermis-Isolated, Aggrecan-Sensitive Subpopulation With High Chondrogenic Potential
Ying Deng, Jerry C. Hu, and Kyriacos A. Athanasiou 168
- Three-Dimensional Cartilage Tissue Engineering Using Adult Stem Cells From Osteoarthritis Patients
Wael Kafienah, Sanjay Mistry, Sally C. Dickinson, Trevor J. Sims, Ian Learmonth, and Anthony P. Hollander 177
- Mechanisms of Cartilage Growth: Modulation of Balance Between Proteoglycan and Collagen In Vitro Using Chondroitinase ABC
Anna Asanbaeva, Koichi Masuda, Eugene J.-M. A. Thonar, Stephen M. Klisch, and Robert L. Sah 188
- Exposure of Human Cartilage Tissue to Low Concentrations of Blood for a Short Period of Time Leads to Prolonged Cartilage Damage: An In Vitro Study
Nathalie W. D. Jansen, Goris Roosendaal, Johannes W. J. Bijlsma, Jeroen DeGroot, and Floris P. J. G. Lafteber 199

Osteoporosis

- Fracture Risk With Intermittent High-Dose Oral Glucocorticoid Therapy
Frank de Vries, Madelon Bracke, Hubert G. M. Leufkens, Jan-Willem J. Lammers, Cyrus Cooper, and Tjeerd P. van Staa 208

Clinical Images

- Visualization of the Inner Synovial Surface With Three-Dimensional Ultrasonography
Ji Hyeon Ju, Chong-Hyeon Yoon, Ho-Youn Kim, and Sung-Hwan Park 214

Spondylarthropathy

- HLA-B27 Up-Regulation Causes Accumulation of Misfolded Heavy Chains and Correlates With the Magnitude of the Unfolded Protein Response in Transgenic Rats: Implications for the Pathogenesis of Spondylarthritides-like Disease
Matthew J. Turner, Monica L. DeLay, Shuzhen Bai, Erin Klenk, and Robert A. Colbert 215
- Microdamage and Altered Vascularity at the Entesis-Bone Interface Provides an Anatomic Explanation for Bone Involvement in the HLA-B27-Associated Spondylarthritides and Allied Disorders
M. Benjamin, H. Toumi, D. Suzuki, S. Redman, P. Emery, and D. McGonagle 224
- Association of a *TNAP* Haplotype With Ankylosing Spondylitis
Hing Wo Tsui, Robert D. Inman, John D. Reveille, and Florence W. L. Tsui 234

Systemic Lupus Erythematosus Clinical Studies

- Effect of Glutathione S-Transferase Polymorphisms and Proximity to Hazardous Waste Sites on Time to Systemic Lupus Erythematosus Diagnosis: Results From the Roxbury Lupus Project
Elizabeth W. Karlson, Julie Watts, James Signorovitch, Marco Bonetti, Elizabeth Wright, Glinda S. Cooper, Timothy E. McAlindon, Karen H. Costenbader, Elena M. Massarotti, Lisa M. Fitzgerald, Ramina Jajoo, M. Elaine Husni, Anne H. Fossel, Helen Pankey, Wei-Zi Ding, Robert Knorr, Suzanne Condon, and Patricia A. Fraser 244
- A Serology-Based Approach Combined With Clinical Examination of 125 Ro/SSA-Positive Patients to Define Incidence and Prevalence of Subacute Cutaneous Lupus Erythematosus
Karin Popovic, Fredrik Nyberg, Marie Wahren-Herlenius, and Filippa Nyberg 255

Neuropsychiatric Events at the Time of Diagnosis of Systemic Lupus Erythematosus: An International Inception Cohort Study	
<i>J. G. Hanly, M. B. Urowitz, J. Sanchez-Guerrero, S. C. Bae, C. Gordon, D. J. Wallace, D. Isenberg, G. S. Alarcón, A. Clarke, S. Bernatsky, J. T. Merrill, M. Petri, M. A. Dooley, D. Gladman, P. R. Fortin, K. Steinsson, I. Bruce, S. Manzi, M. Khamashta, A. Zoma, C. Aranow, E. Ginzler, R. Van Vollenhoven, J. Font, G. Sturfelt, O. Nived, R. Ramsey-Goldman, K. Kalunian, J. Douglas, K. Thompson, and V. Farewell, for the Systemic Lupus International Collaborating Clinics</i>	265
Effects of Short-Term Infliximab Therapy on Autoantibodies in Systemic Lupus Erythematosus	
<i>Martin Aringer, Günter Steiner, Winfried B. Graninger, Elisabeth Höfler, Carl W. Steiner, and Josef S. Smolen</i>	274
Systemic Lupus Erythematosus and Antiphospholipid Basic Science Studies	
Binding of Antiphospholipid Antibodies to Discontinuous Epitopes on Domain I of Human β_2 -Glycoprotein I: Mutation Studies Including Residues R39 to R43	
<i>Yiannis Ioannou, Charis Pericleous, Ian Giles, David S. Latchman, David A. Isenberg, and Anisur Rahman</i>	280
Altered Lipid Raft-Associated Proximal Signaling and Translocation of CD45 Tyrosine Phosphatase in B Lymphocytes From Patients With Systemic Lupus Erythematosus	
<i>Fabian Flores-Borja, Panagiotis S. Kabouridis, Elizabeth C. Jury, David A. Isenberg, and Rizgar A. Mageed</i>	291
Natural Killer T Cells in Families of Patients With Systemic Lupus Erythematosus: Their Possible Role in Regulation of IgG Production	
<i>Matthew R. J. Green, Amy S. M. Kennell, Maggie J. Larche, Martin H. Seifert, David A. Isenberg, and Myer R. Salaman</i>	303
Systemic Sclerosis	
Imatinib Mesylate Reduces Production of Extracellular Matrix and Prevents Development of Experimental Dermal Fibrosis	
<i>Jörg H. W. Distler, Astrid Jüngel, Lars C. Huber, Ursula Schulze-Horsel, Jochen Zwerina, Renate E. Gay, Beat A. Michel, Thomas Hauser, Georg Schett, Steffen Gay, and Oliver Distler</i>	311
Recombinant Human Anti-Transforming Growth Factor β 1 Antibody Therapy in Systemic Sclerosis: A Multicenter, Randomized, Placebo-Controlled Phase I/II Trial of CAT-192	
<i>Christopher P. Denton, Peter A. Merkel, Daniel E. Furst, Dinesh Khanna, Paul Emery, Vivien M. Hsu, Nancy Silliman, James Streisand, John Powell, Anita Åkesson, John Coppock, Frank van den Hoogen, Ariane Herrick, Maureen D. Mayes, Douglas Veale, Joanna Haas, Stephen Ledbetter, Joseph H. Korn, Carol M. Black, and James R. Seibold, on behalf of the CAT-192 Study Group and the Scleroderma Clinical Trials Consortium</i>	323
Postnatal Induction of Transforming Growth Factor β Signaling in Fibroblasts of Mice Recapitulates Clinical, Histologic, and Biochemical Features of Scleroderma	
<i>Sonali Sonnylal, Christopher P. Denton, Bing Zheng, Douglas R. Keene, Ruming He, Henry P. Adams, Carolyn S. VanPelt, Yong J. Geng, Jenny M. Deng, Richard R. Behringer, and Benoit de Crombrughe</i>	334
TRAPS	
Association Between Reduced Levels of <i>MEFV</i> Messenger RNA in Peripheral Blood Leukocytes and Acute Inflammation	
<i>Duran Üstek, Cumhur Gökhan Ekmekci, Fatih Selçukbiricik, Aris Cakiris, Basar Oku, Burcak Vural, Hakan Yanar, Korhan Taviloglu, Ugur Özbek, and Ahmet Gül</i>	345
Pain	
Sensitization of Unmyelinated Sensory Fibers of the Joint Nerve to Mechanical Stimuli by Interleukin-6 in the Rat: An Inflammatory Mechanism of Joint Pain	
<i>Daniel Brenn, Frank Richter, and Hans-Georg Schaible</i>	351
Moderation of Psychosocial Risk Factors Through Dysfunction of the Hypothalamic-Pituitary-Adrenal Stress Axis in the Onset of Chronic Widespread Musculoskeletal Pain: Findings of a Population-Based Prospective Cohort Study	
<i>J. McBeth, A. J. Silman, A. Gupta, Y. H. Chiu, D. Ray, R. Morriss, C. Dickens, Y. King, and G. J. Macfarlane</i>	360
Myopathy	
Restricted T Cell Receptor BV Gene Usage in the Lungs and Muscles of Patients With Idiopathic Inflammatory Myopathies	
<i>Pernilla Englund, Jan Wahlström, Maryam Fathi, Elsbeth Rasmussen, Johan Grunewald, Göran Tornling, and Ingrid E. Lundberg</i>	372

Letters

Effect of Dosage on Coxib- or Nonsteroidal Antiinflammatory Drug-Associated Cardiovascular Risk? Comment on the Article by Solomon et al <i>Maarten Boers</i>	384
Reply <i>Daniel H. Solomon, Jerry Avorn, Til Stürmer, Robert J. Glynn, Helen Mogun, and Sebastian Schneeweiss</i> ..	384
Methodologic Issues in the Assessment of the Efficacy of Radiation Synovectomy for Arthritis of the Knee: Comment on the Article by Jahangier et al <i>Willm Uwe Kampen and Norbert Czech</i>	385
Evidence of the Efficacy of Radiation Synovectomy With Yttrium-90: Comment on the Article by Jahangier et al <i>Gynter Mödder and Hans Eckhard Langer</i>	386
Specificity of Enzyme-Linked Immunosorbent Assay for IgG Anti-NR2 Glutamate Receptor Antibodies: Comment on the Concise Communication by Yoshio et al <i>Shunsei Hirohata, Yoshiyuki Arinuma, and Tamiko Yanagida</i>	386
Cortisol Metabolism by 11 β -Hydroxysteroid Dehydrogenase as a Novel Target in the Treatment of Inflammation- or Immune-Mediated Bone Loss: Comment on the Article by Makrygiannakis et al <i>Thomas Wilckens and Ariane Volkmann</i>	387
ACR Announcements	A13

VOLUME 56

FEBRUARY 2007

NO. 2

Special Articles

Editorial: Exploiting T Cell Crosstalk as a Vaccination Strategy for Rheumatoid Arthritis <i>Berent Prakken and Salvatore Albani</i>	389
Editorial: "Resurrection of Thrombin" in the Pathophysiology of the Antiphospholipid Syndrome <i>Takao Koike and Tatsuya Atsuta</i>	393
Editorial: Translating Regulatory T Cells in Rheumatoid Arthritis: Revisiting the Past? <i>Stanford L. Peng</i>	395
Review: Circadian Rhythms in Rheumatoid Arthritis: Implications for Pathophysiology and Therapeutic Management <i>Rainer H. Straub and Maurizio Cutolo</i>	399
Review: The Role of T Cells in the Pathogenesis of Osteoarthritis <i>Lazaros I. Sakkas and Chris D. Platsoucas</i>	409

Rheumatoid Arthritis Clinical Studies

The HLA-DRB1 Shared Epitope Alleles Differ in the Interaction With Smoking and Predisposition to Antibodies to Cyclic Citrullinated Peptide <i>Annette H. M. van der Helm-van Mil, Kirsten N. Verpoort, Saskia le Cessie, Tom W. J. Huizinga, René R. P. de Vries, and René E. M. Toes</i>	425
A Prediction Rule for Disease Outcome in Patients With Recent-Onset Undifferentiated Arthritis: How to Guide Individual Treatment Decisions <i>Annette H. M. van der Helm-van Mil, Saskia le Cessie, Henrike van Dongen, Ferdinand C. Breedveld, René E. M. Toes, and Tom W. J. Huizinga</i>	433
Angiotensin II Type 1 Receptor as a Novel Therapeutic Target in Rheumatoid Arthritis: In Vivo Analyses in Rodent Models of Arthritis and Ex Vivo Analyses in Human Inflammatory Synovitis <i>A. Price, J. C. Lockhart, W. R. Ferrell, W. Gsell, S. McLean, and R. D. Sturrock</i>	441
Fc γ Receptor Type IIIA Genotype and Response to Tumor Necrosis Factor α -Blocking Agents in Patients With Rheumatoid Arthritis <i>Alf Kastbom, Johan Bratt, Sofia Ernestam, Jon Lampa, Leonid Padyukov, Peter Söderkvist, and Thomas Skogh</i>	448
Vaccination With Selected Synovial T Cells in Rheumatoid Arthritis <i>Guangjie Chen, Ningli Li, Ying C. Q. Zang, Dongqing Zhang, Dongyi He, Guozhang Feng, Liqing Ni, Rong Xu, Li Wang, Baihua Shen, and Jingwu Z. Zhang</i>	453

Rheumatoid Arthritis Basic Science Studies

Tumor Necrosis Factor α Acceleration of Inflammatory Responses by Down-Regulating Heme Oxygenase 1 in Human Peripheral Monocytes <i>Yohei Kirino, Mitsuhiro Takeno, Shuji Murakami, Masayoshi Kobayashi, Hideo Kobayashi, Kenji Miura, Haruko Ideguchi, Shigeru Ohno, Atsuhisa Ueda, and Yoshiaki Ishigatsubo</i>	464
--	-----

Psoriatic Arthritis

- Adalimumab for Long-Term Treatment of Psoriatic Arthritis: Forty-Eight Week Data From the Adalimumab Effectiveness in Psoriatic Arthritis Trial
Dafna D. Gladman, Philip J. Mease, Christopher T. Ritchlin, Ernest H. S. Choy, John T. Sharp, Peter A. Ory, Renee J. Perdok, and Eric H. Sasso 476

Spondylarthritis

- Evidence for Uncoupling of Inflammation and Joint Remodeling in a Mouse Model of Spondylarthritis
Rik J. U. Lories, Inge Derese, Cosimo De Bari, and Frank P. Luyten 489

Inflammatory Arthritis

- Suppression of Immune Responses in Collagen-Induced Arthritis by a Rationally Designed CD80-Binding Peptide Agent
Mythily Srinivasan, Rajaraman Eri, Susan L. Zunt, Don-John Summerlin, David D. Brand, and Janice S. Blum 498
- Where FoxP3-Dependent Regulatory T Cells Impinge on the Development of Inflammatory Arthritis
Linh T. Nguyen, Jonathan Jacobs, Diane Mathis, and Christophe Benoist..... 509
- A Novel DNA Vaccine Targeting Macrophage Migration Inhibitory Factor Protects Joints From Inflammation and Destruction in Murine Models of Arthritis
Shin Onodera, Shigeki Ohshima, Harukazu Tohyama, Kazunori Yasuda, Jun Nishihira, Yoichiro Iwakura, Ikkei Matsuda, Akio Minami, and Yoshikazu Koyama 521
- Therapeutic Effect of Urocortin on Collagen-Induced Arthritis by Down-Regulation of Inflammatory and Th1 Responses and Induction of Regulatory T Cells
Elena Gonzalez-Rey, Alejo Chorny, Nieves Varela, Francisco O'Valle, and Mario Delgado..... 531
- Amelioration of Collagen-Induced Arthritis in Rats by Nanogold
Chiau-Yuang Tsai, Ai-Li Shiau, Shih-Yao Chen, Yu-Hung Chen, Pai-Chiao Cheng, Meng-Ya Chang, Dong-Hwang Chen, Chen-Hsi Chou, Chrong-Reen Wang, and Chao-Liang Wu..... 544

Osteoarthritis Clinical Studies

- Glucosamine Sulfate in the Treatment of Knee Osteoarthritis Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study Using Acetaminophen as a Side Comparator
Gabriel Herrero-Beaumont, José Andrés Román Ivorra, María del Carmen Trabado, Francisco Javier Blanco, Pere Benito, Emilio Martín-Mola, Javier Paulino, José Luis Marenco, Armando Porto, Armando Laffon, Domingos Araújo, Manuel Figueroa, and Jaime Branco 555
- Association of Hospital and Surgeon Procedure Volume With Patient-Centered Outcomes of Total Knee Replacement in a Population-Based Cohort of Patients Age 65 Years and Older
Jeffrey N. Katz, Nizar N. Mahomed, John A. Baron, Jane A. Barrett, Anne H. Fossel, Alisha H. Creel, John Wright, Elizabeth A. Wright, and Elena Losina 568

Osteoarthritis and Cartilage Biology Basic Science Studies

- Aggrecan Degradation in Human Articular Cartilage Explants Is Mediated by Both ADAMTS-4 and ADAMTS-5
Ruo-Hua Song, Micky D. Tortorella, Anne-Marie Malfait, James T. Alston, Zhiyong Yang, Elizabeth C. Arner, and David W. Griggs 575
- Identification of Markers to Characterize and Sort Human Articular Chondrocytes With Enhanced In Vitro Chondrogenic Capacity
Shawn Patrick Grogan, Andrea Barbero, Jose Diaz-Romero, Anne-Marie Cleton-Jansen, Stephan Soeder, Robert Whiteside, Pancras C. W. Hogendoorn, Jian Farhadi, Thomas Aigner, Ivan Martin, and Pierre Mainil-Varlet 586

Systemic Lupus Erythematosus Basic Science Studies

- Autoantibodies to RNA Helicase A: A New Serologic Marker of Early Lupus
Yoshioki Yamasaki, Sonali Narain, Hideo Yoshida, Liza Hernandez, Tolga Barker, Paulette C. Hahn, Eric S. Sobel, Mark S. Segal, Hanno B. Richards, Edward K. L. Chan, Westley H. Reeves, and Minoru Satoh 596
- Beta₂-Glycoprotein I Binds Thrombin via Exosite I and Exosite II: Anti-β₂-Glycoprotein I Antibodies Potentiate the Inhibitory Effect of β₂-Glycoprotein I on Thrombin-Mediated Factor XIa Generation
Soheila Rahgozar, Qiuxia Yang, Bill Giannakopoulos, Xiaokai Yan, Spiros Miyakis, and Steven A. Krilis ... 605

Systemic Lupus Erythematosus Clinical Studies

- Systemic Lupus Erythematosus in a Multiethnic US Cohort: XLIII. The Significance of Thrombocytopenia as a Prognostic Factor
Mónica Fernández, Graciela S. Alarcón, Mandar Apte, Rosa M. Andrade, Luis M. Vilá, and John D. Reveille, for the LUMINA Study Group..... 614

Accelerated Damage Accrual Among Men With Systemic Lupus Erythematosus: XLIV. Results From a Multiethnic US Cohort	
<i>Rosa M. Andrade, Graciela S. Alarcón, Mónica Fernández, Mandar Apte, Luis M. Vilá, and John D. Reveille, for the LUMINA Study Group</i>	622
Childhood Arthritis	
Longitudinal Examination of Lipid Profiles in Pediatric Systemic Lupus Erythematosus	
<i>Talin Sarkissian, Joseph Beyene, Brian Feldman, Brian McCrindle, and Earl D. Silverman</i>	631
Safety and Efficacy of Meningococcal C Vaccination in Juvenile Idiopathic Arthritis	
<i>Evelien Zonneveld-Huijssoon, Arash Ronaghy, Marion A. J. van Rossum, Ger T. Rijkers, Fiona R. M. van der Klis, Elisabeth A. M. Sanders, Patricia E. Vermeer-de Bondt, Arno W. Hoes, Jan Jaap van der Net, Carla Engels, Wietse Kuis, Berent J. Prakken, Maarten J. D. van Tol, and Nico M. Wulffraat</i>	639
Prevalence, Risk Factors, and Outcome of Uveitis in Juvenile Idiopathic Arthritis: A Long-Term Followup Study	
<i>R. K. Saurenmann, A. V. Levin, B. M. Feldman, J. B. Rose, R. M. Laxer, R. Schneider, and E. D. Silverman</i>	647
First Report of Macrophage Activation Syndrome in Hyperimmunoglobulinemia D With Periodic Fever Syndrome	
<i>Donato Rigante, Ettore Capoluongo, Barbara Bertoni, Valentina Ansuini, Antonio Chiaretti, Marco Piastra, Silvia Pulitanò, Orazio Genovese, Adele Compagnone, and Achille Stabile</i>	658
Vasculitis	
Increased Expression of TRAIL Receptor 3 on Eosinophils in Churg-Strauss Syndrome	
<i>Hideo Mitsuyama, Wataru Matsuyama, Masaki Watanabe, Yuko Shirahama, Ikkou Higashimoto, Takashi Wada, Mitsuhiro Osame, and Kimiyoshi Arimura</i>	662
Clinical Images	
Blue-Purple Ears	
<i>H. A. Martens and M. Bijl</i>	673
Myositis	
Immunolocalization of Interleukin-1 Receptors in the Sarcolemma and Nuclei of Skeletal Muscle in Patients With Idiopathic Inflammatory Myopathies	
<i>Cecilia Grundtman, Stina Salomonsson, Christina Dorph, Joseph Bruton, Ulf Andersson, and Ingrid E. Lundberg</i>	674
Calcium Pyrophosphate Deposition Disease	
Methotrexate as an Alternative Therapy for Chronic Calcium Pyrophosphate Deposition Disease: An Exploratory Analysis	
<i>Amélie Chollet-Janin, Axel Finckh, Jean Dudler, and Pierre-André Guerne</i>	688
Letters	
Retraction of the Suggestion to Use the Term "Reiter's Syndrome" Sixty-Five Years Later: The Legacy of Reiter, a War Criminal, Should Not Be Eponymic Honor but Rather Condemnation	
<i>Richard S. Panush, Daniel J. Wallace, Rabbi Elliot N. Dorff, and Ephraim P. Engleman</i>	693
Effect of the 34C>T Variant in the <i>AMPD1</i> Gene on the Clinical Response to Methotrexate in Patients With Rheumatoid Arthritis: Comment on the Article by Wessels et al	
<i>Niels P. Riksen, Gerard A. Rongen, Paul Smits, Piet van Riel, and Pilar Barrera</i>	694
Reply	
<i>Judith A. M. Wessels, Tom W. J. Huizinga, Henk-Jan Guchelaar, and Robert de Jonge</i>	694
Tumor Necrosis Factor α Blockers and Metastases: Comment on the Article by Setoguchi et al	
<i>Hugh McGrath, Jr.</i>	695
Reply	
<i>Soko Setoguchi, Daniel H. Solomon, Michael E. Weinblatt, Jeffrey N. Katz, Jerry Avorn, Robert J. Glynn, E. Francis Cook, Greg Carney, and Sebastian Schneeweiss</i>	696
The Enigmatic Duality of High-Density Lipoprotein—Cardioprotective yet Potentially Atherogenic: Comment on the Article by McMahon et al	
<i>Melvin Khee-Shing Leow</i>	696
Transdermal Fentanyl in Patients With Osteoarthritis: Comment on the Article by Langford et al	
<i>Bernard Bannwarth</i>	697
Correlation Between Serum and Synovial Fluid Estrogen Concentrations: Comment on the Article by Sowers et al	
<i>Pascal Richette, Kathleen Laborde, Carole Boutron, Thomas Bardin, Marie-Thérèse Corvol, and Jean-François Savouret</i>	698
Reply	
<i>MaryFran R. Sowers</i>	698

Are the CLASSification Criteria for Psoriatic ARthritis Better Than Existing Criteria for Diagnosing Psoriatic Arthritis? Comment on the Article by Taylor et al

Dennis McGonagle and Ai Lyn Tan 699

Reply

William Taylor, Dafna Gladman, Philip Helliwell, Antonio Marchesoni, Philip Mease, and Herman Mielants 700

ACR Announcements A16

VOLUME 56

MARCH 2007

NO. 3

Special Articles

In Memoriam: John Heath Vaughan, MD, 1921–2006

Eng M. Tan 701

Editorial: Histologic Deterioration and More Flares: The Case Against Azathioprine Plus Methylprednisolone in the Treatment of Proliferative Lupus Nephritis

Tak Mao Chan 702

Editorial: Urine Proteomics for the Early Diagnosis of Acute Glomerulonephritis: Has the Time Come?

Dimitrios T. Boumpas and Takashi Kuroiwa 705

Editorial: Regulatory T Cell Defects in Rheumatoid Arthritis

Sujata Sarkar and David A. Fox 710

Review: Lessons From Musculoskeletal Stem Cell Research: The Key to Successful Regenerative Medicine Development

Dennis McGonagle, Cosimo De Bari, Peter Arnold, and Elena Jones 714

The United States Rheumatology Workforce: Supply and Demand, 2005–2025

Chad L. Deal, Roderick Hooker, Timothy Harrington, Neal Birnbaum, Paul Hogan, Ellen Bouchery, Marisa Klein-Gitelman, and Walter Barr 722

American College of Rheumatology Response to the 2006 Rheumatology Workforce Study

Neal Birnbaum 730

Rheumatoid Arthritis Basic Science Studies

Proinflammatory Mediator–Induced Reversal of CD4+,CD25+ Regulatory T Cell–Mediated Suppression in Rheumatoid Arthritis

Jocea M. R. van Amelsfort, Joel A. G. van Roon, Madelon Noordegraaf, Kim M. G. Jacobs, Johannes W. J. Bijlsma, Floris P. J. G. Lafeyber, and Leonie S. Taams 732

Antiviral Gene Expression in Rheumatoid Arthritis: Role of IKK ϵ and Interferon Regulatory Factor 3

Susan E. Sweeney, Ling Mo, and Gary S. Firestein 743

Serum Macrophage Inhibitory Cytokine 1 in Rheumatoid Arthritis: A Potential Marker of Erosive Joint Destruction

David A. Brown, John Moore, Heiko Johnen, Tom J. Smeets, Asne R. Bauskin, Tamara Kuffner, Helen Weedon, Samuel T. Milliken, Paul P. Tak, Malcolm D. Smith, and Samuel N. Breit 753

Expression and Proinflammatory Role of Proteinase-Activated Receptor 2 in Rheumatoid Synovium: Ex Vivo Studies Using a Novel Proteinase-Activated Receptor 2 Antagonist

Elizabeth B. Kelso, William R. Ferrell, John C. Lockhart, Iona Elias-Jones, Todd Hembrough, Lynette Dunning, J. Alastair Gracie, and Iain B. McInnes 765

Rheumatoid Arthritis Clinical Studies

Early Effects of Rituximab on the Synovial Cell Infiltrate in Patients With Rheumatoid Arthritis

Koen Vos, Rogier M. Thurlings, Carla A. Wijbrandts, Dirkjan van Schaardenburg, Daniëlle M. Gerlag, and Paul P. Tak 772

Up-Regulation of Metastasis-Promoting S100A4 (Mts-1) in Rheumatoid Arthritis: Putative Involvement in the Pathogenesis of Rheumatoid Arthritis

Jörg Klingelhöfer, Ladislav Šenolt, Bo Baslund, Gitte Helle Nielsen, Inge Skibshøj, Karel Pavelka, Michel Neidhart, Steffen Gay, Noona Ambartsumian, Birgitte Schmidt Hansen, Jørgen Petersen, Eugene Lukanidin, and Mariam Grigorian 779

Influence of Inflammatory Polyarthritis on Cancer Incidence and Survival: Results From a Community-Based Prospective Study

Jarrod Franklin, Mark Lunt, Diane Bunn, Deborah Symmons, and Alan Silman 790

Novel Action of <i>n</i> -3 Polyunsaturated Fatty Acids: Inhibition of Arachidonic Acid-Induced Increase in Tumor Necrosis Factor Receptor Expression on Neutrophils and a Role for Proteases <i>Nahid Moghaddami, James Irvine, Xiuhui Gao, Phulwinder K. Grover, Maurizio Costabile, Charles S. Hii, and Antonio Ferrante</i>	799
Elevated Plasma Asymmetric Dimethyl-L-Arginine Levels Are Linked to Endothelial Progenitor Cell Depletion and Carotid Atherosclerosis in Rheumatoid Arthritis <i>Andrzej Surdacki, Jens Martens-Lobenhoffer, Alicja Wloch, Ewa Marewicz, Tomasz Rakowski, Ewa Wieczorek-Surdacka, Jacek S. Dubiel, Juliusz Pryjma, and Stefanie M. Bode-Böger</i>	809
Glucocorticoids and Cardiovascular Events in Rheumatoid Arthritis: A Population-Based Cohort Study <i>John M. Davis, III, Hilal Maradit Kremers, Cynthia S. Crowson, Paulo J. Nicola, Karla V. Ballman, Terry M. Therneau, Véronique L. Roger, and Sherine E. Gabriel</i>	820
Erratum	
Error in reported concentration of interleukin-2 used in cell culture, in article by Michel et al (Arthritis Rheum, January 2007).....	830
Psoriatic Arthritis	
Effects of Tumor Necrosis Factor Blockade on Cardiovascular Risk Factors in Psoriatic Arthritis: A Double-Blind, Placebo-Controlled Study <i>Naveed Sattar, Philippa Crompton, Lynne Cherry, David Kane, Gordon Lowe, and Iain B. McInnes</i>	831
A Longitudinal Study of the Effect of Disease Activity and Clinical Damage on Physical Function Over the Course of Psoriatic Arthritis: Does the Effect Change Over Time? <i>Janice A. Husted, Brian D. Tom, Vernon T. Farewell, Catherine T. Schentag, and Dafna D. Gladman</i>	840
Experimental Arthritis	
Suppression of Inflammation and Structural Damage in Experimental Arthritis Through Molecular Targeted Therapy With PPI-2458 <i>Gerhard Hannig, Sylvie G. Bernier, Jennifer G. Hoyt, Beth Doyle, Ed Clark, Russell M. Karp, Jeanine Lorusso, and William F. Westlin</i>	850
Interleukin-4 Regulates Proteoglycan-Induced Arthritis by Specifically Suppressing the Innate Immune Response <i>Yanxia Cao, Frank Brombacher, Miklos Tunyogi-Csapo, Tibor T. Glant, and Alison Finnegan</i>	861
Cartilage Biology	
Tenocyte Responses to Mechanical Loading In Vivo: A Role for Local Insulin-Like Growth Factor 1 Signaling in Early Tendinosis in Rats <i>Alexander Scott, Jill L. Cook, David A. Hart, David C. Walker, Vincent Duronio, and Karim M. Khan</i>	871
Boundary Lubrication of Articular Cartilage: Role of Synovial Fluid Constituents <i>Tannin A. Schmidt, Nicholas S. Gastelum, Quynhhoa T. Nguyen, Barbara L. Schumacher, and Robert L. Sah</i>	882
Regulation of Matrix Metalloproteinase Gene Expression by a Retinoid X Receptor-Specific Ligand <i>Peter S. Burrage, Jonathan T. Huntington, Michael B. Sporn, and Constance E. Brinckerhoff</i>	892
Osteoarthritis	
Increased Collagen and Aggrecan Degradation With Age in the Joints of <i>Timp3</i> ^{-/-} Mice <i>Solmaz Sahebjam, Rama Khokha, and John S. Mort</i>	905
Bone Biology	
Bradykinin Potentiates Cytokine-Induced Prostaglandin Biosynthesis in Osteoblasts by Enhanced Expression of Cyclooxygenase 2, Resulting in Increased RANKL Expression <i>Anna Bernhold Brechter and Ulf H. Lerner</i>	910
Systemic Lupus Erythematosus	
Treatment With Cyclophosphamide Delays the Progression of Chronic Lesions More Effectively Than Does Treatment With Azathioprine Plus Methylprednisolone in Patients With Proliferative Lupus Nephritis <i>Cecile Grootscholten, Ingeborg M. Bajema, Sandrine Florquin, Eric J. Steenbergen, Carine J. Peutz-Kootstra, Roel Goldschmeding, Marc Bijl, E. Christiaan Hagen, Hans C. van Houwelingen, Ronald H. W. M. Derksen, and Jo H. M. Berden, for the Dutch Working Party on Systemic Lupus Erythematosus</i>	924
Induction of Autoimmune Depression in Mice by Anti-Ribosomal P Antibodies via the Limbic System <i>Aviva Katzav, Inna Solodkev, Ori Brodsky, Joab Chapman, Chaim G. Pick, Miri Blank, Wei Zhang, Morris Reichlin, and Yehuda Shoenfeld</i>	938
Excreted Urinary Mediators in an Animal Model of Experimental Immune Nephritis With Potential Pathogenic Significance <i>Tianfu Wu, Chun Xie, Madhavi Bhaskarabhatla, Mei Yan, Amanda Leone, Su Sin Chen, Xin J. Zhou, Chaim Putterman, and Chandra Mohan</i>	949

Autoinflammatory Disease

A Splice Site Mutation Confirms the Role of *LPIN2* in Majeed Syndrome

Zakiya S. Al-Mosawi, Khulood K. Al-Saad, Roya Ijadi-Maghsoodi, Hatem I. El-Shanti, and Polly J. Ferguson

960

Childhood Arthritis

The Diagnostic Significance of Soluble CD163 and Soluble Interleukin-2 Receptor α -Chain in Macrophage Activation Syndrome and Untreated New-Onset Systemic Juvenile Idiopathic Arthritis

Jack Bleasing, Anne Prada, David M. Siegel, Joyce Villanueva, Judyann Olson, Norman T. Ilowite, Hermine I. Brunner, Thomas Griffin, Thomas B. Graham, David D. Sherry, Murray H. Passo, Athimalaipet V. Ramanan, Alexandra Filipovich, and Alexei A. Grom

965

No Evidence for Genetic Association of Interferon Regulatory Factor 1 in Juvenile Idiopathic Arthritis

Mark S. Fife, Laura Gathercole, Emma M. Ogilvie, Carmel J. W. Stock, Lisa F. Mack, Rachelle P. Donn, Wendy Thomson, and Patricia Woo

972

RANKL:Osteoprotegerin Ratio and Bone Mineral Density in Children With Untreated Juvenile Dermatomyositis

Kelly A. Rouster-Stevens, Craig B. Langman, Heather E. Price, Roopa Seshadri, Richard M. Shore, Kathy Abbott, and Lauren M. Pachman

977

Musculoskeletal Abnormalities of the Tibia in Juvenile Rheumatoid Arthritis

Elena M. O. Felin, Sampath Prahalad, E. Wayne Askew, and Laurie J. Moyer-Mileur

984

Vasculitis

Primary Necrotizing Lymphocytic Central Nervous System Vasculitis Due to Perforin Deficiency in a Four-Year-Old Girl

Despina Moshous, Oliver Feyen, Petra Lankisch, Klaus Schwarz, Jörg Schaper, Marion Schneider, Dagmar Dilloo, Hans-Jürgen Laws, Bernd C. Schwahn, and Tim Niehues

995

Limitations of Therapy and a Guarded Prognosis in an American Cohort of Takayasu Arteritis Patients

Kathleen Maksimowicz-McKinnon, Tiffany M. Clark, and Gary S. Hoffman

1000

Clinical Image

Abdominal Vasculitis in Systemic Lupus Erythematosus

Chien-Hsueh Tung and Ning-Sheng Lai

1009

Systemic Sclerosis

A Macrophage Marker, Siglec-1, Is Increased on Circulating Monocytes in Patients With Systemic Sclerosis and Induced by Type I Interferons and Toll-like Receptor Agonists

Michael R. York, Taro Nagai, Alyson J. Mangini, Raphaël Lemaire, Jean Maguire van Seventer, and Robert Lafyatis

1010

Gout

Pharmacokinetics and Pharmacodynamics of Intravenous PEGylated Recombinant Mammalian Urate Oxidase in Patients With Refractory Gout

John S. Sundy, Nancy J. Ganson, Susan J. Kelly, Edna L. Scarlett, Claudia D. Rehrig, William Huang, and Michael S. Hershfield

1021

American College of Rheumatology Slide Competition Winners

Winners of the 2006 American College of Rheumatology Annual Slide Competition

American College of Rheumatology Audiovisual Aids Subcommittee

1029

Letters

Reply to Letter by Yazici and Yazici Commenting on the Two-Year Report on the Trial of Etanercept and Methotrexate with Radiographic and Patient Outcomes

Désirée van der Heijde and Lars Klareskog

1031

Association of Tumor Necrosis Factor α Polymorphism and Radiographic Progression in Rheumatoid Arthritis: Comment on the Article by Khanna et al

A. H. van der Helm-van Mil, F. A. Kurreeman, R. E. Toes, and T. W. Huizinga

1032

Reply

Dinesh Khanna, Hui Wu, Grace S. Park, Richard H. Gold, Betty P. Tsao, Harold E. Paulus, Lony C. Lim, Navanit Lal, Cabrini Delaney, and John T. Sharp

1033

Epigenetic Considerations in Investigating the Cause of Systemic Lupus Erythematosus: Comment on the Article by Chagnon et al

Wesley H. Brooks

1035

The Existence of Human TII B Cells Remains Unproven: Comment on the Article by Daridon et al

Gary Sims and Peter Lipsky

1035

Clinical Image

Intracardiac Thrombosis in the Antiphospholipid Syndrome

Luiz Sergio Guedes-Barbosa, Dely Cristina Martins, and Andrea Barros

1036

ACR Announcements

A13

Special Articles

- ACR Presidential Address: Mentors and Heroes: The Foundation and Future of Rheumatology
Mary K. Crow 1037
- Editorial: The Role of Varus and Valgus Alignment in Knee Osteoarthritis
Leena Sharma 1044
- Editorial: Estrogens and Lupus: Bubbling Cauldron or Another Overrated Witches' Brew?
Michael D. Lockshin and Jill P. Buyon 1048
- Review: Psoriatic Arthritis: Current Concepts on Pathogenesis-Oriented Therapeutic Options
Anthony M. Turkiewicz and Larry W. Moreland 1051

Rheumatoid Arthritis Basic Science Studies

- Decoy Receptor 3 Expressed in Rheumatoid Synovial Fibroblasts Protects the Cells Against Fas-Induced Apoptosis
Shinya Hayashi, Yasushi Miura, Takayuki Nishiyama, Makoto Mitani, Koji Tateishi, Yoshitada Sakai, Akira Hashiramoto, Masahiro Kurosaka, Shunichi Shiozawa, and Minoru Doita 1067
- Up-Regulation of Stromal Cell-Derived Factor 1 (CXCL12) Production in Rheumatoid Synovial Fibroblasts Through Interactions With T Lymphocytes: Role of Interleukin-17 and CD40L-CD40 Interaction
Kyoung-Woon Kim, Mi-La Cho, Hae-Rim Kim, Ji-Hyeon Ju, Mi-Kyung Park, Hye-Jwa Oh, Joon-Seok Kim, Sung-Hwan Park, Sang-Heon Lee, and Ho-Youn Kim 1076
- Histone Deacetylase/Acetylase Activity in Total Synovial Tissue Derived From Rheumatoid Arthritis and Osteoarthritis Patients
Lars C. Huber, Matthias Brock, Hossein Hemmatzad, Olivier T. Giger, Falk Moritz, Michelle Trenkmann, Jörg H. W. Distler, Renate E. Gay, Christoph Kolling, Holger Moch, Beat A. Michel, Steffen Gay, Oliver Distler, and Astrid Jüngel 1087
- Analysis of Vascular Gene Expression in Arthritic Synovium by Laser-Mediated Microdissection
Atsushi Hashimoto, Ingo H. Tamer, Rainer M. Böhle, Andreas Gaumann, Mirko Manetti, Oliver Distler, Jürgen Steinmeyer, Ann-Kristin Ulfgrén, Andreas Schulz, Steffen Gay, Ulf Müller-Ladner, and Elena Neumann 1094
- LIGHT Up-Regulated on B Lymphocytes and Monocytes in Rheumatoid Arthritis Mediates Cellular Adhesion and Metalloproteinase Production by Synoviocytes
Young Mo Kang, So Young Kim, Jin Hee Kang, Seung Woo Han, Eon Jeong Nam, Hee Soo Kyung, Jae Yong Park, and In San Kim 1106

Rheumatoid Arthritis Clinical Studies

- Bone Erosions and Bone Marrow Edema as Defined by Magnetic Resonance Imaging Reflect True Bone Marrow Inflammation in Rheumatoid Arthritis
Esther Jimenez-Boj, Iris Nöbauer-Huhmann, Beatrice Hanslik-Schnabel, Ronald Dorotka, Axel-Hugo Wanivenhaus, Franz Kainberger, Siegfried Trattnig, Roland Axtmann, Wayne Tsuji, Sonja Hermann, Josef Smolen, and Georg Schett 1118
- Risk of Serious Bacterial Infections Among Rheumatoid Arthritis Patients Exposed to Tumor Necrosis Factor α Antagonists
Jeffrey R. Curtis, Nivedita Patkar, Aiyuan Xie, Carolyn Martin, Jeroan J. Allison, Michael Saag, Deborah Shatin, and Kenneth G. Saag 1125

Sjögren's Syndrome

- Aberrant Expression of BAFF by B Lymphocytes Infiltrating the Salivary Glands of Patients With Primary Sjögren's Syndrome
Capucine Daridon, Valérie Devauchelle, Pascal Hutin, Rozenn Le Berre, Christine Martins-Carvalho, Boutahar Bendaoud, Maryvonne Dueymes, Alain Saraux, Pierre Youinou, and Jacques-Olivier Pers 1134

Experimental Arthritis

- Interferon- γ Regulates Susceptibility to Collagen-Induced Arthritis Through Suppression of Interleukin-17
Cong-Qiu Chu, David Swart, Dina Alcorn, Joel Tocker, and Keith B. Elkon 1145
- Blockade of the Interleukin-21/Interleukin-21 Receptor Pathway Ameliorates Disease in Animal Models of Rheumatoid Arthritis
Deborah A. Young, Martin Hegen, Hak Ling Margery Ma, Matthew J. Whitters, Leo M. Albert, Leslie Lowe, Mayra Senices, Paul W. Wu, Barbara Sibley, Yelena Leathurby, Tom P. Brown, Cheryl Nickerson-Nutter, James C. Keith, Jr., and Mary Collins 1152
- A Tumor Necrosis Factor Receptor Loop Peptide Mimic Inhibits Bone Destruction to the Same Extent as Anti-Tumor Necrosis Factor Monoclonal Antibody in Murine Collagen-Induced Arthritis
Hiroaki Saito, Takefumi Kojima, Mariko Takahashi, William C. Horne, Roland Baron, Teruo Amagasa, Keiichi Ohya, and Kazuhiro Aoki 1164

Cell Therapy Using Allogeneic Bone Marrow Mesenchymal Stem Cells Prevents Tissue Damage in Collagen-Induced Arthritis	
<i>Andrea Augello, Roberta Tasso, Simone Maria Negrini, Ranieri Cancedda, and Giuseppina Pennesi</i>	1175
Selective Therapeutic Control of C5a and the Terminal Complement Complex by Anti-C5 Single-Chain Fv in an Experimental Model of Antigen-Induced Arthritis in Rats	
<i>Fabio Fischetti, Paolo Durigutto, Paolo Macor, Roberto Marzari, Renzo Carretta, and Francesco Tedesco</i>	1187
Osteoarthritis	
A Randomized Crossover Trial of a Wedged Insole for Treatment of Knee Osteoarthritis	
<i>Kristin Baker, Joyce Goggins, Hui Xie, Karen Szumowski, Michael LaValley, David J. Hunter, and David T. Felson</i>	1198
Association Between Valgus and Varus Alignment and the Development and Progression of Radiographic Osteoarthritis of the Knee	
<i>G. M. Brouwer, A. W. van Tol, A. P. Bergink, J. N. Belo, R. M. D. Bernsen, M. Reijman, H. A. P. Pols, and S. M. A. Bierma-Zeinstra</i>	1204
Knee Alignment Does Not Predict Incident Osteoarthritis: The Framingham Osteoarthritis Study	
<i>David J. Hunter, Jingbo Niu, David T. Felson, William F. Harvey, K. Douglas Gross, Paula McCree, Piran Aliabadi, Burton Sack, and Yuqing Zhang</i>	1212
Systemic Lupus Erythematosus Basic Science Studies	
Examining the Role of CD1d and Natural Killer T Cells in the Development of Nephritis in a Genetically Susceptible Lupus Model	
<i>Jun-Qi Yang, Xiangshu Wen, Hongzhu Liu, Gbolahan Folayan, Xin Dong, Min Zhou, Luc Van Kaer, and Ram Raj Singh</i>	1219
Structural Insertion/Deletion Variation in IRF5 Is Associated With a Risk Haplotype and Defines the Precise IRF5 Isoforms Expressed in Systemic Lupus Erythematosus	
<i>Sergey V. Kozyrev, Susanna Lewén, Prasad M. V. Linga Reddy, Bernardo Pons-Estel and the Argentine Collaborative Group, Torsten Witte and the German Collaborative Group, Peter Junker, Helle Laustrup, Carmen Gutiérrez, Ana Suárez, Maria Francisca González-Escribano, Javier Martín and the Spanish Collaborative Group, and Marta E. Alarcón-Riquelme</i>	1234
Interleukin-6 and Chemokines in the Neuropsychiatric Manifestations of Systemic Lupus Erythematosus	
<i>H. Fragoso-Loyo, Y. Richaud-Patin, A. Orozco-Narváez, L. Dávila-Maldonado, Y. Atisha-Fregoso, L. Llorente, and J. Sánchez-Guerrero</i>	1242
Systemic Lupus Erythematosus Clinical Studies	
Reproductive and Menopausal Factors and Risk of Systemic Lupus Erythematosus in Women	
<i>Karen H. Costenbader, Diane Feskanich, Meir J. Stampfer, and Elizabeth W. Karlson</i>	1251
Histopathologic and Clinical Outcome of Rituximab Treatment in Patients With Cyclophosphamide-Resistant Proliferative Lupus Nephritis	
<i>Iva Gunnarsson, Birgitta Sundelin, Thorunn Jónsdóttir, Stefan H. Jacobson, Elisabet Welin Henriksson, and Ronald F. van Vollenhoven</i>	1263
Autoinflammatory Disease	
The Clinical Continuum of Cryopyrinopathies: Novel <i>CIAS1</i> Mutations in North American Patients and a New Cryopyrin Model	
<i>Ivona Aksentijevich, Christopher D. Putnam, Elaine F. Remmers, James L. Mueller, Julie Le, Richard D. Kolodner, Zachary Moak, Michael Chuang, Frances Austin, Raphaela Goldbach-Mansky, Hal M. Hoffman, and Daniel L. Kastner</i>	1273
Childhood Arthritis	
Positive Association of SLC26A2 Gene Polymorphisms With Susceptibility to Systemic-Onset Juvenile Idiopathic Arthritis	
<i>Rebecca Lamb, Wendy Thomson, the British Society of Paediatric and Adolescent Rheumatology, Emma M. Ogilvie, and Rachelle Donn</i>	1286
Interstitial Pneumonitis in Blau Syndrome With Documented Mutation in <i>CARD15</i>	
<i>Mara L. Becker, Tammy M. Martin, Trudy M. Doyle, and Carlos D. Rosé</i>	1292
Myositis	
Clinical and Immunogenetic Features of Patients With Autoantibodies to Asparaginyl-Transfer RNA Synthetase	
<i>Michito Hirakata, Akira Suwa, Tetsuya Takada, Shinji Saio, Sonoko Nagai, Ekkehard Genth, Yeong W. Song, Tsuneyo Mimori, and Ira N. Targoff</i>	1295
A New Murine Model to Define the Critical Pathologic and Therapeutic Mediators of Polymyositis	
<i>Takahiko Sugihara, Chiyoko Sekine, Takashi Nakae, Kuniko Kohyama, Masayoshi Harigai, Yoichiro Iwakura, Yoh Matsumoto, Nobuyuki Miyasaka, and Hitoshi Kohsaka</i>	1304

Vasculitis

Role of Matrix Metalloproteinases, Proinflammatory Cytokines, and Oxidative Stress-Derived Molecules in Hepatitis C Virus-Associated Mixed Cryoglobulinemia Vasculitis Neuropathy

David Saadoun, Ivan Bieche, François-Jérôme Authier, Ingrid Laurendeau, Florence Jambou,

Jean Charles Piette, Michel Vidaud, Thierry Maisonobe, and Patrice Cacoub 1315

Lyme Disease

High Levels of Inflammatory Chemokines and Cytokines in Joint Fluid and Synovial Tissue Throughout the Course of Antibiotic-Refractory Lyme Arthritis

Junghee J. Shin, Lisa J. Glickstein, and Allen C. Steere 1325

Fibromyalgia and Pain Syndromes

Gabapentin in the Treatment of Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

Lesley M. Arnold, Don L. Goldenberg, Sharon B. Stanford, Justine K. Lalonde, H. S. Sandhu,

Paul E. Keck, Jr., Jeffrey A. Welge, Fred Bishop, Kevin E. Stanford, Evelyn V. Hess, and James I. Hudson . 1336

Arthritic Pain Is Processed in Brain Areas Concerned With Emotions and Fear

B. Kulkarni, D. E. Bentley, R. Elliott, P. J. Julyan, E. Boger, A. Watson, Y. Boyle, W. El-Deredy,

and A. K. P. Jones 1345

Risk Factors for More Severe Regional Musculoskeletal Symptoms: A Two-Year Prospective Study of a General Working Population

Johan H. Andersen, Jens P. Haahr, and Poul Frost 1355

Concise Communication

Liver X Receptor Is a Therapeutic Target in Collagen-Induced Arthritis

Subba R. Chintalacharuvu, George E. Sandusky, Thomas P. Burris, Glenna C. Burner, and Sunil Nagpal 1365

Letters

What is Juvenile Psoriatic Arthritis? Comment on the Article by Stoll et al

Alberto Martini 1368

The Irreversible Component of the Disability Index of the Health Assessment Questionnaire:

Comment on the Article by Aletaha et al

James F. Fries 1368

Reply

Daniel Aletaha, Josef S. Smolen, and Michael M. Ward 1369

Erratum

Error in Reported Plasma Half-Life of Intravenous PEGylated Recombinant Mammalian Urate Oxidase, in Article by Sundy et al (Arthritis Rheum, March 2007) 1370

ACR Announcements

..... A12

VOLUME 56

MAY 2007

NO. 5

Special Articles

Editorial: Will Targeting B Cells Be the Answer for Sjögren's Syndrome?

R. John Looney 1371

Special Article: The Futility of Current Approaches to Chondroprotection

David T. Felson and Young-jo Kim 1378

Review: Premature Atherosclerotic Cardiovascular Disease in Systemic Lupus Erythematosus

Peter E. Westerweel, Remco K. M. A. C. Luyten, Hein A. Koomans, Ronald H. W. M. Derksen,

and Marianne C. Verhaar 1384

Economics of Arthritis

Medical Care Expenditures and Earnings Losses Among Persons With Arthritis and Other Rheumatic Conditions in 2003, and Comparisons With 1997

Edward Yelin, Louise Murphy, Miriam G. Cisternas, Aimee J. Foreman, David J. Pasta, and

Charles G. Helmick 1397

Rheumatoid Arthritis

Association of DRB1 Shared Epitope Genotypes With Early Mortality in Rheumatoid Arthritis: Results of Eighteen Years of Followup From the Early Rheumatoid Arthritis Study

D. L. Matthey, W. Thomson, W. E. R. Ollier, M. Batley, P. G. Davies, A. K. Gough, J. Devlin, P. Prouse,

D. W. James, P. L. Williams, J. Dixey, J. Winfield, N. L. Cox, G. Koduri, and A. Young 1408

B Cell Depletion May Be More Effective Than Switching to an Alternative Anti-Tumor Necrosis Factor Agent in Rheumatoid Arthritis Patients With Inadequate Response to Anti-Tumor Necrosis Factor Agents <i>Axel Finckh, Adrian Ciurea, Laure Brulhart, Diego Kyburz, Burkhard Möller, Silvia Dehler, Sylvie Revaz, Jean Dudler, and Cem Gabay, on behalf of the physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis</i>	1417
Efficacy of Methotrexate Treatment in Patients With Probable Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Trial <i>Henrike van Dongen, Jill van Aken, Leroy R. Lard, Karen Visser, H. Karel Ronda, Harry M. J. Hulsmans, Irene Speyer, Marie-Louise Westedt, André J. Peeters, Cornelia F. Allaart, René E. M. Toes, Ferdinand C. Breedveld, and Tom W. J. Huizinga</i>	1424
The Effect of Methotrexate and Anti-Tumor Necrosis Factor Therapy on the Risk of Lymphoma in Rheumatoid Arthritis in 19,562 Patients During 89,710 Person-Years of Observation <i>Frederick Wolfe and Kaleb Michaud</i>	1433
The Antiinflammatory Mechanism of Methotrexate Depends on Extracellular Conversion of Adenine Nucleotides to Adenosine by Ecto-5'-Nucleotidase: Findings in a Study of Ecto-5'-Nucleotidase Gene-Deficient Mice <i>M. Carmen Montesinos, Masahide Takedachi, Linda F. Thompson, Tuere F. Wilder, Patricia Fernández, and Bruce N. Cronstein</i>	1440
Strong Combined Gene-Environment Effects in Anti-Cyclic Citrullinated Peptide-Positive Rheumatoid Arthritis: A Nationwide Case-Control Study in Denmark <i>Merete Pedersen, Søren Jacobsen, Peter Garred, Hans O. Madsen, Mette Klarlund, Arne Svejgaard, Bo V. Pedersen, Jan Wohlfahrt, and Morten Frisch</i>	1446
Association of Anti-Cyclic Citrullinated Peptide Antibody Levels With <i>PADI4</i> Haplotypes in Early Rheumatoid Arthritis and With Shared Epitope Alleles in Very Late Rheumatoid Arthritis <i>Seongwon Cha, Chan-Bum Choi, Tae-Un Han, Changsoo Paul Kang, Changwon Kang, and Sang-Cheol Bae</i>	1454
Clinical Images	
Rheumatologic Irony <i>Jochen Zwerina, Enijad Sahimbegovic, Bernhard Manger, and Georg Schett</i>	1463
Sjögren's Syndrome	
BAFF-Modulated Repopulation of B Lymphocytes in the Blood and Salivary Glands of Rituximab-Treated Patients With Sjögren's Syndrome <i>Jacques-Olivier Pers, Valérie Devauchelle, Capucine Daridon, Boutahar Bendaoud, Rozenn Le Berre, Anne Bordron, Pascal Hutin, Yves Renaudineau, Maryvonne Dueymes, Séverine Loisel, Christian Berthou, Alain Saraux, and Pierre Youinou</i>	1464
Spondylarthritis	
Alteration of Antigen-Independent Immunologic Synapse Formation Between Dendritic Cells From HLA-B27-Transgenic Rats and CD4+ T Cells: Selective Impairment of Costimulatory Molecule Engagement by Mature HLA-B27 <i>Cécile Hacquard-Bouder, Maria-Sole Chimenti, Benoît Giquel, Emmanuel Donnadieu, Ingrid Fert, Alain Schmitt, Claudine André, and Maxime Breban</i>	1478
Experimental Arthritis	
Mycobacterial Hsp65-IgG-Expressing Tolerogenic B Cells Confer Protection Against Adjuvant-Induced Arthritis in Lewis Rats <i>Shailesh R. Satpute, Nadejda Soukhareva, David W. Scott, and Kamal D. Moudgil</i>	1490
Osteoarthritis	
Presentation of Arthritogenic Peptide to Antigen-Specific T Cells by Fibroblast-Like Synoviocytes <i>Chinh N. Tran, Michael J. Davis, Laura A. Tesmer, Judith L. Endres, Christopher D. Motyl, Craig Smuda, Emily C. Somers, Kevin C. Chung, Andrew G. Urquhart, Steven K. Lundy, Susan Kovats, and David A. Fox</i>	1497
Delayed Gadolinium-Enhanced Magnetic Resonance Imaging of the Meniscus: An Index of Meniscal Tissue Degeneration? <i>Nitya Krishnan, Sanjay K. Shetty, Ashley Williams, Brandon Mikulis, Charles McKenzie, and Deborah Burstein</i>	1507
Longitudinal Performance Evaluation and Validation of Fixed-Flexion Radiography of the Knee for Detection of Joint Space Loss <i>Michael C. Nevitt, Charles Peterfy, Ali Guermazi, David T. Felson, Jeff Duryea, Thasia Woodworth, Hepei Chen, Kent Kwok, and Tamara B. Harris</i>	1512

Smoking Interacts With Family History With Regard to Change in Knee Cartilage Volume and Cartilage Defect Development <i>Changhai Ding, Flavia Cicuttini, Leigh Blizzard, and Graeme Jones</i>	1521
Role of Apoptotic and Matrix-Degrading Genes in Articular Cartilage and Meniscus of Mature and Aged Rabbits During Development of Osteoarthritis <i>Andrew T. Pennock, Catherine M. Robertson, Bryan C. Emmerson, Frederick L. Harwood, and David Amiel</i>	1529
Cartilage Biology	
The Effects of Glucosamine Hydrochloride on Subchondral Bone Changes in an Animal Model of Osteoarthritis <i>Susanne X. Wang, Sheila Laverty, Mircea Dumitriu, Anna Plaas, and Marc D. Grynpas</i>	1537
Induction of Increased cAMP Levels in Articular Chondrocytes Blocks Matrix Metalloproteinase-Mediated Cartilage Degradation, but Not Aggrecanase-Mediated Cartilage Degradation <i>Morten Asser Karsdal, Eren Ufuk Sumer, Helle Wulf, Suzi H. Madsen, Claus Christiansen, Amanda J. Fosang, and Bodil-Cecilie Sondergaard</i>	1549
Systemic Lupus Erythematosus	
Activation Signal Transduction by $\beta 1$ Integrin in T Cells From Patients With Systemic Lupus Erythematosus <i>Shingo Nakayamada, Kazuyoshi Saito, Kazuhisa Nakano, and Yoshiya Tanaka</i>	1559
Involvement of Renal Tubular Toll-like Receptor 9 in the Development of Tubulointerstitial Injury in Systemic Lupus <i>Ariela Benigni, Cristina Caroli, Lorena Longaretti, Elena Gagliardini, Carla Zoja, Miriam Galbusera, Daniela Moiola, Paola Romagnani, Angela Tincani, Laura Andreoli, and Giuseppe Remuzzi</i>	1569
Identification of Distinct Gene Expression Profiles in the Synovium of Patients With Systemic Lupus Erythematosus <i>A. Nzeusseu Toukap, C. Galant, I. Theate, A. L. Maudoux, R. J. U. Lories, F. A. Houssiau, and B. R. Lauwerys</i>	1579
Differential Tissue Targeting of Autoimmunity Manifestations by Autoantigen-Associated Y RNAs <i>Eric L. Greidinger, YunJuan Zang, Laisel Martinez, Kimberly Jaimes, Mehdi Nassiri, Pablo Bejarano, Glen N. Barber, and Robert W. Hoffman</i>	1589
The Innate Immune Component Ficolin 3 (Hakata Antigen) Mediates the Clearance of Late Apoptotic Cells <i>Christian Honoré, Tina Hummelshoj, Bjarke E. Hansen, Hans O. Madsen, Paul Eggleton, and Peter Garred</i>	1598
Epistatic Effect of Plasminogen Activator Inhibitor 1 and β -Fibrinogen Genes on Risk of Glomerular Microthrombosis in Lupus Nephritis: Interaction With Environmental/Clinical Factors <i>Rujun Gong, Zhihong Liu, and Leishi Li</i>	1608
Protection Against Autoimmune Nephritis in MyD88-Deficient MRL/lpr Mice <i>Atsushi Sadanaga, Hitoshi Nakashima, Mitsuteru Akahoshi, Kohsuke Masutani, Katsuhisa Miyake, Takashi Igawa, Naonobu Sugiyama, Hiroaki Niuro, and Mine Harada</i>	1618
Cyclin-Dependent Kinase Inhibition Limits Glomerulonephritis and Extends Lifespan of Mice With Systemic Lupus <i>Carla Zoja, Federica Casiraghi, Sara Conti, Daniela Corna, Daniela Rottoli, Regiane A. Cavinato, Giuseppe Remuzzi, and Ariela Benigni</i>	1629
Antiphospholipid Syndrome	
Some Antiphospholipid Antibodies Recognize Conformational Epitopes Shared by β_2 -Glycoprotein I and the Homologous Catalytic Domains of Several Serine Proteases <i>Wei-Shiang Lin, Pei-Chih Chen, Cheng-De Yang, EunJung Cho, Bevra H. Hahn, Jennifer Grossman, Kwan-Ki Hwang, and Pojen P. Chen</i>	1638
Childhood Arthritis	
Differential Recognition of Heat-Shock Protein dnaJ-Derived Epitopes by Effector and Treg Cells Leads to Modulation of Inflammation in Juvenile Idiopathic Arthritis <i>Margherita Massa, Maristella Passalia, Silvia Magni Manzoni, Rita Campanelli, Laura Ciardelli, Gisella Puga Yung, Sylvia Kamphuis, Angela Pistorio, Valentina Meli, Alessandro Sette, Berent Prakken, Alberto Martini, and Salvatore Albani</i>	1648

Plasmacytoid Dendritic Cells in Inflamed Muscle of Patients With Juvenile Dermatomyositis <i>Consuelo M. López de Padilla, Abbe N. Vallejo, Kelly T. McNallan, Richard Vehe, Stephen A. Smith, Allan B. Dietz, Stanimir Vuk-Pavlovic, and Ann M. Reed</i>	1658
Are Common Symptoms in Childhood Associated With Chronic Widespread Body Pain in Adulthood? Results From the 1958 British Birth Cohort Study <i>Gareth T. Jones, Alan J. Silman, Chris Power, and Gary J. Macfarlane</i>	1669
Errata	
Errors in Citation of Panels in Figure 1 of Article by York et al (Arthritis Rheum, March 2007), and Errors in Dose Escalation Section of Article by Westhovens et al (Arthritis Rheum, April 2006)	1675
Systemic Sclerosis	
Impact of Oral Cyclophosphamide on Health-Related Quality of Life in Patients With Active Scleroderma Lung Disease: Results From the Scleroderma Lung Study <i>Dinesh Khanna, Xiaohong Yan, Donald P. Tashkin, Daniel E. Furst, Robert Elashoff, Michael D. Roth, Richard Silver, Charlie Strange, Marcy Bolster, James R. Seibold, David J. Riley, Vivien M. Hsu, John Varga, Dean E. Schraufnagel, Arthur Theodore, Robert Simms, Robert Wise, Fredrick Wigley, Barbara White, Virginia Steen, Charles Read, Maureen Mayes, Ed Parsley, Kamal Mubarak, M. Kari Connolly, Jeffrey Golden, Mitchell Oltman, Barri Fessler, Naomi Rothfield, Mark Metersky, and Philip J. Clements, for the Scleroderma Lung Study Group</i>	1676
CCL18 as an Indicator of Pulmonary Fibrotic Activity in Idiopathic Interstitial Pneumonias and Systemic Sclerosis <i>Antje Prasse, Dmitri V. Pechkovsky, Galen B. Toews, Markus Schäfer, Stephan Eggeling, Corinna Ludwig, Martin Germann, Florian Kollert, Gernot Zissel, and Joachim Müller-Quernheim</i>	1685
Involvement of the Constitutive Complex Formation of c-Ski/SnoN With Smads in the Impaired Negative Feedback Regulation of Transforming Growth Factor β Signaling in Scleroderma Fibroblasts <i>Masatoshi Jinnin, Hironobu Ihn, Yoshihiro Mimura, Yoshihide Asano, and Kunihiro Tamaki</i>	1694
Autoinflammatory Disease	
Country as the Primary Risk Factor for Renal Amyloidosis in Familial Mediterranean Fever <i>Isabelle Touitou, Tamara Sarkisian, Myrna Medlej-Hashim, Mehmet Tunca, Avi Livneh, Daniel Cattani, Fatos Yalçinkaya, Seza Özen, Hassan Majeed, Huri Ozdogan, Daniel Kastner, David Booth, Eldad Ben-Chetrit, Denis Pugnère, Cécile Michelon, Fabienne Séguret, and Ruth Gershoni-Baruch, for the International Study Group for Phenotype-Genotype Correlation in Familial Mediterranean Fever</i>	1706
Whipple's Arthritis	
Cultivation of <i>Tropheryma whipplei</i> From the Synovial Fluid in Whipple's Arthritis <i>Xavier Puéchal, Florence Fenollar, and Didier Raoult</i>	1713
Letters	
Vitamin D and Rheumatoid Arthritis: Comment on the Letter by Nielsen et al <i>Maurizio Cutolo, Kati Otsa, Maria Yprus, and Bruno Serio</i>	1719
Altered Expression of 11 β -Hydroxysteroid Dehydrogenases in Rheumatoid Arthritis Synovial Cells: Comment on the Article by Haas et al <i>Martin Schmidt and Rainer H. Straub</i>	1720
Skin-Lightening Creams Are a Possible Exposure Risk for Systemic Lupus Erythematosus: Comment on the Article by Finckh et al <i>K. Michael Pollard and Per Hultman</i>	1721
Reply <i>Axel Finckh, Glinda S. Cooper, Karen H. Costenbader, and Elizabeth W. Karlson</i>	1721
Benefit of High-Dose Intravenous Methylprednisolone as Induction Therapy for Giant Cell Arteritis: Comment on the Article by Mazlumzadeh et al <i>Kayvan Arashvand</i>	1722
Differences Between Active Treatment and Placebo Groups in the Study of Induction Treatment of Giant Cell Arteritis With High-Dose Glucocorticoids: Comment on the Article by Mazlumzadeh et al <i>Ana M. Bertoli, Yvonne M. Font, Anaida Nadal, and Luis M. Vilá</i>	1723
Reply <i>Jörg J. Goronzy, Cornelia M. Weyand, Gene G. Hunder, and Mehrdad Mazlumzadeh</i>	1723
Clinical Images	
Chronic Intestinal Pseudoobstruction and the "Hide-Bound" Bowel Sign <i>Akira Hokama, Yasushi Ihama, Kazuto Kishimoto, Satomi Yara, Fukunori Kinjo, and Jiro Fujita</i>	1724
ACR Announcements	A14

Special Articles

Editorial: T Cell Alterations and Lymphoid Neogenesis Favoring Autoimmunity in Wegener's Granulomatosis

- Peter Lamprecht, Wolfgang L. Gross, and Dieter Kabelitz* 1725
- Review: Emerging Patterns of Risk Factor Make-Up Enable Subclassification of Rheumatoid Arthritis
Annette H. M. van der Helm-van Mil, Tom W. J. Huizinga, René R. P. de Vries, and René E. M. Toes 1728
- Review: Are We at a Stage to Predict Autoimmune Rheumatic Diseases?
Nicola Bizzaro, Renato Tozzoli, and Yehuda Shoenfeld 1736

Rheumatoid Arthritis

Interaction Between Smoking, the Shared Epitope, and Anti-Cyclic Citrullinated Peptide: A Mixed Picture in Three Large North American Rheumatoid Arthritis Cohorts

- Hye-Soon Lee, Patricia Irigoyen, Marlena Kern, Annette Lee, Franak Batliwalla, Houman Khalili, Frederick Wolfe, Raymond F. Lum, Elena Massarotti, Michael Weisman, Claire Bombardier, Elizabeth W. Karlson, Lindsey A. Criswell, Robert Vlietinck, and Peter K. Gregersen* 1745

Anti-Tumor Necrosis Factor α Therapy and the Risk of Serious Bacterial Infections in Elderly Patients With Rheumatoid Arthritis

- Sebastian Schneeweiss, Soko Setoguchi, Michael E. Weinblatt, Jeffrey N. Katz, Jerry Avorn, Paul E. Sax, Raisa Levin, and Daniel H. Solomon* 1754

A Clinical Pharmacogenetic Model to Predict the Efficacy of Methotrexate Monotherapy in Recent-Onset Rheumatoid Arthritis

- Judith A. M. Wessels, Sjoerd M. van der Kooij, Saskia le Cessie, Wietske Kievit, Pilar Barrera, Cornelia F. Allaart, Tom W. J. Huizinga, and Henk-Jan Guchelaar, for the Pharmacogenetics Collaborative Research Group* 1765

Tumor Necrosis Factor α Activates Release of B Lymphocyte Stimulator by Neutrophils Infiltrating the Rheumatoid Joint

- Lakhvir K. Assi, See Heng Wong, Andreas Ludwig, Karim Raza, Caroline Gordon, Michael Salmon, Janet M. Lord, and Dagmar Scheel-Toellner* 1776

Interleukin-18 Induces Angiogenic Factors in Rheumatoid Arthritis Synovial Tissue Fibroblasts via Distinct Signaling Pathways

- Mohammad A. Amin, Pamela J. Mansfield, Angela Pakozdi, Phillip L. Campbell, Salahuddin Ahmed, Rita J. Martinez, and Alisa E. Koch* 1787

Experimental Arthritis

Female Mice Are More Susceptible to Developing Inflammatory Disorders due to Impaired Transforming Growth Factor β Signaling in Salivary Glands

- Seshagiri R. Nandula, Shoba Amarnath, Alfredo Molinolo, Bidhan C. Bandyopadhyay, Bradford Hall, Corinne M. Goldsmith, Changyu Zheng, Jonas Larsson, Taduru Sreenath, WanJun Chen, Indu S. Ambudkar, Stefan Karlsson, Bruce J. Baum, and Ashok B. Kulkarni* 1798

Targeted Mast Cell Silencing Protects Against Joint Destruction and Angiogenesis in Experimental Arthritis in Mice

- Manfred Kneilling, Lothar Hülner, Bernd J. Pichler, Reinhard Mailhammer, Lars Morawietz, Samuel Solomon, Martin Eichner, Joseph Sabatino, Tilo Biedermann, Veit Krenn, Wolfgang A. Weber, Harald Illges, Roland Haubner, and Martin Röcken* 1806

The Role of Vascular Cell Adhesion Molecule 1/Very Late Activation Antigen 4 in Endothelial Progenitor Cell Recruitment to Rheumatoid Arthritis Synovium

- Matthew D. Silverman, Christian S. Haas, Ali M. Rad, Ali S. Arbab, and Alisa E. Koch* 1817

Fluvastatin Reverses Endothelial Dysfunction and Increased Vascular Oxidative Stress in Rat Adjuvant-Induced Arthritis

- Yoshisuke Haruna, Yoshitaka Morita, Toyotaka Yada, Minoru Satoh, David A. Fox, and Naoki Kashihara* 1827

Activation of Invariant Natural Killer T Cells by Synthetic Glycolipid Ligands Suppresses Autoantibody-Induced Arthritis

- Shinjiro Kaieda, Chiharu Tomi, Shinji Oki, Takashi Yamamura, and Sachiko Miyake* 1836

Ankylosing Spondylitis

Serum Matrix Metalloproteinase 3 Is an Independent Predictor of Structural Damage Progression in Patients With Ankylosing Spondylitis

- Walter P. Maksymowych, Robert Landewé, Barbara Conner-Spady, Maxime Dougados, Herman Mielants, Hille van der Tempel, A. Robin Poole, Nandi Wang, and Désirée van der Heijde* 1846

Osteoarthritis

Global Analyses of Gene Expression in Early Experimental Osteoarthritis

- C. T. G. Appleton, V. Pitelka, J. Henry, and F. Beier 1854

Cartilage Biology

Chondrogenic Differentiation of Bovine Synovium: Bone Morphogenetic Proteins 2 and 7 and Transforming Growth Factor β 1 Induce the Formation of Different Types of Cartilaginous Tissue

- Nahoko Shintani and Ernst B. Hunziker 1869

Toll-like Receptors and Chondrocytes: The Lipopolysaccharide-Induced Decrease in Cartilage Matrix Synthesis Is Dependent on the Presence of Toll-like Receptor 4 and Antagonized by Bone Morphogenetic Protein 7

- K. Bobacz, I. G. Sunk, J. G. Hofstaetter, L. Amoyo, C. D. Toma, S. Akira, T. Weichhart, M. Saemann, and J. S. Smolen 1880

Systemic Lupus Erythematosus

Urinary Lipocalin-2 Is Associated With Renal Disease Activity in Human Lupus Nephritis

- Milena Pitashny, Noa Schwartz, Xiaoping Qing, Bernard Hojaili, Cynthia Aranow, Meggan Mackay, and Chaim Putterman 1894

Altered Coronary Vasomotor Function in Young Patients With Systemic Lupus Erythematosus

- Kumiko Hirata, Amudha Kadirvelu, Mitsuyo Kinjo, Robert Sciacca, Kenichi Sugioka, Ryo Otsuka, AnnaMaria Choy, Sook K. Chow, Minoru Yoshiyama, Junichi Yoshikawa, Shunichi Homma, and Chim C. Lang 1904

Low Number of Regulatory T Cells in Skin Lesions of Patients With Cutaneous Lupus Erythematosus

- B. Franz, B. Fritzsche, A. Riehl, N. Oberle, C.-D. Klemke, J. Sykora, S. Quick, C. Stumpf, M. Hartmann, A. Enk, T. Ruzicka, P. H. Krammer, E. Suri-Payer, and A. Kuhn 1910

Apoptosis-Induced Acetylation of Histones Is Pathogenic in Systemic Lupus Erythematosus

- Jürgen W. Dieker, Justin H. Fransen, Casandra C. van Bavel, Jean-Paul Briand, Cor W. Jacobs, Sylviane Muller, Jo H. Berden, and Johan van der Vlag 1921

Reduced Expression of Decay-Accelerating Factor 1 on CD4+ T Cells in Murine Systemic Autoimmune Disease

- David M. Cauvi, Gabrielle Cauvi, and K. Michael Pollard 1934

Protection Against Renal Disease in (NZB \times NZW) F_1 Lupus-Prone Mice After Somatic B Cell Gene Vaccination With Anti-DNA Immunoglobulin Consensus Peptide

- Francesca Ferrera, Bevrá H. Hahn, Marta Rizzi, Marissa Anderson, John FitzGerald, Enrico Millo, Francesco Indiveri, Fu-Dong Shi, Gilberto Filaci, and Antonio La Cava 1945

Childhood Arthritis

Specific Gene Expression Profiles in Systemic Juvenile Idiopathic Arthritis

- Emma Mary Ogilvie, Arshad Khan, Mike Hubank, Paul Kellam, and Patricia Woo 1954

Prevalence and Etiology of Low Bone Mineral Density in Juvenile Systemic Lupus Erythematosus

- Sandrine Compeyrot-Lacassagne, Pascal N. Tyrrell, Eshetu Atenafu, Andrea S. Doria, Derek Stephens, David Gilday, and Earl D. Silverman 1966

Epidemiology of Juvenile Idiopathic Arthritis in a Multiethnic Cohort: Ethnicity as a Risk Factor

- R. K. Saurenmann, J. B. Rose, P. Tyrrell, B. M. Feldman, R. M. Laxer, R. Schneider, and E. D. Silverman 1974

Systemic Sclerosis

Improvement of Vascular Endothelial Function Using the Oral Endothelin Receptor Antagonist Bosentan in Patients With Systemic Sclerosis

- P. P. Sfikakis, C. Papatheofis, K. S. Stamatelopoulos, D. Tousoulis, K. G. Fragiadaki, P. Katsichti, C. Stefanadis, and M. Mavrikakis 1985

Impairment of Endothelial Cell Differentiation From Bone Marrow-Derived Mesenchymal Stem Cells: New Insight Into the Pathogenesis of Systemic Sclerosis

- P. Cipriani, S. Guiducci, I. Miniati, M. Cinelli, S. Urbani, A. Marrelli, V. Dolo, A. Pavan, R. Saccardi, A. Tyndall, R. Giacomelli, and M. Matucci Cerinic 1994

Bronchoalveolar Lavage Cellular Profiles in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease Are Not Predictive of Disease Progression

- Nicole S. L. Goh, Srihari Veeraraghavan, Sujal R. Desai, Derek Cramer, David M. Hansell, Christopher P. Denton, Carol M. Black, Roland M. du Bois, and Athol U. Wells 2005

Normal Circulating Serum Amyloid P Component Concentration in Systemic Sclerosis

- Glenys A. Tennent, Magdalena Dziadzio, Eva Triantafyllidou, Phillip Davies, J. Ruth Gallimore, Christopher P. Denton, and Mark B. Pepys 2013

Comprehensive Investigation of Disease-Specific Short Peptides in Sera From Patients With Systemic Sclerosis: Complement C3f-des-arginine, Detected Predominantly in Systemic Sclerosis Sera, Enhances Proliferation of Vascular Endothelial Cells <i>Yang Xiang, Toshihiro Matsui, Kosuke Matsuo, Kota Shimada, Shigeto Tohma, Hiroshi Nakamura, Kayo Masuko, Kazuo Yudoh, Kusuki Nishioka, and Tomohiro Kato</i>	2018
Clinical, Immunologic, and Genetic Features of Familial Systemic Sclerosis <i>Shervin Assassi, Frank C. Arnett, John D. Reveille, Pravit Gourh, and Maureen D. Mayes</i>	2031
Pain	
Amelioration of Pain and Histopathologic Joint Abnormalities in the Coll-1L-1 β ^{XAT} Mouse Model of Arthritis by Intraarticular Induction of μ -Opioid Receptor Into the Temporomandibular Joint <i>Stephanos Kyrkanides, Paolo M. Fiorentino, Jen-nie H. Miller, Yanjun Gan, Yu-Ching Lai, Solomon S. Shaftel, J. Edward Puzas, Maria G. Piacino, M. Kerry O'Banion, and Ross H. Tallents</i>	2038
Gout	
Coffee Consumption and Risk of Incident Gout in Men: A Prospective Study <i>Hyon K. Choi, Walter Willett, and Gary Curhan</i>	2049
Psoriasis	
TNF Polymorphisms in Psoriasis: Association of Psoriatic Arthritis With the Promoter Polymorphism TNF-857 Independent of the PSORS1 Risk Allele <i>Kristian Reich, Ulrike Hüffmeier, Inke R. König, Jesús Lascorz, Jörg Lohmann, Jörg Wendler, Heiko Traupe, Rotraut Mössner, André Reis, and Harald Burkhardt</i>	2056
Vasculitis	
Microscopic Polyangiitis Presenting as a "Pulmonary-Muscle" Syndrome: Is Subclinical Alveolar Hemorrhage the Mechanism of Pulmonary Fibrosis? <i>Julius Birnbaum, Sonye Danoff, Frederic B. Askin, and John H. Stone</i>	2065
Inflammatory Rheumatic Disease and Smoking Are Predictors of Aortic Inflammation: A Controlled Study of Biopsy Specimens Obtained at Coronary Artery Surgery <i>Ivana Hollan, Helge Scott, Kjell Saatvedt, Richard Prayson, Knut Mikkelsen, Hans C. Nossent, Ingjerd Lien Kvelstad, Matthew H. Liang, and Øystein T. Førre</i>	2072
Functional Defect of Circulating Regulatory CD4 ⁺ T Cells in Patients With Wegener's Granulomatosis in Remission <i>Wayel H. Abdulhadi, Coen A. Stegeman, Ymke M. van der Geld, Berber Doornbos-van der Meer, Pieter C. Limburg, and Cees G. M. Kallenberg</i>	2080
Concise Communications	
Prevalence of Adult Systemic Lupus Erythematosus in California and Pennsylvania in 2000: Estimates Obtained Using Hospitalization Data <i>Eliza F. Chakravarty, Thomas M. Bush, Susan Manzi, Ann E. Clarke, and Michael M. Ward</i>	2092
Risk of Interstitial Lung Disease Associated With Leflunomide Treatment in Korean Patients With Rheumatoid Arthritis <i>Ji Hyeon Ju, Sung-Il Kim, Jun-Hee Lee, Sang-Il Lee, Wan-Hee Yoo, Jung-Yoon Choe, Seung-Hie Chung, Jisoo Lee, You-Hyun Lee, Shin-Seok Lee, Hyun-Jung Yoon, Chong-Hyeon Yoon, Ho-Youn Kim, and Sung-Hwan Park</i>	2094
Letters	
Mannose-Binding Lectin and Agalactosyl IgG and Risk of Ischemic Heart Disease in Rheumatoid Arthritis: Comment on the Article by Troelsen et al <i>Sander I. van Leuven and Erik S. G. Stroes</i>	2097
Reply <i>Lone Troelsen, Peter Garred, Hans O. Madsen, and Søren Jacobsen</i>	2097
Corticosteroids in Preventing Severe Lupus Flares: Do All Patients Have the Same Risk? Comment on the Article by Tseng et al <i>José Luis Callejas-Rubio, Raquel Rios-Fernández, Cristina Tomás-Jiménez, and Norberto Ortego-Centeno</i> ..	2098
Reply <i>Chung-E Tseng, Jill P. Buyon, Mimi Kim, H. Michael Belmont, and Steven B. Abramson</i>	2099
Treatment of Patients With Neonatal-Onset Multisystem Inflammatory Disease/Chronic Infantile Neurologic, Cutaneous, Articular Syndrome: Comment on the Article by Matsubara et al <i>Raphaela Goldbach-Mansky, Frank Pucino, and Daniel L. Kastner</i>	2099
Reply <i>Tomoyo Matsubara, Masanari Hasegawa, Susumu Furukawa, and Hal M. Hoffman</i>	2101

Identification of Transition From Primary Raynaud's Phenomenon to Secondary Raynaud's Phenomenon by Nailfold Videocapillaroscopy: Comment on the Article by Hirschl et al <i>Maurizio Cutolo, Carmen Pizzorni, and Alberto Sulli</i>	2102
Reply <i>Mirko Hirschl and Michael Kundi</i>	2103
Clinical Images	
Rheumatoid Nodules in Synovium <i>Cesar Diaz-Torne, H. Ralph Schumacher, Eugene Einhorn, and Frank Pessler</i>	2104

VOLUME 56

JULY 2007

NO. 7

Special Articles

Editorial: The Efficacy of Glucosamine Sulfate in Osteoarthritis: Financial and Nonfinancial Conflict of Interest <i>Jean-Yves Reginster</i>	2105
Review: Interleukin-17 in Fashion, at Last: Ten Years After Its Description, Its Cellular Source Has Been Identified <i>Pierre Miossec</i>	2111
Review: Progressive Multifocal Leukoencephalopathy in Rheumatic Diseases: Evolving Clinical and Pathologic Patterns of Disease <i>Leonard H. Calabrese, Eamonn S. Molloy, DeRen Huang, and Richard M. Ransohoff</i>	2116

Rheumatoid Arthritis Clinical Studies

Infliximab and Methotrexate as Induction Therapy in Patients With Early Rheumatoid Arthritis <i>A. E. van der Bijl, Y. P. M. Goekoop-Ruiterman, J. K. de Vries-Bouwstra, S. ten Wolde, K. H. Han, M. V. van Krugten, C. F. Allaart, F. C. Breedveld, and B. A. C. Dijkmans</i>	2129
Resistance of Rheumatoid Arthritis Patients to Changing Therapy: Discordance Between Disease Activity and Patients' Treatment Choices <i>Frederick Wolfe and Kaleb Michaud</i>	2135
Association Between Serum Vitamin D Metabolite Levels and Disease Activity in Patients With Early Inflammatory Polyarthritis <i>Sanjeev Patel, Tracey Farragher, Jacqueline Berry, Diane Bunn, Alan Silman, and Deborah Symmons</i>	2143
Endogenous HLA-DR-Restricted Presentation of the Cartilage Antigens Human Cartilage gp-39 and Melanoma Inhibitory Activity in the Inflamed Rheumatoid Joint <i>M. J. C. van Lierop, L. den Hoed, J. Houbiers, J. Vencovsky, S. Ruzickova, O. Krystufkova, M. van Schaardenburg, F. van den Hoogen, B. Vandooren, D. Baeten, F. De Keyser, G. Sønderstrup, E. Bos, and A. M. Boots</i>	2150

Rheumatoid Arthritis Basic Science Studies

Effects of Infliximab Therapy on Gene Expression Levels of Tumor Necrosis Factor α , Tristetraprolin, T Cell Intracellular Antigen 1, and Hu Antigen R in Patients With Rheumatoid Arthritis <i>Makoto Sugihara, Akito Tsutsumi, Eiji Suzuki, Ei Wakamatsu, Takeshi Suzuki, Hiroshi Ogishima, Taichi Hayashi, Yusuke Chino, Wataru Ishii, Mizuko Mamura, Daisuke Goto, Isao Matsumoto, Satoshi Ito, and Takayuki Sumida</i>	2160
Angiopoietin 1 Directly Induces Destruction of the Rheumatoid Joint by Cooperative, but Independent, Signaling via ERK/MAPK and Phosphatidylinositol 3-Kinase/Akt <i>Akira Hashiramoto, China Sakai, Kohsuke Yoshida, Ken Tsumiyama, Yasushi Miura, Kazuko Shiozawa, Masato Nose, Koichiro Komai, and Shunichi Shiozawa</i>	2170
Inhibition of Forkhead Box Class O Family Member Transcription Factors in Rheumatoid Synovial Tissue <i>J. Ludikhuize, D. de Launay, D. Groot, T. J. M. Smeets, M. Vinkennoog, M. E. Sanders, S. W. Tas, P. P. Tak, and K. A. Reedquist</i>	2180
Increased Macrophage Activation Mediated Through Toll-like Receptors in Rheumatoid Arthritis <i>QiQuan Huang, Yingyu Ma, Adedamola Adebayo, and Richard M. Pope</i>	2192
Association of a Haplotype in the Promoter Region of the Interferon Regulatory Factor 5 Gene With Rheumatoid Arthritis <i>Snaevar Sigurdsson, Leonid Padyukov, Fina A. S. Kurreeman, Ulrika Liljedahl, Ann-Christin Wiman, Lars Alfredsson, René Toes, Johan Rönnelid, Lars Klareskog, Tom W. J. Huizinga, Gunnar Alm, Ann-Christine Syvänen, and Lars Rönnblom</i>	2202

Sjögren's Syndrome

Human Chorionic Gonadotropin Prevents Sjögren's Syndrome-Like Exocrinopathy in Mice

Na Li, Toshikatsu Shigihara, Athanasios G. Tzioufas, Abner L. Notkins, Ji-Won Yoon, and Hee-Sook Jun . 2211
Proteomic Study of Salivary Peptides and Proteins in Patients With Sjögren's Syndrome Before and After
Pilocarpine Treatment

G. Peluso, M. De Santis, R. Inzitari, C. Fanali, T. Cabras, I. Messina, M. Castagnola, and

G. F. Ferraccioli 2216

Sjögren's Syndrome Disease Damage Index and Disease Activity Index: Scoring Systems for the
Assessment of Disease Damage and Disease Activity in Sjögren's Syndrome, Derived From an Analysis
of a Cohort of Italian Patients

*Claudio Vitali, Gianluigi Palombi, Chiara Baldini, Maurizio Benucci, Stefano Bombardieri,
Michele Covelli, Nicoletta Del Papa, Salvatore De Vita, Oscar Epis, Franco Franceschini, Roberto Gerli,
Marcello Govoni, Susanna Maddali Bongi, Wanda Maglione, Sergio Migliaresi,*

Carlomaurizio Montecucco, Maddalena Orefice, Roberta Priori, Antonio Tavoni, and Guido Valesini 2223

Spondylarthritis

Two HLA-B*27 Alleles Differently Associated With Spondylarthritis, B*2709 and B*2705, Display Similar
Intracellular Trafficking and Oligomer Formation

Benoît Hacquet, Sophie Carmouse, Céline Denais, Aïcha Cherfa, Maria-Sole Chimenti, Ingrid Fert,

Cécile Hacquard-Bouder, Maxime Breban, and Claudine André 2232

Clinical Images

Iloprost-Induced Vascular Remodeling

Athina Pyrasopoulou and Spyros Aslanidis 2243

Experimental Arthritis

Interferon- γ Protects Against the Development of Structural Damage in Experimental Arthritis by
Regulating Polymorphonuclear Neutrophil Influx Into Diseased Joints

*Anwen S. Williams, Peter J. Richards, Eleri Thomas, Sara Carty, Mari A. Nowell, Rhian M. Goodfellow,
Colin M. Dent, Bryan D. Williams, Simon A. Jones, and Nicholas Topley* 2244

Antigen-Specific Suppression of Established Arthritis in Mice by Dendritic Cells Deficient in NF- κ B

*Ela Martin, Christelle Capini, Emily Duggan, Viviana P. Lutzky, Philip Stumbles, Allison R. Pettit,
Brendan O'Sullivan, and Ranjeny Thomas* 2255

Osteoarthritis

Glucosamine for Pain in Osteoarthritis: Why Do Trial Results Differ?

Steven C. Vlad, Michael P. LaValley, Timothy E. McAlindon, and David T. Felson 2267

Steroid Injection for Osteoarthritis of the Hip: A Randomized, Double-Blind, Placebo-Controlled Trial

*Robert G. W. Lambert, Edna J. Hutchings, Michael G. A. Grace, Gian S. Jhangri, Barbara Conner-Spady,
and Walter P. Maksymowych* 2278

The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Reduces the Development of
Cartilage Lesions in an Experimental Dog Model of Osteoarthritis: In Vivo Protective Effects Mediated
Through the Inhibition of Key Signaling and Catabolic Pathways

*Christelle Boileau, Johanne Martel-Pelletier, Hassan Fahmi, François Mineau, Martin Boily, and
Jean-Pierre Pelletier* 2288

Calcineurin Modulates the Catabolic and Anabolic Activity of Chondrocytes and Participates in the
Progression of Experimental Osteoarthritis

*Seung-Ah Yoo, Bo-Hyoung Park, Hyung-Ju Yoon, Joo-Yup Lee, Joo-Hyoun Song, Hyun Ah Kim,
Chul-Soo Cho, and Wan-Uk Kim* 2299

Cartilage Biology

Differential Regulation of Lubricin/Superficial Zone Protein by Transforming Growth Factor β /Bone
Morphogenetic Protein Superfamily Members in Articular Chondrocytes and Synovial Cells

Takahiro Niikura and A. Hari Reddi 2312

Calcium Signaling Leads to Mitochondrial Depolarization in Impact-Induced Chondrocyte Death in
Equine Articular Cartilage Explants

C. A. M. Huser and M. E. Davies 2322

Hsp90 Mediates Insulin-like Growth Factor 1 and Interleukin-1 β Signaling in an Age-Dependent Manner
in Equine Articular Chondrocytes

Amber K. Boehm, Mayank Seth, Karen G. Mayr, and Lisa A. Fortier 2335

Systemic Lupus Erythematosus

Clinical Criteria for Systemic Lupus Erythematosus Precede Diagnosis, and Associated Autoantibodies
Are Present Before Clinical Symptoms

*Latisha D. Heinlen, Micah T. McClain, Joan Merrill, Yasmin W. Akbarali, Colin C. Edgerton,
John B. Harley, and Judith A. James* 2344

Gonad Evaluation in Male Systemic Lupus Erythematosus <i>Pollyana Maria F. Soares, Eduardo Ferreira Borba, Eloisa Bonfa, Jorge Hallak, André Luiz Corrêa, and Clovis Artur A. Silva</i>	2352
Predominance of CD8+ T Lymphocytes Among Periglomerular Infiltrating Cells and Link to the Prognosis of Class III and Class IV Lupus Nephritis <i>Lionel Couzi, Pierre Merville, Colette Deminière, Jean-François Moreau, Christian Combe, Jean-Luc Pellegrin, Jean-François Viallard, and Patrick Blanco</i>	2362
Altered Gene Expression in Mice With Lupus Treated With Edratide, a Peptide That Ameliorates the Disease Manifestations <i>Anat Elmann, Amir Sharabi, Molly Dayan, Heidy Zinger, Ron Ophir, and Edna Mozes</i>	2371
Antiphospholipid Syndrome	
Aspirin for Primary Thrombosis Prevention in the Antiphospholipid Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial in Asymptomatic Antiphospholipid Antibody-Positive Individuals <i>Doruk Erkan, Melanie J. Harrison, Roger Levy, Margaret Peterson, Michelle Petri, Lisa Sammaritano, Aynur Unalp-Arida, Veronica Vilela, Yusuf Yazici, and Michael D. Lockshin</i>	2382
Arginine Mutation Alters Binding of a Human Monoclonal Antibody to Antigens Linked to Systemic Lupus Erythematosus and the Antiphospholipid Syndrome <i>Anastasia Lambrianides, Ian Giles, Yiannis Ioannou, Lesley Mason, David S. Latchman, Jessica J. Manson, David A. Isenberg, and Anisur Rahman</i>	2392
Childhood Arthritis	
Autoimmune Diseases in a Danish Cohort of 4,866 Carriers of Constitutional Structural Chromosomal Rearrangements <i>Iben Bache, Nete M. Nielsen, Klaus Rostgaard, Niels Tommerup, and Morten Frisch</i>	2402
Autologous Stem Cell Transplantation in Children With Severe Progressive Systemic or Polyarticular Juvenile Idiopathic Arthritis: Long-Term Followup of a Prospective Clinical Trial <i>D. M. C. Brinkman, I. M. de Kleer, R. ten Cate, M. A. J. van Rossum, W. P. Bekkering, A. Fasth, M. J. D. van Tol, W. Kuis, N. M. Wulffraat, and J. M. Vossen</i>	2410
Systemic Sclerosis	
Relationship Between Change in Skin Score and Disease Outcome in Diffuse Cutaneous Systemic Sclerosis: Application of a Latent Linear Trajectory Model <i>Lynne Shand, Mark Lunt, Svetlana Nihtyanova, Mansour Hoseini, Alan Silman, Carol M. Black, and Christopher P. Denton</i>	2422
Impairment of the Antifibrotic Effect of Hepatocyte Growth Factor in Lung Fibroblasts From African Americans: Possible Role in Systemic Sclerosis <i>Galina S. Bogatkevich, Anna Ludwicka-Bradley, Kristin B. Highland, Faye Hant, Paul J. Nietert, C. Beth Singleton, Carol A. Feghali-Bostwick, and Richard M. Silver</i>	2432
Evidence of Potential Interaction of Chemokine Genes in Susceptibility to Systemic Sclerosis <i>Eun Bong Lee, Jinying Zhao, Jeong Yeon Kim, Momiao Xiong, and Yeong Wook Song</i>	2443
C1D Is a Major Autoantibody Target in Patients With the Polymyositis-Scleroderma Overlap Syndrome <i>Geurt Schilders, Wilma Vree Egberts, Reinout Raijmakers, and Ger J. M. Pruijn</i>	2449
Clinical Images	
Myositis Ossificans of the Upper Extremity <i>Kyung-Su Park, Seok-Gu Kang, Chul-Soo Cho, and Ho-Youn Kim</i>	2454
Vasculitis	
Pathogenic Effects of Antimyeloperoxidase Antibodies in Patients With Microscopic Polyangiitis <i>Philippe Guilpain, Amélie Servettaz, Claire Goulvestre, Sandrine Barrieu, Didier Borderie, Christiane Chéreau, Niloufar Kavian, Christian Pagnoux, Loïc Guillevin, Bernard Weill, Luc Mouthon, and Frédéric Batteux</i>	2455
Concise Communication	
Up-Regulation of δ -Opioid Receptors and κ -Opioid Receptors in the Skin of Fibromyalgia Patients <i>Souzan Salemi, Andre Aeschlimann, Uwe Wollina, Renate E. Gay, Beat A. Michel, Steffen Gay, and Haiko Sprott</i>	2464
Clinical Images	
Takayasu Arteritis Diagnosed by Positron Emission Tomography <i>Kunihiro Yamaoka, Kazuyoshi Saito, Shingo Nakayamada, Makiko Yamamoto, and Yoshiya Tanaka</i>	2466

Letters

- The Usefulness of Subcutaneous Fat Tissue Aspiration Biopsy for Early Confirmation of Amyloidosis in Patients With Active Ankylosing Spondylitis: Comment on the Article by van Gameren et al
Kai Immonen, Heikki Helin, Kari Lehtinen, and Markku Hakala 2467
- Reply
Ingrid I. van Gameren, Bouke P. C. Hazenberg, Johan Bÿzet, and Martin H. van Rijswijk 2468

VOLUME 56

AUGUST 2007

NO. 8

Special Articles

- Editorial: Antiresorptive Agents and Osteoarthritis: More Than a Bone to Pick?
Steven B. Abramson and Stephen Honig 2469
- Editorial: Modern Molecular Analysis of a Traditional Disease: Progression in Osteoarthritis
Linda J. Sandell 2474
- Editorial: The Mystery of HLA-B27: If It Isn't One Thing, It's Another
Joel D. Taurog 2478
- Special Article: The Concept of a "Synovio-Enthesal Complex" and Its Implications for Understanding Joint Inflammation and Damage in Psoriatic Arthritis and Beyond
Dennis McGonagle, Rik J. U. Lories, Ai Lyn Tan, and Michael Benjamin 2482

Rheumatoid Arthritis

- Inflammation and Ectopic Lymphoid Structures in Rheumatoid Arthritis Synovial Tissues Dissected by Genomics Technology: Identification of the Interleukin-7 Signaling Pathway in Tissues With Lymphoid Neogenesis
Trienke C. G. Timmer, Belinda Baltus, Mark Vondenhoff, Tom W. J. Huizinga, Paul P. Tak, Cornelis L. Verweij, Reina E. Mebius, and Tineke C. T. M. van der Pouw Kraan 2492
- Mutation and Citrullination Modifies Vimentin to a Novel Autoantigen for Rheumatoid Arthritis
Holger Bang, Karl Egerer, Anke Gauliard, Kirsten LÛthke, Paul E. Rudolph, Gert Fredenhagen, Wigbert Berg, Eugen Feist, and Gerd-R. Burmester 2503
- Fractalkine Is a Novel Chemoattractant for Rheumatoid Arthritis Fibroblast-like Synoviocyte Signaling Through MAP Kinases and Akt
Michael V. Volin, Nha Huynh, Karolina Klosowska, Kyle K. Chong, and James M. Woods 2512
- Modulation of Interleukin-6 and Matrix Metalloproteinase 2 Expression in Human Fibroblast-like Synoviocytes by Functional Ionotropic Glutamate Receptors
Sophie Flood, Rheinallt Parri, Anwen Williams, Victor Duance, and Deborah Mason 2523
- In Vivo Inhibition of Angiogenesis by Interleukin-13 Gene Therapy in a Rat Model of Rheumatoid Arthritis
Christian S. Haas, M. Asif Amin, Jeffrey H. Ruth, Brittany L. Allen, Salahuddin Ahmed, Angela Pakozdi, James M. Woods, Shiva Shahrara, and Alisa E. Koch 2535
- Association of Interleukin-6 and Interleukin-10 Genotypes With Radiographic Damage in Rheumatoid Arthritis Is Dependent on Autoantibody Status
I. Marinou, J. Healy, D. Mewar, D. J. Moore, M. C. Dickson, M. H. Binks, D. S. Montgomery, K. Walters, and A. G. Wilson 2549
- Abatacept Treatment Does Not Exacerbate Chronic *Mycobacterium tuberculosis* Infection in Mice
Carolyn L. Bigbee, Daryl G. Gonchoroff, George Vratsanos, Steven G. Nadler, Helen G. Haggerty, and JoAnne L. Flynn 2557

Sjögren's Syndrome

- Modified Aquaporin 5 Expression and Distribution in Submandibular Glands From NOD Mice Displaying Autoimmune Exocrinopathy
Muhammad S. Soyfoo, Carine De Vriese, Huguette Debaix, Maria D. Martin-Martinez, Chantal Mathieu, Olivier Devuyt, Serge D. Steinfeld, and Christine Delporte 2566
- Low Salivary Dehydroepiandrosterone and Androgen-Regulated Cysteine-Rich Secretory Protein 3 Levels in Sjögren's Syndrome
Mikael Laine, Pauliina Porola, Lene Udby, Lars Kjeldsen, Jack B. Cowland, Niels Borregaard, Jarkko Hietanen, Mona Ståhle, Antti Pihakari, and Yrjö T. Kontinen 2575

Experimental Arthritis

- Pharmacologic Induction of Heme Oxygenase 1 Reduces Acute Inflammatory Arthritis in Mice
Mourad Benallaoua, Mathias François, Frédéric Batteux, Natacha Thelie, John Y.-J. Shyy, Catherine Fitting, Lydia Tsagris, Jorge Boczkowski, Jean-François Savouret, Marie-Thérèse Corvol, Serge Poiradeau, and François Rannou 2585
- Freund's Complete Adjuvant Induces Arthritis in Mice Lacking a Functional Interferon- γ Receptor by Triggering Tumor Necrosis Factor α -Driven Osteoclastogenesis
Lies Geboes, Bert De Klerck, Maarten Van Balen, Hilde Kelchtermans, Tania Mitera, Louis Boon, Chris De Wolf-Peters, and Patrick Matthys 2595
- Prostaglandin E₂ Exacerbates Collagen-Induced Arthritis in Mice Through the Inflammatory Interleukin-23/Interleukin-17 Axis
Amir F. Sheibanie, Tanzilya Khayrullina, Fayez F. Safadi, and Doina Ganea 2608
- Association of Arthritis With a Gene Complex Encoding C-Type Lectin-like Receptors
Johnny C. Lorentzen, Line Flornes, Carina Eklöw, Liselotte Bäckdahl, Ulrica Ribbhammar, Jian Ping Guo, Marina Smolnikova, Erik Dissen, Maria Seddighzadeh, Anthony J. Brookes, Lars Alfredsson, Lars Klareskog, Leonid Padyukov, and Sigbjörn Fossum 2620

Spondylarthritis

- A Common Genetic Background for Inflammatory Bowel Disease and Ankylosing Spondylitis: A Genealogic Study in Iceland
Bjarni Thjodleifsson, Árni J. Geirsson, Sigurdur Björnsson, and Ingvar Bjarnason 2633
- Identification of Previously Unrecognized Predisposing Factors for Ankylosing Spondylitis From Analysis of HLA-B27 Extended Haplotypes in Sardinia
Isabella Cascino, Fabiana Paladini, Francesca Belfiore, Alberto Cauli, Claudia Angelini, Maria Teresa Fiorillo, Alessandro Mathieu, and Rosa Sorrentino 2640
- Evidence That the p38 MAP Kinase Pathway Is Dysregulated in HLA-B27-Expressing Human Monocytic Cells: Correlation With HLA-B27 Misfolding
Anna S. Sahlberg, Markus A. Penttinen, Kaisa M. Heiskanen, Robert A. Colbert, Lea Sistonen, and Kaisa Granfors 2652

Osteoarthritis

- Increased Expression of the Collagen Receptor Discoidin Domain Receptor 2 in Articular Cartilage as a Key Event in the Pathogenesis of Osteoarthritis
Lin Xu, Haibing Peng, Sonya Glasson, Peter L. Lee, Kenpan Hu, Kosei Ijiri, Bjorn R. Olsen, Mary B. Goldring, and Yefu Li 2663

Cartilage Biology

- The Effect of Oral Calcitonin on Cartilage Turnover and Surface Erosion in an Ovariectomized Rat Model
Bodil-Cecilie Sondergaard, Svetlana Oestergaard, Claus Christiansen, Laszlo B. Tankó, and Morten Asger Karsdal 2674

Systemic Lupus Erythematosus

- Clinical and Genetic Risk Factors for Pneumonia in Systemic Lupus Erythematosus
Brent W. Kinder, Michelle M. Freemer, Talmadge E. King, Jr., Raymond F. Lum, Joanne Nititham, Kim Taylor, Jeffrey C. Edberg, S. Louis Bridges, Jr., and Lindsey A. Criswell 2679
- Anti- β_2 -Glycoprotein I Antibodies Induce Monocyte Release of Tumor Necrosis Factor α and Tissue Factor by Signal Transduction Pathways Involving Lipid Rafts
Maurizio Sorice, Agostina Longo, Antonella Capozzi, Tina Garofalo, Roberta Misasi, Cristiano Alessandri, Fabrizio Conti, Brigitta Buttari, Rachele Riganò, Elena Ortona, and Guido Valesini 2687

Psoriasis

- Infliximab Inhibits Progression of Radiographic Damage in Patients With Active Psoriatic Arthritis Through One Year of Treatment: Results From the Induction and Maintenance Psoriatic Arthritis Clinical Trial 2
D. van der Heijde, A. Kavanaugh, D. D. Gladman, C. Antoni, G. G. Krueger, C. Guzzo, B. Zhou, L. T. Dooley, K. de Vlam, P. Geusens, C. Birbara, D. Halter, and A. Beutler, for the IMPACT 2 Study Group 2698
- Improved Survival in Psoriatic Arthritis With Calendar Time
Yaser Ali, Brian D. M. Tom, Catherine T. Schentag, Vernon T. Farewell, and Dafna D. Gladman 2708
- Development of Psoriasis After B Cell Depletion With Rituximab
Shouvik Dass, Edward M. Vital, and Paul Emery 2715

Childhood Arthritis

- Seasonal Birth Patterns in Myositis Subgroups Suggest an Etiologic Role of Early Environmental Exposures
Leora J. Vegosen, Clarice R. Weinberg, Terrance P. O'Hanlon, Ira N. Targoff, Frederick W. Miller, and Lisa G. Rider 2719

Myositis

Novel Conformation of Histidyl-Transfer RNA Synthetase in the Lung: The Target Tissue in Jo-1 Autoantibody-Associated Myositis

Stuart M. Levine, Nina Raben, Dan Xie, Frederic B. Askin, Rubin Tudor, Marissa Mullins, Antony Rosen, and Livia A. Casciola-Rosen 2729

Systemic Sclerosis

Clinical Subsets, Skin Thickness Progression Rate, and Serum Antibody Levels in Systemic Sclerosis Patients With Anti-Topoisomerase I Antibody

Achini Perera, Noreen Fertig, Mary Lucas, Tatiana S. Rodriguez-Reyna, Paul Hu, Virginia D. Steen, and Thomas A. Medsger, Jr. 2740

Hand Vascular Involvement Assessed by Magnetic Resonance Angiography in Systemic Sclerosis

Y. Allanore, R. Seror, A. Chevrot, A. Kahan, and J. L. Drapé 2747

Trichostatin A Prevents the Accumulation of Extracellular Matrix in a Mouse Model of

Bleomycin-Induced Skin Fibrosis

Lars C. Huber, Jörg H. W. Distler, Falk Moritz, Hossein Hemmatazad, Thomas Hauser, Beat A. Michel, Renate E. Gay, Marco Matucci-Cerinic, Steffen Gay, Oliver Distler, and Astrid Jüngel 2755

Autoinflammatory Disease

Mutant Tumor Necrosis Factor Receptor Associated With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome Is Altered Antigenically and Is Retained Within Patients' Leukocytes

Ian Todd, Paul M. Radford, Noura Daffa, Susan E. Bainbridge, Richard J. Powell, and Patrick J. Tighe 2765

Late-Onset Tumor Necrosis Factor Receptor-Associated Periodic Syndrome in Multiple Sclerosis

Patients Carrying the TNFRSF1A R92Q Mutation

Tania Kümpfel, Lisa-Ann Hoffmann, Heike Rübsamen, Walter Pöllmann, Wolfgang Feneberg, Reinhard Hohlfeld, and Peter Lohse 2774

An Unexpectedly High Frequency of MEFV Mutations in Patients With Anti-Citrullinated Protein Antibody-Negative Palindromic Rheumatism

Juan D. Cañete, Juan I. Arostegui, Rubén Queiró, Jordi Gratacós, M. Victoria Hernández, Marta Larrosa, Mercedes Alperí, Conchita Moll, Josefa Rius, Raimon Sanmartí, and Jordi Yagüe 2784

Vasculitis

Adjunctive Methotrexate for Treatment of Giant Cell Arteritis: An Individual Patient Data

Meta-Analysis

Alfred D. Mahr, Juan A. Jover, Robert F. Spiera, César Hernández-García, Benjamin Fernández-Gutiérrez, Michael P. LaValley, and Peter A. Merkel 2789

Reactivity of γ/δ T Cells to Human 60-kd Heat-Shock Protein and Their Cytotoxicity to Aortic

Endothelial Cells in Takayasu Arteritis

Sunil Kumar Chauhan, Mahavir Singh, and Soniya Nityanand 2798

Clinical Images

Earth, Moon, and Stars in a Patient With Gouty Arthritis

Ji Hyeon Ju, Ho-Youn Kim, and Sung-Hwan Park 2802

Concise Communications

A Polymorphism in Human Platelet Antigen 6b and Risk of Thrombocytopenia in Patients With Systemic Lupus Erythematosus

Olga Amengual, Tatsuya Atsumi, Yukiko Komano, Hiroshi Kataoka, Tetsuya Horita, Shinsuke Yasuda, and Takao Koike 2803

The HLA-B*2709 Subtype in a Woman with Early Ankylosing Spondylitis

Ignazio Olivieri, Salvatore D'Angelo, Enrico Scarano, Vincenzo Santospirito, and Angela Padula 2805

A Sardinian Patient With Ankylosing Spondylitis and HLA-B*2709 Co-Occurring With HLA-B*1403

Alberto Cauli, Alessandra Vacca, Antonella Mameli, Giuseppe Passiu, Maria Teresa Fiorillo, Rosa Sorrentino, and Alessandro Mathieu 2807

Clinical Image

Dual-Energy Computed Tomographic Molecular Imaging of Gout

Thorsten R. C. Johnson, Sabine Weckbach, Herbert Kellner, Maximilian F. Reiser, and Christoph R. Becker 2809

Letters

Antiviral Therapy for Cryoglobulinemic Neuropathy: Comment on the Article by Saadoun et al

Franco Gemignani, Francesca Brindani, and Adriana Marbini 2810

Reply

David Saadoun, Jean-Charles Piette, and Patrice Cacoub 2810

Thrombocytopenia as a Prognostic Factor in Hispanic Patients With Systemic Lupus Erythematosus: Comment on the Article by Fernández et al <i>Cristina Drenkard and Antonio R. Villa</i>	2811
Reply <i>Mónica Fernández, Graciela S. Alarcón, Luis M. Vilá, and John D. Reveille</i>	2812
The Validity of the Inclusion of "Lupus Headache" in the Systemic Lupus Erythematosus Disease Activity Index <i>Richard Davey, John Bamford, and Paul Emery</i>	2812
Antibodies to Bovine Serum Albumin Do Not Affect the Results of Enzyme-Linked Immunosorbent Assays for IgG Anti-NR2 Glutamate Receptor Antibodies: Reply to the Letter by Hirohata et al <i>Taku Yoshio, Hiroshi Okamoto, and Seiji Minota</i>	2813
ACR Announcements	A16

VOLUME 56

SEPTEMBER 2007

NO. 9

Special Articles

Editorial: The Future of Pediatric Rheumatology: Many Questions Remain <i>Thomas J. A. Lehman</i>	2815
Editorial: Mutations in Cryopyrin: Bypassing Roadblocks in the Caspase 1 Inflammasome for Interleukin-1 β Secretion and Disease Activity <i>Charles A. Dinarello</i>	2817
Editorial: Systemic Humoral Autoimmunity but Joint-Specific Inflammation: The Syndrome of Rheumatoid Arthritis <i>Xiaobo Wu, Fei Shih, and John P. Atkinson</i>	2823

Rheumatoid Arthritis Basic Science Studies

Pre-B Cell Colony-Enhancing Factor/Visfatin, a New Marker of Inflammation in Rheumatoid Arthritis With Proinflammatory and Matrix-Degrading Activities <i>Fabia Brentano, Olivier Schorr, Caroline Ospelt, Joanna Stanczyk, Renate E. Gay, Steffen Gay, and Diego Kyburz</i>	2829
Protein Isoprenylation Regulates Secretion of Matrix Metalloproteinase 1 From Rheumatoid Synovial Fibroblasts: Effects of Statins and Farnesyl and Geranylgeranyl Transferase Inhibitors <i>Aryeh M. Abeles, Nada Marjanovic, Jean Park, Mukundan Attur, Edwin S. Chan, Hayfez Al-Mussawir, Mandar Dave, Mark C. Fisher, Steven A. Stuchin, Steven B. Abramson, and Michael H. Pillinger</i>	2840
Regulation of Apoptosis in Fibroblast-like Synoviocytes by the Hypoxia-Induced Bcl-2 Family Member Bcl-2/Adenovirus E1B 19-kd Protein-Interacting Protein 3 <i>Wafa Kammouni, Keng Wong, Guoping Ma, Gary S. Firestein, Spencer B. Gibson, and Hani S. El-Gabalawy</i>	2854
Differential Regulation of Matrix Metalloproteinase 2 and Matrix Metalloproteinase 9 by Activated Protein C: Relevance to Inflammation in Rheumatoid Arthritis <i>Meilang Xue, Lyn March, Philip N. Sambrook, and Christopher J. Jackson</i>	2864
Development of an Ex Vivo Cellular Model of Rheumatoid Arthritis: Critical Role of CD14-Positive Monocyte/Macrophages in the Development of Pannus Tissue <i>Toshiko Nozaki, Kyoko Takahashi, Osamu Ishii, Sachio Endo, Kyoji Hioki, Toshihito Mori, Tadahiro Kikukawa, Dimitrios T. Boumpas, Shoichi Ozaki, and Hidehiro Yamada</i>	2875

Rheumatoid Arthritis Clinical Studies

Biologic Treatment of Rheumatoid Arthritis and the Risk of Malignancy: Analyses From a Large US Observational Study <i>Frederick Wolfe and Kaleb Michaud</i>	2886
Serious Infection Following Anti-Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis: Lessons From Interpreting Data From Observational Studies <i>W. G. Dixon, D. P. M. Symmons, M. Lunt, K. D. Watson, K. L. Hyrich, British Society for Rheumatology Biologics Register Control Centre Consortium, and A. J. Silman, on behalf of the British Society for Rheumatology Biologics Register</i>	2896

Reduction in the Incidence of Myocardial Infarction in Patients With Rheumatoid Arthritis Who Respond to Anti-Tumor Necrosis Factor α Therapy: Results From the British Society for Rheumatology Biologics Register <i>W. G. Dixon, K. D. Watson, M. Lunt, K. L. Hyrich, British Society for Rheumatology Biologics Register Control Centre Consortium, A. J. Silman, and D. P. M. Symmons, on behalf of the British Society for Rheumatology Biologics Register</i>	2905
Association of Smoking With the Constitution of the Anti-Cyclic Citrullinated Peptide Response in the Absence of HLA-DRB1 Shared Epitope Alleles <i>K. N. Verpoort, E. A. M. Papendrecht-van der Voort, A. H. M. van der Helm-van Mil, C. M. Jol-van der Zijde, M. J. D. van Tol, J. W. Drijfhout, F. C. Breedveld, R. R. P. de Vries, T. W. J. Huizinga, and R. E. M. Toes</i>	2913
Early Changes in Serum Type II Collagen Biomarkers Predict Radiographic Progression at One Year in Inflammatory Arthritis Patients After Biologic Therapy <i>Ronan H. Mullan, Clare Matthews, Barry Bresnihan, Oliver FitzGerald, Lindsay King, A. Robin Poole, Ursula Fearon, and Douglas J. Veale</i>	2919
The Performance of Anti-Cyclic Citrullinated Peptide Antibodies in Predicting the Severity of Radiologic Damage in Inflammatory Polyarthritis: Results from the Norfolk Arthritis Register <i>M. Bukhari, W. Thomson, H. Naseem, D. Bunn, A. Silman, D. Symmons, and A. Barton</i>	2929
Immunology	
Distinct Regulation of Interleukin-17 in Human T Helper Lymphocytes <i>Zhi Chen, Cristina M. Tato, Linda Muul, Arian Laurence, and John J. O'Shea</i>	2936
Experimental Arthritis	
Enhanced Efficacy of Regulatory T Cell Transfer Against Increasing Resistance, by Elevated Foxp3 Expression Induced in Arthritic Murine Hosts <i>Junko Ohata, Tomoko Miura, Todd A. Johnson, Shohei Hori, Steven F. Ziegler, and Hitoshi Kohsaka</i>	2947
Inhibition of Toll-like Receptor 4 Breaks the Inflammatory Loop in Autoimmune Destructive Arthritis <i>Shahla Abdollahi-Roodsaz, Leo A. B. Joosten, Mieke F. Roelofs, Timothy R. D. J. Radstake, Giovanni Matera, Calin Popa, Jos W. M. van der Meer, Mihai G. Netea, and Wim B. van den Berg</i>	2957
Circulating C3 Is Necessary and Sufficient for Induction of Autoantibody-Mediated Arthritis in a Mouse Model <i>Paul A. Monach, Admar Verschoor, Jonathan P. Jacobs, Michael C. Carroll, Amy J. Wagers, Christophe Benoist, and Diane Mathis</i>	2968
Targeting of Gr-1+, CCR2+ Monocytes in Collagen-Induced Arthritis <i>Hilke Brühl, Josef Cihak, Jiří Plachý, Leoni Kunz-Schughart, Marianne Niedermeier, Andrea Denzel, Manuel Rodriguez Gomez, Yvonne Talke, Bruno Luckow, Manfred Stangassinger, and Matthias Mack</i>	2975
Osteoarthritis	
Correlation of the Development of Knee Pain With Enlarging Bone Marrow Lesions on Magnetic Resonance Imaging <i>David T. Felson, Jingbo Niu, Ali Guermazi, Frank Roemer, Piran Aliabadi, Margaret Clancy, James Torner, C. Elizabeth Lewis, and Michael C. Nevitt</i>	2986
Varus Foot Alignment and Hip Conditions in Older Adults <i>K. Douglas Gross, Jingbo Niu, Yu Qing Zhang, David T. Felson, Christine McLennan, Marian T. Hannan, Kenneth G. Holt, and David J. Hunter</i>	2993
Inverse Relationship Between Matrix Remodeling and Lipid Metabolism During Osteoarthritis Progression in the STR/Ort Mouse <i>James W. Watters, Chun Cheng, Maureen Pickarski, Gregg A. Wesolowski, Ya Zhuo, Tadashi Hayami, Wei Wang, John Szumiloski, Robert L. Phillips, and Le T. Duong</i>	2999
Cartilage Biology	
Low Molecular Weight Isoforms of the Aggrecanases Are Responsible for the Cytokine-Induced Proteolysis of Aggrecan in a Porcine Chondrocyte Culture System <i>Alison J. Powell, Christopher B. Little, and Clare E. Hughes</i>	3010
Interleukin-1 β Impairment of Transforming Growth Factor β 1 Signaling by Down-Regulation of Transforming Growth Factor β Receptor Type II and Up-Regulation of Smad7 in Human Articular Chondrocytes <i>C. Baugé, F. Legendre, S. Leclercq, J. M. Elissalde, J. P. Pujol, P. Galéra, and K. Boumédiène</i>	3020
Enhanced Integrative Repair of the Porcine Meniscus In Vitro by Inhibition of Interleukin-1 or Tumor Necrosis Factor α <i>Amy L. McNulty, Franklin T. Moutos, J. Brice Weinberg, and Farshid Guilak</i>	3033
Clinical Image	
Bamboo Spine in a Patient With Ankylosing Spondylitis <i>Ji Hyeon Ju, Ho-Youn Kim, and Sung-Hwan Park</i>	3043

Systemic Lupus Erythematosus

- Delayed Memory B Cell Recovery in Peripheral Blood and Lymphoid Tissue in Systemic Lupus Erythematosus After B Cell Depletion Therapy
Jennifer H. Anolik, Jennifer Barnard, Teresa Owen, Bo Zheng, Sunil Kemshetti, R. John Looney, and Iñaki Sanz 3044
- CD19 Hyperexpression Augments *Sle1*-Induced Humoral Autoimmunity but Not Clinical Nephritis
Xiaoyan Shi, Chun Xie, Sooghee Chang, Xin J. Zhou, Thomas Tedder, and Chandra Mohan 3057
- Menopause Hormonal Therapy in Women With Systemic Lupus Erythematosus
Jorge Sánchez-Guerrero, Marisol González-Pérez, Marta Durand-Carbajal, Pilar Lara-Reyes, Luisa Jiménez-Santana, Juanita Romero-Díaz, and María-del-Carmen Cravioto 3070

Childhood Arthritis

- Association of a CD24 Gene Polymorphism With Susceptibility to Systemic Lupus Erythematosus
Elena Sánchez, Anna-Karin Abelson, Jose M. Sabio, Miguel A. González-Gay, Norberto Ortego-Centeno, Juan Jiménez-Alonso, Enrique de Ramón, Julio Sánchez-Román, Miguel A. López-Nevot, Iva Gunnarsson, Elisabet Svenungsson, Gunnar Sturfelt, Lennart Truedsson, Andreas Jönsen, Maria Francisca González-Escribano, Torsten Witte and the German Systemic Lupus Erythematosus Study Group, Marta E. Alarcón-Riquelme, and Javier Martín 3080
- Adapted Versions of the Sharp/van der Heijde Score Are Reliable and Valid for Assessment of Radiographic Progression in Juvenile Idiopathic Arthritis
Angelo Ravelli, Maka Ioseliani, Ximena Norambuena, Juliana Sato, Angela Pistorio, Federica Rossi, Nicolino Ruperto, Silvia Magni-Manzoni, Nicola Ullmann, and Alberto Martini 3087
- A Randomized, Placebo-Controlled Trial of Infliximab Plus Methotrexate for the Treatment of Polyarticular-Course Juvenile Rheumatoid Arthritis
Nicolino Ruperto, Daniel J. Lovell, Ruben Cuttica, Nick Wilkinson, Patricia Woo, Graciela Espada, Carine Wouters, Earl D. Silverman, Zsolt Balogh, Michael Henrickson, Maria-Teresa Apaz, Eileen Baildam, Anders Fasth, Valeria Gerloni, Pekka Lahdenne, Anne-Marie Prieur, Angelo Ravelli, Rotraud K. Saurenmann, Maria Luz Gamir, Nico Wulffraat, Laszlo Marodi, Ross E. Petty, Rik Joos, Francesco Zulian, Deborah McCurdy, Barry L. Myones, Kalman Nagy, Peter Reuman, Ilona Szer, Suzanne Travers, Anna Beutler, Greg Keenan, Jason Clark, Sudha Visvanathan, Adedigbo Fasanmade, Aparna Raychaudhuri, Alan Mendelsohn, Alberto Martini, and Edward H. Giannini, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group 3096
- Rituximab for the Treatment of Juvenile Dermatomyositis: A Report of Four Pediatric Patients
Megan A. Cooper, Donna L. Willingham, Diane E. Brown, Anthony R. French, Fei F. Shih, and Andrew J. White 3107

Myositis

- A Possible Mechanism for Endogenous Activation of the Type I Interferon System in Myositis Patients With Anti-Jo-1 or Anti-Ro 52/Anti-Ro 60 Autoantibodies
Maija-Leena Eloranta, Sevim Barbasso Helmers, Ann-Kristin Ulfgrén, Lars Rönnblom, Gunnar V. Alm, and Ingrid E. Lundberg 3112
- Anti-Jo-1 Antibody Levels Correlate With Disease Activity in Idiopathic Inflammatory Myopathy
Kerry B. Stone, Chester V. Oddis, Noreen Fertig, Yasuhiro Katsumata, Mary Lucas, Molly Vogt, Robyn Domsic, and Dana P. Ascherman 3125
- Identification of a Novel Autoantibody Directed Against Small Ubiquitin-like Modifier Activating Enzyme in Dermatomyositis
Zoë Betteridge, Harsha Gunawardena, Jean North, Jenna Slinn, and Neil McHugh 3132

Autoinflammatory Disease

- Pattern of Interleukin-1 β Secretion in Response to Lipopolysaccharide and ATP Before and After Interleukin-1 Blockade in Patients With *CIAS1* Mutations
Marco Gattorno, Sara Tassi, Sonia Carta, Laura Delfino, Francesca Ferlito, Maria Antonietta Pelagatti, Andrea D'Ossualdo, Antonella Buoncompagni, Maria Giannina Alpigiani, Maria Alessio, Alberto Martini, and Anna Rubartelli 3138

Vasculitis

- Febrile Temperatures Control Antineutrophil Cytoplasmic Autoantibody-Induced Neutrophil Activation via Inhibition of Phosphatidylinositol 3-Kinase/Akt
Sibylle von Vietinghoff, Mira Choi, Susanne Rolle, Friedrich C. Luft, and Ralph Kettritz 3149
- HLA-DRB4 as a Genetic Risk Factor for Churg-Strauss Syndrome
Augusto Vaglio, Davide Martorana, Umberto Maggiore, Chiara Grasselli, Adele Zanetti, Alberto Pesci, Giovanni Garini, Paolo Manganelli, Paolo Bottero, Bruno Tumati, Renato A. Sinico, Mario Savi, Carlo Buzio, and Tauro M. Neri, on behalf of the Secondary and Primary Vasculitis Study Group 3159

Concise Communications

- B Cell Infiltration in Systemic Sclerosis–Associated Interstitial Lung Disease
Robert Lafyatis, Carl O'Hara, Carol A. Feghali-Bostwick, and Eric Matteson..... 3167
- Meta-Analysis Evidence of a Differential Risk of the FCRL3 –169T→C Polymorphism in White and East Asian Rheumatoid Arthritis Patients
Ann B. Begovich, Monica Chang, and Steven J. Schrodi 3168

Letter

- Suppressive Treatment of Calcium Pyrophosphate Deposition Disease
Bruce Rothschild 3172

Erratum

- Errors in Name of Granting Agency and in Author Academic Degrees in Article by Soyfoo et al (Arthritis Rheum, August 2007)..... 3172

- ACR Announcements A16

VOLUME 56

SEPTEMBER SUPPLEMENT 2007

NO. 9

Annual Scientific Meetings of the American College of Rheumatology and the Association of Rheumatology Health Professionals S1

VOLUME 56

OCTOBER 2007

NO. 10

Special Articles

- Editorial: Nephrogenic Systemic Fibrosis and Gadolinium Exposure: Association and Lessons for Idiopathic Fibrosing Disorders
Shawn E. Cowper, Phillip H. Kuo, and Richard Bucala..... 3173
- Editorial: Molecular Basis of the Interaction of Inflammation and Exercise: Keep on Walking!
Theodore R. Oegema 3176
- Editorial: T Cells and the Loss of Immunologic Tolerance in Sjögren's Syndrome and Systemic Lupus Erythematosus
Robert W. Hoffman..... 3180
- Review: The Role of Interleukin-1 and the Inflammasome in Gout: Implications for Therapy
Richard M. Pope and Jürg Tschopp..... 3183

Epidemiology

- Systemic Autoimmune Disease Mortality and Occupational Exposures
L. S. Gold, M. H. Ward, M. Dosemeci, and A. J. De Roos 3189

Editor's Note

- Circumstances in Which Publication of Material Previously Published as an "Abstract" Will Be Considered Duplicate Publication..... 3201

Rheumatoid Arthritis

- BAFF Synthesis by Rheumatoid Synoviocytes Is Positively Controlled by $\alpha 5 \beta 1$ Integrin Stimulation and Is Negatively Regulated by Tumor Necrosis Factor α and Toll-like Receptor Ligands
Ghada Alsaleh, Laurent Messer, Noha Semaan, Nathalie Boulanger, Jacques-Eric Gottenberg, Jean Sibilia, and Dominique Wachsmann 3202
- Fractalkine Mediates T Cell–Dependent Proliferation of Synovial Fibroblasts in Rheumatoid Arthritis
Hirokazu Sawai, Yong W. Park, Xiaowen He, Jörg J. Goronzy, and Cornelia M. Weyand 3215
- Disease Activity Early in the Course of Treatment Predicts Response to Therapy After One Year in Rheumatoid Arthritis Patients
Daniel Aletaha, Julia Funovits, Edward C. Keystone, and Josef S. Smolen 3226
- Biomarkers Predict Radiographic Progression in Early Rheumatoid Arthritis and Perform Well Compared With Traditional Markers
Steven Young-Min, Tim Cawston, Nicola Marshall, David Coady, Stephan Christgau, Tore Saxne, Simon Robins, and Ian Griffiths..... 3236

Do Tumor Necrosis Factor Inhibitors Cause Uveitis? A Registry-Based Study <i>Lyndell L. Lim, Frederick W. Fraunfelder, and James T. Rosenbaum</i>	3248
Experimental Arthritis	
Blocking of Experimental Arthritis by Cleavage of IgG Antibodies In Vivo <i>Kutty Selva Nandakumar, Björn P. Johansson, Lars Björck, and Rikard Holmdahl</i>	3253
Role of Raloxifene as a Potent Inhibitor of Experimental Postmenopausal Polyarthritis and Osteoporosis <i>Caroline Jochems, Ulrika Islander, Anna Kallkopf, Marie Lagerquist, Claes Ohlsson, and Hans Carlsten</i>	3261
Clinical Images	
Polymyositis and Vasculitis <i>Jeremy S. Youse, Samar Harris, and Harris V. K. Naina</i>	3270
Inflammation	
CXCR5- and CCR7-Dependent Lymphoid Neogenesis in a Murine Model of Chronic Antigen-Induced Arthritis <i>Antje M. Wengner, Uta E. Höpken, Peter K. Petrow, Sven Hartmann, Uta Schurigt, Rolf Bräuer, and Martin Lipp</i>	3271
Cartilage Biology	
Biomechanical Signals Inhibit IKK Activity to Attenuate NF- κ B Transcription Activity in Inflamed Chondrocytes <i>Anar Dossumbekova, Mirela Anghelina, Shashi Madhavan, Lingli He, Ning Quan, Thomas Knobloch, and Sudha Agarwal</i>	3284
Hypoxia-Inducible Factor 2 α Is Essential for Hypoxic Induction of the Human Articular Chondrocyte Phenotype <i>Jérôme E. Lafont, Sonia Talma, and Christopher L. Murphy</i>	3297
Water-Soluble C60 Fullerene Prevents Degeneration of Articular Cartilage in Osteoarthritis Via Down-Regulation of Chondrocyte Catabolic Activity and Inhibition of Cartilage Degeneration During Disease Development <i>Kazuo Yudoh, Kiyoshi Shishido, Hideki Murayama, Mitsunobu Yano, Kenji Matsubayashi, Hiroya Takada, Hiroshi Nakamura, Kayo Masuko, Tomohiro Kato, and Kusuki Nishioka</i>	3307
Osteoarthritis	
Wnt Signaling Antagonists Are Potential Prognostic Biomarkers for the Progression of Radiographic Hip Osteoarthritis in Elderly Caucasian Women <i>Nancy E. Lane, Michael C. Nevitt, Li-Yung Lui, Patricia de Leon, and Maripat Corr, for the Study of Osteoporotic Fractures Research Group</i>	3319
Neutrophil Gelatinase-Associated Lipocalin Is Expressed in Osteoarthritis and Forms a Complex With Matrix Metalloproteinase 9 <i>Kalpna Gupta, Meenakshi Shukla, Jack B. Cowland, Charles J. Malesud, and Tariq M. Haqqi</i>	3326
The Chemical Biomarkers C2C, Coll2-1, and Coll2-1NO ₂ Provide Complementary Information on Type II Collagen Catabolism in Healthy and Osteoarthritic Mice <i>L. G. Ameye, M. Deberg, M. Oliveira, A. Labasse, J. M. Aeschlimann, and Y. Henrotin</i>	3336
Central Role of the MEK/ERK MAP Kinase Pathway in a Mouse Model of Rheumatoid Arthritis: Potential Proinflammatory Mechanisms <i>Melissa J. Thiel, Caralee J. Schaefer, Mark E. Lesch, James L. Mobley, David T. Dudley, Haile Tecle, Stephen D. Barrett, Denis J. Schrier, and Craig M. Flory</i>	3347
Prevention of Cartilage Destruction With Intraarticular Osteoclastogenesis Inhibitory Factor/Osteoprotegerin in a Murine Model of Osteoarthritis <i>Sadanori Shimizu, Yoshinori Asou, Soichiro Itoh, Ung-il Chung, Hiroshi Kawaguchi, Kenichi Shinomiya, and Takeshi Muneta</i>	3358
Role of Subchondral Bone in Osteoarthritis Development: A Comparative Study of Two Strains of Guinea Pigs With and Without Spontaneously Occurring Osteoarthritis <i>Tomoya Muraoka, Hiroshi Hagino, Toru Okano, Makoto Enokida, and Ryota Teshima</i>	3366
Systemic Lupus Erythematosus	
Variation in the Relative Copy Number of the TLR7 Gene in Patients With Systemic Lupus Erythematosus and Healthy Control Subjects <i>James Kelley, Martin R. Johnson, Graciela S. Alarcón, Robert P. Kimberly, and Jeffrey C. Edberg</i>	3375
In Vivo Adjuvant Activity of the RNA Component of the Sm/RNP Lupus Autoantigen <i>Kindra M. Kelly-Scumpia, Dina C. Nacionales, Philip O. Scumpia, Jason S. Weinstein, Sonali Narain, Lyle L. Moldawer, Minoru Satoh, and Westley H. Reeves</i>	3379
T Cell Epitopes of the La/SSB Autoantigen in Humanized Transgenic Mice Expressing the HLA Class II Haplotype DRB1*0301/DQB1*0201 <i>Nadine L. Dudek, Shannon Maier, Zhen-Jun Chen, Philip A. Mudd, Stuart I. Mannering, David C. Jackson, Weiguang Zeng, Catherine L. Keech, Kassie Hamlin, Zi-jian Pan,</i>	

<i>Karen Davis-Schwarz, Jennifer Workman-Azbill, Michael Bachmann, James McCluskey, and A. Darise Farris</i>	3387
Opsonization of Late Apoptotic Cells by Systemic Lupus Erythematosus Autoantibodies Inhibits Their Uptake via an Fcγ Receptor-Dependent Mechanism	
<i>Esther Reefman, Gerda Horst, Marije T. Nijk, Pieter C. Limburg, Cees G. M. Kallenberg, and Marc Bijl</i>	3399
Rate and Determinants of Progression of Atherosclerosis in Systemic Lupus Erythematosus	
<i>Mary J. Roman, Mary K. Crow, Michael D. Lockshin, Richard B. Devereux, Stephen A. Paget, Lisa Sammaritano, Daniel M. Levine, Adrienne Davis, and Jane E. Salmon</i>	3412
Characterization of Discriminant Human Brain Antigenic Targets in Neuropsychiatric Systemic Lupus Erythematosus Using an Immunoproteomic Approach	
<i>Didier Lefranc, David Launay, Sylvain Dubucquoi, Jérôme de Seze, Patricia Dussart, Marie Vermersch, Eric Hachulla, Pierre-Yves Hatron, Patrick Vermersch, Luc Mouthon, and Lionel Prin</i>	3420
Clinical Image	
Popliteal Artery Pseudoaneurysm Following Arthroscopic Synovectomy	
<i>Bora Lee, Sung-Won Park, Jong-Chun Nah, Seung-Woo Kim, Bon-Il Koo, Wook-Hyun Cho, Jung-Ju Sir, and Suk-Koo Choi</i>	3432
Systemic Sclerosis and Scleroderma-like Syndromes	
Cutaneous Changes of Nephrogenic Systemic Fibrosis: Predictor of Early Mortality and Association With Gadolinium Exposure	
<i>Derrick J. Todd, Anna Kagan, Lori B. Chibnik, and Jonathan Kay</i>	3433
Severe Fibrosis and Increased Expression of Fibrogenic Cytokines in the Gastric Wall of Systemic Sclerosis Patients	
<i>Mirko Manetti, Elena Neumann, Anna Franca Milia, Ingo H. Tarner, Paolo Bechi, Marco Matucci-Cerinic, Lidia Ibba-Manneschi, and Ulf Müller-Ladner</i>	3442
Antiangiogenic Plasma Activity in Patients With Systemic Sclerosis	
<i>Mary Jo Mulligan-Kehoe, Mary C. Drinane, Jessica Mollmark, Livia Casciola-Rosen, Laura K. Hummers, Amy Hall, Antony Rosen, Fredrick M. Wigley, and Michael Simons</i>	3448
Presence of CD4+CD8+ Double-Positive T Cells With Very High Interleukin-4 Production Potential in Lesional Skin of Patients With Systemic Sclerosis	
<i>Yann Parel, Michel Aurrand-Lions, Agneta Scheja, Jean-Michel Dayer, Eddy Roosnek, and Carlo Chizzolini</i>	3459
Down-Regulation of Collagen and Connective Tissue Growth Factor Expression With Hepatocyte Growth Factor in Lung Fibroblasts From White Scleroderma Patients via Two Signaling Pathways	
<i>Galina S. Bogatkevich, Anna Ludwicka-Bradley, Kristin B. Highland, Faye Hant, Paul J. Nietert, C. Beth Singleton, and Richard M. Silver</i>	3468
T Cells Expressing Allograft Inflammatory Factor 1 Display Increased Chemotaxis and Induce a Profibrotic Phenotype in Normal Fibroblasts In Vitro	
<i>Francesco Del Galdo and Sergio A. Jiménez</i>	3478
Childhood Arthritis	
Laser Doppler Flowmetry for Assessing Localized Scleroderma in Children	
<i>Lisa Weibel, Kevin J. Howell, Maria Teresa Visentin, Alain Rudiger, Christopher P. Denton, Francesco Zulian, Patricia Woo, and John I. Harper</i>	3489
Vasculitis	
Evidence for a Different Anatomic Basis for Joint Disease Localization in Polymyalgia Rheumatica in Comparison With Rheumatoid Arthritis	
<i>Helena Marzo-Ortega, Laura A. Rhodes, Ai Lyn Tan, Steven F. Tanner, Philip G. Conaghan, Elizabeth M. A. Hensor, Philip O'Connor, Aleksandra Radjenovic, Colin T. Pease, Paul Emery, and Dennis McGonagle</i>	3496
PLA1/A2 Polymorphism of the Platelet Glycoprotein Receptor IIIa and Risk of Cranial Ischemic Complications in Giant Cell Arteritis	
<i>Carlo Salvarani, Bruno Casali, Enrico Farnetti, Nicolò Pipitone, Debora Formisano, Davide Nicoli, PierLuigi Macchioni, Luca Cimino, GianLuigi Bajocchi, Maria Grazia Catanoso, Giovanna Restuccia, Alessandra Ghinoli, and Luigi Boiardi</i>	3502
Letters	
Retirement Rates and Distribution of the United States Rheumatology Workforce: Comment on the Article by Deal et al	
<i>Rahul K. Patel</i>	3509
Correct Citation Regarding Interleukin-6 Levels in Cerebrospinal Fluid From Patients With Neuropsychiatric Lupus: Comment on the Article by Fragosio-Loyo et al	
<i>Shunsei Hirohata</i>	3509

Reply

- Hilda Frago-Loyo, Luis Llorente, and Jorge Sánchez-Guerrero* 3509
 Development of Adjuvant Monoarthritis Is Critically Dependent on the Induction Protocol: Comment on the Article by Busso et al
William Ferrell, Elizabeth Kelso, John Lockhart, and Lynette Dunning 3510

Errata

- Error in Name of Sixth Author in Article by Abeles et al (Arthritis Rheum, September 2007) and Error in Assignment of Allele Calls in Article by Eyre et al (Arthritis Rheum, November 2006) 3510

- ACR Announcements** A14

VOLUME 56

NOVEMBER 2007

NO. 11

Special Articles

- Editorial: Tribology: A Portal to Understand Joint Failure?
Markus A. Wimmer, Thomas M. Schmid, and Joshua J. Jacobs 3511
 Editorial: Role of Protease-Activated Receptor 2 in Joint Inflammation
Francis F. Y. Lam 3514
 Editorial: Bisphosphonates and Glucocorticoids: Effects on Bone Quality
Willem F. Lems 3518
 Review: Epigenetics in Inflammatory Rheumatic Diseases
Lars C. Huber, Joanna Stanczyk, Astrid Jüngel, and Steffen Gay 3523

Rheumatoid Arthritis Basic Science Studies

- Protease-Activated Receptor 2 Mediates the Proinflammatory Effects of Synovial Mast Cells
H. S. Palmer, E. B. Kelso, J. C. Lockhart, C. P. Sommerhoff, R. Plevin, F. G. Goh, and W. R. Ferrell 3532
 Peptidyl Arginine Deiminase Type 2 (PAD-2) and PAD-4 but Not PAD-1, PAD-3, and PAD-6 Are Expressed in Rheumatoid Arthritis Synovium in Close Association With Tissue Inflammation
Céline Foulquier, Mireille Sebbag, Cyril Clavel, Sabine Chapuy-Regaud, Roula Al Badine, Marie-Claire Méchin, Christian Vincent, Rachida Nachat, Michiyuki Yamada, Hidenari Takahara, Michel Simon, Marina Guerrin, and Guy Serre 3541
 Rheumatoid Arthritis Fibroblast-like Synoviocytes Express BCMA and Are Stimulated by APRIL
Katsuya Nagatani, Kenji Itoh, Kyoichi Nakajima, Hirohumi Kuroki, Yozo Katsuragawa, Makoto Mochizuki, Shinichi Aotsuka, and Akio Mimori 3554
 Microparticles Stimulate the Synthesis of Prostaglandin E₂ Via Induction of Cyclooxygenase 2 and Microsomal Prostaglandin E Synthase 1
Astrid Jüngel, Oliver Distler, Ursula Schulze-Horsel, Lars C. Huber, Huy Riem Ha, Beat Simmen, Joachim R. Kalden, David S. Pisetsky, Steffen Gay, and Jörg H. W. Distler 3564

Rheumatoid Arthritis Clinical Studies

- Radiographic Joint Damage in Early Rheumatoid Arthritis Is Highly Dependent on Body Mass Index
Gisela Westhoff, Rolf Rau, and Angela Zink 3575
 The Widening Mortality Gap Between Rheumatoid Arthritis Patients and the General Population
Angel Gonzalez, Hilal Maradit Kremers, Cynthia S. Crowson, Paulo J. Nicola, John M. Davis, III, Terry M. Therneau, Veronique L. Roger, and Sherine E. Gabriel 3583

Sjögren's Syndrome

- Salivary Proteomic and Genomic Biomarkers for Primary Sjögren's Syndrome
Shen Hu, Jianghua Wang, Jiska Meijer, Sonya Jeong, Yongming Xie, Tianwei Yu, Hui Zhou, Sharon Henry, Arjan Vissink, Justin Pijpe, Cees Kallenberg, David Elashoff, Joseph A. Loo, and David T. Wong 3588

Spondylarthritis

- Histopathologic Changes at "Synovio-Enthesal Complexes" Suggesting a Novel Mechanism for Synovitis in Osteoarthritis and Spondylarthritis
Michael Benjamin and Dennis McGonagle 3601

Osteoarthritis Clinical Studies

- Efficacy and Safety of Intraarticular Hylan or Hyaluronic Acids for Osteoarthritis of the Knee: A Randomized Controlled Trial
Peter Jüni, Stephan Reichenbach, Sven Trelle, Beatrice Tschannen, Simon Wandel, Beat Jordi, Maya Züllig, Reto Guetg, Hans Jörg Häuselmann, Hans Schwarz, Robert Theiler, Hans Rudolf Ziswiler,

<i>Paul A. Dieppe, Peter M. Villiger, and Matthias Egger, for the Swiss Viscosupplementation Trial Group</i>	3610
Carpal Tunnel Syndrome and Keyboard Use at Work: A Population-Based Study	
<i>Isam Atroshi, Christina Gummesson, Ewald Ornstein, Ragnar Johnsson, and Jonas Ranstam</i>	3620
Morphologic Changes in the Vastus Medialis Muscle in Patients With Osteoarthritis of the Knee	
<i>Bernd Fink, Monika Egl, Joachim Singer, Martin Fuerst, Michael Bubenheim, and Eva Neuen-Jacob</i>	3626
Early Identification of Radiographic Osteoarthritis of the Hip Using an Active Shape Model to Quantify Changes in Bone Morphometric Features: Can Hip Shape Tell Us Anything About the Progression of Osteoarthritis?	
<i>Jennifer S. Gregory, Jan H. Waarsing, Judd Day, Huibert A. Pols, Max Reijman, Harrie Weinans, and Richard M. Aspden</i>	3634
Urinary TIINE Concentrations in a Randomized Controlled Trial of Doxycycline in Knee Osteoarthritis: Implications of the Lack of Association Between TIINE Levels and Joint Space Narrowing	
<i>Ivan G. Otterness, Kenneth D. Brandt, Marie-Pierre Hellio Le Graverand, and Steven A. Mazzuca</i>	3644
Development and Characterization of a Fusion Protein Between Thermally Responsive Elastin-like Polypeptide and Interleukin-1 Receptor Antagonist: Sustained Release of a Local Antiinflammatory Therapeutic	
<i>Mohammed F. Shamji, Helawe Betre, Virginia B. Kraus, Jun Chen, Ashutosh Chilkoti, Rajeswari Pichika, Koichi Masuda, and Lori A. Setton</i>	3650

Osteoarthritis Basic Science Studies

Association Between Friction and Wear in Diarthrodial Joints Lacking Lubricin	
<i>Gregory D. Jay, Jahn R. Torres, David K. Rhee, Heikki J. Helminen, Mika M. Hytinen, Chung-Ja Cha, Khaled Elsaid, Kyung-Suk Kim, Yajun Cui, and Matthew L. Warman</i>	3662
Double-Knockout of ADAMTS-4 and ADAMTS-5 in Mice Results in Physiologically Normal Animals and Prevents the Progression of Osteoarthritis	
<i>Manas K. Majumdar, Roger Askew, Scott Schelling, Nancy Stedman, Tracey Blanchet, Bei Hopkins, Elisabeth A. Morris, and Sonya S. Glasson</i>	3670
Comparative Proteomic Characterization of Articular Cartilage Tissue From Normal Donors and Patients With Osteoarthritis	
<i>Jiang Wu, Wei Liu, Amanda Bemis, Eunice Wang, Yongchang Qiu, Elisabeth A. Morris, Carl R. Flannery, and Zhiyong Yang</i>	3675
Increased Expression of Discoidin Domain Receptor 2 Is Linked to the Degree of Cartilage Damage in Human Knee Joints: A Potential Role in Osteoarthritis Pathogenesis	
<i>Ilse-Gerlinde Sunk, Klaus Bobacz, Jochen G. Hofstaetter, Love Amoyo, Afschin Soleiman, Josef Smolen, Lin Xu, and Yefu Li</i>	3685
Transforming Growth Factor α Suppression of Articular Chondrocyte Phenotype and Sox9 Expression in a Rat Model of Osteoarthritis	
<i>C. Thomas G. Appleton, Shirine E. Usmani, Suzanne M. Bernier, Thomas Aigner, and Frank Beier</i>	3693

Cartilage Biology

Mechanotransduction of Bovine Articular Cartilage Superficial Zone Protein by Transforming Growth Factor β Signaling	
<i>Corey P. Neu, Afshin Khalafi, Kyriakos Komvopoulos, Thomas M. Schmid, and A. Hari Reddi</i>	3706
Activin A Is an Anticatabolic Autocrine Cytokine in Articular Cartilage Whose Production Is Controlled by Fibroblast Growth Factor 2 and NF-κB	
<i>Susan Alexander, Fiona Watt, Yasunobu Sawaji, Monika Hermansson, and Jeremy Saklatvala</i>	3715

Bone Biology

The Aminobisphosphonate Risedronate Preserves Localized Mineral and Material Properties of Bone in the Presence of Glucocorticoids	
<i>Guive Balooch, Wei Yao, Joel W. Ager, Mehdi Balooch, Ravi K. Nalla, Alexandra E. Porter, Robert O. Ritchie, and Nancy E. Lane</i>	3726

Systemic Lupus Erythematosus

Association of Reactive Oxygen and Nitrogen Intermediate and Complement Levels With Apoptosis of Peripheral Blood Mononuclear Cells in Lupus Patients	
<i>James C. Oates, Libby W. Farrelly, Ann F. Hofbauer, Wei Wang, and Gary S. Gilkeson</i>	3738
Overexpression of Human Decoy Receptor 3 in Mice Results in a Systemic Lupus Erythematosus-like Syndrome	
<i>Bing Han, Paul A. Moore, Jiangping Wu, and Hongyu Luo</i>	3748

Type I Interferon as a Novel Risk Factor for Endothelial Progenitor Cell Depletion and Endothelial Dysfunction in Systemic Lupus Erythematosus <i>Pui Y. Lee, Yi Li, Hanno B. Richards, Fay S. Chan, Haoyang Zhuang, Sonali Narain, Edward J. Butfiloski, Eric S. Sobel, Westley H. Reeves, and Mark S. Segal</i>	3759
Deficiency of the Type I Interferon Receptor Protects Mice From Experimental Lupus <i>Dina C. Nacionales, Kindra M. Kelly-Scumpia, Pui Y. Lee, Jason S. Weinstein, Robert Lyons, Eric Sobel, Minoru Satoh, and Westley H. Reeves</i>	3770
Myositis	
Type I Interferon-Inducible Gene Expression in Blood Is Present and Reflects Disease Activity in Dermatomyositis and Polymyositis <i>Ronan J. Walsh, Sek Won Kong, Yihong Yao, Bahija Jallal, Peter A. Kiener, Jack L. Pinkus, Alan H. Beggs, Anthony A. Amato, and Steven A. Greenberg</i>	3784
Childhood Arthritis	
Gene Expression Profiling of Peripheral Blood From Patients With Untreated New-Onset Systemic Juvenile Idiopathic Arthritis Reveals Molecular Heterogeneity That May Predict Macrophage Activation Syndrome <i>Ndate Fall, Michael Barnes, Sherry Thornton, Lorie Luyrink, Judyann Olson, Norman T. Ilowite, Beth S. Gottlieb, Thomas Griffin, David D. Sherry, Susan Thompson, David N. Glass, Robert A. Colbert, and Alexei A. Grom</i>	3793
NOD2 Gene-Associated Pediatric Granulomatous Arthritis: Clinical Diversity, Novel and Recurrent Mutations, and Evidence of Clinical Improvement With Interleukin-1 Blockade in a Spanish Cohort <i>Juan I. Aróstegui, Cristina Arnal, Rosa Merino, Consuelo Modesto, María Antonia Carballo, Purificación Moreno, Julia García-Consuegra, Antonio Naranjo, Eduardo Ramos, Pilar de Paz, Josefa Rius, Susana Plaza, and Jordi Yagüe</i>	3805
Systemic Sclerosis	
The Nuclear Autoantigen CENP-B Displays Cytokine-like Activities Toward Vascular Smooth Muscle Cells <i>Geneviève Robitaille, Jill Hénault, Marie-Soleil Christin, Jean-Luc Senécal, and Yves Raymond</i>	3814
Pattern and Distribution of Myocardial Fibrosis in Systemic Sclerosis: A Delayed Enhanced Magnetic Resonance Imaging Study <i>George E. Tzelepis, Nikolaos L. Kelekis, Sotiris C. Plastiras, Panayiotis Mitseas, Nikolaos Economopoulos, Christos Kampolis, Elias J. Gialafos, Ioannis Moyssakis, and Haralampos M. Moutsopoulos</i>	3827
Prevention of Vascular Damage in Scleroderma and Autoimmune Raynaud's Phenomenon: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Angiotensin-Converting Enzyme Inhibitor Quinapril <i>A. E. Gliddon, C. J. Doré, C. M. Black, N. McHugh, R. Moots, C. P. Denton, A. Herrick, T. Barnes, J. Camilleri, K. Chakravarty, P. Emery, B. Griffiths, N. D. Hopkinson, P. Hickling, P. Lanyon, C. Laversuch, T. Lawson, R. Mallya, M. Nisar, C. Rhys-Dillon, T. Sheeran, and P. J. Maddison</i>	3837
Vasculitis	
Vascular Endothelial Damage and Repair in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis <i>K. de Groot, C. Goldberg, F. H. Bahlmann, A. Woywodt, H. Haller, D. Fliser, and M. Haubitz</i>	3847
Gout	
Misdiagnosis of a Chylous Cyst as Chest Wall Gouty Tophus: A Case of True Pseudogout <i>Leena G. Adhikesavan, William T. Ayoub, and H. Ralph Schumacher</i>	3854
Amyloidosis	
Soft Tissue, Joint, and Bone Manifestations of AL Amyloidosis: Clinical Presentation, Molecular Features, and Survival <i>Tatiana Prokaeva, Brian Spencer, Maurya Kaut, Al Ozonoff, Gheorghe Doros, Lawreen H. Connors, Martha Skinner, and David C. Seldin</i>	3858
Concise Communication	
Absence of Changes in the Number of Synovial Sublining Macrophages After Ineffective Treatment for Rheumatoid Arthritis: Implications for Use of Synovial Sublining Macrophages as a Biomarker <i>Carla A. Wijbrandts, Clarissa E. Vergunst, Jasper J. Haringman, Danielle M. Gerlag, Tom J. M. Smeets, and Paul P. Tak</i>	3869
Erratum	
Incorrect table of contents section classification for the article by Sánchez et al (Arthritis Rheum, September 2007)	3871

Letters

Does Knee Malalignment Predispose to Osteoarthritis? Comment on the Articles by Brouwer et al and Hunter et al and the Editorial by Sharma	
<i>Paul Monach</i>	3872
Reply	
<i>Leena Sharma</i>	3872
Editor's Note	
<i>Michael D. Lockshin</i>	3872
The Futility of Current Approaches to Chondroprotection—a Different Perspective: Comment on the Article by Felson and Kim	
<i>K. D. Brandt, E. L. Radin, P. A. Dieppe, and L. van de Putte</i>	3873
Reply	
<i>David T. Felson and Young-Jo Kim</i>	3874
Do Activated Human Dendritic Cells Diminish the Suppressive Functions of CD4+, CD25+ Regulatory T Cells? Comment on the Article by van Amelsfort et al	
<i>Jagadeesh Bayry, Srinivasa V. Kaveri, and David F. Tough</i>	3874
Why Publish a Secondary Analysis of Only One Treatment Group in the Behandelstrategieën voor Reumatoïde Artritis Trial? Comment on the Article by van der Bijl et al	
<i>Maarten Boers</i>	3876
Reply	
<i>A. E. van der Bijl, C. F. Allaart, F. C. Breedveld, P. J. S. M. Kerstens, and B. A. C. Dijkmans</i>	3876
Macrophage Activation Is a Key Component in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis: Comment on the Article by Bleesing et al	
<i>Bradley J. Bloom</i>	3877
Premature Atherosclerosis in Systemic Lupus Erythematosus: Comment on the Article by Westerweel et al	
<i>Rohini Handa and Surya Prakash Bhatt</i>	3878
Reply	
<i>Peter E. Westerweel, Remco K. M. A. C. Luyten, Hein A. Koomans, Ronald H. W. M. Derksen, and Marianne C. Verhaar</i>	3879
Periodic Fever and Apoptosis of Accumulated Neutrophils in Familial Mediterranean Fever: Comment on the Article by Touitou et al	
<i>Kozo Yasui and Takashi Yamazaki</i>	3879
Reply	
<i>Isabelle Touitou</i>	3880
ACR Announcements	A16

VOLUME 56

DECEMBER 2007

NO. 12

Special Articles

Editorial: FRZB: A Bone and Joint Connection	
<i>M. Corr and N. E. Lane</i>	3881
Editorial: It Is the Best of Times; It Is the Worst of Times: Is There a Way Forward? A Plethora of Treatment Options for Rheumatoid Arthritis, but Critical Trial Design Issues	
<i>James R. O'Dell</i>	3884
Review: Can Sciatica Induced by Disc Herniation Be Treated With Tumor Necrosis Factor α Blockade?	
<i>Philippe Goupille, Denis Mulleman, Gilles Paintaud, Hervé Watier, and Jean-Pierre Valat</i>	3887
Rheumatoid Arthritis Clinical Studies	
Safety and Efficacy of Additional Courses of Rituximab in Patients With Active Rheumatoid Arthritis: An Open-Label Extension Analysis	
<i>Edward Keystone, Roy Fleischmann, Paul Emery, Daniel E. Furst, Ronald van Vollenhoven, Joan Bathon, Maxime Dougados, Andrew Baldassare, Gianfranco Ferraccioli, Andrew Chubick, James Udell, Matthew W. Cravets, Sunil Agarwal, Simon Cooper, and Fabio Magrini</i>	3896
Immunohistochemical Analysis as a Means to Predict Responsiveness to Rituximab Treatment	
<i>Y. K. Onno Teng, E. W. Nivine Levarht, Mojtaba Hashemi, Ingeborg M. Bajema, René E. M. Toes, Tom W. J. Huizinga, and Jacob M. van Laar</i>	3909

Treatment of Early Rheumatoid Arthritis: A Randomized Magnetic Resonance Imaging Study Comparing the Effects of Methotrexate Alone, Methotrexate in Combination With Infliximab, and Methotrexate in Combination With Intravenous Pulse Methylprednisolone <i>Patrick Durez, Jacques Malghem, Adrien Nzeuseu Toukap, Geneviève Depresseux, Bernard R. Lauwerys, René Westhovens, Frank P. Luyten, Luc Corluy, Frédéric A. Houssiau, and Patrick Verschuere</i>	3919
Disease Remission and Sustained Halting of Radiographic Progression With Combination Etanercept and Methotrexate in Patients With Rheumatoid Arthritis <i>D. van der Heijde, L. Klareskog, R. Landewé, G. A. W. Bruyn, A. Cantagrel, P. Durez, G. Herrero-Beaumont, Y. Molad, C. Codreanu, G. Valentini, R. Zahora, R. Pedersen, D. MacPeck, J. Wajdula, and S. Fatenejad, for the TEMPO Study Investigators</i>	3928
Circulating Levels of Tumor Necrosis Factor Receptors Are Highly Predictive of Mortality in Patients With Rheumatoid Arthritis <i>Derek L. Matvey, John R. Glossop, Nicola B. Nixon, and Peter T. Dawes</i>	3940
Clinical Images	
A Rheumatoid Arthritis Patient With Swelling of the Shoulder <i>H. A. Martens and M. D. Posthumus</i>	3948
Rheumatoid Arthritis Basic Science Studies	
Fine Specificity of the Anti-Citrullinated Protein Antibody Response Is Influenced by the Shared Epitope Alleles <i>K. N. Verpoort, K. Cheung, A. Ioan-Facsinay, A. H. M. van der Helm-van Mil, J. K. de Vries-Bouwstra, C. F. Allaart, J. W. Drijfhout, R. R. P. de Vries, F. C. Breedveld, T. W. J. Huizinga, G. J. M. Pruijn, and R. E. M. Toes</i>	3949
HO-1 Promoter Polymorphism Associated With Rheumatoid Arthritis <i>Blanca Rueda, Javier Oliver, Gema Robledo, Miguel A. López-Nevot, Alejandro Balsa, Dora Pascual-Salcedo, Miguel A. González-Gay, Maria F. González-Escribano, and Javier Martín</i>	3953
Type IV Collagen α -Chain Composition in Synovial Lining From Trauma Patients and Patients With Rheumatoid Arthritis <i>P. Poduval, T. Sillat, A. Beklen, V. P. Kouri, I. Virtanen, and Y. T. Kontinen</i>	3959
Beneficial Effect of Galectin 9 on Rheumatoid Arthritis by Induction of Apoptosis of Synovial Fibroblasts <i>Masako Seki, Ken-mei Sakata, Souichi Oomizu, Tomohiro Arikawa, Atsuko Sakata, Masaki Ueno, Atsuya Nobumoto, Toshiro Niki, Naoki Saita, Kanako Ito, Shu-Yan Dai, Shigeki Katoh, Nozomu Nishi, Michishi Tsukano, Kouichiro Ishikawa, Akira Yamauchi, Vijay Kuchroo, and Mitsuomi Hirashima</i>	3968
Sjögren's Syndrome	
Rates of Infiltration by Macrophages and Dendritic Cells and Expression of Interleukin-18 and Interleukin-12 in the Chronic Inflammatory Lesions of Sjögren's Syndrome: Correlation With Certain Features of Immune Hyperactivity and Factors Associated With High Risk of Lymphoma Development <i>M. N. Manoussakis, S. Boiu, P. Korkolopoulou, E. K. Kapsogeorgou, N. Kavantzias, P. Ziakas, E. Patsouris, and H. M. Moutsopoulos</i>	3977
Association of an IRF5 Gene Functional Polymorphism With Sjögren's Syndrome <i>Corinne Miceli-Richard, Emmanuelle Comets, Pascale Loiseau, Xavier Puechal, Eric Hachulla, and Xavier Mariette</i>	3989
Augmented Interferon- α Pathway Activation in Patients With Sjögren's Syndrome Treated With Etanercept <i>Clio P. Mavragani, Timothy B. Niewold, Niki M. Moutsopoulos, Stanley R. Pillemer, Sharon M. Wahl, and Mary K. Crow</i>	3995
Spondylarthritis	
Adalimumab Significantly Reduces Both Spinal and Sacroiliac Joint Inflammation in Patients With Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study <i>Robert G. W. Lambert, David Salonen, Proton Rahman, Robert D. Inman, Robert L. Wong, Steven G. Einstein, Glen T. D. Thomson, Andre Beaulieu, Denis Choquette, and Walter P. Maksymowych, for the M03-606 Study Group</i>	4005
Experimental Arthritis	
Collagen-Induced Arthritis as a Model of Hyperalgesia: Functional and Cellular Analysis of the Analgesic Actions of Tumor Necrosis Factor Blockade <i>Julia J. Inglis, Clare A. Notley, David Essex, Alex W. Wilson, Marc Feldmann, Praveen Anand, and Richard Williams</i>	4015
Longitudinal Assessment of Synovial, Lymph Node, and Bone Volumes in Inflammatory Arthritis in Mice by In Vivo Magnetic Resonance Imaging and Microfocal Computed Tomography <i>Steven T. Proulx, Edmund Kwok, Zhigang You, M. Owen Papuga, Christopher A. Beck, David J. Shealy, Christopher T. Ritchlin, Hani A. Awad, Brendan F. Boyce, Lianping Xing, and Edward M. Schwarz</i>	4024

Osteoarthritis Clinical Studies

- Can Biochemical Markers Serve as Surrogates for Imaging in Knee Osteoarthritis?
C. R. Davis, J. Karl, R. Granell, J. R. Kirwan, J. Fasham, J. Johansen, P. Garnero, and M. Sharif 4038
- Effect of Meniscal Damage on the Development of Frequent Knee Pain, Aching, or Stiffness
M. Englund, J. Niu, A. Guermazi, F. W. Roemer, D. J. Hunter, J. A. Lynch, C. E. Lewis, J. Torner, M. C. Nevitt, Y. Q. Zhang, and D. T. Felson 4048
- The Efficacy and Safety of Diacerein in the Treatment of Painful Osteoarthritis of the Knee:
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study With Primary End Points at Two
Months After the End of a Three-Month Treatment Period
*Karel Pavelka, Tomáš Trč, Karel Karpaš, Petr Vitek, Marie Sedláčková, Věra Vlasáková, Jana Böhmová,
and Jozef Rovenský* 4055

Osteoarthritis Basic Science Studies

- Resemblance of Osteophytes in Experimental Osteoarthritis to Transforming Growth Factor β -Induced
Osteophytes: Limited Role of Bone Morphogenetic Protein in Early Osteoarthritic Osteophyte
Formation
*E. N. Blaney Davidson, E. L. Vitters, H. M. van Beuningen, F. A. J. van de Loo, W. B. van den Berg, and
P. M. van der Kraan* 4065
- Involvement of Protein Kinase C ζ in Interleukin-1 β Induction of ADAMTS-4 and Type 2 Nitric Oxide
Synthase via NF- κ B Signaling in Primary Human Osteoarthritic Chondrocytes
*Priya S. Chockalingam, Usha Varadarajan, Richard Sheldon, Eric Fortier, Edward R. LaVallie,
Elisabeth A. Morris, Paul J. Yaworsky, and Manas K. Majumdar* 4074
- Hypoxia-Inducible Factor 1 α Is Involved in the Prostaglandin Metabolism of Osteoarthritic Cartilage
Through Up-Regulation of Microsomal Prostaglandin E Synthase 1 in Articular Chondrocytes
C. Grimmer, D. Pfander, B. Swoboda, T. Aigner, L. Mueller, F. F. Hennig, and K. Gelse 4084

Cartilage Biology

- Articular Cartilage and Biomechanical Properties of the Long Bones in Frzb-Knockout Mice
*Rik J. U. Lories, Jenny Peeters, Astrid Bakker, Przemko Tylzanowski, Inge Derese, Jan Schrooten,
J. Tergg Thomas, and Frank P. Luyten* 4095

Bone Biology

- Treg Cells Suppress Osteoclast Formation: A New Link Between the Immune System and Bone
*Mario M. Zaiss, Roland Axmann, Jochen Zwerina, Karin Polzer, Eva Gückel, Alla Skapenko,
Hendrik Schulze-Koops, Nikki Horwood, Andrew Cope, and Georg Schett* 4104

Systemic Lupus Erythematosus

- British Isles Lupus Assessment Group 2004 Index Is Valid for Assessment of Disease Activity in
Systemic Lupus Erythematosus
*Chee-Seng Yee, Vernon Farewell, David A. Isenberg, Anisur Rahman, Lee-Suan Teh, Bridget Griffiths,
Ian N. Bruce, Yasmeen Ahmad, Athiveeraramapandian Prabu, Mohammed Akil, Neil McHugh,
David D'Cruz, Munther A. Khamashta, Peter Maddison, and Caroline Gordon* 4113
- Role of Hypoxia and cAMP in the Transdifferentiation of Human Fetal Cardiac Fibroblasts: Implications
for Progression to Scarring in Autoimmune-Associated Congenital Heart Block
*Robert M. Clancy, Ping Zheng, Marguerita O'Mahony, Peter Izmirly, Jiri Zavadil, Lawrence Gardner, and
Jill P. Buyon* 4120
- Hyperexpression of Cyclooxygenase 2 in the Lupus Immune System and Effect of Cyclooxygenase 2
Inhibitor Diet Therapy in a Murine Model of Systemic Lupus Erythematosus
Li Zhang, Anne M. Bertucci, Kimberly A. Smith, Luting Xu, and Syamal K. Datta 4132
- Reduced B Lymphocyte and Immunoglobulin Levels After Atacicept Treatment in Patients With
Systemic Lupus Erythematosus: Results of a Multicenter, Phase Ib, Double-Blind, Placebo-Controlled,
Dose-Escalating Trial
*Maria Dall'Era, Eliza Chakravarty, Daniel Wallace, Mark Genovese, Michael Weisman,
Arthur Kavanaugh, Kenneth Kalunian, Patricia Dhar, Emmanuelle Vincent, Claudia Pena-Rossi,
David Wofsy, and the Merck Serono and ZymoGenetics Atacicept Study Group* 4142

Childhood Arthritis

- Functional Magnetic Resonance Imaging Assessment of Cognitive Function in Childhood-Onset Systemic
Lupus Erythematosus: A Pilot Study
*Mark W. DiFrancesco, Scott K. Holland, M. Douglas Ris, Caleb M. Adler, Shannen Nelson,
Melissa P. DelBello, Mekibib Altaye, and Hermine I. Brunner* 4151
- Identification of Novel Susceptibility Genes in Childhood-Onset Systemic Lupus Erythematosus Using a
Uniquely Designed Candidate Gene Pathway Platform
*Chaim O. Jacob, Andreas Reiff, Don L. Armstrong, Barry L. Myones, Earl Silverman,
Marisa Klein-Gitelman, Deborah McCurdy, Linda Wagner-Weiner, James J. Nocton, Aaron Solomon, and
Raphael Zidovetzki* 4164

Acute Kawasaki Disease Is Associated With Reverse Regulation of Soluble Receptor for Advance Glycation End Products and Its Proinflammatory Ligand S100A12 <i>Helmut Wittkowski, Keiichi Hirono, Fukiko Ichida, Thomas Vogl, Fei Ye, Xing Yanlin, Kazuyoshi Saito, Keiichi Uese, Toshio Miyawaki, Dorothee Viemann, Johannes Roth, and Dirk Foell</i>	4174
Autoinflammatory Disease	
Elevated CD16 Expression by Monocytes From Patients With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome <i>Ian Todd, Paul M. Radford, Loems Ziegler-Heitbrock, Amir M. Ghaemmaghami, Richard J. Powell, and Patrick J. Tighe</i>	4182
Systemic Sclerosis	
Endothelin Is a Downstream Mediator of Profibrotic Responses to Transforming Growth Factor β in Human Lung Fibroblasts <i>Xu Shi-wen, Laura Kennedy, Elisabetta A. Renzoni, George Bou-Gharios, Roland M. du Bois, Carol M. Black, Christopher P. Denton, David J. Abraham, and Andrew Leask</i>	4189
Persistence of Abnormal Bronchoalveolar Lavage Findings After Cyclophosphamide Treatment in Scleroderma Patients With Interstitial Lung Disease <i>Shikha Mittoo, Fredrick M. Wigley, Robert Wise, Huiqing Xiao, and Laura Hummers</i>	4195
Hypoxia-Induced Increase in the Production of Extracellular Matrix Proteins in Systemic Sclerosis <i>Jörg H. W. Distler, Astrid Jüngel, Margarita Pileckyte, Jochen Zwerina, Beat A. Michel, Renate E. Gay, Orylia Kowal-Bielecka, Marco Matucci-Cerinic, Georg Schett, Hugo H. Marti, Steffen Gay, and Oliver Distler</i>	4203
Lyme Disease	
Antibody Responses to <i>Borrelia burgdorferi</i> in Patients With Antibiotic-Refractory, Antibiotic-Responsive, or Non-Antibiotic-Treated Lyme Arthritis <i>Priya Kannian, Gail McHugh, Barbara J. B. Johnson, Rendi M. Bacon, Lisa J. Glickstein, and Allen C. Steere</i>	4216
Concise Communication	
Drug-Specific and Time-Dependent Risks of Bacterial Infection Among Patients With Rheumatoid Arthritis Who Were Exposed to Tumor Necrosis Factor α Antagonists <i>Jeffrey R. Curtis, Juan Xi, Nivedita Patkar, Aiyuan Xie, Kenneth G. Saag, and Carolyn Martin</i>	4226
Letters	
Osteoporosis, Vitamin D Deficiency, and Supplementation in Juvenile Systemic Lupus Erythematosus: Comment on the Article by Compeyrot-Lacassagne et al <i>Sonja Praprotnik and Matija Tomsic</i>	4228
Reply <i>Sandrine Compeyrot-Lacassagne and Earl D. Silverman</i>	4228
Serum Amyloid P and Fibrosis in Systemic Sclerosis: Comment on the Article by Tennent et al <i>Darrell Pilling, Christopher D. Buckley, Mike Salmon, and Richard H. Gomer</i>	4229
Reply <i>Mark B. Pepys, Glenys A. Tennent, and Christopher P. Denton</i>	4229
Erratum	
Incorrect Spelling of Author Name in Article by Desailoud et al (Arthritis Rheum, July 1998)	4230
Late-Breaking Abstracts and Fellow Abstracts, American College of Rheumatology, 2007 Annual Scientific Meeting	4231
Reviewers	4318
Contents, Volume 56, 2007	4325
Indexes	4362
ACR Announcements	A16

AUTHOR INDEX

Arthritis and Rheumatism, Volume 56, Numbers 1-12, 2007

A

Abbott K, 977
 Abdollahi-Roodsaz S, 2957
 Abdulahad WH, 2080
 Abeles AM, 2840
 Abelson A-K, 3080
 Abraham DJ, 4189
 Abramson SB, 2099, 2469, 2840
 Adams HP, 334
 Adebayo A, 2192
 Adhikesavan LG, 3854
 Adler CM, 4151
 Aeschlimann A, 2464
 Aeschlimann JM, 3336
 Agarwal S, 3284, 3896
 Ager JW, 3726
 Ahmad Y, 4113
 Ahmed S, 1787, 2535
 Aigner T, 586, 3693, 4084
 Akahoshi M, 1618
 Akbarali YW, 2344
 Åkesson A, 323
 Akil M, 4113
 Akira S, 1880
 Aksentijevich I, 1273
 Al-Mosawi ZS, 960
 Al-Mussawir H, 2840
 Al-Saad KK, 960
 Alarcón GS, 265, 614, 622, 2812, 3375
 Alarcón-Riquelme ME, 1234, 3080
 Albani S, 389, 1648
 Albert LM, 1152
 Alcorn D, 1145
 Alencar H, 117
 Alessandri C, 2687
 Alessio M, 3138
 Aletaha D, 1369, 3226
 Alexander S, 3715
 Alfredsson L, 2202, 2620
 Ali Y, 2708
 Aliabadi P, 129, 1212, 2986
 Allaart CF, 1424, 1765, 2129, 3876, 3949
 Allanore Y, 2747
 Allen BL, 2535
 Allison JJ, 1125
 Alm GV, 2202, 3112
 Alperí M, 2784
 Alpígnani MG, 3138
 Alsaleh G, 3202
 Alston JT, 575
 Altaye M, 4151
 Amagasa T, 1164
 Amarnath S, 1798
 Amato AA, 3784
 Ambartsumian N, 779
 Ambudkar IS, 1798
 Amengual O, 2803

American College of
 Rheumatology Audiovisual
 Aids Subcommittee, 1029
 Ameye LG, 3336
 Amiel D, 1529
 Amin MA, 1787, 2535
 Amin S, 129
 Amos CI, 58
 Amoyo L, 1880, 3685
 Anand P, 4015
 Andersen JH, 1355
 Anderson M, 1945
 Andersson U, 674
 Andrade RM, 614, 622
 André C, 1478, 2232
 Andreoli L, 1569
 Angelini C, 2640
 Anghelina M, 3284
 Anolik JH, 3044
 Ansuini V, 658
 Antoni C, 2698
 Aoki K, 1164
 Aotsuka S, 3554
 Apaz M-T, 3096
 Appleton CTG, 1854, 3693
 Apte M, 614, 622
 Aranow C, 265, 1894
 Arashvand K, 1722
 Araújo D, 555
 Arbab AS, 1817
 Argentine Collaborative Group,
 1234
 Arikawa T, 3968
 Arimura K, 662
 Aringer M, 274
 Arinuma Y, 386
 Armstrong DL, 4164
 Arnal C, 3805
 Arner EC, 575
 Arnett FC, 2031
 Arnold LM, 1336
 Arnold P, 714
 Aróstegui JI, 2784, 3805
 Asanbaeva A, 188
 Asano Y, 1694
 Ascherman DP, 3125
 Askew EW, 984
 Askew R, 3670
 Askin FB, 2065, 2729
 Aslanidis S, 2243
 Asou Y, 3358
 Aspden RM, 3634
 Assassi S, 2031
 Assi LK, 1776
 Atenafu E, 1966
 Athanasiou KA, 168
 Atisha-Fregoso Y, 1242
 Atkins SR, 43
 Atkinson JP, 2823
 Atroshi I, 3620
 Atsumi T, 393, 2803
 Attur M, 2840

Augello A, 1175
 Aurrand-Lions M, 3459
 Austin F, 1273
 Authier F-J, 1315
 Avorn J, 384, 696, 1754
 Awad HA, 4024
 Axmann R, 1118, 4104
 Ayoub WT, 3854

B

Bache I, 2402
 Bachmann M, 3387
 Bäckdahl L, 2620
 Bacon RM, 4216
 Badine RA, 3541
 Bae S-C, 265, 1454
 Baeten D, 2150
 Bahlmann FH, 3847
 Bai S, 215
 Baildam E, 3096
 Bainbridge SE, 2765
 Bajema IM, 924, 3909
 Bajocchi G, 3502
 Baker K, 1198
 Bakker A, 4095
 Baldassare A, 3896
 Baldini C, 2223
 Ballman KV, 820
 Balogh Z, 3096
 Balooch G, 3726
 Balooch M, 3726
 Balsa A, 3953
 Baltus B, 2492
 Bamford J, 2812
 Bandyopadhyay BC, 1798
 Bang H, 2503
 Bannwarth B, 697
 Barber GN, 1589
 Barbero A, 586
 Bardin T, 698
 Barerra P, 1765
 Barker T, 596
 Barnard J, 3044
 Barnes M, 3793
 Barnes T, 3837
 Baron JA, 568
 Baron R, 1164
 Barr W, 722
 Barrera P, 694
 Barrett JA, 568
 Barrett SD, 3347
 Barrieu S, 2455
 Barros A, 1036
 Barton A, 2929
 Baslund B, 779
 Bathon J, 3896
 Batley M, 1408
 Batliwalla F, 1745
 Batteux F, 2455, 2585
 Baugé C, 3020
 Baum BJ, 1798
 Bauskin AR, 753
 Bayry J, 3874
 Beaulieu A, 4005
 Bechi P, 3442
 Beck CA, 4024
 Becker CR, 2809
 Becker ML, 1292
 Beggs AH, 3784
 Begovich AB, 3168
 Behrens M, 69
 Behringer RR, 334
 Beier F, 1854, 3693
 Bejarano P, 1589
 Bekkering WP, 2410
 Beklen A, 3959
 Belfiore F, 2640
 Belmont HM, 2099
 Belo JN, 1204
 Bemis A, 3675
 Ben-Chetrit E, 1706
 Benallaoua M, 2585
 Bendaoud B, 1134, 1464
 Benigni A, 1569, 1629
 Benito P, 555
 Benjamin M, 224, 2482, 3601
 Benoist C, 509, 2968
 Bentley DE, 1345
 Benucci M, 2223
 Berden JHM, 924, 1921
 Berg W, 2503
 Bergink AP, 1204
 Bernatsky S, 265
 Bernier SG, 850
 Bernier SM, 3693
 Bernsen RMD, 1204
 Berry J, 2143
 Berthou C, 1464
 Bertoli AM, 1723
 Bertoni B, 658
 Berucci AM, 4132
 Betre H, 3650
 Betteridge Z, 3132
 Beutler A, 2698, 3096
 Beyene J, 631
 Bhaskarabhatla M, 949
 Bhatt SP, 3878
 Bieche I, 1315
 Biedermann T, 1806
 Bierma-Zeinstra SMA, 1204
 Bigbee CL, 2557
 Bijl M, 673, 924, 3399
 Bijlsma JWW, 199, 732
 Binks MH, 2549
 Birbara C, 2698
 Birnbaum J, 2065
 Birnbaum N, 722, 730
 Bishop F, 1336
 Bizzaro N, 1736
 Bjarnason I, 2633
 Björck L, 3253
 Björnsson S, 2633
 Black CM, 323, 2005, 2422, 3837, 4189

- Blanchet T, 3670
 Blanco FJ, 555
 Blanco P, 2362
 Blank M, 938
 Bleesing J, 965
 Blizzard L, 1521
 Blom AB, 147
 Bloom BJ, 3877
 Blum JS, 498
 Bobacz K, 1880, 3685
 Boczkowski J, 2585
 Bode-Böger SM, 809
 Boehm AK, 2335
 Boers M, 384, 3876
 Bogatkevich GS, 2432, 3468
 Boger E, 1345
 Bohle RM, 1094
 Böhmová J, 4055
 Boiardi L, 3502
 Boileau C, 2288
 Boily M, 2288
 Boiu S, 3977
 Bolster M, 1676
 Bombardier C, 1745
 Bombardieri S, 2223
 Bonetti M, 244
 Bonfa E, 2352
 Bongartz T, 43
 Bongi SM, 2223
 Boon L, 2595
 Booth D, 1706
 Booth SL, 129
 Boots AM, 2150
 Borderie D, 2455
 Bordron A, 1464
 Borregaard N, 2575
 Bos E, 2150
 Bottero P, 3159
 Bou-Gharios G, 4189
 Bouchery E, 722
 Boulanger N, 3202
 Boumédiene K, 3020
 Boumpas DT, 705, 2875
 Boutron C, 698
 Boyce BF, 4024
 Boyle Y, 1345
 Bracke M, 208
 Branco J, 555
 Brand DD, 498
 Brandt KD, 3644, 3873
 Bratt J, 448
 Bräuer R, 3271
 Breban M, 1478, 2232
 Brechter AB, 910
 Breedveld FC, 433, 1424, 2129, 2913, 3876, 3949
 Breit SN, 753
 Brenn D, 351
 Brentano F, 2829
 Bresnahan B, 2919
 Briand J-P, 1921
 Bridges SL Jr., 2679
 Brinckerhoff CE, 892
 Brindani F, 2810
 Brinkman DMC, 2410
 British Society for Rheumatology Biologics Register, 13, 2896, 2905
 British Society for Rheumatology Biologics Register Control Centre Consortium, 2896, 2905
 British Society of Paediatric and Adolescent Rheumatology, 1286
 Brock M, 1087
 Brodsky O, 938
 Brombacher F, 861
 Brookes AJ, 2620
 Brooks WH, 1035
 Brouwer GM, 1204
 Brown DA, 753
 Brown DE, 3107
 Brown TP, 1152
 Bruce IN, 265, 4113
 Brühl H, 2975
 Brulhart L, 1417
 Brunner HI, 965, 4151
 Bruton J, 674
 Bruyn RLGAW, 3928
 Bubenheim M, 3626
 Bucala R, 3173
 Buckley CD, 4229
 Bukhari M, 2929
 Bunn D, 790, 2143, 2929
 Buoncompagni A, 3138
 Burkhardt H, 2056
 Burner GC, 1365
 Burmester G-R, 2503
 Burrage PS, 892
 Burris TP, 1365
 Burstein D, 1507
 Bush TM, 2092
 Busso N, 101
 Butfiloski EJ, 3759
 Buttari B, 2687
 Buyon JP, 1048, 2099, 4120
 Buzio C, 3159
 Býzet J, 2468

C

 Cabras T, 2216
 Cacoub P, 1315, 2810
 Cakiris A, 345
 Calabrese LH, 2116
 Callejas-Rubio JL, 2098
 Camilleri J, 3837
 Campanelli R, 1648
 Campbell PL, 1787
 Cancedda R, 1175
 Cañete JD, 2784
 Cantagrel A, 3928
 Cao Y, 861
 Capini C, 2255
 Capoluongo E, 658
 Capozzi A, 2687
 Carballo MA, 3805
 Carlsten H, 3261
 Carmouse S, 2232
 Carney G, 696
 Caroli C, 1569
 Carretta R, 1187
 Carroll MC, 2968
 Carta S, 3138
 Carty S, 2244
 Casali B, 3502
 Cascino I, 2640
 Casciola-Rosen L, 2729, 3448
 Casiraghi F, 1629
 Castagnola M, 2216
 CAT-192 Study Group, 323
 Catanoso MG, 3502
 Cattani D, 1706
 Cauli A, 2640, 2807
 Cauvi DM, 1934
 Cauvi G, 1934
 Cavinato RA, 1629
 Cawston T, 3236
 Cenni B, 101
 Cerinic MM, 1994
 Cha C-J, 3662
 Cha S, 1454
 Chakravarty EF, 2092, 4142
 Chakravarty K, 3837
 Chan EKL, 596
 Chan ES, 2840
 Chan FS, 3759
 Chan TM, 702
 Chang M, 3168
 Chang M-Y, 544
 Chang S, 3057
 Chapman J, 938
 Chapman K, 137
 Chapuy-Regaud S, 3541
 Chauhan SK, 2798
 Chen D-H, 544
 Chen G, 453
 Chen H, 1512
 Chen J, 3650
 Chen P-C, 1638
 Chen PP, 1638
 Chen S-Y, 544
 Chen SS, 949
 Chen W, 1798
 Chen WV, 58
 Chen Y-H, 544
 Chen Z, 2936
 Chen Z-J, 3387
 Cheng C, 2999
 Cheng P-C, 544
 Chéreau C, 2455
 Cherfa A, 2232
 Cherry L, 831
 Cheung K, 3949
 Chevrot A, 2747
 Chiarzatti A, 658
 Chibnik LB, 3433
 Chichester CO, 108
 Chilkoti A, 3650
 Chimenti M-S, 1478, 2232
 Chino Y, 2160
 Chintalacharuvu SR, 1365
 Chiu YH, 360
 Chizzolini C, 3459
 Cho C-S, 2299, 2454
 Cho E, 1638
 Cho M-L, 1076
 Cho W-H, 3432
 Chockalingam PS, 4074
 Choe J-Y, 2094
 Choi C-B, 1454
 Choi HK, 2049
 Choi M, 3149
 Choi S-K, 3432
 Chollet-Janin A, 688
 Chong KK, 2512
 Choquette D, 4005
 Chorny A, 531
 Chou C-H, 544
 Chow SK, 1904
 Choy A, 1904
 Choy EHS, 476
 Christgau S, 3236
 Christiansen C, 1549, 2674
 Christin M-S, 3814
 Chu C-Q, 1145
 Chuang M, 1273
 Chubick A, 3896
 Chun M, 117
 Chung KC, 1497
 Chung S-H, 2094
 Chung U-i, 3358
 Ciardelli L, 1648
 Cicuttini F, 1521
 Cihak J, 2975
 Cimino L, 3502
 Cinelli M, 1994
 Cipriani P, 1994
 Cisternas MG, 1397
 Ciurea A, 1417
 Clancy M, 129, 2986
 Clancy RM, 4120
 Clark B, 29
 Clark E, 850
 Clark J, 3096
 Clark TM, 1000
 Clarke AE, 265, 2092
 Clavel C, 3541
 Clements PJ, 1676
 Cleton-Jansen A-M, 586
 Coady D, 3236
 Codreanu C, 3928
 Colbert RA, 215, 2652, 3793
 Collins M, 1152
 Combe C, 2362
 Comets E, 3989
 Compagnone A, 658
 Compeyrot-Lacassagne S, 1966, 4228
 Conaghan PG, 3496
 Condon S, 244
 Conner-Spady B, 1846, 2278
 Connolly MK, 1676
 Connors LH, 3858
 Conti F, 2687
 Conti S, 1629
 Cook EF, 696
 Cook JL, 871
 Cooper C, 208
 Cooper GS, 244, 1721
 Cooper MA, 3107
 Cooper S, 3896
 Cope A, 4104
 Coppock J, 323
 Corluy L, 3919
 Corna D, 1629

Corr M, 3319, 3881
 Corrêa AL, 2352
 Corvol M-T, 698, 2585
 Costabile M, 799
 Costenbader KH, 244, 1251, 1721
 Couzi L, 2362
 Covelli M, 2223
 Cowland JB, 2575, 3326
 Cowper SE, 3173
 Cox NL, 1408
 Cramer D, 2005
 Cravets MW, 3896
 Cravioto M-d-C, 3070
 Creel AH, 568
 Criswell LA, 58, 1745, 2679
 Crompton P, 831
 Cronstein BN, 1440
 Crow MK, 1037, 3412, 3995
 Crowson CS, 820, 3583
 Cucchiari M, 158
 Cui Y, 3662
 Curhan G, 2049
 Curtis JR, 1125, 4226
 Cutolo M, 1, 399, 1719, 2102
 Cuttica R, 3096
 Czech N, 385

D

Daffa N, 2765
 Dai S-Y, 3968
 Dalbeth N, 29
 Dall'Era M, 4142
 D'Angelo S, 2805
 Danoff S, 2065
 Daridon C, 1134, 1464
 Dass S, 2715
 Datta SK, 4132
 Dave M, 2840
 Davey R, 2812
 David CS, 69
 Davidson ENB, 4065
 Davies ME, 2322
 Davies P, 2013
 Davies PG, 1408
 Dávila-Maldonado L, 1242
 Davis A, 3412
 Davis CR, 4038
 Davis JM III, 820, 3583
 Davis MJ, 1497
 Davis-Schwarz K, 3387
 Dawes PT, 3940
 Day J, 3634
 Dayan M, 2371
 Dayer J-M, 3459
 D'Cruz D, 4113
 De Bari C, 489, 714
 de Crombrughe B, 334
 de Groot K, 3847
 de Jonge R, 694
 De Keyser F, 2150
 de Kleer JM, 2410
 De Klerck B, 2595
 de Launay D, 2180
 de Leon P, 3319
 de Paz P, 3805
 de Ramón E, 3080

De Roos AJ, 3189
 De Santis M, 2216
 de Seze J, 3420
 De Vita S, 2223
 de Vlam K, 2698
 de Vries F, 208
 de Vries RRP, 425, 1728, 2913, 3949
 de Vries-Bouwstra JK, 2129, 3949
 De Vriese C, 2566
 De Wolf-Peeters C, 2595
 Deal CL, 722
 Debaix H, 2566
 Deberg M, 3336
 DeGroot J, 199
 Dehler S, 1417
 del Carmen Trabado M, 555
 Del Galdo F, 3478
 Del Papa N, 2223
 Delaney C, 1033
 DeLay ML, 215
 DelBello MP, 4151
 Delfino L, 3138
 Delgado M, 531
 Delporte C, 2566
 Deminière C, 2362
 den Hoed L, 2150
 Denais C, 2232
 Deng JM, 334
 Deng Y, 168
 Dent CM, 2244
 Denton CP, 323, 334, 2005, 2013, 2422, 3489, 3837, 4189, 4229
 Denzel A, 2975
 Depresseux G, 3919
 Derese I, 489, 4095
 Derksen RHHW, 924, 1384, 3879
 Desai SR, 2005
 Devauchelle V, 1134, 1464
 Devereux RB, 3412
 Devlin J, 1408
 Devuyst O, 2566
 Dhar P, 4142
 Diaz-Romero J, 586
 Diaz-Torne C, 2104
 Dickens C, 360
 Dickinson SC, 177
 Dickson MC, 2549
 Dieker JW, 1921
 Dieppe PA, 3610, 3873
 Dietz AB, 1658
 DiFrancesco MW, 4151
 Dijkman BAC, 2129, 3876
 Dilloo D, 995
 Dinarello CA, 2817
 Ding C, 1521
 Ding W-Z, 244
 Dissen E, 2620
 Distler JHW, 311, 1087, 2755, 3564, 4203
 Distler O, 311, 1087, 1094, 2755, 3564, 4203
 Dixey J, 1408
 Dixon WG, 2896, 2905

Doherty M, 137
 Doita M, 1067
 Dolo V, 1994
 Domsic R, 3125
 Dong X, 1219
 Donn R, 972, 1286
 Donnadiou E, 1478
 Dooley LT, 2698
 Dooley MA, 265
 Doré CJ, 3837
 Dorff REN, 693
 Doria AS, 1966
 Doros G, 3858
 Dorotka R, 1118
 Dorph C, 674
 Dosemeci M, 3189
 Dossumbekova A, 3284
 D'Ossualdo A, 3138
 Dougados M, 1846, 3896
 Douglas J, 265
 Doyle B, 850
 Doyle TM, 1292
 Drapé JL, 2747
 Drenkard C, 2811
 Drijfhout JW, 2913, 3949
 Drinane MC, 3448
 du Bois RM, 2005, 4189
 Duance V, 2523
 Dubiel JS, 809
 Dubucquoi S, 3420
 Dudek NL, 3387
 Dudley J, 688, 1417
 Dudley DT, 3347
 Dueymes M, 1134, 1464
 Duggan E, 2255
 Dumitriu M, 1537
 Dunning L, 765, 3510
 Duong LT, 2999
 Durand-Carbajal M, 3070
 Durez P, 3919, 3928
 Durigutto P, 1187
 Duronio V, 871
 Duryea J, 1512
 Dussart P, 3420
 Dutch Working Party on Systemic Lupus Erythematosus, 924
 Dziadzio M, 2013

E

Economopoulos N, 3827
 Edberg JC, 2679, 3375
 Edgerton CC, 2344
 Egberts WV, 2449
 Egerer K, 2503
 Eggeling S, 1685
 Egger M, 3610
 Eggleston P, 1598
 Egl M, 3626
 Eichner M, 1806
 Einhorn E, 2104
 Einstein SG, 4005
 Eklöw C, 2620
 Ekmekci CG, 345
 El-Deredy W, 1345
 El-Gabalawy HS, 2854
 El-Shanti HI, 960

Elashoff D, 3588
 Elashoff R, 1676
 Elias-Jones I, 765
 Elissalde JM, 3020
 Elkon KB, 1145
 Elliott R, 1345
 Elmann A, 2371
 Eloranta M-L, 3112
 Elsaid KA, 108, 3662
 Emery P, 224, 323, 2715, 2812, 3496, 3837, 3896
 Emmerson BC, 1529
 Endo S, 2875
 Endres JL, 89, 1497
 Engels C, 639
 Engleman EP, 693
 Englund M, 4048
 Englund P, 372
 Enk A, 1910
 Enokida M, 3366
 Epis O, 2223
 Eri R, 498
 Erkan D, 2382
 Ernestam S, 448
 Espada G, 3096
 Essex D, 4015

F

Fahmi H, 2288
 Fall N, 3793
 Fanali C, 2216
 Farewell VT, 265, 840, 2708, 4113
 Farhadi J, 586
 Farnetti E, 3502
 Farragher T, 2143
 Farrelly LW, 3738
 Farris AD, 3387
 Fasanmade A, 3096
 Fasham J, 4038
 Fasth A, 2410, 3096
 Fatenejad S, 3928
 Fathi M, 372
 Fearon U, 2919
 Feghali-Bostwick CA, 2432, 3167
 Feifel R, 101
 Feist E, 2503
 Feldman BM, 631, 647, 1974
 Feldmann M, 4015
 Felin EMO, 984
 Felson DT, 129, 1198, 1212, 1378, 1512, 2267, 2986, 2993, 3874, 4048
 Feneberg W, 2774
 Feng G, 453
 Fenollar F, 1713
 Ferguson PJ, 960
 Ferlito F, 3138
 Fernández M, 614, 622, 2812
 Fernández P, 1440
 Fernández-Gutiérrez B, 2789
 Ferraccioli GF, 2216, 3896
 Ferrante A, 799
 Ferreira Borba E, 2352
 Ferrell WR, 441, 765, 3510, 3532

Ferrera F, 1945
 Fert I, 1478, 2232
 Fertig N, 2740, 3125
 Feskanich D, 1251
 Fessler B, 1676
 Feyen O, 995
 Fife MS, 972
 Figueroa M, 555
 Filaci G, 1945
 Filipovich A, 965
 Finckh A, 688, 1417, 1721
 Fink B, 3626
 Finnegan A, 861
 Fiorentino PM, 2038
 Fiorillo MT, 2640, 2807
 Firestein GS, 743, 2854
 Fischetti F, 1187
 Fisher MC, 2840
 Fitting C, 2585
 FitzGerald J, 1945
 Fitzgerald LM, 244
 FitzGerald O, 2919
 Flannery CR, 3675
 Fleischmann R, 3896
 Fliser D, 3847
 Flood S, 2523
 Flores-Borja F, 291
 Flornes L, 2620
 Florquin S, 924
 Flory CM, 3347
 Flynn JL, 2557
 Foell D, 4174
 Folayan G, 1219
 Font J, 265
 Font YM, 1723
 Foreman AJ, 1397
 Formisano D, 3502
 Førre ØT, 2072
 Fortier E, 4074
 Fortier LA, 2335
 Fortin PR, 265
 Fosang AJ, 1549
 Fossel AH, 244, 568
 Fossum S, 2620
 Foulquier C, 3541
 Fox DA, 89, 710, 1497, 1827
 Fragiadaki KG, 1985
 Fragosio-Loyo H, 1242, 3509
 Franceschini F, 2223
 François M, 2585
 Franklin J, 790
 Fransén JH, 1921
 Franz B, 1910
 Fraser PA, 244
 Frasnelli M, 101
 Fraunfelder FW, 3248
 Fredenhausen G, 2503
 Freemer MM, 2679
 French AR, 3107
 Fries JF, 1368
 Frisch M, 1446, 2402
 Fritzscheing B, 1910
 Frost P, 1355
 Fuerst M, 3626
 Fujita J, 1724
 Funovits J, 3226
 Furst DE, 323, 1676, 3896

Furukawa S, 2101

G

Gabay C, 1417
 Gabriel SE, 820, 3583
 Gagliardini E, 1569
 Galant C, 1579
 Galbusera M, 1569
 Galéra P, 3020
 Gallimore JR, 2013
 Gamir ML, 3096
 Gan Y, 2038
 Ganea D, 2608
 Ganson NJ, 1021
 Gao X, 799
 García-Consuegra J, 3805
 Gardner L, 4120
 Garini G, 3159
 Garner P, 4038
 Garofalo T, 2687
 Garred P, 21, 1446, 1598, 2097
 Gastelum NS, 882
 Gathercole L, 972
 Gattorno M, 3138
 Gauliard A, 2503
 Gaumann A, 1094
 Gay RE, 311, 1087, 2464, 2755, 2829, 4203
 Gay S, 4, 311, 779, 1087, 1094, 2464, 2755, 2829, 3523, 3564, 4203
 Geboes L, 2595
 Geirsson AJ, 2633
 Gelse K, 4084
 Gemignani F, 2810
 Geng YJ, 334
 Genovese M, 4142
 Genovese O, 658
 Genth E, 1295
 Gerlag DM, 772, 3869
 Gerli R, 2223
 Gerloni V, 3096
 German Collaborative Group, 1234
 German Systemic Lupus Erythematosus Study Group, 3080
 Germann M, 1685
 Gershoni-Baruch R, 1706
 Geusens P, 2698
 Ghaemmaghami AM, 4182
 Ghinai A, 3502
 Giacomelli R, 1994
 Gialafos EJ, 3827
 Giannakopoulos B, 605
 Giannini EH, 3096
 Gibson SB, 2854
 Giger OT, 1087
 Gilday D, 1966
 Giles I, 280, 2392
 Gilkeson GS, 3738
 Ginzler E, 265
 Giquel B, 1478, 2232
 Gladman DD, 265, 476, 700, 840, 2698, 2708
 Glant TT, 861
 Glass DN, 3793

Glasson S, 2663, 3670
 Glickstein LJ, 1325, 4216
 Gliddon AE, 3837
 Glossop JR, 3940
 Glynn RJ, 384, 696
 Goekoop-Ruiterman YPM, 2129
 Goggins J, 1198
 Goh FG, 3532
 Goh NSL, 2005
 Gold LS, 3189
 Gold RH, 1033
 Goldbach-Mansky R, 1273, 2099
 Goldberg C, 3847
 Golden J, 1676
 Goldenberg DL, 1336
 Goldring MB, 2663
 Goldschmeding R, 924
 Goldsmith CM, 1798
 Gomer RH, 4229
 Gomez MR, 2975
 Gonchoroff DG, 2557
 Gong R, 1608
 Gonzalez A, 3583
 González-Escribano MF, 1234, 3080, 3953
 González-Gay MA, 3080, 3953
 González-Pérez M, 3070
 Gonzalez-Rey E, 531
 Goodfellow RM, 2244
 Gordon C, 265, 1776, 4113
 Goronzy JJ, 1723, 3215
 Goto D, 2160
 Gottberg J-E, 3202
 Gottlieb BS, 3793
 Gough AK, 1408
 Goulvestre C, 2455
 Goupille P, 3887
 Gourh P, 2031
 Govoni M, 2223
 Grace MGA, 2278
 Gracie JA, 765
 Graham TB, 965
 Granell R, 4038
 Granfors K, 2652
 Graninger WB, 274
 Grasselli C, 3159
 Gratacós J, 2784
 Green MRJ, 303
 Greenberg SA, 3784
 Gregersen PK, 58, 1745
 Gregory JS, 3634
 Gregory K, 29
 Greidinger EL, 1589
 Griffin T, 965, 3793
 Griffiths B, 3837, 4113
 Griffiths I, 3236
 Griffiths MM, 69
 Griggs DW, 575
 Grigorian M, 779
 Grimmer C, 4084
 Grogan SP, 586
 Grom AA, 965, 3793
 Groot D, 2180
 Grootscholten C, 924
 Gross KD, 1212, 2993
 Gross WL, 1725
 Grossman J, 1638

Grover PK, 799
 Grundtman C, 674
 Grunewald J, 372
 Grynias MD, 1537
 Gsell W, 441
 Gu X, 58
 Guchelaar H-J, 694, 1765
 Gückel E, 4104
 Guedes-Barbosa LS, 1036
 Guermazi A, 129, 1512, 2986, 4048
 Guerne P-A, 688
 Guerrin M, 3541
 Guetg R, 3610
 Guiducci S, 1994
 Guilak F, 3033
 Guillemin L, 2455
 Guilpain P, 2455
 Gül A, 345
 Gummeson C, 3620
 Gunawardena H, 3132
 Gunnarsson I, 1263, 3080
 Guo JP, 2620
 Gupta A, 360
 Gupta K, 3326
 Gutiérrez C, 1234
 Guzzo C, 2698

H

Ha HR, 3564
 Haahr JP, 1355
 Haas CS, 1817, 2535
 Haas J, 323
 Hachulla E, 3420, 3989
 Hacquard-Bouder C, 1478, 2232
 Hagen EC, 924
 Haggerty HG, 2557
 Hagino H, 3366
 Hahn BH, 1638, 1945
 Hahn PC, 596
 Hakala M, 2467
 Hall A, 3448
 Hall B, 1798
 Hallak J, 2352
 Haller H, 3847
 Halter D, 2698
 Hamada D, 30
 Hamilton J, 101
 Hamlin K, 3387
 Han B, 3748
 Han KH, 2129
 Han SW, 1106
 Han T-U, 1454
 Handa R, 3878
 Hanly JG, 265
 Hannan MT, 2993
 Hannig G, 850
 Hansell DM, 2005
 Hansen BE, 1598
 Hansen BS, 779
 Hanslik-Schnabel B, 1118
 Hant F, 2432, 3468
 Haqqi TM, 3326
 Harada M, 1618
 Harigai M, 1304
 Haringman JJ, 3869
 Harley JB, 2344

- Harper JJ, 3489
Harriman G, 117
Harrington T, 722
Harris S, 3270
Harris TB, 1512
Harrison MJ, 2382
Hart DA, 871
Hartmann M, 1910
Hartmann S, 3271
Haruna Y, 1827
Harvey WF, 1212
Harwood FL, 1529
Hasegawa M, 2101
Hashemi M, 3909
Hashimoto A, 1094
Hashimoto A, 1067, 2170
Hatron P-Y, 3420
Haubitz M, 3847
Haubner R, 1806
Häuselmann HJ, 3610
Hauser T, 311, 2755
Hayami T, 2999
Hayashi S, 1067
Hayashi T, 2160
Hayer S, 79
Hazenber BPC, 2468
He D, 453
He L, 3284
He R, 334
He X, 3215
Healy AM, 117
Healy J, 2549
Hegen M, 1152
Heinlen LD, 2344
Heiskanen KM, 2652
Helin H, 2467
Heliö Le Graverand M-P, 3644
Helliwell P, 700
Helmers SB, 3112
Helmick CG, 1397
Helminen HJ, 3662
Hembrough T, 765
Hemmatzad H, 1087, 2755
Hénault J, 3814
Hennig FF, 4084
Henrickson M, 3096
Henriksson EW, 1263
Henrotin Y, 3336
Henry J, 1854
Henry S, 3588
Hensor EMA, 3496
Hepperle M, 117
Hermann S, 79, 1118
Hermansson M, 3715
Hernandez L, 596
Hernández MV, 2784
Hernández-García C, 2789
Herrero-Beaumont G, 555, 3928
Herrick A, 323, 3837
Hershfield MS, 1021
Hess EV, 1336
Hickling P, 3837
Hietanen J, 2575
Higashimoto I, 662
Highland KB, 2432, 3468
Hii CS, 799
Hindnavis V, 89
Hioki K, 2875
Hirakata M, 1295
Hirashima M, 3968
Hirata K, 1904
Hirohata S, 386, 3509
Hirono K, 4174
Hirschl M, 2103
Hoes AW, 639
Hofbauer AF, 3738
Hoffman GS, 1000
Hoffman HM, 1273, 2101
Hoffman RW, 1589, 3180
Hoffmann L-A, 2774
Höfler E, 274
Hofstaetter JG, 1880, 3685
Hogan P, 722
Hogendoorn PCW, 586
Hohlfeld R, 2774
Hojaili B, 1894
Hokama A, 1724
Hollan I, 2072
Holland SK, 4151
Hollander AP, 177
Holmdahl R, 3253
Holt KG, 2993
Holthuysen AE, 147
Homma S, 1904
Honig S, 2469
Honore C, 1598
Hooker R, 722
Höpkén UE, 3271
Hopkins B, 3670
Hopkinson ND, 3837
Hori S, 2947
Horita T, 2803
Horne WC, 1164
Horst G, 3399
Horwood N, 4104
Hoseini M, 2422
Houbiers J, 2150
Houssiau FA, 1579, 3919
Howell KJ, 3489
Hoyt JG, 850
Hsu VM, 323, 1676
Hu JC, 168
Hu K, 2663
Hu P, 2740
Hu S, 3588
Huang D, 2116
Huang Q, 2192
Huang W, 1021
Hubank M, 1954
Huber LC, 4, 311, 1087, 2755, 3523, 3564
Hudson JJ, 1336
Hüffmeier U, 2056
Hughes CE, 3010
Huizinga TWJ, 425, 433, 694, 1032, 1424, 1728, 1765, 2202, 2492, 2913, 3909, 3949
Hulsman HJM, 1424
Hultman P, 1721
Hültner L, 1806
Hummelshoj T, 1598
Hammers LK, 3448, 4195
Hunder GG, 1723
Hunter DJ, 129, 1198, 1212, 2993, 4048
Huntington JT, 892
Hunziker EB, 1869
Huser CAM, 2322
Husni ME, 244
Husted JA, 840
Hutchings EJ, 2278
Hutin P, 1134, 1464
Huynh N, 2512
Hwang K-K, 1638
Hyrich KL, 13, 2896, 2905
Hytinen MM, 3662
I
Ibba-Manneschi L, 3442
Ichida F, 4174
Iclozan C, 43
Ideguchi H, 464
Ieong S, 3588
Igawa T, 1618
Ihama Y, 1724
Ihn H, 1694
Ijadi-Maghsoodi R, 960
Ijiri K, 2663
Illges H, 1806
Ilwite NT, 965, 3793
Immonen K, 2467
IMPACT 2 Study Group, 2698
Indiveri F, 1945
Inglis JJ, 4015
Inman RD, 234, 4005
Inoue H, 30
International Study Group for Phenotype-Genotype Correlation in Familial Mediterranean Fever, 1706
Inzitari R, 2216
Ioan-Facsinay A, 3949
Ioannou Y, 280, 2392
Ioseliani M, 3087
Irigoyen P, 1745
Irvine J, 799
Isenberg DA, 265, 280, 291, 303, 2392, 4113
Ishigatsubo Y, 464
Ishii O, 2875
Ishii W, 2160
Ishikawa K, 3968
Islander U, 3261
Itakura M, 30
Ito K, 3968
Ito S, 2160
Itoh K, 3554
Itoh S, 3358
Iwakura Y, 521, 1304
Izmailova ES, 117
Izmirly P, 4120
J
Jackson CJ, 2864
Jackson DC, 3387
Jacob CO, 4164
Jacobs CW, 1921
Jacobs J, 509
Jacobs JJ, 3511
Jacobs JP, 2968
Jacobs KMG, 732
Jacobsen S, 21, 1446, 2097
Jacobson SH, 1263
Jaffee B, 117
Jaimes K, 1589
Jajoo R, 244
Jallal B, 3784
Jambou F, 1315
James DW, 1408
James JA, 2344
Jansen NWD, 199
Jawaheer D, 58
Jay GD, 108, 3662
Jhangri GS, 2278
Jiménez SA, 3478
Jiménez-Alonso J, 3080
Jimenez-Boj E, 1118
Jiménez-Santana L, 3070
Jinnin M, 1694
Jochems C, 3261
Johansen J, 4038
Johansson BP, 3253
Johnen H, 753
Johnson BJB, 4216
Johnson MR, 3375
Johnson TA, 2947
Johnson TRC, 2809
Johnsson R, 3620
Jol-van der Zijde CM, 2913
Jones AKP, 1345
Jones E, 714
Jones G, 1521
Jones GT, 1669
Jones SA, 2244
Jónsdóttir T, 1263
Jönsen A, 3080
Joos R, 3096
Joosten LAB, 2957
Jordi B, 3610
Jover JA, 2789
Ju JH, 214, 1076, 2094, 2802, 3043
Julyan PJ, 1345
Jun H-S, 2211
Jüngel A, 311, 1087, 2755, 3523, 3564, 4203
Jüni P, 3610
Junker P, 1234
Jury EC, 291
K
Kabelitz D, 1725
Kabouridis PS, 291
Kadirvelu A, 1904
Kaer LV, 1219
Kafienah W, 177
Kagan A, 3433
Kahan A, 2747
Kaieda S, 1836
Kainberger F, 1118
Kalden JR, 3564
Kallenberg CGM, 2080, 3399, 3588
Kalkopf A, 3261
Kalunian K, 265, 4142
Kamatani N, 30

- Kammouni W, 2854
Kampen WU, 385
Kamphuis S, 1648
Kampolis C, 3827
Kane D, 831
Kang C, 1454
Kang CP, 1454
Kang JH, 1106
Kang S-G, 2454
Kang YM, 1106
Kannian P, 4216
Kapsogeorgou EK, 3977
Karl J, 4038
Karlson EW, 244, 1251, 1721, 1745
Karlsson S, 1798
Karp RM, 850
Karpaš K, 4055
Karsdal MA, 1549, 2674
Kashihara N, 1827
Kastbom A, 448
Kastner DL, 1273, 1706, 2099
Kataoka H, 2803
Kato T, 2018, 3307
Katoh S, 3968
Katsichti P, 1985
Katsumata Y, 3125
Katsuragawa Y, 3554
Katz JN, 568, 696, 1754
Katzav A, 938
Kaut M, 3858
Kavanaugh A, 2698, 4142
Kavantzias N, 3977
Kaveri SV, 3874
Kavian N, 2455
Kawaguchi H, 3358
Kay J, 3433
Keck PE Jr., 1336
Keech CL, 3387
Keenan G, 3096
Keene DR, 334
Keith JC Jr., 1152
Kelchtermans H, 2595
Kelekis NL, 3827
Kellam P, 1954
Kelley J, 3375
Kellner H, 2809
Kelly SJ, 1021
Kelly-Scumpia KM, 3379, 3770
Kelso EB, 765, 3510, 3532
Kemshetti S, 3044
Kennedy L, 4189
Kennell ASM, 303
Kern M, 1745
Kerstens PJSM, 3876
Kettritz R, 3149
Keystone EC, 3226, 3896
Khalafi A, 3706
Khalili H, 1745
Khamashta MA, 265, 4113
Khan A, 1954
Khan KM, 871
Khanna D, 323, 1033, 1676
Khayrullina T, 2608
Khokha R, 905
Kiener PA, 3784
Kievit W, 1765
Kikukawa T, 2875
Kim H-R, 1076
Kim H-Y, 214, 1076, 2094, 2454, 2802, 3043
Kim HA, 2299
Kim IS, 1106
Kim J-S, 1076
Kim JY, 2443
Kim K-S, 3662
Kim K-W, 1076
Kim M, 2099
Kim S-I, 2094
Kim S-W, 3432
Kim SY, 1106
Kim W-U, 2299
Kim Y-J, 1378, 3874
Kimberly RP, 3375
Kinder BW, 2679
King L, 2919
King TE Jr., 2679
King Y, 360
Kinjo F, 1724
Kinjo M, 1904
Kirino Y, 464
Kirwan JR, 4038
Kishimoto K, 1724
Kjeldsen L, 2575
Klareskog L, 1031, 2202, 2620, 3928
Klarlund M, 1446
Klein-Gitelman M, 722, 4164
Klemke C-D, 1910
Klenk E, 215
Klingelhöfer J, 779
Klisch SM, 188
Kłosowska K, 2512
Kneilling M, 1806
Knobloch T, 3284
Knorr R, 244
Kobayashi H, 464
Kobayashi M, 464
Koch AE, 1787, 1817, 2535
Koduri G, 1408
Kohn D, 158
Kohsaka H, 1304, 2947
Kohyama K, 1304
Koike T, 393, 2803
Kojima T, 1164
Kollert F, 1685
Kolling C, 1087
Kolodner RD, 1273
Komai K, 2170
Komano Y, 2803
Kontopoulos K, 3706
Kong SW, 3784
König IR, 2056
Kontinen YT, 2575, 3959
Koo B-I, 3432
Koomans HA, 1384, 3879
Korb A, 79
Korkolopoulou P, 3977
Korn JH, 323
Kouri VP, 3959
Kovats S, 1497
Kowal-Bielecka O, 4203
Koyama Y, 521
Kozyrev SV, 1234
Krammer PH, 1910
Kraus VB, 3650
Kremers HM, 820, 3583
Krenn V, 1806
Krilis SA, 605
Krishnan N, 1507
Krueger GG, 2698
Krystufkova O, 2150
Kuchroo V, 3968
Kuffner T, 753
Kuhn A, 1910
Kuis W, 639, 2410
Kulkarni AB, 1798
Kulkarni B, 1345
Kümpfel T, 2774
Kundi M, 2103
Kunika K, 30
Kunz-Schughart L, 2975
Kuo PH, 3173
Kuroiwa T, 705
Kuroki H, 3554
Kurosaka M, 1067
Kurrceman FAS, 1032, 2202
Kvelstad IL, 2072
Kwoh K, 1512
Kwok E, 4024
Kyburz D, 1417, 2829
Kyrkanides S, 2038
Kyung HS, 1106
- L**
- La Cava A, 1945
Labasse A, 3336
Laborde K, 698
Lafeber FPJG, 199, 732
Laffon A, 555
Lafont JE, 3297
Lafyatis R, 1010, 3167
Lagerquist M, 3261
Lahdenne P, 3096
Lai N-S, 1009
Lai Y-C, 2038
Laine M, 2575
Lal N, 1033
Lalonde JK, 1336
Lam FFY, 3514
Lamb R, 1286
Lambert RGW, 2278, 4005
Lambrianides A, 2392
Lammers J-WJ, 208
Lampa J, 448
Lamprecht P, 1725
Landewé R, 1846
Lane JH, 117
Lane NE, 3319, 3726, 3881
Lang CC, 1904
Langer HE, 386
Langman CB, 977
Lankisch P, 995
Lanyon P, 3837
Lara-Reyes P, 3070
Larche MJ, 303
Lard LR, 1424
Larrosa M, 2784
Larsson J, 1798
Lascorz J, 2056
Latchman DS, 280, 2392
Launay D, 3420
Laurence A, 2936
Laurendeau I, 1315
Laustrop H, 1234
Lauwerys BR, 1579, 3919
LaValley M, 1198, 2267, 2789
LaValle ER, 4074
Laversuch C, 3837
Lavery S, 1537
Laws H-J, 995
Lawson T, 3837
Laxer RM, 647, 1974
Le J, 1273
Le Berre R, 1134, 1464
le Cessie S, 425, 433, 1765
Learnmonth I, 177
Leask A, 4189
Leathurby Y, 1152
Leclercq S, 3020
Ledbetter S, 323
Lee A, 1745
Lee B, 3432
Lee EB, 2443
Lee H-S, 1745
Lee J, 2094
Lee J-H, 2094
Lee J-Y, 2299
Lee PL, 2663
Lee PY, 3759, 3770
Lee S-H, 1076
Lee S-I, 2094
Lee S-S, 2094
Lee Y-H, 2094
Lefranc D, 3420
Legendre F, 3020
Lehman TJA, 2815
Lehtinen K, 2467
Lemaire R, 1010
Lems WF, 3518
Lemster B, 43
Leone A, 949
Leow MK-S, 696
Lerner UH, 910
Lesch ME, 3347
Leufkens HGM, 208
Levarht EWN, 3909
Levin AV, 647
Levin R, 1754
Levine DM, 3412
Levine SM, 2729
Levy R, 2382
Lewén S, 1234
Lewis CE, 2986, 4048
Li L, 1608
Li N, 453, 2211
Li Y, 2663, 3685, 3759
Liang MH, 2072
Libregts S, 147
Liljedahl U, 2202
Lim LC, 1033
Lim LL, 3248
Limburg PC, 2080, 3399
Lin W-S, 1638
Linga Reddy PMV, 1234
Lipp M, 3271
Lipsky P, 1035
Little CB, 3010

Liu H, 1219
 Liu W, 3675
 Liu Z, 1608
 Livneh A, 1706
 Llorente L, 1242, 3509
 Lockhart JC, 441, 765, 3510, 3532
 Lockshin MD, 1048, 2382, 3412, 3872
 Lohmann J, 2056
 Lohse P, 2774
 Loiseau P, 3989
 Loisel S, 1464
 Longaretti L, 1569
 Longo A, 2687
 Loo JA, 3588
 Looney RJ, 1371, 3044
 López de Padilla CM, 1658
 López-Nevot MA, 3080, 3953
 Lord JM, 1776
 Lorentzen JC, 2620
 Lories RJU, 489, 1579, 2482, 4095
 Lorusso J, 850
 Losina E, 568
 Loughlin J, 137
 Lovell DJ, 3096
 Lowe G, 831
 Lowe L, 1152
 Lucas M, 2740, 3125
 Luckow B, 2975
 Ludikhuize J, 2180
 Ludwicka-Bradley A, 2432, 3468
 Ludwig A, 1776
 Ludwig C, 1685
 Luft FC, 3149
 Lui L-Y, 3319
 Lukanidin E, 779
 Lum RF, 58, 1745, 2679
 LUMINA Study Group, 614, 622
 Lundberg IE, 372, 674, 3112
 Lundy SK, 1497
 Lunt M, 13, 790, 2422, 2896, 2905
 Luo H, 3748
 Lüthke K, 2503
 Luthra HS, 69
 Lutzky VP, 2255
 Luyrink L, 3793
 Luyten FP, 489, 3919, 4095
 Luyten RKM, 1384, 3879
 Lynch JA, 4048
 Lyons R, 3770

M

M03-606 Study Group, 4005
 Ma G, 2854
 Ma HLM, 1152
 Ma Y, 2192
 Macchioni P, 3502
 Macfarlane GJ, 360, 1669
 Mack LF, 972
 Mack M, 2975
 Mackay M, 1894
 Macor P, 1187
 MacPeck D, 3928

Maddison PJ, 3837, 4113
 Madhavan S, 3284
 Madry H, 158
 Madsen HO, 21, 1446, 1598, 2097
 Madsen SH, 1549
 Mageed RA, 291
 Maggiore U, 3159
 Maglione W, 2223
 Magni-Manzoni S, 3087
 Magrini F, 3896
 Mahmood U, 117
 Mahomed NN, 568
 Mahr AD, 2789
 Maier S, 3387
 Mailhammer R, 1806
 Mainil-Varlet P, 586
 Maisonneuve T, 1315
 Majeed H, 1706
 Majumdar MK, 3670, 4074
 Maksimowicz-McKinnon K, 1000
 Maksymowych WP, 1846, 2278, 4005
 Malemud CJ, 3326
 Malfait A-M, 575
 Malghem J, 3919
 Malloy R, 3837
 Mameli A, 2807
 Mamura M, 2160
 Manetti M, 1094, 3442
 Mangalam A, 69
 Manganello P, 3159
 Manger B, 1463
 Mangini AJ, 1010
 Manninger SI, 3387
 Manoussakis MN, 3977
 Mansfield PJ, 1787
 Manson JJ, 2392
 Manzi S, 265, 2092
 Manzoni SM, 1648
 Marbini A, 2810
 March L, 2864
 Marchesoni A, 700
 Marengo JL, 555
 Marewicz E, 809
 Mariette X, 3989
 Marinou I, 2549
 Marjanovic N, 2840
 Marodi L, 3096
 Marrelli A, 1994
 Marshall N, 3236
 Martel-Pelletier J, 2288
 Martens HA, 673, 3948
 Martens-Lobenhoff J, 809
 Marti HH, 4203
 Martin C, 1125, 4226
 Martin E, 2255
 Martin I, 586
 Martin J, 1234, 3080, 3953
 Martin TM, 1292
 Martin-Martinez MD, 2566
 Martin-Mola E, 555
 Martinez L, 1589
 Martinez RJ, 1787
 Martini A, 1368, 1648, 3087, 3096, 3138

Martins DC, 1036
 Martins-Carvalho C, 1134
 Martorana D, 3159
 Marzari R, 1187
 Marzo-Ortega H, 3496
 Mason D, 2523
 Mason L, 2392
 Massa M, 1648
 Massarotti E, 244, 1745
 Masuda K, 188, 3650
 Masuko K, 2018, 3307
 Masutani K, 1618
 Matera G, 2957
 Mathieu A, 2640, 2807
 Mathieu C, 2566
 Mathis D, 509, 2968
 Matsubara T, 2101
 Matsubayashi K, 3307
 Matsuda I, 521
 Matsui T, 2018
 Matsumoto I, 2160
 Matsumoto Y, 1304
 Matsuo K, 2018
 Matsuyama W, 662
 Matteson EL, 43, 3167
 Matthey DL, 1408, 3940
 Matthews C, 2919
 Matthys P, 2595
 Matucci-Cerinic M, 2755, 3442, 4203
 Maudoux AL, 1579
 Mavragani CP, 3995
 Mavrikakis M, 1985
 Mayes MD, 323, 1676, 2031
 Mayr KG, 2335
 Mazlumzadeh M, 1723
 Mazzuca SA, 3644
 McAlindon TE, 244, 2267
 McBeth J, 360
 McClain MT, 2344
 McCluskey J, 3387
 McCree P, 1212
 McCrindle B, 631
 McCurdy D, 3096, 4164
 McGonagle D, 224, 699, 714, 2482, 3496, 3601
 McGrath H Jr., 695
 McHugh G, 4216
 McHugh N, 3132, 3837, 4113
 McInnes IB, 765, 831
 McKenzie C, 1507
 McLean S, 441
 McLennan C, 2993
 McNallan KT, 1658
 McNulty AL, 3033
 McQueen F, 29
 Mease PJ, 476, 700
 Mebius RE, 2492
 Méchin M-C, 3541
 Medlej-Hashim M, 1706
 Medsger TA Jr., 2740
 Meijer J, 3588
 Meli V, 1648
 Mendelsohn A, 3096
 Merck Serono and ZymoGenetics Atacicept Study Group, 4142

Merino R, 3805
 Merkel PA, 323, 2789
 Merrill J, 265, 2344
 Merville P, 2362
 Messana I, 2216
 Messer L, 3202
 Metersky M, 1676
 Mewar D, 2549
 Miceli-Richard C, 3989
 Michaud K, 1433, 2135, 2886
 Michel BA, 311, 1087, 2464, 2755, 4203
 Michel JJ, 43
 Michelin C, 1706
 Mielants H, 700, 1846
 Migliaresi S, 2223
 Mikkelsen K, 2072
 Mikulis B, 1507
 Milia AF, 3442
 Miller FW, 2719
 Miller J-nH, 2038
 Milliken ST, 753
 Millo E, 1945
 Mimori A, 3554
 Mimori T, 1295
 Mimura Y, 1694
 Minami A, 521
 Mineau F, 2288
 Miniati I, 1994
 Minota S, 2813
 Miossec P, 2111
 Misasi R, 2687
 Mistry S, 177
 Mitani M, 1067
 Mitera T, 2595
 Mitsos P, 3827
 Mitsuyama H, 662
 Mittoo S, 4195
 Miura K, 464
 Miura T, 2947
 Miura Y, 1067, 2170
 Miyake K, 1618
 Miyake S, 1836
 Miyakis S, 605
 Miyasaka N, 1304
 Miyatake K, 30
 Miyawaki T, 4174
 Mo L, 743
 Moak Z, 1273
 Mobley JL, 3347
 Moch H, 1087
 Mochizuki M, 3554
 Mödder G, 386
 Modesto C, 3805
 Moghaddami N, 799
 Mogun H, 384
 Mohan C, 949, 3057
 Moiola D, 1569
 Molad Y, 3928
 Moldawer LL, 3379
 Molinolo A, 1798
 Moll C, 2784
 Möller B, 1417
 Mollmark J, 3448
 Molloy ES, 2116
 Monach PA, 2968, 3872
 Montecucco C, 2223

Montesinos MC, 1440
 Montgomery DS, 2549
 Moore DJ, 2549
 Moore J, 753
 Moore PA, 3748
 Moots R, 3837
 Morawietz L, 1806
 Moreau J-F, 2362
 Moreland LW, 1051
 Moreno P, 3805
 Mori T, 2875
 Morita Y, 1827
 Moritani M, 30
 Moritz F, 4, 1087, 2755
 Morris EA, 3670, 3675, 4074
 Morriss R, 360
 Mort JS, 905
 Moshous D, 995
 Mössner R, 2056
 Motyl CD, 1497
 Moudgil KD, 1490
 Moulton L, 2455, 3420
 Moutos FT, 3033
 Moutsopoulos HM, 3827, 3977
 Moutsopoulos NM, 3995
 Moyer-Mileur LJ, 984
 Moyssakis I, 3827
 Mozes E, 2371
 Mubarak K, 1676
 Mudd PA, 3387
 Mueller JL, 1273
 Mueller L, 4084
 Muller RH, 2919
 Mülleman D, 3887
 Muller S, 1921
 Müller-Ladner U, 1094, 3442
 Müller-Quernheim J, 1685
 Mulligan-Kehoe MJ, 3448
 Mullins M, 2729
 Muneta T, 3358
 Murakami S, 464
 Muraoka T, 3366
 Murayama H, 3307
 Murphy CL, 3297
 Murphy L, 1397
 Muul L, 2936
 Myones BL, 3096, 4164

N

Nachat R, 3541
 Nacionales DC, 3379, 3770
 Nadal A, 1723
 Nadler SG, 2557
 Nagai S, 1295
 Nagai T, 1010
 Nagatani K, 3554
 Nagpal S, 1365
 Nagy K, 3096
 Nah J-C, 3432
 Naina HVK, 3270
 Nakae T, 1304
 Nakajima K, 3554
 Nakamura H, 2018, 3307
 Nakano K, 1559
 Nakano S, 30
 Nakashima H, 1618
 Nakayamada S, 1559, 2466

Nalla RK, 3726
 Nam EJ, 1106
 Nandakumar KS, 3253
 Nandula SR, 1798
 Narain S, 596, 3379, 3759
 Naranjo A, 3805
 Nascem H, 2929
 Nassiri M, 1589
 Negrini SM, 1175
 Neidhart M, 779
 Nelson S, 4151
 Neri TM, 3159
 Netea MG, 2957
 Neu CP, 3706
 Neuen-Jacob E, 3626
 Neumann E, 1094, 3442
 Nevitt MC, 1512, 2986, 3319, 4048
 Nguyen LT, 509
 Nguyen QT, 882
 Ni L, 453
 Nickerson-Nutter C, 1152
 Nicola PJ, 820, 3583
 Nicoli D, 3502
 Niedermeier M, 2975
 Niehues T, 995
 Nielsen GH, 779
 Nielsen NM, 2402
 Nietert PJ, 2432, 3468
 Niewold TB, 3995
 Nihtyanova S, 2422
 Niikura T, 2312
 Niuro H, 1618
 Nijk MT, 3399
 Niki T, 3968
 Nisar M, 3837
 Nishi N, 3968
 Nishihira J, 521
 Nishioka K, 2018, 3307
 Nishiyama T, 1067
 Nititham J, 2679
 Nityanand S, 2798
 Niu J, 129, 1212, 2986, 2993, 4048
 Nived O, 265
 Nixon NB, 3940
 Nöbauer-Huhmann I, 1118
 Nobumoto A, 3968
 Nocton J, 4164
 Noordegraaf M, 732
 Norambuena X, 3087
 North J, 3132
 Nose M, 2170
 Nossent HC, 2072
 Notkins AL, 2211
 Notley CA, 4015
 Nowell MA, 2244
 Nozaki T, 2875
 Nyberg F, 255
 Nzeusseu Toukap A, 1579

O

Oates JC, 3738
 O'Banion MK, 2038
 Oberle N, 1910
 Ocain T, 117
 O'Connor P, 3496

Oddis CV, 3125
 O'Dell JR, 3884
 Oegema TR, 3176
 Oene MV, 137
 Oestergaard S, 2674
 Ogilvie EM, 972, 1286, 1954
 Ogishima H, 2160
 Oh H-J, 1076
 O'Hanlon TP, 2719
 O'Hara C, 3167
 Ohata J, 2947
 Ohlsson C, 3261
 Ohno S, 464
 Ohshima S, 521
 Ohya K, 1164
 Okamoto H, 2813
 Okano T, 3366
 Oki S, 1836
 Oku B, 345
 Oliveira M, 3336
 Oliver J, 3953
 Olivieri I, 2805
 Ollier WER, 1408
 Olman M, 1676
 Olsen BR, 2663
 Olson J, 965, 3793
 O'Mahony M, 4120
 Onodera S, 521
 Oomizu S, 3968
 Ophir R, 2371
 Orefice M, 2223
 Ornstein E, 3620
 Orozco-Narváez A, 1242
 Ortego-Centeno N, 2098, 3080
 Ortona E, 2687
 Ory PA, 476
 Osabe D, 30
 Osame M, 662
 O'Shea JJ, 2936
 Ospelt C, 2829
 O'Sullivan B, 2255
 Otsa K, 1719
 Otsuka R, 1904
 Otterness IG, 3644
 O'Valle F, 531
 Owen T, 3044
 Ozaki S, 2875
 Özbek U, 345
 Ozdogan H, 1706
 Özen S, 1706
 Ozonoff A, 3858

P

Pachman LM, 977
 Padula A, 2805
 Padyukov L, 448, 2202, 2620
 Paediatric Rheumatology International Trials Organisation, 3096
 Paget SA, 3412
 Pagnoux C, 2455
 Paintaud G, 3887
 Pakozdi A, 1787, 2535
 Paladini F, 2640
 Palmer HS, 3532
 Palombi G, 2223
 Pan Z-j, 3387
 Pankey H, 244
 Panush RS, 693
 Papamichael C, 1985
 Papendrecht-van der Voort EAM, 2913
 Papuga MO, 4024
 Parcel Y, 3459
 Park B-H, 2299
 Park GS, 1033
 Park J, 2840
 Park JY, 1106
 Park K-S, 2454
 Park M-K, 1076
 Park S-H, 214, 1076, 2094, 2802, 3043
 Park S-W, 3432
 Park YW, 3215
 Parri R, 2523
 Parsley E, 1676
 Pascual-Salcedo D, 3953
 Passalia M, 1648
 Passiu G, 2807
 Passo MH, 965
 Pasta DJ, 1397
 Patel RK, 3509
 Patel S, 2143
 Patkar N, 1125, 4226
 Patsouris E, 3977
 Paulino J, 555
 Paulus HE, 1033
 Pavan A, 1994
 Pavelka K, 779, 4055
 Paz N, 117
 Pease CT, 3496
 Pechkovsky DV, 1685
 Pedersen BV, 1446
 Pedersen M, 1446
 Pedersen R, 3928
 Pediatric Rheumatology Collaborative Study Group, 3096
 Peeters J, 1424, 4095
 Pelagatti MA, 3138
 Pellegrin J-L, 2362
 Pelletier J-P, 2288
 Peluso G, 2216
 Pena-Rossi C, 4142
 Peng H, 2663
 Peng SL, 395
 Pennesi G, 1175
 Pennock AT, 1529
 Penttinen MA, 2652
 Pepys MB, 2013, 4229
 Perdok RJ, 476
 Perera A, 2740
 Pericleous C, 280
 Pers J-O, 1134, 1464
 Pesci A, 3159
 Pessler F, 2104
 Peterfy C, 1512
 Petersen J, 779
 Peterson M, 2382
 Petri M, 265, 2382
 Petrow PK, 3271
 Pettit AR, 2255
 Petty RE, 3096
 Peutz-Kootstra CJ, 924

Pfander D, 4084
 Pharmacogenetics Collaborative Research Group, 1765
 Phillips RL, 2999
 Piancino MG, 2038
 Piastra M, 658
 Pichika R, 3650
 Pichler BJ, 1806
 Pick CG, 938
 Pickarski M, 2999
 Piette JC, 1315, 2810
 Pihakari A, 2575
 Pijsse J, 3588
 Pilecky M, 4203
 Pillemer SR, 3995
 Pilling D, 4229
 Pillinger MH, 2840
 Pinkus JL, 3784
 Pipitone N, 3502
 Pisetsky DS, 3564
 Pistorio A, 1648, 3087
 Pitashny M, 1894
 Pitelka V, 1854
 Pizzorni C, 2102
 Plaas A, 1537
 Plachý J, 2975
 Plastiras SC, 3827
 Platsoucas CD, 409
 Plaza S, 3805
 Plevin R, 3532
 Poduval P, 3959
 Poiradeau S, 2585
 Pollard KM, 1721, 1934
 Pöllmann W, 2774
 Pals HA, 1204, 3634
 Polzer K, 4104
 Pons-Estel B, 1234
 Poole AR, 1846, 2919
 Popa C, 2957
 Pope RM, 2192, 3183
 Popovic K, 255
 Porola P, 2575
 Porter AE, 3726
 Porto A, 555
 Posthumus MD, 3948
 Powell AJ, 3010
 Powell J, 323
 Powell RJ, 2765, 4182
 Power C, 1669
 Prabu A, 4113
 Prada A, 965
 Prahald S, 984
 Prakken B, 389, 639, 1648
 Praprotnik S, 4228
 Prasse A, 1685
 Prayson R, 2072
 Price A, 441
 Price HE, 977
 Pricur A-M, 3096
 Prin L, 3420
 Priori R, 2223
 Prokaeva T, 3858
 Proulx ST, 4024
 Prouse P, 1408
 Pruijn GJM, 2449, 3949
 Pryjma J, 809
 Pucino F, 2099

Puéal X, 1713, 3989
 Pugnère D, 1706
 Pujol JP, 3020
 Pulitanò S, 658
 Putnam CD, 1273
 Putterman C, 949, 1894
 Puzas JE, 2038
 Pyrasopoulou A, 2243

Q

Qing X, 1894
 Qiu Y, 3675
 Quan N, 3284
 Queiró R, 2784
 Quick S, 1910

R

Raben N, 2729
 Rad AM, 1817
 Radford PM, 2765, 4182
 Radin EL, 3873
 Radjenovic A, 3496
 Radstake TRDJ, 2957
 Rahgozar S, 605
 Rahman A, 280, 2392, 4113
 Rahman P, 4005
 Rajmakers R, 2449
 Rakowski T, 809
 Ramanan AV, 965
 Ramos E, 3805
 Ramsey-Goldman R, 265
 Rannou F, 2585
 Ransohoff RM, 2116
 Ranstam J, 3620
 Raoult D, 1713
 Rasmussen E, 372
 Rau R, 3575
 Ravelli A, 3087, 3096
 Ray D, 360
 Raychaudhuri A, 3096
 Raymond Y, 3814
 Raza K, 1776
 Read C, 1676
 Reddi AH, 2312, 3706
 Redlich K, 79
 Redman S, 224
 Reed AM, 1658
 Reedquist KA, 2180
 Reefman E, 3399
 Reeve VM, 30
 Reeves WH, 596, 3379, 3759, 3770
 Reginster J-Y, 2105
 Rehrig CD, 1021
 Reich K, 2056
 Reichenbach S, 3610
 Reichlin M, 938
 Reiff A, 4164
 Reijman M, 1204, 3634
 Reis A, 2056
 Reiser MF, 2809
 Remmers EF, 1273
 Remuzzi G, 1569, 1629
 Renaudineau Y, 1464
 Renzoni EA, 4189
 Restuccia G, 3502

Reuman P, 3096
 Revaz S, 1417
 Reveille JD, 234, 614, 622, 2031, 2812
 Rhee DK, 3662
 Rhodes LA, 3496
 Rhys-Dillon C, 3837
 Ribbhammar U, 2620
 Richards HB, 596, 3759
 Richards PJ, 2244
 Richaud-Patin Y, 1242
 Richette P, 698
 Richter F, 351
 Rider LG, 2719
 Riehl A, 1910
 Riganò R, 2687
 Rigante D, 658
 Rijkers GT, 639
 Riksen NP, 694
 Riley DJ, 1676
 Rios-Fernández R, 2098
 Ris MD, 4151
 Ritchie RO, 3726
 Ritchlin CT, 476, 4024
 Rius J, 2784, 3805
 Rizzi M, 1945
 Robertson CM, 1529
 Robins S, 3236
 Robitaille G, 3814
 Robledo G, 3953
 Röcken M, 1806
 Rodriguez-Reyna TS, 2740
 Roelofs MF, 2957
 Roemer F, 2986, 4048
 Roger VL, 820, 3583
 Rogers G, 129
 Rolle S, 3149
 Romagnani P, 1569
 Roman MJ, 3412
 Román Ivorra JA, 555
 Romero-Díaz J, 3070
 Ronaghy A, 639
 Rondan HK, 1424
 Rongen GA, 694
 Rönnblom L, 2202, 3112
 Rönnelid J, 2202
 Roosendaal G, 199
 Roosnek E, 3459
 Rosé CD, 1292
 Rose JB, 647, 1974
 Rosen A, 2729, 3448
 Rosenbaum JT, 3248
 Rossi F, 3087
 Rostgaard K, 2402
 Roth J, 4174
 Roth MD, 1676
 Rothfield N, 1676
 Rothschild B, 3172
 Rottoli D, 1629
 Rouster-Stevens KA, 977
 Rovenský J, 4055
 Rubartelli A, 3138
 Rübsamen H, 2774
 Rudiger A, 3489
 Rudolph PE, 2503
 Rueda B, 3953
 Ruperto N, 3087, 3096

Ruth JH, 2535
 Ruzicka T, 1910
 Ruzickova S, 2150

S

Saadoun D, 1315, 2810
 Saag KG, 1125, 4226
 Saag M, 1125
 Saatvedt K, 2072
 Sabatino J, 1806
 Sabio JM, 3080
 Saccardi R, 1994
 Sack B, 129, 1212
 Sadanaga A, 1618
 Saemann M, 1880
 Safadi FF, 2608
 Sah RL, 188, 882
 Sahebjam S, 905
 Sahimbegovic E, 1463
 Sahlberg AS, 2652
 Saita N, 3968
 Saito H, 1164
 Saito K, 1559, 2466, 4174
 Sakai C, 2170
 Sakai Y, 1067
 Sakata A, 3968
 Sakata K-m, 3968
 Sakkas LI, 409
 Saklatvala J, 3715
 Salaman MR, 303
 Salemi S, 2464
 Salmon JE, 3412
 Salmon M, 1776, 4229
 Salomonsson S, 674
 Salonen D, 4005
 Salvarani C, 3502
 Sambrook PN, 2864
 Sammaritano L, 2382, 3412
 Sánchez E, 3080
 Sánchez-Guerrero J, 265, 1242, 3070, 3509
 Sánchez-Román J, 3080
 Sandell LJ, 2474
 Sanders EAM, 639
 Sanders ME, 2180
 Sandhu HS, 1336
 Sandusky GE, 1365
 Sanmartí R, 2784
 Santospirito V, 2805
 Sanz I, 3044
 Saraux A, 1134, 1464
 Sarkar S, 89, 710
 Sarkisian T, 1706
 Sarkisian T, 631
 Sasso EH, 476
 Sato J, 3087
 Sato S, 1295
 Satoh M, 596, 1827, 3379, 3770
 Satpute SR, 1490
 Sattar N, 831
 Saurenmann RK, 647, 1974, 3096
 Savi M, 3159
 Savouret J-F, 698, 2585
 Sawai H, 3215
 Sawaji Y, 3715
 Sax PE, 1754

- Saxne T, 3236
 Scafe CR, 30
 Scarano E, 2805
 Scarlett EL, 1021
 Schaefer CJ, 3347
 Schäfer M, 1685
 Schaible H-G, 351
 Schaper J, 995
 Scheel-Toellner D, 1776
 Scheja A, 3459
 Schelling S, 3670
 Schentag CT, 840, 2708
 Schett G, 79, 311, 1118, 1463, 4104, 4203
 Schilders G, 2449
 Schmid TM, 3511, 3706
 Schmidt M, 1720
 Schmidt TA, 882
 Schmitt A, 1478
 Schneeweiss S, 384, 696, 1754
 Schneider M, 995
 Schneider R, 647, 1974
 Schopf L, 117
 Schorr O, 2829
 Schraufnagel DE, 1676
 Schrier DJ, 3347
 Schrodi SJ, 3168
 Schrooten J, 4095
 Schulz A, 1094
 Schulze-Horsel U, 311, 3564
 Schulze-Koops H, 4104
 Schumacher BL, 882
 Schumacher HR, 2104, 3854
 Schurig U, 3271
 Schwahn BC, 995
 Schwartz N, 1894
 Schwarz EM, 4024
 Schwarz H, 3610
 Schwarz K, 995
 Sciacca R, 1904
 Scleroderma Clinical Trials Consortium, 323
 Scleroderma Lung Study Group, 1676
 Scott A, 871
 Scott DW, 1490
 Scott H, 2072
 Scumpia PO, 3379
 Sebbag M, 3541
 Secondary and Primary Vasculitis Study Group, 3159
 Seddighzadeh M, 2620
 Sedláčková M, 4055
 Segal MS, 596, 3759
 Séguret F, 1706
 Seibold JR, 323, 1676
 Seifert MH, 303
 Seki M, 3968
 Sekine C, 1304
 Selçukbiricik F, 345
 Seldin DC, 3858
 Semaan N, 3202
 Senécal J-L, 3814
 Senices M, 1152
 Senolt L, 779
 Seriole B, 1719
 Seror R, 2747
 Serre G, 3541
 Servettaz A, 2455
 Seshadri R, 977
 Seth M, 2335
 Setoguchi S, 696, 1754
 Sette A, 1648
 Setton LA, 3650
 Sfrikakis PP, 1985
 Shaftel SS, 2038
 Shahrara S, 2535
 Shamji MF, 3650
 Shand L, 2422
 Sharabi A, 2371
 Sharif M, 4038
 Sharma L, 1044, 3872
 Sharp JT, 476, 1033
 Shatin D, 1125
 Shealy DJ, 4024
 Sheehan T, 29
 Sheeran T, 3837
 Sheibanie AF, 2608
 Sheldon R, 4074
 Shen B, 453
 Sherry DD, 965, 3793
 Shetty SK, 1507
 Shi F-D, 1945
 Shi X, 3057
 Shi-wen X, 4189
 Shiao A-L, 544
 Shigihara T, 2211
 Shih F, 2823, 3107
 Shimada K, 2018
 Shimizu S, 3358
 Shin JJ, 1325
 Shinomiya F, 30
 Shinomiya K, 3358
 Shintani N, 1869
 Shiozawa K, 2170
 Shiozawa S, 1067, 2170
 Shirahama Y, 662
 Shishido K, 3307
 Shoenfeld Y, 938, 1736
 Shore RM, 977
 Shukla M, 3326
 Shyy JY-J, 2585
 Sibilia J, 3202
 Sibley B, 1152
 Siegel DM, 965
 Signorovitch J, 244
 Sigurdsson S, 2202
 Sillat T, 3959
 Sillman N, 323
 Silman AJ, 13, 360, 790, 1669, 2143, 2422, 2896, 2905, 2929
 Silva CAA, 2352
 Silver RM, 1676, 2432, 3468
 Silverman ED, 631, 647, 1966, 1974, 3096, 4164, 4228
 Silverman MD, 1817
 Simmen B, 3564
 Simms R, 1676
 Simon M, 3541
 Simons M, 3448
 Sims G, 1035
 Sims TJ, 177
 Singer J, 3626
 Singh M, 2798
 Singh RR, 1219
 Singleton CB, 2432, 3468
 Sinico RA, 3159
 Sir J-J, 3432
 Sistonen L, 2652
 Skapenko A, 4104
 Skibshøj I, 779
 Skinner M, 3858
 Skogh T, 448
 Slinn J, 3132
 Smeets TJM, 753, 2180, 3869
 Smith KA, 4132
 Smith MD, 753
 Smith SA, 1658
 Smits P, 694
 Smolen JS, 79, 274, 1118, 1369, 1880, 3226, 3685
 Smolnikova M, 2620
 Smuda C, 1497
 So A, 101
 Soares PMF, 2352
 Sobel ES, 596, 3759, 3770
 Söderkvist P, 448
 Soeder S, 586
 Solciman A, 3685
 Solodceev I, 938
 Solomon A, 4164
 Solomon DH, 384, 696, 1754
 Solomon S, 1806
 Somers EC, 1497
 Sommerhoff CP, 3532
 Sondergaard B-C, 1549, 2674
 Sønderstrup G, 2150
 Song J-H, 2299
 Song R-H, 575
 Song YW, 1295, 2443
 Sonnylal S, 334
 Sorice M, 2687
 Sorrentino R, 2640, 2807
 Soukhareva N, 1490
 Sowers MR, 698
 Soyfoo MS, 2566
 Spanish Collaborative Group, 1234
 Spector TD, 137
 Spencer B, 3858
 Speyer I, 1424
 Spiera RF, 2789
 Sporn MB, 892
 Sprott H, 2464
 Sreenath T, 1798
 Srinivasan M, 498
 Stabile A, 658
 Stähle M, 2575
 Stamatelopoulou KS, 1985
 Stampfer MJ, 1251
 Stanczyk J, 2829, 3523
 Stanford KE, 1336
 Stanford SB, 1336
 Stangassinger M, 2975
 Stedman N, 3670
 Steen VD, 1676, 2740
 Steenberg EJ, 924
 Steere AC, 1325, 4216
 Stefanadis C, 1985
 Stegeman CA, 2080
 Steiner CW, 274
 Steiner G, 274
 Steinfeld SD, 2566
 Steinhoff M, 101
 Steinmeyer J, 1094
 Steinsson K, 265
 Stephens D, 1966
 Stock CJW, 972
 Stone JH, 2065
 Stone KB, 3125
 Strange C, 1676
 Straub RH, 399, 1720
 Streisand J, 323
 Stroes ESG, 2097
 Stuchin SA, 2840
 Study of Osteoporotic Fractures Research Group, 3319
 Stumbles P, 2255
 Stumpf C, 1910
 Sturfelt G, 265, 3080
 Sturmer T, 384
 Sturrock RD, 441
 Suárez A, 1234
 Sugihara M, 2160
 Sugihara T, 1304
 Sugioaka K, 1904
 Sugiyama N, 1618
 Sulli A, 2102
 Sumer EU, 1549
 Sumida T, 2160
 Summerlin D-J, 498
 Sundelin B, 1263
 Sundry JS, 1021
 Sunk IG, 1880, 3685
 Surdacki A, 809
 Surdulescu GL, 137
 Suri-Payer E, 1910
 Suwa A, 1295
 Suzuki D, 224
 Suzuki E, 2160
 Suzuki T, 2160
 Svejgaard A, 1446
 Svenungsson E, 3080
 Swart D, 1145
 Sweeney SE, 743
 Swiss Clinical Quality Management Program for Rheumatoid Arthritis, 1417
 Swiss Viscosupplementation Trial Group, 3610
 Swoboda B, 4084
 Sykora J, 1910
 Symmons DPM, 13, 790, 2143, 2896, 2905, 2929
 Systemic Lupus International Collaborating Clinics, 265
 Syvänen A-C, 2202
 Szer I, 3096
 Szumiloski J, 2999
 Szumowski K, 1198

T

- Taams LS, 732
 Tak PP, 753, 772, 2180, 2492, 3869
 Takada H, 3307
 Takada T, 1295
 Takahara H, 3541

Takahashi K, 2875
 Takahashi M, 1164
 Takata Y, 30
 Takedachi M, 1440
 Takeno M, 464
 Talke Y, 2975
 Tallents RH, 2038
 Talma S, 3297
 Tamaki K, 1694
 Tan AL, 699, 2482, 3496
 Tan EM, 701
 Tanaka Y, 1559, 2466
 Taneja V, 69
 Tankó LB, 2674
 Tanner SF, 3496
 Targoff IN, 1295, 2719
 Tarner IH, 1094, 3442
 Tas SW, 2180
 Tashkin DP, 1676
 Tassi S, 3138
 Tasso R, 1175
 Tateishi K, 1067
 Tato CM, 2936
 Taurog JD, 2478
 Taviloglu K, 345
 Tavoni A, 2223
 Taylor K, 2679
 Taylor W, 700
 Tectle H, 3347
 Tedder T, 3057
 Tedesco F, 1187
 Teh L-S, 4113
 TEMPO Study Investigators, 3928
 ten Cate R, 2410
 ten Wolde S, 2129
 Teng YKO, 3909
 Tennent GA, 2013, 4229
 Terwilliger EF, 158
 Teshima R, 3366
 Tesmer LA, 89, 1497
 Theate I, 1579
 Theiler R, 3610
 Thelmer N, 2585
 Theodore A, 1676
 Therneau TM, 820, 3583
 Thiel MJ, 3347
 Thjodleifsson B, 2633
 Thomas E, 2244
 Thomas JT, 4095
 Thomas R, 2255
 Thompson K, 265
 Thompson LF, 1440
 Thompson S, 3793
 Thomson GTD, 4005
 Thomson W, 972, 1286, 1408, 2929
 Thonar EJ-MA, 188
 Thornton S, 3793
 Thurlings RM, 772
 Thurn T, 158
 Tighe PJ, 2765, 4182
 Timmer TCG, 2492
 Tincani A, 1569
 Tocker J, 1145
 Todd DJ, 3433
 Todd I, 2765, 4182

Toes REM, 425, 433, 1032, 1424, 1728, 2202, 2913, 3909, 3949
 Toews GB, 1685
 Tohma S, 2018
 Tohyama H, 521
 Tom BDM, 840, 2708
 Toma CD, 1880
 Tomás-Jiménez C, 2098
 Tomi C, 1836
 Tommerup N, 2402
 Tomsic M, 4228
 Topley N, 2244
 Torner J, 2986, 4048
 Tornling G, 372
 Torres JR, 3662
 Tortorella MD, 575
 Tough DF, 3874
 Touitou I, 1706, 3880
 Toukap AN, 3919
 Touni H, 224
 Tousoulis D, 1985
 Tozzoli R, 1736
 Tran CN, 1497
 Trattig S, 1118
 Traupe H, 2056
 Travers S, 3096
 Trê T, 4055
 Trelle S, 3610
 Trenkmann M, 1087
 Triantafyllidou E, 2013
 Troelsen LN, 21, 2097
 Truedsson L, 3080
 Tsagris L, 2585
 Tsai C-Y, 544
 Tsao BP, 1033
 Tschannen B, 3610
 Tschopp J, 3183
 Tseng C-E, 2099
 Tsui FWL, 234
 Tsui HW, 234
 Tsuiji W, 1118
 Tsukano M, 3968
 Tsumiyama K, 2170
 Tsutsumi A, 2160
 Tudor R, 2729
 Tumiaty B, 3159
 Tunca M, 1706
 Tung C-H, 1009
 Tunyogi-Csapo M, 861
 Turesson C, 43
 Turkiewicz AM, 1051
 Turner MJ, 215
 Tylzanowski P, 4095
 Tyndall A, 1994
 Tyrrell PN, 1966, 1974
 Tzelepis GE, 3827
 Tzioufas AG, 2211

U

Udby L, 2575
 Udell J, 3896
 Ueda A, 464
 Ueno M, 3968
 Uese K, 4174
 Ulfgren A-K, 1094, 3112
 Ullmann N, 3087

Unalp-Arida A, 2382
 Urbani S, 1994
 Urowitz MB, 265
 Urquhart AG, 1497
 Usmani SE, 3693
 Üstek D, 345

V

Vacca A, 2807
 Vaglio A, 3159
 Valat J-P, 3887
 Valdes AM, 137
 Valentini G, 3928
 Valesini G, 2223, 2687
 Vallejo AN, 43, 1658
 van Aken J, 1424
 van Amelsfort JMR, 732
 Van Balen M, 2595
 van Bavel CC, 1921
 van Beuningen HM, 4065
 van de Loo FAJ, 4065
 van de Putte L, 3873
 van den Berg WB, 147, 2957, 4065
 van den Hoogen F, 323, 2150
 van der Bijl AE, 2129, 3876
 van der Geld YM, 2080
 van der Heijde D, 1031, 1846, 2698, 3928
 van der Helm-van Mil AHM, 425, 433, 1032, 1728, 2913, 3949
 van der Klis FRM, 639
 van der Kooij SM, 1765
 van der Kraan PM, 147, 4065
 van der Meer BD, 2080
 van der Meer JWM, 2957
 van der Net JJ, 639
 van der Pouw Kraan TCTM, 2492
 van der Tempel H, 1846
 van der Vlag J, 1921
 van Dongen H, 433, 1424
 van Gameren II, 2468
 van Houwelingen HC, 924
 van Krugten MV, 2129
 van Laar JM, 3909
 van Lent PL, 147
 van Leuven SI, 2097
 van Lierop MJC, 2150
 van Riel P, 694
 van Rijswijk MH, 2468
 van Rooijen N, 147
 van Roon JAG, 732
 van Rossum MAJ, 639, 2410
 van Schaardenburg D, 772
 van Schaardenburg M, 2150
 van Seventer JM, 1010
 van Staa TP, 208
 van Wajdula J, 1204
 van Tol MJD, 639, 2410, 2913
 van Vollenhoven RF, 265, 1263, 3896
 Vandooren B, 2150
 VanPelt CS, 334
 Varadarajan U, 4074
 Varela N, 531
 Varga J, 1676
 Veale DJ, 323, 2919
 Veeraraghavan S, 2005
 Vegosen LJ, 2719
 Vehe R, 1658
 Vencovsky J, 2150
 Vergunst CE, 3869
 Verhaar MC, 1384, 3879
 Vermeer-de Bondt PE, 639
 Vermersch M, 3420
 Vermersch P, 3420
 Verpoort KN, 425, 2913, 3949
 Verschoor A, 2968
 Verschueren P, 3919
 Verweij CL, 2492
 Viallard J-F, 2362
 Vidaud M, 1315
 Viemann D, 4174
 Vilá LM, 614, 622, 1723, 2812
 Vilela V, 2382
 Villa AR, 2811
 Villanueva J, 965
 Villiger PM, 3610
 Vincent C, 3541
 Vincent E, 4142
 Vinkenog M, 2180
 Virtanen I, 3959
 Visentin MT, 3489
 Visser K, 1424
 Vissink A, 3588
 Visvanathan S, 3096
 Vital EM, 2715
 Vitali C, 2223
 Vitek P, 4055
 Vitters EL, 4065
 Vlad SC, 2267
 Vlasáková V, 4055
 Vlietinck R, 1745
 Vogl T, 4174
 Vogt M, 3125
 Volin MV, 2512
 Volkman A, 387
 von Vietinghoff S, 3149
 Vondenhoff M, 2492
 Vos K, 772
 Vossen JM, 2410
 Vratisnos G, 2557
 Vuk-Pavlovic S, 1658
 Vural B, 345

W

Waarsing JH, 3634
 Wachsmann D, 3202
 Wada T, 662
 Wagers AJ, 2968
 Wagner-Weiner L, 4164
 Wahl SM, 3995
 Wahlström J, 372
 Wahren-Herlenius M, 255
 Wajdula J, 3928
 Wakamatsu E, 2160
 Walker DC, 871
 Wallace DJ, 265, 693, 4142
 Walsh RJ, 3784
 Walters K, 2549
 Wandel S, 3610
 Wang C-R, 544

Wang E, 3675
Wang J, 3588
Wang L, 453
Wang N, 1846
Wang SX, 1537
Wang W, 2999, 3738
Wanivenhaus A-H, 1118
Ward MH, 3189
Ward MM, 1369, 2092
Warman ML, 3662
Wasko MC, 43
Watanabe M, 662
Watier H, 3887
Watson A, 1345
Watson KD, 13, 2896, 2905
Watt F, 3715
Watters JW, 2999
Watts J, 244
Weber WA, 1806
Weckbach S, 2809
Weedon H, 753
Weibel L, 3489
Weichhart T, 1880
Weill B, 2455
Weimer A, 158
Weinans H, 3634
Weinberg CR, 2719
Weinberg JB, 3033
Weinblatt ME, 696, 1754
Weinstein JS, 3379, 3770
Weisman M, 1745, 4142
Weissleder R, 117
Welge JA, 1336
Wells AU, 2005
Wen X, 1219
Wendler J, 2056
Wener MH, 58
Wengner AM, 3271
Wesolowski GA, 2999
Wessels JAM, 694, 1765
Westedt M-L, 1424
Westerweel PE, 1384, 3879
Westhoff G, 3575
Westhovens R, 3919
Westlin WF, 850
Weyand CM, 1723, 3215
White AJ, 3107
White B, 1676
Whiteside R, 586
Whitters MJ, 1152
Wieczorek-Surdacka E, 809
Wigley FM, 1676, 3448, 4195

Wijbrandts CA, 772, 3869
Wilckens T, 387
Wilder TF, 1440
Wilkinson N, 3096
Willett W, 2049
Williams A, 1507
Williams AS, 2244, 2523
Williams BD, 2244
Williams PL, 1408
Williams R, 4015
Willingham DL, 3107
Wilson AG, 2549
Wilson AW, 4015
Wiman A-C, 2202
Wimmer MA, 3511
Winfield J, 1408
Wise R, 1676, 4195
Witte T, 1234, 3080
Wittkowski H, 4174
Wloch A, 809
Wofsy D, 4142
Wohlfahrt J, 1446
Wolfe F, 1433, 1745, 2135, 2886
Wollheim FA, 9
Wollina U, 2464
Wong DT, 3588
Wong K, 2854
Wong RL, 4005
Wong SH, 1776
Woo P, 972, 1954, 3096, 3489
Woods JM, 2512, 2535
Woodworth T, 1512
Workman-Azbill J, 3387
Wouters C, 3096
Woywodt A, 3847
Wright EA, 244, 568
Wright J, 568
Wu C-L, 544
Wu H, 1033
Wu J, 3675, 3748
Wu PW, 1152
Wu T, 949
Wu X, 2823
Wulf H, 1549
Wulffraat NM, 639, 2410, 3096

X

Xi J, 4226
Xiang Y, 2018
Xiao H, 4195
Xie A, 1125, 4226
Xie C, 949, 3057

Xie D, 2729
Xie H, 1198
Xie Y, 3588
Xing L, 4024
Xiong M, 2443
Xu L, 2663, 3685, 4132
Xu R, 453
Xu Y, 117
Xue M, 2864

Y

Yada T, 1827
Yagüe J, 2784, 3805
Yalçinkaya F, 1706
Yamada H, 2875
Yamada M, 3541
Yamamoto M, 2466
Yamamura T, 1836
Yamaoka K, 2466
Yamasaki Y, 596
Yamauchi A, 3968
Yamazaki T, 3879
Yan M, 949
Yan X, 605, 1676
Yanagida T, 386
Yanar H, 345
Yang C-D, 1638
Yang J-Q, 1219
Yang Q, 605
Yang Z, 575, 3675
Yanlin X, 4174
Yano M, 3307
Yao W, 3726
Yao Y, 3784
Yara S, 1724
Yasuda K, 521
Yasuda S, 2803
Yasui K, 3879
Yasui N, 30
Yaworsky PJ, 4074
Yazici Y, 2382
Ye F, 4174
Yee C-S, 4113
Yclin E, 1397
Yoo S-A, 2299
Yoo W-H, 2094
Yoon C-H, 214, 2094
Yoon H-J, 2094, 2299
Yoon J-W, 2211
York MR, 1010
Yoshida H, 596
Yoshida K, 2170

Yoshikawa J, 1904
Yoshio T, 2813
Yoshiyama M, 1904
You Z, 4024
Youinou P, 1134, 1464
Young A, 1408
Young DA, 1152
Young-Min S, 3236
Youse JS, 3270
Yprus M, 1719
Yu T, 3588
Yudoh K, 2018, 3307
Yung GP, 1648

Z

Zahora R, 3928
Zaiss MM, 4104
Zanetti A, 3159
Zang Y, 1589
Zang YCQ, 453
Zavadil J, 4120
Zeng W, 3387
Zhang D, 453
Zhang JZ, 453
Zhang L, 4132
Zhang W, 938
Zhang YQ, 1212, 2993, 4048
Zhao J, 2443
Zheng B, 334, 3044
Zheng C, 1798
Zheng P, 4120
Zhou B, 2698
Zhou H, 3588
Zhou M, 1219
Zhou XJ, 949, 3057
Zhuang H, 3759
Zhuo Y, 2999
Ziakas P, 3977
Zidovetzki R, 4164
Ziegler SF, 2947
Ziegler-Heitbrock L, 4182
Zinger H, 2371
Zink A, 3575
Zissel G, 1685
Ziswiler HR, 3610
Zoja C, 1569, 1629
Zoma A, 265
Zonneveld-Huijssoon E, 639
Zulian F, 3096, 3489
Züllig M, 3610
Zunt SL, 498
Zwerina J, 311, 1463, 4104, 4203

SUBJECT INDEX

Arthritis & Rheumatism, Volume 56, Numbers 1–12, 2007

A

- Abatacept, effects on chronic tuberculosis infection in mice, 2557
- Acetaminophen, vs. glucosamine sulfate for knee OA, 555
- ACPA. *See* Anti-citrullinated protein antibody (ACPA)
- ACR. *See* American College of Rheumatology (ACR)
- Acrocyanosis, type I cryoglobulinemia in, clinical image, 673
- Acromioclavicular joint cyst, clinical image, 3948
- Active shape model of bone changes in proximal femur, for predicting radiographic hip OA progression, 3634
- Activin A, production and matrix catabolism in articular cartilage, 3715
- Adalimumab
- AS, efficacy for spinal and sacroiliac joint inflammation, 4005
 - for long-term treatment of PsA, 476
 - RA, outcomes from switching anti-TNF agents, 13
 - uveitis and, 3248
- Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT), 476
- ADAMTS proteins
- ADAMTS-4 and ADAMTS-5 in cytokine-induced aggrecan proteolysis, porcine chondrocyte culture, 3010
 - ADAMTS-4 and ADAMTS-5 mediating aggrecan degradation in human articular cartilage explants, 575
 - OA, disease progression in double-knockout ADAMTS-4/ADAMTS-5 mice, 3670
 - OA, protein kinase C ζ regulation of ADAMTS-4 via NF- κ B signaling in chondrocytes, 4074
- Adenine/uridine-rich element binding proteins, infliximab effects on gene expression levels in RA, 2160
- Adenosine monophosphate (AMP)
- cAMP and transdifferentiation of fetal cardiac fibroblasts, 4120
 - cAMP induction in articular chondrocytes blocking cartilage degradation in vitro, 1549
 - MTX in ecto-5'-nucleotidase conversion of AMP to adenosine, 1440
- Adenosine triphosphate, effects on IL-1 β secretion in CINCA and Muckle-Wells syndrome, 3138
- ADEPT. *See* Adalimumab Effectiveness in Psoriatic Arthritis (ADEPT)
- Adjunctive therapy. *See* Combination therapy
- Adjuvant-induced arthritis
- Freund's complete, PAR-2 activation and, 101, 3510
 - Hsp65-IgG-expressing B cells protecting against, rat study, 1490
 - IL-13 gene therapy inhibition of angiogenesis in rat model of RA, 2535
- Adrenomedullin, expression by hypoxia-exposed cardiac fibroblasts, 4120
- African Americans
- SLE, glutathione S-transferase polymorphisms and proximity to hazardous waste sites, 244
 - SLE, skin-lightening creams as risk factor, 1721
 - SSc, hepatocyte growth factor impairment in lung fibroblasts, 2432
- Aged patients. *See* Older adults
- Aggrecan
- degradation in human articular cartilage explants, mediation by ADAMTS-4 and ADAMTS-5, 575
 - low molecular weight aggrecanase isoforms in cytokine-induced proteolysis, in vitro study, 3010
 - TIMP-3 deficiency and increased degradation in mouse joints, 905
- Aggrecanase
- low molecular weight isoforms in cytokine-induced aggrecan proteolysis, in vitro study, 3010
 - OA, apoptotic and matrix-degrading genes in articular cartilage and meniscus, rabbit study, 1529
- Aging
- Hsp90 age-dependent mediation of insulin-like growth factor 1 and IL-1 β signaling in chondrocytes, 2335
 - increased collagen and aggrecan degradation in mouse joints, MMP/TIMP-3 imbalance and, 905
- Akt, activation in RA by fractalkine/fibroblast-like synoviocyte signaling, 2512
- Alefacept, as targeted biologic response modifier for PsA, 1051
- Allograft inflammatory factor 1, in T cell migration and profibrotic cytokines production in SSc, 3478
- α -galactosylceramide, NKT cell activation by SGL-S23 in autoantibody-induced arthritis, mouse study, 1836
- Alveolar hemorrhage, subclinical, as pulmonary fibrosis mechanism, 2065
- American College of Rheumatology (ACR)
- annual slide competition, 2006 winners, 1029
 - presidential address, 1037
 - rheumatology workforce 2005–2025, response to study, 730
- AMP. *See* Adenosine monophosphate (AMP)
- AMPD1 gene, 34C>T variant effects on clinical response to MTX in RA, 694
- Amyloid P, normal serum component concentration in SSc, 2013, 4229
- Amyloidosis
- AL, manifestations in soft tissue, joint, and bone, 3858
 - AS, fat tissue aspiration for confirmation of, 2467
 - renal, country as risk factor for familial Mediterranean fever, 1706, 3879
- Anakinra, for NOD2 gene-associated pediatric granulomatous arthritis, 3805
- ANCA. *See* Antineutrophil cytoplasmic antibody (ANCA)
- Androgens, insufficiency in SS salivary tissues, 2575
- Angiogenesis
- inhibitors in SSc, 3448
 - RA, IL-13 gene therapy inhibition of, in rat model, 2535
 - RA, synovial vascular gene expression in, laser-mediated microdissection analysis, 1094
 - targeted mast cell silencing protecting against, mouse study, 1806
 - VCAM-1/very late activation antigen 4 role in endothelial progenitor cell recruitment to RA synovium, mouse study, 1817
- Angiography, polymyositis and vasculitis, clinical image, 3270
- Angiopoietin 1, stimulation of ERK/MAPK and PI 3-kinase/Akt pathways in RA joint destruction, 2170
- Angiostatin, antiangiogenic, in SSc, 3448
- Angiotensin II type 1 receptor, as therapeutic target in RA, 441
- Angiotensin-converting enzyme (ACE) inhibitors, preventing vascular damage in SSc and Raynaud's phenomenon, 3837
- Animal models. *See* Name of specific animal studies
- Ankylosing spondylitis (AS)
- adalimumab efficacy for spinal and sacroiliac joint inflammation, 4005
 - bamboo spine, clinical image, 3043
 - co-occurring HLA-B*2709 and HLA-B*1403 alleles in, 2807
 - fat tissue aspiration for confirmation of amyloidosis in, 2467
 - HLA-B27 association with, molecular basis, 2478
 - HLA-B27 extended haplotypes, previously unrecognized predisposing factors in, 2640
 - HLA-B*2709 subtype in, 2805
 - with inflammatory bowel disease, in Icelandic families, 2633
 - MMP-3 as predictor of radiographic disease progression, 1846
 - p38 MAPK dysregulation in HLA-B27-expressing monocytes, 2652
 - TNAP haplotype association with, 234
- Anti-asparaginyl-transfer RNA synthetase autoantibodies, in myositis, 1295

- Anti- β_2 -glycoprotein I antibodies, in thrombin-mediated factor XIa, 605
- Antibody response, to *Borrelia burgdorferi*, 4216
- Anticardiolipin antibodies, predictive value of, 1736
- Anticentromere antibodies, predictive value of, 1736
- Anti-citrullinated protein antibody (ACPA)
- gender and, in mouse RA models vs. human disease, 1
 - MEFV* mutations in ACPA-negative palindromic rheumatism, 2784
 - predictive value of, 1736
 - RA, HLA-DRB1 SE alleles influencing specificity of response, 3949
 - RA, smoking and ACPA response in absence of HLA-DRB1 SE alleles, 2913
 - RA heterogeneity, linkage analysis, 58
 - RA subclassifications and, 1728
 - rituximab effects on production in RA, 3909
- Anti-DNA antibody, somatic B cell gene vaccination with IgG for lupus nephritis in mice, 1945
- Anti-DNA topoisomerase I, predictive value of, 1736
- Antigen-induced arthritis
- antigen-specific suppression of established arthritis by NF- κ B-deficient DC in mice, 2255
 - CXCR5- and CCR7-dependent lymphoid neogenesis in, mouse model, 3271
 - fluvastatin and vascular dysfunction in, rat study, 1827
 - lubricin and proteolytic susceptibility in cartilage damage, 108
 - PAR-2 activation in, 101, 3510
 - protective effects of IFN γ in mice, 2244
 - therapeutic control of C5a and terminal complement complex by anti-C5 single-chain Fv, in rats, 1187
- Antigen-presenting cells, MHC-typed fibroblast-like synoviocytes as, 1497
- Anti-Jo-1 antibody
- idiopathic inflammatory myopathy and levels of, 3125
 - IFN α activation in myositis, 3112
- Antimyeloperoxidase antibodies, in microscopic polyangiitis, 2455
- Antineutrophil cytoplasmic antibody (ANCA)
- circulating CD34+ hematologic and endothelial progenitor cells in ANCA-associated vasculitis, 3847
 - heat exposure and neutrophil activation by, 3149
- Anti-NR2 antibodies, IgG glutamate receptor, ELISA specificity for, 386, 2813
- Antinuclear antibodies, predictive value of, 1736
- Antinucleosome antibodies, predictive value of, 1736
- Antiphospholipid antibodies (aPL)
- aspirin for thrombosis prophylaxis in asymptomatic aPL-positive individuals, 2382
 - binding to discontinuous epitopes in human β_2 -glycoprotein I domain I, 280
 - recognizing SE of β_2 -glycoprotein I and serine proteases in APS, 1638
- Antiphospholipid Antibody Acetylsalicylic Acid (APLASA) study, 2382
- Antiphospholipid syndrome (APS)
- anti- β_2 -glycoprotein I antibodies and monocyte release of TNF α and tissue factor via lipid rafts, 2687
 - aPL recognizing SE of β_2 -glycoprotein I and serine proteases, 1638
 - arginine mutation and B3 monoclonal antibody binding to APS-linked antigens, 2392
 - aspirin for primary thrombosis prevention in, 2382
 - intracardiac thrombosis in, clinical image, 1036
- Anti-RNA helicase A, as marker for early SLE, 596
- Anti-ribosomal P antibodies, induction of autoimmune depression in mice, 938
- Anti-Ro 52 antibody, in IFN α activation in myositis, 3112
- Anti-Ro 60 antibody, in IFN α activation in myositis, 3112
- Anti-Ro autoimmunity, differential tissue targeting by Y RNAs in TLR activation, 1589
- Anti-Ro/La antibodies, predictive value of, 1736
- Antisperm antibodies, evaluation in male SLE, 2352
- Anti-SSA/Ro antibodies
- hypoxia and production in congenital heart block, 4120
 - in subacute CLE, 255
- Anti-TNF therapy
- abatacept effects on chronic tuberculosis infection in mice, 2557
 - collagen-induced arthritis, analgesic effects of, 4015
 - collagen-induced arthritis, anti-TNF α monoclonal antibody vs. WP9QY cyclic peptide for bone destruction inhibition, 1164
 - infection risk following, 2896
 - PsA, adalimumab for long-term treatment of, 476
 - RA, bacterial infection risk in elderly and, 1754
 - RA, lymphoma risk of, 1433
 - RA, myocardial infarction incidence vs. DMARDs, 2905
 - RA, outcomes after switching agents, 13
 - RA, predictors of response to, 2160
 - RA, rituximab for B cell depletion vs. alternate agents, 1417
 - for sciatica, review, 3887
- Anti-topoisomerase I antibody, skin thickness progression rate and disease outcome in SSc with, 2740
- Antiviral therapy, for hepatitis C virus-associated mixed cryoglobulinemia vasculitis, 2810
- Aorta
- γ/δ T cell cytotoxicity to endothelial cells in Takayasu arteritis, 2798
 - inflammatory rheumatic disease and smoking predicting inflammation of, 2072
- aPL. See Antiphospholipid antibodies (aPL)
- APLEC genes, in RA susceptibility, 2620
- Apolipoprotein AI, TNF blockade and cardiovascular risk in PsA, 831
- Apoptosis
- acetylation of histones in SLE and, 1921
 - chondrocytes, calcium signaling and mitochondrial depolarization in, 2322
 - chondrocytes, recombinant osteoprotegerin preventing in mouse model of OA, 3358
 - Fas-induced, decoy receptor 3 expression in FLS as protection against, 1067
 - in FLS, induction by galactin 9 in RA vs. OA, 3968
 - OA, apoptotic and matrix-degrading genes in articular cartilage and meniscus, rabbit study, 1529
 - opsonization of apoptotic cells by SLE autoantibodies, 3399
 - peripheral blood mononuclear cells in SLE, reactive oxygen/nitrogen intermediates and complement levels in, 3738
 - RA, regulation in FLS by BNIP-3 protein, 2854
 - SLE, ficolin 3 in clearance of late apoptotic cells, 1598
 - TRAIL receptor 3 suppression in Churg-Strauss syndrome and, 662
- APRIL, stimulation of RA FLS by, 3554
- APS. See Antiphospholipid syndrome (APS)
- Aquaporin 5, in submandibular glands of mice with autoimmune exocrinopathy, 2566
- Arachidonic acid, *n*-3 polyunsaturated fatty acid antagonism in TNFR expression on neutrophils, 799
- Arginine
- asymmetric dimethyl-L-arginine in endothelial progenitor cell depletion and carotid atherosclerosis in RA, 809
 - mutations and altered antibody binding to SLE- and APS-linked antigens, 2392
- Arm, myositis ossificans of, clinical image, 2454
- Arthritis. See also specific types of arthritis
- cancer incidence and survival in inflammatory polyarthritis, 790
 - health care expenditures and earnings loss, 2003 compared with 1997, 1397
 - PAR-2 activation in, mouse studies, 101, 3510
 - undifferentiated, prediction rule for disease outcome, 433
- AS. See Ankylosing spondylitis (AS)
- Asparaginyl-transfer RNA synthetase autoantibodies, in myositis, 1295

Aspirin, for primary thrombosis prevention in APS, 2382
 ASPN gene, sex and ethnic differences in genetic susceptibility to knee OA, 137
 Atacicept, for SLE, 4142
 Atherosclerosis
 inflammatory rheumatic disease and smoking as predictors of aortic inflammation, 2072
 premature cardiovascular disease in SLE, 1384, 3878
 RA, asymmetric dimethyl-L-arginine in endothelial progenitor cell depletion and, 809
 rates and determinants of progression in SLE, 3412
 Autoantibodies
 anti-Jo-1 and anti-Ro 52/anti-Ro 60, in IFN α activation in myositis, 3112
 for autoimmune disease prediction, 1736
 CID protein as target in PM-scleroderma overlap syndrome, 2449
 DM, anti-SUMO-1 antibody in, 3132
 mutated and citrullinated vimentin as RA biomarker, 2503
 prediagnosis onset of, and clinical criteria for SLE, 2344
 RA, antibody status and association of IL-6 and IL-10 genotypes with radiographic damage, 2549
 RA subclassifications and, 1728
 response in OA, 409
 Ro/SSA, hypoxia and production in congenital heart block, 4120
 Ro/SSA, in subacute cutaneous SLE, 255
 SLE, opsonization of apoptotic cells and inhibition of uptake via Fc γ receptors, 3399
 SLE, to RNA helicase A, 596
 SLE, short-term infliximab therapy and, 274
 SSc, diffuse cutaneous vs. limited cutaneous, 9
 SSc, familial, 2031
 Autoantigens
 ficolin 3 in clearance of late apoptotic cells, 1598
 MHC-typed FLS as antigen-presenting cells to T cells, 1497
 Autoimmune diseases. *See also Names of specific diseases*
 in carriers of constitutional structural chromosomal rearrangements, 2402
 differential tissue targeting by Y RNAs in TLR activation, 1589
 HLA-B27 in SpA, 4
 prediction with autoantibodies, 1736
 reduced expression of Daf1 on CD4 T cells in mice, 1934
 SLE-like syndrome in mice overexpressing decoy receptor 3, 3748
 systemic, mortality and occupational exposures, 3189
 Autoinflammatory diseases. *See also Names of specific diseases*
 country as risk factor for renal amyloidosis in familial Mediterranean fever, 1706, 3879
 cryopyrinopathies and *CIAS1* mutations, 1273
 identification of, 2817
 late-onset TRAPS in multiple sclerosis, 2774
 Majeed syndrome, *LPIN2* mutation in, 960
 TRAPS-associated mutations and structural alterations in TNFRSF1A, 2765
 Azathioprine with methylprednisolone
 for proliferative lupus nephritis, case against, 702
 for proliferative lupus nephritis, cyclophosphamide vs., 924

B

B cell depletion therapy
 in primary SS, 1371
 psoriasis development after treatment with rituximab, 2715
 RA, B cell subset responses to rituximab, 3909
 RA, rituximab vs. alternate anti-TNF agents for, 1417
 SLE, delayed memory B cell recovery after rituximab treatment, 3044
 B cells
 Hsp65-IgG-expressing, protecting against adjuvant-induced arthritis, rat study, 1490

B cells (*cont'd*)
 infiltration in SS-associated ILD, 3167
 RA, rituximab effects on synovial cell infiltrates, 772
 SLE, activation by U1 RNA, 3379
 SLE, atacicept effects on levels of, 4142
 SLE, delayed memory B cell recovery after rituximab treatment, 3044
 SLE, generalized hyperactivity and CD19 overexpression, 3057
 SLE, proximal signaling and translocation of CD45 tyrosine phosphatase, 291
 somatic B cell vaccination with anti-DNA IgG, in lupus-prone mice, 1945
 SS, aberrant expression of BAFF in salivary glands, 1134
 SS, BAFF-modulated repopulation of, following rituximab therapy, 1464
 therapeutic targeting in SS, 1371
 transitional type II, existence in humans unproven, 1035
 B lymphocyte stimulator (BLyS). *See* BAFF
 B lymphocytes. *See* B cells
 BAFF
 RA, TNF α activation of release by neutrophils, 1776
 regulatory factors in rheumatoid synovocyte synthesis of, 3202
 SS, aberrant expression in salivary glands by B lymphocytes, 1134
 SS, etanercept causing overexpression, 3995
 SS, modulating repopulation of B lymphocytes following rituximab treatment, 1464
 BCMA, expression in RA FLS, 3554
 β_2 -glycoprotein I
 aPL binding to discontinuous epitopes on domain I of, 280
 aPL recognizing SE with serine proteases in APS, 1638
 binding
 of thrombin via exosite I and exosite II, 605
 11 β -hydroxysteroid dehydrogenases
 altered expression in RA synovial cells, 1720
 cortisone/cortisol shuttle as therapeutic target for bone loss in RA, 387
 Binding sites
 anti- β_2 -glycoprotein I antibodies and monocyte release of TNF α and tissue factor in AS via lipid rafts, 2687
 B3 monoclonal antibody binding to SLE- and APS-linked antigens, 2392
 Biologic therapy
 RA, and risk of malignancy, 2886
 RA, type II collagen biomarkers and response to, 2919
 Biologic response modifiers, targeted, for PsA therapy, 1051
 Biomarkers
 AS, MMP-3 as predictor of cartilage damage, 1846
 comparative proteomic profiles of normal and OA cartilage, 3675
 identification of markers for articular chondrocytes with enhanced in vitro chondrogenic capacity, 586
 insulin-like growth factor I in tendinosis, 871
 OA, type II collagen catabolism markers in mice, 3336
 OA of hip, Frizzled-related protein and Dkk-1 and disease progression, 3319
 RA, autoantibody to mutated and citrullinated vimentin as, 2503
 RA, IgG autoantibodies as, 2823
 RA, pre-B cell colony-enhancing factor as inflammatory marker, 2829
 RA, predicting radiographic progression in early disease, 3236
 RA, serum MIC-1 as marker for joint destruction, 753
 RA, synovial sublining macrophages as, 3869
 RA, type II collagen biomarkers and response to biologic therapy, 2919
 salivary, for primary SS, 3588
 SLE, autoantibodies to RNA helicase A as, 596
 SLE, urinary lipocalin-2 as renal disease marker, 1894

Biomarkers (cont'd)

- SSc, CCL18 as marker for idiopathic interstitial pneumonias and lung disease, 1685
- SSc, Siglec-1 induction by IFN α and TLR agonists, 1010
- as surrogates for imaging in knee OA, 4038
- urine, for glomerulonephritis diagnosis, 705
- Biomechanical signals and IKK inhibition in NF- κ B transcription, 3284
- Bisphosphonates, as antiresorptive agent in OA, 2469
- Blau syndrome
 - with early-onset sarcoidosis, *NOD2* gene mutations in, 3805
 - interstitial pneumonitis with *CARD15* mutation in, 1292
- Blood proteins, normal serum amyloid P component concentration in SSc, 2013, 4229
- BMD. *See* Bone mineral density (BMD)
- BMI. *See* Body mass index (BMI)
- BMP. *See* Bone morphogenetic protein (BMP)
- Body mass index (BMI)
 - OA of knee, varus and valgus malalignment in disease progression and, 1204, 3872
 - RA, radiographic joint damage and, 3575
- Bone
 - AL amyloidosis manifestations in, 3858
 - OA, FRZB gene deletion and biomechanical properties of long bones in mice, 4095
 - subchondral, in OA development in guinea pigs, 3366
- Bone damage
 - enthesitis-associated, in HLA-B27-associated SpA, 224
 - inflammatory arthritis, MRI and microfocus CT assessments of, 4024
 - mesenchymal stem cells preventing, in collagen-induced arthritis, 1175
 - RA, 11 β -hydroxysteroid dehydrogenase cortisone/cortisol shuttle as therapeutic target for, 387
 - RA, bone erosion and bone marrow edema, MRI identifying, 1118
- Bone marrow
 - lesion development and OA knee pain, 2986
 - RA, B cell response to rituximab, 3909
 - RA, bone erosion and bone marrow edema, MRI identifying, 1118
 - RA, MTX alone vs. combination with infliximab or methylprednisolone for prevention of edema, MRI study, 3919
- Bone mineral density (BMD)
 - JRA, abnormalities of tibia, 984
 - juvenile DM, RANKL:osteoprotegerin ratio and, 977
 - low, prevalence and etiology in juvenile SLE, 1966, 4228
 - OA, glucosamine hydrochloride effects on subchondral bone changes, rabbit study, 1537
 - in postmenopausal women, 3518
 - prednisolone with risedronate preventing GC-induced changes in bone properties, 3726
- Bone morphogenetic protein (BMP)
 - BMP-2 vs. BMP-7 in chondrogenic differentiation of bovine synovium, 1869
 - BMP-7 as LPS antagonist in cartilage matrix synthesis, 1880
 - chondrogenic differentiation of bovine synovium, 1869
 - differential regulation of lubricin/superficial zone protein in articular chondrocytes and synoviocytes, 2312
 - experimental arthritis, BMP-2 vs. TGF β role in osteophyte formation, mouse study, 4065
- Borrelia burgdorferi*, antibody responses in Lyme arthritis, 4216
- Bosentan, for vascular endothelial function in SSc, 1985
- Boston Osteoarthritis of the Knee Study (BOKS), knee OA progression and vitamin D deficiency, 129
- Bradykinin receptors, potentiation of cytokine-induced prostaglandin biosynthesis in osteoblasts, 910
- Brain mapping
 - immunoproteomic characterization of neuropsychiatric SLE brain antigenic targets, 3420
 - knee OA, PET scan of areas in pain processing, 1345

British Isles Lupus Assessment Group (BILAG), validity of 2004 index for SLE disease activity assessment, 4113

Bronchoalveolar lavage

- SSc, cell profiles in ILD not predictive of disease progression, 2005
- SSc with ILD, persistence of abnormal findings following cyclophosphamide treatment, 4195

C

- C protein-induced myositis, as PM model, 1304
- CID protein, as autoantibody target in PM-scleroderma overlap syndrome, 2449
- Calcineurin, in modulation of chondrocytes and OA progression in mice, 2299
- Calcitonin
 - as antiresorptive agent in OA, 2469
 - effect on cartilage degradation and surface erosion in ovariectomized rats, 2674
- Calcium, signaling and mitochondrial depolarization in equine chondrocyte death, 2322
- Calcium pyrophosphate deposition disease, MTX for, 688, 3172
- CALM1* gene, sex and ethnic differences in knee OA susceptibility, 137
- cAMP (cyclic AMP). *See* Adenosine monophosphate
- Cancer
 - inflammatory polyarthritis influence on incidence and survival, 790
 - RA biologic therapy and risk of, 2886
 - TNF α blockers and metastases, 695
- Capillaries, iloprost-induced vascular remodeling, clinical image, 2243
- CARD15* gene, mutation in Blau syndrome with interstitial pneumonitis, 1292
- Cardiovascular disease
 - APS, intracardiac thrombosis in, clinical image, 1036
 - inflammatory rheumatic disease and smoking in aortic inflammation, 2072
 - PsA, TNF blockade and risk factors, 831
 - RA, anti-TNF therapy vs. DMARDs and myocardial infarction incidence, 2905
 - RA, glucocorticoids and, 820
 - risk factors and COX-2 inhibitors or NSAIDs, 384
 - SLE, coronary vasomotor function impairment in young women, 1904
 - SLE, premature atherosclerosis in, 1384, 3878
 - SSc, myocardial fibrosis in, 3827
- Carotid artery disease, asymmetric dimethyl-L-arginine and endothelial progenitor cell depletion in RA, 809
- Carpal tunnel syndrome
 - AL amyloidosis in, 3858
 - keyboard use and prevalence of, 3620
- Cartilage
 - activin A regulation and matrix catabolism in, 3715
 - aggrecan degradation in human articular cartilage explants, mediation by ADAMTS-4 and ADAMTS-5, 575
 - biomechanical signals inhibiting IKK activity in NF- κ B transcription in chondrocytes, 3284
 - boundary lubrication and synovial fluid constituents, 882
 - chondrogenic differentiation of bovine synovium, 1869
 - DIAS cells, isolation and chondroinduction of, 168
 - growth mechanisms, in vitro studies, 188
 - hypoxic induction of matrix synthesis, 3297
 - IL-1 and TNF α inhibition and integrative repair of porcine meniscus in vitro, 3033
 - IL-1 β impairment of TGF β 1 signaling in human chondrocytes, 3020
 - low molecular weight aggrecanase isoforms in cytokine-induced aggrecan proteolysis, in vitro study, 3010
 - OA, comparative proteomic profiles of normal and OA cartilage, 3675
 - OA, 3-dimensional tissue engineering of adult stem cells, 177
 - OA, failure of chondroprotective agents, 1378, 3873

Cartilage (*cont'd*)

- OA, glucosamine hydrochloride effects on subchondral bone changes, rabbit study, 1537
- OA, hypoxia-inducible factor 1 α and up-regulation of microsomal PGES-1 in articular chondrocytes, 4084
- OA, increased discoidin domain receptor 2 expression in pathogenesis, 2663
- OA, molecular analysis of disease progression, 2474
- OA, restoration of extracellular matrix by overexpression of *SOX9*, 158
- superficial zone protein mechanotransduction by TGF β signaling, 3706
- Cartilage damage
 - AS, MMP-3 as predictor of, 1846
 - exposure to low concentrations of blood, in vitro study, 199
 - lubricin expression and proteolytic susceptibility in antigen-induced arthritis, 108
 - mesenchymal stem cells preventing, in collagen-induced arthritis, 1175
 - MMP/TIMP-3 imbalance and, 905
 - NGAL-MMP-9 complex preventing, 3326
 - OA, apoptotic and matrix-degrading genes in articular cartilage and meniscus, rabbit study, 1529
 - OA, C60 fullerene preventing, rabbit study, 3307
 - OA, cAMP induction in articular chondrocytes blocking, 1549
 - OA, discoidin domain receptor 2 expression and, 3685
 - OA, friction and wear in joints lacking lubricin, mouse study, 3662
 - OA, FRZB gene deletion in mice and, 4095
 - OA, macrophages in MMP-3-mediated cartilage destruction, 147
 - OA, matrix remodeling and lipid metabolism in STR/Ort mice, 2999
 - OA, osteoprotegerin preventing destruction in mice, 3358
 - OA, pioglitazone reducing lesion development in dogs, 2288
 - OA, smoking/family history interactions in cartilage loss and defects, 1521
 - OA, subchondral bone role in guinea pigs, 3366
 - oral calcitonin and surface erosion in ovariectomized rats, 2674
- CASPAR. *See* Classification Criteria for Psoriatic Arthritis (CASPAR)
- Caspase 1 inflammasome, bypassing roadblocks for IL-1 β secretion and disease activity, 2817
- Caspase 8, apoptotic and matrix-degrading genes in OA cartilage and meniscus, rabbit study, 1529
- CAT-192, for dcSSc therapy, 323
- Cathepsin B, expression and cartilage damage in antigen-induced arthritis, 108
- CCL5. *See* RANTES
- CCP. *See* Cyclic citrullinated peptide (CCP)
- CCR2, Gr-1 +, CCR2+ monocyte targeting in collagen-induced arthritis, mouse study, 2975
- CCR7 chemokine receptors, lymphoid neogenesis in antigen-induced arthritis, mouse study, 3271
- CD1d, in lupus nephritis, mouse study, 1219
- CD4+ T cells
 - CD80-binding competitive antagonist peptides suppression of, in collagen-induced arthritis, 498
 - in CLE skin lesions, 1910
 - Daf1 expression in autoimmunity in mice, 1934
 - defects in WG remission, 2080
 - IL-17 regulation in, 2936
 - juvenile DM, expression of plasmacytoid DC in inflamed muscles, 1658
 - osteoclast formation suppression by, 4104
 - RA, proinflammatory mediator reversal of Treg-mediated suppression, 732, 3874
 - SLE, activation by U1 RNA, 3379
 - SpA, immunologic synapse formation with DC in HLA-B27 transgenic rats, 1478
 - SSc, CD4+CD8+ double-positive T cells in skin lesions, 3459

CD4+ T cells (*cont'd*)

- synovial fibroblast regulation by, 3215
- CD8
 - CD4+CD8+ double-positive T cells in SSc skin lesions, 3459
 - in periglomerular infiltrates in lupus nephritis, 2362
- CD14
 - in pannus tissue development, 2875
 - TLR-2 and TLR-4 mediation of activation in RA synovial fluid, 2192
- CD16, elevated expression in TRAPS, 4182
- CD19, overexpression and B cell hyperactivity in SLE, 3057
- CD20, in B cell depletion therapy for RA, 3909
- CD24, A57V polymorphism in SLE susceptibility, 3080, 3871
- CD25
 - in CLE skin lesions, 1910
 - proinflammatory mediator reversal of Treg-mediated suppression in RA, 732, 3874
 - suppression of osteoclast formation, 4104
 - in WG remission, 2080
- CD34, hematologic and endothelial progenitor cells in ANCA-associated vasculitis, 3847
- CD40, interaction with stromal cell-derived factor 1 up-regulation in rheumatoid synovial fibroblasts, 1076
- CD45, proximal signaling and translocation in SLE B lymphocytes, 291
- CD56, expression in senescent T cells in RA, 43
- CD73, MTX antiinflammatory mechanisms and ecto-5'-nucleotidase conversion of AMP to adenosine, 1440
- CD80-binding competitive antagonist peptides, in collagen-induced arthritis, 498
- CD82, synovial vascular gene expression, RA vs. OA, analysis by laser-mediated microdissection, 1094
- CD123, plasmacytoid dendritic cell expression of, in juvenile DM, 1658
- CD163, in diagnosis of macrophage activation syndrome in systemic JIA, 965, 3877
- CD169 sialoadhesin, expression in SSc, 1010
- Celecoxib, dietary use for SLE in mice, 4132
- Cell adhesion molecules, LIGHT up-regulation in RA, 1106
- Cell death. *See* Apoptosis
- Cells, cultured, *Tropheryma whippelii* from synovial fluid, in Whipple's arthritis, 1713
- Cellular senescence, CD56-expressing T cells in RA, 43
- CENP-B, binding to vascular smooth muscle cells, 3814
- Central nervous system (CNS), perforin deficiency and primary vasculitis in child, 995
- Cerebrospinal fluid (CSF), IL-6 and chemokines in neuropsychiatric SLE, 1242, 2509
- Cerebrovascular disorders, glycoprotein IIIa PIA1/A2 polymorphism and ischemia in GCA, 3502
- Chemokines
 - CSF, in neuropsychiatric SLE, 1242, 3509
 - gene interactions in SSc susceptibility, 2443
 - in synovial fluid and tissue in Lyme arthritis, 1325
- Chest, misdiagnosis of chylous cyst as chest wall gouty tophus, 3854
- Children. *See also* Juvenile terms
 - childhood-onset SLE, functional MRI assessment of cognitive function, 4151
 - common symptoms in childhood associated with chronic widespread pain in adulthood, 1669
 - interstitial pneumonitis in Blau syndrome with *CARD15* mutation, 1292
 - juvenile DM, RANKL:osteoprotegerin ratio and BMD in, 977
 - local scleroderma, assessment with laser Doppler flowmetry, 3489
 - macrophage activation syndrome in hyperimmunoglobulinemia D with periodic fever syndrome, case study, 658
 - NOD2* gene-associated pediatric granulomatous arthritis, 3805
 - NOMID treatment response, 2099
 - primary CNS vasculitis from perforin deficiency in, 995
 - seasonal birth patterns in myositis, 2719

Children. *See also* Juvenile terms (*cont'd*)

- uveitis prevalence, risk factors, and outcome in JIA, 647
- Cholesterol, lipid profiles in pediatric SLE, longitudinal study, 631
- Chondrocytes
 - biomechanical signals inhibiting IKK in NF- κ B transcription, 3284
 - calcium signaling and mitochondrial depolarization in apoptosis, 2322
 - differential regulation of lubricin/superficial zone protein by TGF β and BMP in, 2312
 - Hsp90 age-dependent mediation of insulin-like growth factor 1 and IL-1 β signaling in, 2335
 - human articular, TLRs and, 1880
 - hypoxia-inducible factor 2 α in phenotype induction, 3297
 - IL-1 β impairment of TGF β 1 signaling in, 3020
 - LG268 regulation of MMP-3 and MMP-13 gene expression in, 892
 - low molecular weight aggrecanase isoforms in cytokine-induced aggrecan proteolysis, porcine model, 3010
 - markers for articular chondrocytes with enhanced in vitro chondrogenic capacity, 586
 - OA, calcineurin modulation and disease progression in mice, 2299
 - OA, cAMP induction blocking cartilage degradation, 1549
 - OA, exercise and, 3176
 - OA, hypoxia-inducible factor 1 α and up-regulation of microsomal PGES-1 in, 4084
 - OA, protein kinase C ζ regulation of ADAMTS-4 and NOS-2 via NF- κ B signaling, 4074
 - OA, recombinant osteoprotegerin preventing apoptosis in mice, 3358
 - OA, TGF α suppression of phenotype and *SOX9* expression in rats, 3693
- Chondrogenesis
 - LPS suppression dependent on TLR-4 presence in, 1880
 - markers for articular chondrocytes with enhanced in vitro chondrogenic capacity, 586
- Chondroitinase ABC, in vitro cartilage growth and glycosaminoglycan inhibition, 188
- Chromosome rearrangements, autoimmune diseases in carriers of, 2402
- Chronic infantile neurologic, cutaneous, articular syndrome (CINCA)
 - CIAS1* mutations and, 1273
 - IL-1 β secretion and *CIAS1* mutations, 3138
- Chronic intestinal pseudoobstruction in SSc, with "hide-bound" bowel sign, clinical image, 1724
- Chronic widespread pain
 - in adults, common symptoms in childhood associated with, 1669
 - HPA axis dysfunction and psychosocial risk factors, 360
- Churg-Strauss syndrome
 - HLA-DRB4 as genetic risk factor, 3159
 - TRAIL receptor 3 expression on eosinophils, 662
- Chylous cyst, misdiagnosis as chest wall gouty tophus, 3854
- CIAS1* gene
 - mutations and cryopyrinopathies, 1273
 - mutations and IL-1 β secretion in CINCA and Muckle-Wells syndrome, 3138
- Circadian rhythm, pathophysiology and therapeutic implications in RA, 399
- Classification Criteria for Psoriatic Arthritis (CASPAR criteria)
 - critique of, 699
 - development of, 1051
- CLE. *See* Cutaneous lupus erythematosus (CLE)
- Clinical images
 - abdominal vasculitis in SLE, 1009
 - bamboo spine in AS, 3043
 - blue-purple ears in cryoglobulinemia-associated acrocyanosis, 673
 - chronic intestinal pseudoobstruction and "hide-bound" bowel sign, 1724
 - coincident hereditary hemochromatosis and RA in MCP joints, 1463

Clinical images (*cont'd*)

- gout, dual-energy CT molecular imaging of hands, 2809
- gout, polarizing microscopy resembling night sky images, 2802
- gout, tophaceous, CT image, 29
- iloprost-induced vascular remodeling, 2243
- inner synovial surface, visualization with 3-D ultrasonography, 214
- intracardiac thrombosis in APS, 1036
- polymyositis and vasculitis, 3270
- popliteal artery pseudoaneurysm following arthroscopic synovectomy, 3432
- rheumatoid nodules in synovium, 2104
- swollen shoulder in RA, clinical image, 3948
- Takayasu arteritis diagnosed by PET, 2466
- Clinical trials, design problems in, 3884
- CNS. *See* Central nervous system (CNS)
- Cobalt protoporphyrin IX, inducing heme oxygenase 1 in inflammatory arthritis in mice, 2585
- Coffee, as gout risk factor in men, 2049
- Cognitive function, in childhood-onset SLE, functional MRI assessment, 4151
- COL1A1, imatinib mesylate inhibition of, 311
- COL1A2, imatinib mesylate inhibition of, 311
- COL2A1* gene, sex and ethnic differences in susceptibility to knee OA, 137
- Collagen
 - discoidin domain receptor 2, OA pathogenesis and increased expression in articular cartilage, 2663
 - OA, type II collagen catabolism biomarkers in mice, 3336
 - RA, type II collagen biomarkers and response to biologic therapy, 2919
 - SSc, deposition in gastric wall, 3442
 - SSc, hepatocyte growth factor effects on collagen in lung fibroblasts, 3468
 - type IV α -chain composition in normal and RA synovial lining, 3959
- Collagen degradation
 - aging and TIMP-3 deficiency, in mouse joints, 905
 - LG268 regulation of MMP-3 and MMP-13 gene expression and, 892
 - RA, type II collagen biomarkers and response to biologic therapy, 2919
- Collagen-induced arthritis
 - bone destruction inhibition, WP9QY vs. anti-TNF α monoclonal antibody, 1164
 - CD80-binding peptide agent, suppression of immune response, 498
 - DNA vaccine targeting macrophage migration inhibitory factor in, 521
 - enhanced efficacy of Treg transfer by elevated Foxp3 expression, mouse study, 2947
 - Gr-1+, CCR2+ monocyte targeting in, mouse study, 2975
 - HLA-DR4-transgenic mice mimicking sex bias of human RA, 69
 - human RA vs. mouse model, 1
 - as hyperalgesia model, 4015
 - IdeS cleavage of IgG and blocking of, 3253
 - IL-4 DC expression in, 89
 - IL-21/IL-21R blockade in, 1152
 - induction by complete Freund's adjuvant in IFN γ receptor-deficient mice, 2595
 - IFN γ suppression of IL-17 in, 1145
 - liver X receptor as therapeutic target, 1365
 - MEK/ERK pathway in, 3347
 - mesenchymal stem cells preventing tissue damage, 1175
 - nanogold effects in rats, 544
 - PGE $_2$ exacerbating via IL-23/IL-17 axis, mouse study, 2608
 - TLR-4 inhibition, mouse study, 2957
 - Treg cell biology in, 395
 - urocortin effects on down-regulation of inflammatory and Th1 responses and Treg cell induction, 531

- Combination therapy
 GCA, MTX with corticosteroids, 2789
 infliximab and MTX for early RA, 2129
 polyarticular JRA, infliximab with MTX, 3096
 prednisolone with risedronate preventing GC-induced changes in bone properties, 3726
 proliferative lupus nephritis, azathioprine with methylprednisolone, case against, 702
 proliferative lupus nephritis, azathioprine with methylprednisolone vs. cyclophosphamide, 924
 proliferative lupus nephritis, rituximab plus cyclophosphamide for, 1263
 RA, etanercept with MTX, 3-year outcome in TEMPO study, 3928
 RA, MTX alone vs. combination with infliximab or methylprednisolone, MRI study, 3919
 Comorbidity, in subacute CLE, 255
 COMP gene, sex and ethnic differences in susceptibility to knee OA, 137
 Complement, and apoptosis of peripheral blood mononuclear cells in SLE, 3738
 Complement 5a and 5b-9, therapeutic control by anti-C5 single-chain Fv, 1187
 Complement C3
 in induction of autoantibody-mediated arthritis in mice, 2968
 in K/BxN mouse model of RA, 2823
 Complement C3b, disease-specific short peptides in SSc sera, 2018
 Complement C3f-des-arginine (DRC3f), disease-specific short peptides in SSc sera, 2018
 Computed tomography (CT)
 bamboo spine in AS, clinical image, 3043
 gout, dual-energy molecular imaging of hands, 2809
 microfoam, for inflammatory arthritis assessment in mice, 4024
 peripheral quantitative, for abnormalities of tibia in JRA, 984
 popliteal artery pseudoaneurysm following arthroscopic synovectomy, clinical image, 3432
 Computers, carpal tunnel syndrome prevalence and keyboard use, 3620
 Congenital heart block, hypoxia and cAMP in transdifferentiation of fetal cardiac fibroblasts, 4120
 Connective tissue growth factor, hepatocyte growth factor effects on expression in SSc lung fibroblasts, 3468
 Constitutional structural chromosomal rearrangements, in autoimmune disease, 2402
 Contraceptives, oral, as SLE risk factor, 1251
 Coronary flow reserve, altered function in young women with SLE, 1904
 Corticosteroids
 injections for hip OA, randomized controlled trial, 2278
 MTX/corticosteroid combination therapy for GCA, 2789
 preventing lupus flares, 2098
 Cosmetics, skin-lightening creams and SLE risk, 1721
 COX-2. *See* Cyclooxygenase 2 (COX-2)
 C-reactive protein
 TNF blockade and cardiovascular risk in PsA, 831
 vitamin D serum metabolites and disease activity in early inflammatory polyarthritis, 2143
 Criteria for SLE, prediagnostic onset of autoantibodies, 2344
 Cryoglobulinemia I, in acrocyanosis, clinical image, 673
 Cryopyrin mutations, 2817
 Cryopyrinopathies, clinical continuum and *CLAS1* mutations, 1273
 CSF. *See* Cerebrospinal fluid (CSF)
 CT. *See* Computed tomography (CT)
 C-telopeptides, CTX-II predicting radiographic RA progression, 3236
 Cutaneous lupus erythematosus (CLE)
 subacute, incidence and prevalence, 255
 Treg cells in skin lesions, 1910
 CXCL8. *See* Interleukin-8 (IL-8)
 CXCL16, urinary excretion in experimental immune nephritis, 949
 CXCR5 chemokine receptors, lymphoid neogenesis in antigen-induced arthritis, mouse study, 3271
 Cyclic citrullinated peptide (CCP)
 antibody association with *PADI4* haplotypes in early RA and with SE alleles in late RA, 1454
 HLA-DRB1 SE alleles, smoking and association with anti-CCP antibodies in RA, 425
 RA, interaction between smoking and HLA-DR SE alleles in anti-CCP formation, 1745
 strong combined SE gene-environmental effects in anti-CCP RA, 1446
 Cyclic tensile strain, as IKK inhibitor in NF- κ B transcription in chondrocytes, 3284
 Cyclin-dependent kinase inhibitors, seliciclib effects on glomerulonephritis and life span in mice with SLE, 1629
 Cyclooxygenase 2 (COX-2)
 inhibitors, dosage and cardiovascular risk, 384
 microparticles inducing synthesis of, 3564
 SLE, autoimmune response and effects of inhibitor diet therapy, mouse study, 4132
 in synergistic stimulation of prostaglandin biosynthesis in osteoblasts, 910
 Cyclophosphamide
 impact on health-related quality of life in SSc with lung disease, 1676
 lupus nephritis, proliferative, combination treatment with rituximab for, 1263
 for proliferative lupus nephritis, azathioprine plus methylprednisolone vs., 924
 SSc with ILD, bronchoalveolar lavage findings following treatment, 4195
 Cysteine proteinase inhibitors, IdeS cleavage of IgG and blocking of experimental arthritis, 3253
 Cysteine-rich secretory protein 3, low salivary gland levels in SS, 2575
 Cytokines
 expression in hepatitis C virus-associated mixed cryoglobulinemia vasculitis, 1315
 fibrogenic, in stomach in SSc, 3442
 IL-4 DC regulation of, in collagen-induced arthritis, 89
 juvenile DM, expression of plasmacytoid DC in inflamed muscles, 1658
 Lyme arthritis, in synovial fluid and tissue, 1325
 probiotic, allograft inflammatory factor 1 effects on in vitro production, 3478
 RA, proinflammatory mediator reversal of CD4+, CD25+ Treg-mediated suppression in, 732, 3874
 T cell, in OA, 409

D

- DAS. *See* Disease Activity Score (DAS)
 DAS28. *See* Disease Activity Score in 28 Joints (DAS28)
 DC. *See* Dendritic cells (DC)
 dcSSc. *See* Diffuse cutaneous systemic sclerosis (dcSSc)
 Decay-accelerating factor 1 (Daf1), reduced expression on CD4+ T cells in autoimmunity in mice, 1934
 Decoy receptor 3
 protecting against Fas-induced apoptosis, 1067
 SLE-like syndrome in mice overexpressing, 3748
 Dehydroepiandrosterone (DHEA), low salivary gland levels in SS, 2575
 Dendritic cells (DC)
 activation in SLE by U1 RNA, 3379
 IL-4 expression in collagen-induced arthritis, 89
 plasmacytoid, autoantibodies in IFN α activation in myositis, 3112
 plasmacytoid, in muscle inflammation in juvenile DM, 1658
 RA, proinflammatory mediator reversal of Treg-mediated suppression, 3874

Dendritic cells (DC) (*cont'd*)

- SpA, immunologic synapse formation with CD4+ T cells in HLA-B27-transgenic rats, 1478
 - SS, infiltration and expression of IL-18 and IL-12 in salivary gland lesions, 3977
 - WG, Treg cell modulation in autoimmunity, 1725
- Depression, autoimmune, induction in mice by anti-ribosomal P antibodies, 938

Dermal fibrosis

- imatinib mesylate preventing development in SSc, 311
- trichostatin A preventing extracellular matrix accumulation in SSc, mouse study, 2755

Dermatomyositis (DM). *See also* Juvenile dermatomyositis

- anti-SUMO-1 antibodies in, 3132
- chronic intestinal pseudoobstruction and "hide-bound" bowel sign, clinical image, 1724
- endogenous activation of IFN α in, 3112
- IFN-I gene expression in DM and PM, 3784
- IL-1R interlocalization in muscle fibers, 674
- T cell receptor BV gene usage in, 372

Dermis-isolated, aggrecan-sensitive (DIAS) cells, isolation and chondroinduction of, 168

DHEA. *See* Dehydroepiandrosterone (DHEA)

Diabetes, mesenchymal stem cells for, 714

Diacerin, efficacy in knee OA pain after discontinuation of treatment, 4055

DIAS cells. *See* Dermis-isolated, aggrecan-sensitive (DIAS) cells

Diffuse cutaneous systemic sclerosis (dcSSc)

- CAT-192 therapy for, 323
- change in skin score and disease outcome, 2422
- diffuse vs. limited, 9

Discoidin domain receptor 2

- cartilage damage in knee joints and, 3685
- increased expression in articular cartilage and OA pathogenesis, 2663

Discriminant antigens, for characterization of neuropsychiatric SLE brain antigenic targets, 3420

Disease activity

- idiopathic inflammatory myopathy and anti-Jo-1 antibody levels, 3125

PsA, effects on physical function, HAQ score, 840

RA, early disease activity as predictor of treatment response, 3226

RA, rituximab effects on synovial cell infiltrates in, 772

SLE, urinary lipocalin-2 as renal disease marker, 1894

SLE, validity of 2004 BILAG index for assessment of, 4113

SS Disease Activity Index, scoring of, 2223

- vitamin D serum metabolites and, in early inflammatory polyarthritis, 2143

Disease Activity Score (DAS)

RA, infliximab with MTX for early disease, 2129

RA, pharmacogenetic model for predicting MTX efficacy, 1765

Disease Activity Score in 28 Joints (DAS28), vitamin D serum metabolites and early inflammatory polyarthritis, 2143

Disease localization, anatomic basis for, polymyalgia rheumatica vs. RA, 3496

Disease progression

- AS, MMP-3 as predictor of cartilage damage, 1846
- inflammatory arthritis, MRI and microfocal CT assessments in mice, 4024
- inflammatory polyarthritis, ACPAs predicting severity of radiologic damage, 2929

JIA, Sharp/van der Heijde radiographic scoring system adapted for, 3087

OA, C60 fullerene preventing cartilage degeneration in rabbits, 3307

OA, calcineurin modulation of chondrocytes, 2299

OA, in double-knockout ADAMTS-4/ADAMTS-5 mice, 3670

OA, hip, active shape model of morphologic bone changes, 3634

Disease progression (*cont'd*)

OA, hip, Wnt signaling antagonists as biomarkers for, 3319

OA, knee, alignment not predicting incident disease, 1212

OA, knee, delayed gadolinium-enhanced MRI of meniscus, 1507

OA, knee, varus and valgus malalignment in, 1044, 1204, 3872

OA, knee, vitamin D deficiency and, 129

OA, matrix remodeling and lipid metabolism in STR/Ort mice, 2999

OA, molecular analysis of, 2474

OA, osteoprotegerin for prevention of cartilage destruction in mice, 3358

proliferative lupus nephritis, cyclophosphamide vs. azathioprine plus methylprednisolone for, 924

RA, biomarkers predicting radiographic progression in early disease, 3236

RA, etanercept/MTX combination therapy, 3-year outcome in TEMPO study, 3928

RA, prediction rule for undifferentiated arthritis outcome, 433

RA, rituximab vs. alternate anti-TNF agents and, 1417

RA, type II collagen biomarkers and response to biologic therapy, 2919

SLE, atherosclerosis in, 3412

SS Disease Damage Index, scoring of, 2223

SSc, bronchoalveolar lavage profiles in ILD not predictive of, 2005

SSc, skin thickness progression rate and disease outcome in patients with anti-topoisomerase I antibody, 2740

TLR-4 inhibition and IL-1 expression in autoimmune destructive arthritis, 2957

Treg transfer enhancement by elevated Foxp3 expression in collagen-induced arthritis, mouse study, 2947

Disease scoring. *See* Measuring instruments

Disease-modifying antirheumatic drugs (DMARDs)

incidence of myocardial infarction in RA patients, vs. anti-TNF therapy, 2905

infection risk vs. anti-TNF therapy, 2896

for PsA, 1051

RA patient resistance to changing therapies, 2135

Disease-modifying osteoarthritis drugs (DMOADs), search for, 2469

Dkk-1, as biomarker for radiographic progression of hip OA, 3319

DM. *See* Dermatomyositis (DM)

DMARDs. *See* Disease-modifying antirheumatic drugs (DMARDs)

DMOADs. *See* Disease-modifying osteoarthritis drugs (DMOADs)

DNA methylation, epigenetics and, 3523

Dog studies, pioglitazone reducing cartilage lesion development in OA, 2288

Doxycycline, urinary TIINE concentrations and joint space narrowing in knee OA, 3644

Drug therapy. *See also* specific drug names

OA, failure of chondroprotective agents, 1378, 3873

RA, patient resistance to changing therapies, 2135

RA, pharmacogenetic model for predicting MTX efficacy, 1765

RA, repeat courses of rituximab, safety and efficacy, 3896

SS, B cell targets for, 1371

Dual x-ray absorptiometry (DXA), for tibia abnormalities in JRA, 984

DXA. *See* Dual x-ray absorptiometry (DXA)

E

Edratide (hCDR1), and altered gene expression in mice with SLE, 2371

Efalizumab, as targeted biologic response modifier in PsA, 1051

Elastin-like polypeptide---IL-1Ra fusion protein, development and characterization of, 3650

Elderly patients. *See* Older adults

ELISA. *See* Enzyme-linked immunosorbent assay (ELISA)

Endothelial cells

aortic, γ/δ T cell cytotoxicity in Takayasu arteritis, 2798

CD34+ hematologic and endothelial progenitor cells in ANCA-associated vasculitis, 3847

Endothelial cells (cont'd)

- RA, asymmetric dimethyl-L-arginine in progenitor cell depletion and carotid atherosclerosis, 809
- SLE, IFN-1 as risk factor for progenitor cell depletion, 3759
- VCAM-1/very late activation antigen 4 role in progenitor cell recruitment to RA synovium, mouse study, 1817
- Endothelin 1, as mediator of TGF β effects in lung fibroblasts, 4189
- Endothelin receptor antagonists, for vascular endothelial function in SSc, 1985
- ENMD-1068, and FAR-2 expression in rheumatoid synovium, 765

Enthesis

- enthesitis in SpA, 4
- enthesitis and synovitis, 2482
- microdamage and altered vascularity in HLA-B27-associated SpA, 224
- synovio-entheseal complex in OA and SpA pathophysiology, 3601

Environmental factors

- combined SE gene-environmental effects in anti-CCP-positive RA, 1446
- gadolinium exposure and nephrogenic systemic fibrosis, 3173
- seasonal birth patterns in myositis, 2719
- SLE, glutathione S-transferase polymorphisms and proximity to hazardous waste sites, 244

Enzyme-linked immunosorbent assay (ELISA)

- anti-Jo-1 antibody levels and idiopathic inflammatory myopathy disease activity, 3125
- specificity for IgG anti-NR2 glutamate receptor antibodies in neuropsychiatric SLE, 386, 2813

Eosinophils, TRAIL receptor 3 expression in Churg-Strauss syndrome, 662

Epidemiology

- carpal tunnel syndrome and keyboard use, 3620
- country as risk factor for renal amyloidosis in familial Mediterranean fever, 1706, 3879
- SLE prevalence in California and Pennsylvania in 2000, 2092
- systemic autoimmune disease mortality and occupational exposures, 3189

Epigenetics

- in inflammatory rheumatic diseases, 3523
- in SLE causation, 1035

Epitopes. See also Shared epitope (SE)

- discontinuous, aPL binding on domain I of β_2 -glycoprotein I, 280
- JIA, differential recognition of HSP dnaJ-derived epitopes by effector and Treg cells in inflammatory modulation, 1648
- KM-2, and apoptosis-induced acetylation of histone 4 in SLE pathogenesis, 1921
- T cell, of La/SSB autoantigen in mice expressing HLA-DRB*0301/DQB1*0201, 3387

ERK, PD184352 inhibition of p-ERK, 3347

ERK/MAPK signaling pathway, angiopoietin 1 stimulation in RA joint destruction, 2170

Errata, 830, 1370, 1675, 3172, 3510, 3871

Estrogen

- as antiresorptive agent in OA, 2469
- calcitonin effects on cartilage degradation and surface erosion in ovariectomized rats, 2674
- correlation between serum and synovial fluid concentrations in knee OA, 698
- SLE and, 1048

Etanercept

- PsA, as targeted biologic response modifier, 1051
- RA, etanercept/MTX combination therapy and disease remission, 3-year outcome in TEMPO study, 3928
- RA, Fc γ receptor IIIA genotype and response to, 448
- RA, outcomes from switching anti-TNF agents, 13
- RA, TNF α antagonist exposure and drug-specific and time-dependent risks of infection, 4226

Etanercept (cont'd)

- SpA, TNF α inhibition not affecting joint ankylosis in mice, 489
- SS, augmentation of IFN α activation in, 3995
- uveitis and, 3248

Ethnicity

- FCRL3 polymorphisms and differential RA risk in white and East Asian patients, 3168
- genetic susceptibility to knee OA, 137
- inflammatory bowel disease with AS, in Icelandic families, 2633
- leflunomide-associated risk of ILD in Korean RA patients, 2094
- as risk factor in JIA, 1974
- SSc, hepatocyte growth factor impairment in lung fibroblasts, African Americans vs. Caucasians, 2432

Evidence-based medicine, GRAPPA recommendations for PsA therapy, 1051

Exercise, interaction with inflammation in OA, 3176

Experimental arthritis. See also Antigen-induced arthritis; Collagen-induced arthritis

- adjuvant-induced, Hsp65-IgG-expressing B cells protecting against, rat study, 1490
- adjuvant-induced, IL-13 gene therapy inhibition of angiogenesis in rat model, 2535
- complement C3 in induction of autoantibody-mediated arthritis in mice, 2968
- CXCR5- and CCR7-dependent lymphoid neogenesis in, mouse model, 3271
- Freund's complete adjuvant-induced, PAR-2 activation and, 101, 3510

IdeS cleavage of IgG and blocking of, 3253

NKT cell activation by SGL-S23 suppressing autoantibody-induced arthritis, mouse study, 1836

OA, apoptotic and matrix-degrading genes in articular cartilage and meniscus, rabbit study, 1529

OA, calcineurin modulation of chondrocytes and disease progression in mice, 2299

OA, global analysis of gene expression, rat study, 1854

OA, glucosamine hydrochloride effects on subchondral bone changes, rabbit study, 1537

OA, matrix remodeling and lipid metabolism in STR/Ort mice, 2999

OA, pioglitazone reducing cartilage lesion development in dogs, 2288

PPI-2458 suppression of inflammation and structural damage, 850

proteoglycan-induced, IL-4 suppression of immune response in, 861

RA, C-type lectin-like receptor genes in susceptibility, rat study, 2620

RA, mast cell silencing as protection against joint destruction and angiogenesis, mouse study, 1806

raloxifene for postmenopausal polyarthritis and osteoporosis, mouse model, 3261

TGF β and BMP-2 in osteophyte formation in mice, 4065

TGF β signaling impairment and inflammatory disorders in female mice, 1798

TLR-4 inhibition in autoimmune destructive arthritis, mouse study, 2957

VCAM-1/very late activation antigen 4 role in endothelial progenitor cell recruitment to RA synovium, mouse study, 1817

Extracellular matrix

OA, SOX9 overexpression and restoration of articular cartilage, 158

SSc, dermal hypoxia-induced increase in protein production, 4203

SSc, imatinib mesylate reducing production of, 311

SSc, trichostatin A preventing accumulation in skin fibrosis, mouse study, 2755

F

Factor XVI activation, in β_2 -glycoprotein I regulation of thrombin, 605

Familial cold autoinflammatory syndrome, CLAS1 mutations and, 1273

- Familial Mediterranean fever
country as risk factor for renal amyloidosis in, 1706, 3879
MEFV gene mutations in inflammation, 345
- Family studies
inflammatory bowel disease with AS, 2633
OA, smoking/family history interactions in knee cartilage loss and defects, 1521
SLE, NKT cells in families, 303
SSc, clinical, immunologic, and genetic features of, 2031
- Farnesyl, and MMP-1 secretion in RA synovial fibroblasts, 2840
- Fas gene, apoptotic and matrix-degrading genes in OA articular cartilage and meniscus, rabbit study, 1529
- Fat tissue aspiration, for amyloidosis confirmation in AS, 2467
- Fatty acids, polyunsaturated, inhibition of arachidonic acid-induced TNFR expression on neutrophils, 799
- Fcγ receptors
Fcγ IIIA genotype and TNFα blocker response in RA, 448
inhibition of opsonized apoptotic cell uptake by macrophages, 3399
- FCRL3* polymorphisms, and differential RA risk in white and East Asian patients, 3168
- Feline immunodeficiency virus, as vector for μ-opioid receptor induction in TMJ pain prevention, 2038
- Femur, active shape model of morphologic changes, for predicting hip OA progression, 3634
- Fentanyl, transdermal, for OA, 696
- Fibrinogen, polymorphisms and glomerular microthrombosis risk in lupus nephritis, 1608
- Fibroblast growth factor 2, in activin A regulation, 3715
- Fibroblasts. *See also* Synoviocytes, fibroblast-like
dermal, hypoxia-induced induction of extracellular matrix proteins in, 4203
dermal, postnatal induction of TGFβ signaling in mice, 334
fetal cardiac, hypoxia and transdifferentiation to myofibroblasts, 4120
lung, endothelin 1 as mediator of TGFβ effects, 4189
PD184352 effects on p-ERK levels in, 3347
RA, IL-18 up-regulation and signaling pathways, 1787
RA, microparticle stimulation of PGE₂ synthesis in, 3564
RA, pre-B cell colony-enhancing factor expression in synovial tissues, 2829
RA, protein isoprenylation regulating MMP-1 secretion from, 2840
SSc, c-Ski/SnoN complex formation in impaired regulation of TGFβ signaling, 1694
SSc, lung, hepatocyte growth factor effects on collagen and connective tissue growth factor expression, 3468
SSc, lung, hepatocyte growth factor impairment of, 2432
SSc, trichostatin A preventing extracellular matrix accumulation in skin fibrosis, mouse study, 2755
type IV collagen α-chain composition in normal and RA synovial lining, 3959
- Fibromyalgia (FM), gabapentin for, 1336
- Fibronectin, imatinib mesylate inhibition of mRNA in SSc, 311
- Fibrosis. *See also* Pulmonary fibrosis
dermal, imatinib mesylate preventing in SSc, 311
dermal, trichostatin A preventing extracellular matrix accumulation in SSc, 2755
expression of fibrogenic cytokines in gastric wall in SSc, 3442
nephrogenic systemic, gadolinium exposure and, 3173, 3433
- Ficolin 3, in clearance of late apoptotic cells in SLE, 1598
- Fingers, coincident hereditary hemochromatosis with RA in MCP joints, clinical image, 1463
- FLS. *See* Synoviocytes, fibroblast-like (FLS)
- Fluvastatin, and vascular dysfunction in antigen-induced arthritis, 1827
- FM. *See* Fibromyalgia (FM)
- Foot, varus alignment and hip conditions in older adults, 2993
- FoxO transcription factors, inhibition in rheumatoid synovial tissue, 2180
- Foxp3
absence in K/BxN mice, Treg cells and development of inflammatory arthritis, 509
in CLE skin lesions, 1910
suppression of osteoclast formation, 4104
Treg transfer enhancement by elevated expression in collagen-induced arthritis, mouse study, 2947
- Fractalkine
RA, as chemoattractant for FLS, 2512
RA, mediation of T cell-dependent synovial fibroblast proliferation, 3215
- Fractures, risk with intermittent high-dose GC therapy, 208
- Framingham Osteoarthritis Study
hip conditions and varus foot alignment in older adults, 2993
knee alignment not predicting incident OA, 1212
knee OA progression and vitamin D deficiency, 129
- Freund's complete adjuvant, induction of collagen-induced arthritis in IFNγ receptor-deficient mice, 2595
- Freund's complete adjuvant-induced arthritis, PAR-2 activation in, 101, 3510
- Frizzled-related protein, as biomarker for progression of radiographic hip OA, 3319
- FRZB* gene
deletion affecting articular cartilage and biomechanical properties of long bones in mice, 4095
sex and ethnic differences in genetic susceptibility to knee OA, 137
in WNT signaling pathway, 3881
- Fullerene, C60, for prevention of cartilage degeneration in rabbits, 3307
- Functional magnetic resonance imaging, for cognitive function assessment in childhood-onset SLE, 4151
- Functional status, total knee replacement outcomes in older adults, 568
- Fusion proteins
elastin-like polypeptide--IL-1Ra fusion protein, 3650
IL-21 receptor Fc fusion protein, 1152

G

- Gabapentin, for FM, 1336
- Gadolinium
delayed gadolinium-enhanced MRI of meniscus in knee OA, 1503
nephrogenic systemic fibrosis and exposure to, 3173, 3433
- GAIT. *See* Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)
- Galactin 9, expression in synovium and induction of FLS apoptosis, RA vs. OA, 3968
- Gastric wall, expression of fibrogenic cytokines, in SSc, 3442
- GC. *See* Glucocorticoids (GC)
- GCA. *See* Giant cell arteritis (GCA)
- Gelatinase, high molecular weight, in NGAL-MMP-9 complex, 3326
- Gender. *See also* Men; Sex factors; Women
genetic susceptibility to knee OA and, 137
HLA-DR4-transgenic mice mimicking sex bias of human RA, 69
RA, mouse model vs. human disease, 1
SLE and accelerated damage accrual in men, LUMINA study, 622
SLE and estrogen exposure, 1048
- Gene expression profiles
APRIL receptors, RA vs. OA FLS, 3554
BMP-2, BMP-7, and TGFβ1 in chondrogenic differentiation of bovine synovium, 1869
BNIP3, apoptosis and expression in FLS, 2854
childhood-onset SLE, identification of susceptibility genes using novel microarray platform, 4164
hypoxia and phenotype in fetal cardiac fibroblasts, 4120
in identification of markers for articular chondrocytes with enhanced in vitro chondrogenic capacity, 586
IFN-I in DM and PM, 3784

Gene expression profiles (cont'd)

- IL-7 in RA synovium with ectopic lymphoid structures, 2492
- infiximab effects on adenosine/uridine-rich element binding proteins in anti-TNF therapy, 2160
- MMP-3 and MMP-13, regulation by LG100268 retinoid X receptor, 892
- MMPs, proinflammatory cytokines, and oxidative stress-derived molecules in hepatitis C virus-associated mixed cryoglobulinemia vasculitis, 1315
- OA, apoptotic and matrix-degrading genes in articular cartilage and meniscus, rabbit study, 1529
- OA, global analysis in experimental arthritis, rat study, 1854
- OA, matrix remodeling and lipid metabolism in STR/Ort mice, 2999
- OA, *SOX9* overexpression and restoration of extracellular matrix in articular cartilage, 158
- RA, altered 11 β -hydroxysteroid dehydrogenase expression in synovocytes, 1720
- RA, antiviral, IKK ϵ and IRF3 in, 743
- RA, LIGHT and herpesvirus entry mediator expression in, 1106
- RA, microparticle expression of proinflammatory phenotype in synovial fibroblasts, 3564
- RA, peptidyl arginine deiminase isotypes in synovial tissue inflammation, 3541
- LE, altered expression in mice treated with Edratide, 2371
- SLE, IFN-I-stimulated genes in murine lupus, 3770
- SS, macrophage and DC infiltration and expression of IL-18 and IL-12 in minor salivary gland lesions, 3977
- SSc, impairment of endothelial cell differentiation from mesenchymal stem cells, 1994
- SSc, Siglec-1 marker, induced by IFN α and TLR agonists, 1010
- synovial, in SLE, RA, and OA, 1579
- synovial vascular, analysis by laser-mediated microdissection, RA vs. OA, 1094
- in systemic JIA, 1954
- Gene transfer
 - feline immunodeficiency virus as vector for μ -opioid receptor, 2038
 - OA, *SOX9* overexpression and restoration of extracellular matrix in articular cartilage, 158
 - somatic B cell vaccination with anti-DNA IgG, in lupus-prone mice, 1945
 - Treg transfer enhancement by elevated Foxp3 expression in collagen-induced arthritis, mouse study, 2947
- Genetics. See also Family studies; Mutations; Polymorphisms; Susceptibility, genetic
 - allograft inflammatory factor 1 and profibrotic cytokine phenotype in normal fibroblasts, 3478
 - AS, co-occurring HLA-B*2709 and HLA-B*1403 alleles in, 2807
 - AS, HLA-B*2709 subtype in, 2805
 - AS, *TNAP* haplotype association with, 234
 - CARD15* mutation in Blau syndrome with interstitial pneumonitis, 1292
 - carriers of constitutional structural chromosomal rearrangements, 2402
 - comparative proteomic profiles of normal and OA cartilage, 3675
 - epigenetics in inflammatory rheumatic diseases, 3523
 - hypoxia-inducible factor 2 α in induction of articular chondrocyte phenotype, 3297
 - IFN α / β -inducible gene overexpression in DM and PM, 3784
 - IL-13 inhibition of angiogenesis in rats, 2535
 - inflammatory bowel disease with AS, in Icelandic families, 2633
 - lupus nephritis development, CD1d and NKT cells in mice, 1219
 - NOD2* gene in pediatric granulomatous arthritis, 3805
 - OA, disease progression in double-knockout ADAMTS-4/ADAMTS-5 mice, 3670
 - OA, matrix remodeling and lipid metabolism in STR/Ort mice, 2999
 - OA, microsomal PGES-1 in articular cartilage, 4084
 - OA, type II collagen catabolism biomarkers in mice, 3336

Genetics. See also Family studies; Mutations; Polymorphisms; Susceptibility, genetic (cont'd)

- PsA, pathophysiology and, 1051
- RA, antibody status and association of IL-6 and IL-10 genotypes with radiographic damage, 2549
- RA, anti-CCP, combined SE gene-environmental effects, 1446
- RA, CCP antibody association with *PADI4* haplotypes in early RA and with SE alleles in late RA, 1454
- RA, C-type lectin-like receptor genes in susceptibility, 2620
- RA heterogeneity, linkage analysis of quantitative traits, 58
- RA, HLA-DRB1 SE, smoking and association with anti-CCP antibodies, 425
- RA, HLA-DRB1 SE alleles influencing specificity of ACPA response, 3949
- RA, HLA-DRB1 SE genotypes and early mortality, 1408
- RA, MIC-1 genotype as marker for joint destruction in, 753
- SLE, epigenetic factors in causation, 1035
- SLE, IRF5 structural insertion/deletion variation associated with risk haplotype, 1234
- SLE, pneumonia risk and, 2679
- SS, primary, salivary biomarkers for, 3588
- SSc, CD4+CD8+ double-positive T cells in skin lesions, 3459
- SSc, chemokine gene interactions in susceptibility, 2443
- SSc, familial, clinical and immunologic features, 2031
- T cell epitopes of La/SSB autoantigen in mice expressing HLA-DRB*0301/DOBI*0201, 3387
- T cell receptor BV gene usage in idiopathic myositis, 372
- TGF α suppression of articular chondrocyte phenotype and *Sax9* expression in rat model, 3693
- TLR7* gene copy number variations, SLE patients vs. healthy controls, 3375
- V α genes in AL amyloidosis, 3858
- Geranylgeranyl transferase inhibitors, effects on MMP-1 secretion in RA synovial fibroblasts, 2840
- Giant cell arteritis (GCA)
 - adjunctive MTX with corticosteroids for, 2789
 - glucocorticoid treatment, active vs. placebo for, 1723
 - high-dose methylprednisolone for, 1722
 - PIA1/A2 polymorphism of glycoprotein IIIa and risk of cranial ischemic complications, 3502
- Glomerular microthrombosis, hemostasis factor polymorphisms and risk in lupus nephritis, 1608
- Glomerulonephritis
 - SLE, seliciclib effects and life span in mice, 1629
 - urine proteomics for diagnosis of, 705
- Glucocorticoids (GC)
 - bisphosphonates and bone quality in GC-induced osteoporosis, 3518
 - high-dose, for GCA, 1722, 1723
 - intermittent high-dose, fracture risk with, 208
 - RA, cardiovascular events and, 820
 - RA, cortisone/cortisol shuttle as therapeutic target for bone loss in, 387
 - risedronate preventing GC-induced changes in bone properties, 3726
 - Takayasu arteritis, limitations of therapy with, 1000
- Glucosamine hydrochloride
 - OA, effects on subchondral bone changes, rabbit study, 1537
 - OA, heterogeneity of clinical trial results, 2267
- Glucosamine sulfate
 - OA, efficacy and conflict of interest in clinical trials, 2105
 - OA, heterogeneity of clinical trial results, 2267
 - OA of knee, vs. acetaminophen for, 555
- Glucosamine Unum in Die Efficacy (GUIDE) trial
 - conflict of interest and, 2105
 - for OA of knee, final results, 555
- Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), conflict of interest and, 2105

Glucose-6-phosphate isomerase, IgG autoantibody binding in joint-specific RA, 2823
 Glutamate receptors, modulation of IL-6 and MMP-2 expression in FLS, 2523
 Glutathione S-transferase, polymorphisms and proximity to hazardous waste sites, in SLE diagnosis, 244
 Glycoprotein 39 (gp39), HLA-DR-restricted presentation in RA inflamed joint, 2150
 Glycosaminoglycans
 for identifying markers for articular chondrocytes with enhanced in vitro chondrogenic capacity, 586
 in vitro cartilage growth and manipulation of, 188
 Gout
 coffee intake and risk in men, 2049
 dual-energy CT molecular imaging of hands, 2809
 IL-1 and inflammasome in, 3183
 misdiagnosis of chylous cyst as chest wall gouty tophus, 3854
 PEGylated recombinant mammalian urate oxidase for, 1021
 polarizing microscopy image resembling night sky, clinical image, 2802
 tophaceous, three-dimensional CT, 29
 Granulomatous arthritis, pediatric, *NOD2* gene-associated, 3805
 Granzyme B
 angiotatin production and, 3448
 histidyl-tRNA synthetase cleavage in lung, 2729
 GRAPPA. *See* Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), 1051
 GUIDE trial. *See* Glucosamine Unum in Die Efficacy (GUIDE) trial
 Guinea pigs, subchondral bone in OA, 3366

H

Hand
 gout, dual-energy CT molecular imaging, 2809
 SSc, MR angiography for assessment of vascular abnormalities, 2747
 HAQ. *See* Health Assessment Questionnaire (HAQ)
 Hazardous waste sites, proximity and glutathione S-transferase polymorphisms in SLE, 244
 hCDR1 (Edratide), altered gene expression in mice with SLE and, 2371
 HDL. *See* High-density lipoproteins (HDL)
 Headache, validity of "lupus headache" in SLEDAI, 2812
 Health Assessment Questionnaire (HAQ)
 irreversible component of disability index, 1368
 PsA, disease activity and physical function, 840
 vitamin D serum metabolites and disease activity in early inflammatory polyarthritis, 2143
 Health economics, arthritis-related health care expenditures and earnings loss, 2003 vs. 1997, 1397
 Health-related quality of life, SSc with lung disease, cyclophosphamide impact on, 1676
 Heat, effects on ANCA-induced neutrophil activation, 3149
 Heat-shock proteins (HSP)
 Hsp90 age-dependent mediation of insulin-like growth factor 1 and IL-1 β signaling in chondrocytes, 2335
 Hsp60, γ/δ T cell reactivity in Takayasu arteritis, 2798
 Hsp65-IgG-expressing B cells protecting against adjuvant-induced arthritis, rat study, 1490
 JIA, differential recognition of dnaJ-derived epitopes by effector and Treg cells in inflammatory modulation, 1648
 Hemarthrosis, cartilage damage and exposure to low concentrations of blood, in vitro study, 199
 Hematopoietic stem cell transplantation
 autologous, in children with severe progressive JIA, 2410
 RA, MIC-1 genotyping and response to, 753
 Heme oxygenase 1
 intracellular expression in RA, genotype and, 3953
 reducing inflammatory arthritis in mice, 2585
 TNF α down-regulation of, in human peripheral monocytes in inflammation, 464
 Hemochromatosis, coincident with RA in MCP joints, clinical image, 1463
 Hemodialysis, nephrogenic systemic fibrosis and mortality risk, 3433
 Hemophagocytic lymphohistiocytosis, primary CNS vasculitis vs., 995
 Hepatitis C virus-associated mixed cryoglobulinemia vasculitis, molecular mechanisms, 1315
 Hepatocyte growth factor
 SSc, effects on collagen and connective tissue growth factor expression in lung fibroblasts, 3468
 SSc, impairment in lung fibroblasts, 2432
 Herpesvirus entry mediator, expression in RA, 1106
 High-density lipoproteins (HDL)
 in pediatric SLE, longitudinal study, 631
 proinflammatory, duality of effects, 696
 Hip
 OA, active shape model of morphologic bone changes in, 3634
 OA, steroid injections for, randomized controlled trial, 2278
 OA, varus foot alignment in older adults and, 2993
 OA, Wnt signaling antagonists as prognostic biomarkers for radiographic disease progression, 3319
 Histidyl-tRNA synthetase, in Jo-1 autoantibody-associated myositis, 2729
 Histone acetylase, synovial tissue activity, RA vs. OA, 1087
 Histone deacetylase, synovial tissue activity, RA vs. OA, 1087
 Histone modifications, epigenetics and, 3523
 Histone 4 peptides, apoptosis-induced acetylation in SLE, 1921
 HLA alleles
 OA associations with, 409
 RA subclassification and, 1728
 HLA-B27
 AS, co-occurring HLA-B*2709 and HLA-B*1403, 2807
 AS, HLA-B*2709 subtype, 2805
 AS, molecular basis of association with, 2478
 AS, p38 MAPK dysregulation in HLA-B27-expressing monocytes, 2652
 AS, previously unrecognized predisposing factors in extended haplotypes, 2640
 SpA, autoimmunity and, 4
 SpA, different intracellular trafficking of HLA-B*2705 and HLA-B*2709, 2232
 SpA, enthesitis-associated bone damage in, 224
 SpA, immunologic synapse formation between DC and CD4+ T cells, 1478
 up-regulation and unfolded protein response, 215
 HLA-B14, co-occurring HLA-B*2709 and HLA-B*1403 in AS, 2807
 HLA-DQ2, T cell epitopes of La/SSB autoantigen in mice expressing HLA-DRB*0301/DQB1*0201, 3387
 HLA-DR3, T cell epitopes of La/SSB autoantigen in mice expressing HLA-DRB*0301/DQB1*0201, 3387
 HLA-DR4
 human cartilage gp39 and melanoma inhibitory activity in RA inflamed joint, 2150
 transgenic mice mimicking sex bias of human RA, 69
 HLA-DRB1
 RA, SE alleles influencing specificity of ACPA response, 3949
 T cell epitopes of La/SSB autoantigen in mice expressing HLA-DRB*0301/DQB1*0201, 3387
 HLA-DRB1 shared epitope genes
 RA, alleles in specificity of ACPA response, 3949
 RA, early mortality and, 1408
 RA, interaction with smoking in anti-CCP formation, 1745
 RA, smoking and ACPA response in absence of, 2913

HLA-DRB1 shared epitope genes (*cont'd*)
 smoking and predisposition to CCP antibodies, 425

HLA-DRB4, in Churg-Strauss syndrome, 3159

Hormone replacement therapy
 raloxifene for experimental postmenopausal polyarthritis and osteoporosis in mice, 3261
 in SLE, 3070

Hormones
 circadian rhythm and, 399
 SLE, reproductive and menopausal risk factors in women, 1251
 SLE and estrogen exposure, 1048

HPA axis. *See* hypothalamic-pituitary-adrenal (HPA) axis

HSP. *See* Heat-shock proteins (HSP)

Human antigen R, infliximab effects on gene expression levels in RA, 2160

Human chorionic gonadotropin (HCG), for SS-like exocrinopathy in mice, 2211

Human platelet antigen 6b, polymorphism and thrombocytopenia risk in SLE, 2803

Hyaluronan, in articular cartilage boundary lubrication, 882

Hyaluronic acids, intraarticular, vs. hylan for knee OA, 3610

Hybridoma, HLA-DR-restricted presentation of human cartilage gp39 and melanoma inhibitory activity in RA inflamed joint, 2150

Hydroxychloroquine for calcium pyrophosphate deposition disease, 3172

25-hydroxyvitamin D, disease activity in early inflammatory polyarthritis and, 2143

Hylan, intraarticular, vs. hyaluronic acids for knee OA, 3610

Hyperalgesia, collagen-induced arthritis as model for, 4015

Hyperimmunoglobulinemia D with periodic fever syndrome, macrophage activation syndrome in, case study, 658

Hypothalamic-pituitary-adrenal (HPA) axis, stress response and chronic widespread pain in, 360

Hypoxia
 dermal, induction of extracellular matrix proteins in SSc, 4203
 effects on gene expression in fetal cardiac fibroblasts, 4120
 enhancing cartilage matrix synthesis and SOX9 expression of articular chondrocytes, 3297

Hypoxia-inducible factor 1 α
 hypoxia and expression in fetal cardiac fibroblasts in vitro, 4120
 OA, in up-regulation of microsomal PGES-1 in articular cartilage, 4084
 synovial vascular gene expression, RA vs. OA, analysis by laser-mediated microdissection, 1094

Hypoxia-inducible factor 2 α , in induction of articular chondrocyte phenotype, 3297

I

IdeS, cleavage of IgG and blocking of experimental arthritis, 3253

Idiopathic inflammatory myopathies
 anti-Jo-1 antibody levels and disease activity, 3125
 IL-1R interlocalization in skeletal muscle sarcolemma and nuclei, 674
 juvenile-onset, seasonal birth patterns in, 2719

Idiopathic interstitial pneumonia, CCL18 as biomarker in SSc, 1685

IFN α . *See* interferon- α (IFN α)

IgG
 agalactosyl, serum levels in ischemic heart disease in RA, 21, 2097
 anti-NR2 glutamate receptor antibodies, ELISA specificity for, 386, 2813
 autoantibodies to citrullinated proteins as RA biomarker, 2823
 Hsp65-IgG-expressing B cells protecting against adjuvant-induced arthritis, rat study, 1490
 IdeS cleavage and blocking of experimental arthritis, 3253
 NKT cells and levels in SLE, 303
 serum self-IgG reactivity patterns in proteomic characterization of neuropsychiatric SLE brain antigenic targets, 3420

IgG (*cont'd*)
 SLE, opsonization of apoptotic cells and inhibition of uptake via Fc γ receptor-dependent mechanism, 3399

IgM
 NKT cells and IgM levels in SLE, 303
 RF, linkage analysis in RA heterogeneity, 58

IKK
 biomechanical signals inhibiting activity in NF- κ B transcription, 3284
 IKK-2 inhibition in antibody-induced arthritis, 117
 IKK ϵ and IRF3 antiviral gene expression in RA, 743

IL-1. *See* interleukin-1 (IL-1).

ILD. *See* Interstitial lung disease (ILD)

Iloprost, and vascular remodeling, clinical image, 2243

Imaging. *See also* Clinical images; *Names of specific imaging techniques*
 gout, polarizing microscopy image resembling night sky, 2802
 knee OA, biomarkers as surrogates for, 4038
 RA, NF- κ B activity in antibody-induced arthritis, 117

Imatinib mesylate, for dermal fibrosis in SSc, 311

Immune response
 circadian rhythm and, 399
 differential tissue targeting by Y RNAs in TLR activation, 1589
 IL-4 suppression of, in proteoglycan-induced arthritis, 861
 stem cell therapy and, 714
 suppression in collagen-induced arthritis by CD80-binding competitive antagonist peptides, 498
 T cells and loss of immune tolerance in SS and SLE, 3180

Immunity, innate, in OA, 409

Immunoglobulins, atacept effects in SLE, 4142

Immunosuppression, in stem cell transplantation for severe progressive JIA, 2410

In memoriam, John Heath Vaughan, MD, 701

Inclusion body myositis, IFN α / β -inducible gene expression in, 3784

Induction and Maintenance Psoriatic Arthritis Clinical Trial 2, 2698

Infection
 JC virus, in progressive multifocal leukoencephalopathy, 2116
 RA, anti-TNF therapy and bacterial infection risk in elderly, 1754
 RA, bacterial infection risk and exposure to TNF α antagonists vs. MTX, 1125
 RA, DMARDs vs. anti-TNF therapy in risk of, 2896
 RA, TNF α antagonist exposure and drug-specific/time-dependent risks of, 4226
 tuberculosis in mice, abatacept effects on, 2557

Inflammasome
 caspase 1, bypassing roadblocks for IL-1 β secretion and disease activity, 2817
 in gout, IL-1 β and, 3183

Inflammation
 aortic, inflammatory rheumatic disease and smoking as predictors of, 2072
 biomechanical signals inhibiting IKK in NF- κ B transcription in chondrocytes, 3284
 familial Mediterranean fever, *MEFV* gene mutations in, 345
 JIA, differential recognition of HSP dnaJ-derived epitopes by effector and Treg cells, 1648
 joint, PAR-2 role in, 3514
 OA, acute-phase proteins in, 409
 OA, interaction with exercise in, 3176
 PsA, synovio-entheseal complex in joint damage and, 2482
 RA, pre-B cell colony-enhancing factor as mediator, 2829
 RA synovium, peptidyl arginine deiminase isotype expression in, 3541
 salivary gland, TGF β signaling impairment and, 1798
 TNF α down-regulation of heme oxygenase 1 in human peripheral monocytes, 464

Inflammatory arthritis
 FoxP3-dependent Treg cells in, 509

Inflammatory arthritis (*cont'd*)

- heme oxygenase 1 induction reducing inflammatory arthritis in mice, 2585
- MRI and microfocal CT assessments in mice, 4024
- MTX efficacy in probable RA, 1424
- polyarthritis and cancer incidence and survival, 790
- predicting aortic inflammation, 2072
- tenosynovitis and osteoclast formation in mice, 79
- vitamin D metabolites and disease activity in early polyarthritis, 2143

Inflammatory bowel disease with AS, in Icelandic families, 2633

Inflammatory polyarthritis, ACPAs predicting severity of damage, 2929

Inflammatory rheumatic diseases, epigenetics in, 3523

Infliximab

- polyarticular JRA, combination therapy with MTX, 3096
- PsA, inhibiting radiographic damage progression, 2698
- PsA, as targeted biologic response modifier, 1051
- RA, combination therapy with MTX, MRI study, 3919
- RA, effects on gene expression levels of adenine/uridine-rich element binding proteins in anti-TNF therapy, 2160
- RA, Fcγ receptor IIIA genotype and response in, 448
- RA, MTX with, for early disease, 2129
- RA, outcomes from switching anti-TNF agents, 13
- RA, TNFα antagonist exposure and drug-specific and time-dependent risks of infection, 4226
- SLE, short-term therapy and autoantibodies in, 274
- uveitis and, 3248

Inhibitor of DNA binding/differentiation 2 (Id2), synovial vascular gene expression, RA vs. OA, 1094

Insulin-like growth factor 1

- early tendinosis in rats and, 871
- Hsp90 age-dependent mediation in chondrocytes, 2335

Integrins

- α5β1 integrin, positive regulation of BAFF synthesis by rheumatoid synoviocytes, 3202
- SLE, β1 integrins in T cell activation, 1559

Interferon I (IFN-I)

- gene expression in DM and PM, 3784
- SLE pathogenesis and signaling in IFN-I receptor-deficient mice, 3770
- SLE, as risk factor for endothelial progenitor cell depletion and endothelial dysfunction, 3759

Interferon-α (IFNα)

- endogenous activation in myositis, 3112
- gene overexpression in DM and PM, 3784
- SS, etanercept and augmented production of, 3995
- SSc, Siglec-1 induction by, 1010

Interferon-β (IFNβ)

- gene overexpression in DM and PM, 3784
- RA, antiviral gene expression and inhibition of, 743

Interferon-γ (IFNγ)

- IL-17 suppression in collagen-induced arthritis, 1145
- protective effects in antigen-induced arthritis in mice, 2244
- receptor deficiency and collagen-induced arthritis in mice, 2595
- Interferon regulatory factor 1 (IRF-1), lack of evidence for genetic association in JIA, 972

Interferon regulatory factor 3 (IRF-3), antiviral gene expression in RA, 743

Interleukin-1 (IL-1)

- APRIL expression of IL-1β, in RA FLS, 3554
- bradykinin receptors and interaction with TNFα in osteoblasts, 910
- bypassing roadblocks in IL-1β release, 2817
- Hsp90 age-dependent mediation of IL-1β signaling in chondrocytes, 2335
- IL-1β impairment of TGFβ1 signaling in human chondrocytes, 3020
- IL-1β as LPS mediator in cartilage matrix synthesis, 1880

Interleukin-1 (IL-1) (*cont'd*)

- IL-1β mRNA expression and cartilage damage in antigen-induced arthritis, 108
- IL-1β secretion and *CIAS1* mutations in CINCA and Muckle-Wells syndrome, 3138
- inflammasome and IL-1β role in gout, 3183
- inhibition and integrative repair of porcine meniscus in vitro, 3033
- OA, protein kinase Cζ and IL-1β induction of NF-κB signaling in chondrocytes, 4074
- TLR-4 inhibition and expression in autoimmune destructive arthritis, mouse study, 2957

Interleukin-1 receptor (IL-1R), interlocalization in skeletal muscle sarcolemma and nuclei, 674

Interleukin-1 receptor antagonist (IL-1Ra), elastin-like polypeptide---IL-1Ra fusion protein characterization, 3650

Interleukin-2 receptor (IL-2R), soluble, in macrophage activation syndrome in systemic JIA, 965, 3877

Interleukin-4 (IL-4)

- DC expression in collagen-induced arthritis, 89
- SSc, high production by CD4+CD8+ double-positive T cells in skin lesions, 3459
- suppression of immune response in proteoglycan-induced arthritis, 861

Interleukin-6 (IL-6)

- APRIL expression of, in RA FLS, 3554
- circadian rhythm and, 399
- glutamate receptor modulation of expression in FLS, 2523
- neuropsychiatric SLE and CSF levels of, 1242, 3509
- RA, antibody status and association of genotype with radiographic damage, 2549

Interleukin-7 (IL-7), signaling in RA synovial tissues with lymphoid neogenesis, 2492

Interleukin-8 (IL-8), interactions with RANTES in SSc susceptibility, 2443

Interleukin-10 (IL-10), antibody status and association of genotype with RA radiographic damage, 2549

Interleukin-12 (IL-12), macrophage and DC infiltration and expression in SS salivary gland lesions, 3977

Interleukin-13 (IL-13), inhibition of angiogenesis in rats, 2535

Interleukin-17 (IL-17)

- IFNγ suppression of, in collagen-induced arthritis, 1145
- as molecular target in immune-mediated arthritis, 89
- PGE₂ exacerbating collagen-induced arthritis via IL-23/IL-17 axis, 2608
- RA, cellular source of, 2111
- RA, in up-regulation of stromal cell-derived factor 1 in RA synovial fibroblasts, 1076
- regulation in human T helper cells, 2936

Interleukin-18 (IL-18)

- RA, up-regulation of angiogenic factors in synovial fibroblasts, signaling pathways, 1787
- SS, macrophage and DC infiltration and expression in salivary gland lesions, 3977

Interleukin-21 (IL-21), blockade in RA rodent models, 1152

Interleukin-21 receptor Fc fusion protein, for IL-21 blockade in collagen-induced arthritis, 1152

Interleukin-23 (IL-23), in PGE₂ exacerbation of collagen-induced arthritis via IL-23/IL-17 axis, 2608

Interstitial lung disease (ILD)

- bronchoalveolar lavage profiles not predictive of ILD progression in SSc, 2005
- histidyl-tRNA synthetase conformation in lung, 2729
- leflunomide-associated risk in Korean RA patients, 2094
- microscopic polyangiitis as "pulmonary-muscle" syndrome, 2065
- pneumonitis in Blau syndrome with *CARD15* mutation, 1292
- RA-associated, CD56-expressing T cell senescence in, 43
- SS-associated, B cell infiltration in, 3167

Interstitial lung disease (ILD) (*cont'd*)
 in SSC, bronchoalveolar lavage findings following cyclophosphamide treatment, 4195
 Intervertebral disk herniation, TNF α blockade for treatment of sciatica, review, 3887
 Intracellular signaling peptides, c-Ski/SnoN complex formation in SSC, 1694
 IRAK-1, as childhood-onset SLE susceptibility gene, 4164
 IRF1 gene, lack of evidence for association in JIA, 972
 IRF5 gene
 functional polymorphism in SS, 3989
 SLE, structural insertion/deletion variation in risk haplotype and isoforms, 1234
 SNPs in RA, 2202
 Ischemia, cerebral, glycoprotein IIIa PIA1/A2 polymorphism and risk in GCA, 3502
 Ischemic heart disease, and serum mannose-binding lectin and agalactosyl IgA in RA, 21, 2097

J

Japanese population, *PRKCH* gene encoding protein kinase C isozyme in RA, 30
 JC virus infection, in progressive multifocal leukoencephalopathy, 2116
 JIA. *See* Juvenile idiopathic arthritis (JIA)
 Joint damage
 ACPAs predicting radiologic damage in inflammatory polyarthritis, 2929
 AL amyloidosis manifestations of, 3858
 lubricin expression and cartilage damage in antigen-induced arthritis, 108
 OA, fixed-flexion radiography of knee for detection of joint space loss, 1512
 OA, knee, biomarkers as surrogates for imaging of, 4038
 OA, knee, urinary TIINE concentrations and joint space narrowing in doxycycline treatment, 3644
 OA, matrix remodeling and lipid metabolism in STR/Ort mice, 2999
 PPI-2458 suppression of inflammation and structural damage in experimental arthritis, 850
 PsA, disease activity and physical function, HAQ score, 840
 PsA, infliximab inhibiting radiographic damage progression, 2698
 PsA, synovio-entheseal complex in, 2482
 RA, antibody status and association of IL-6 and IL-10 genotypes with radiographic damage, 2549
 RA, radiographic damage and BMI, 3575
 Joint destruction
 RA, angiopoietin 1 stimulation of ERK/MAPK and PI 3-kinase/Akt pathways in joint destruction, 2170
 RA, pre-B cell colony-enhancing factor as mediator of, 2829
 RA, S100A4 up-regulation in, 779
 RA, serum MIC-1 as marker for, 753
 SpA, inflammation and remodeling uncoupled in mouse model, 489
 targeted mast cell silencing as protection against, mouse study, 1806
 JRA. *See* Juvenile rheumatoid arthritis (JRA)
 Jurkat T cells, allograft inflammatory factor 1 effects on migration in SSC, 3478
 Juvenile dermatomyositis (juvenile DM)
 plasmacytoid DC in inflamed muscle tissue, 1658
 RANKL:osteoprotegerin ratio and BMD in, 977
 rituximab for, 3107
 Juvenile idiopathic arthritis (JIA)
 autologous stem cell transplantation for severe progressive disease, 2410
 differential recognition of HSP dnaJ-derived epitopes by effector and Treg cells in inflammation, 1648
 epidemiology in multiethnic cohort, 1974
 lack of evidence for genetic association with IRF-1, 972

Juvenile idiopathic arthritis (JIA) (*cont'd*)
 meningococcal C vaccination, safety and efficacy in, 639
 Sharp/van der Heijde radiographic scoring system for, 3087
 systemic, gene expression profiles in, 1954
 systemic, macrophage activation syndrome in, 965, 3793, 3877
 systemic, *SLC262A* polymorphisms and susceptibility to, 1286
 uveitis prevalence, risk factors, and outcome in, 647
 Juvenile psoriatic arthritis, classification of, 1368
 Juvenile rheumatoid arthritis (JRA)
 abnormalities of tibia in, 984
 in carriers of constitutional structural chromosomal rearrangements, 2402
 infliximab with MTX for polyarticular JRA, 3096
 Juvenile systemic lupus erythematosus (juvenile SLE)
 abdominal vasculitis in, clinical image, 1009
 lipid profiles in, longitudinal study, 631
 low BMD, prevalence and etiology, 1966, 4228

K

Kawasaki disease, circulating soluble RAGE vs. proinflammatory ligand S100A12 levels in, 4174
 K/BxN serum-induced arthritis, PAR-2 activation in, 101, 3510
 Knee
 lubricin expression and cartilage damage in antigen-induced arthritis, 108
 OA, alignment not predicting incident disease, 1212
 OA, biomarkers as surrogates for imaging, 4038
 OA, correlation between serum and synovial fluid concentrations of estrogen in, 698
 OA, delayed gadolinium-enhanced MRI of meniscus, 1507
 OA, discoidin domain receptor 2 expression and cartilage damage, 3685
 OA, fixed-flexion radiography for detection of joint space loss, 1512
 OA, glucosamine sulfate vs. acetaminophen for, 555
 OA, intraarticular hylan vs. hyaluronic acids for, 3610
 OA, meniscal damage and pain, 4048
 OA, PET scan of brain areas in pain processing, 1345
 OA, radiation synovectomy for, 385, 386
 OA, randomized crossover trial of wedged insole for, 1198
 OA, sex and ethnic differences in genetic susceptibility to, 137
 OA, smoking and family history interactions in knee cartilage loss and defects, 1521
 OA, urinary TIINE concentrations and joint space narrowing in doxycycline treatment, 3644
 OA, varus and valgus malalignment in disease development and progression, 1044, 1204, 3872
 OA, vastus medialis muscle changes, 3626
 OA, vitamin D deficiency and worsening of, 129
 OA pain and bone marrow lesions, 2986
 total replacement, procedure volume and patient-centered outcomes in older adults, 568

L

Laser Doppler flowmetry vs. infrared thermography for assessing localized scleroderma in children, 3489
 LDL. *See* low-density lipoprotein (LDL)
 Lectin, mannose-binding, in ischemic heart disease in RA, 21, 2097
 Leflunomide, and risk of ILD in Korean RA patients, 2094
 LG100268 (LG268), regulating MMP-3 and MMP-13 gene expression, 892
 LIGHT, mediating cellular adhesion and metalloproteinase production by synoviocytes, 1106
 Linkage analysis, quantitative traits in RA, 58
 Lipid rafts, in anti- β_2 -glycoprotein I antibodies and monocyte release of TNF α and tissue factor in AS, 2687
 Lipids, metabolism and matrix remodeling in OA, 2999

Lipocalin-2, urinary, as renal disease marker in SLE, 1894

Lipopolysaccharides
 in IL-1 β secretion in CINCA and Muckle-Wells syndrome with *CLAS1* mutation, 3138
 TLR-4 activation and articular cartilage matrix synthesis, 1880

Lipoproteins
 HDL proinflammatory, duality of effects, 696
 lipid profiles in pediatric SLE, longitudinal study, 631
 TNF blockade and cardiovascular risk in PsA, 831

Liver X receptor, as therapeutic target in collagen-induced arthritis, 1365

Losartan, therapeutic use in mouse RA models and human inflammatory synovitis, 441

Low-density lipoprotein (LDL), in pediatric SLE, longitudinal study, 631

LPIN2 gene, mutations in Majed syndrome, 960

Lubrication, synovial fluid constituents in articular cartilage boundary, 882

Lubricin. *See* Proteoglycan 4 (lubricin)

LUMINA. *See* LUPus in MINorities, NAture versus Nurture study (LUMINA study)

Lungs
 endothelin 1 and TGF β effects in fibroblasts, 4189
 histidyl-tRNA synthetase conformation in, 2729
 restricted T cell receptor BV gene usage in idiopathic myositis, 372
 SSc, cyclophosphamide impact on health-related quality of life, 1676
 SSc, hepatocyte growth factor effects on collagen and connective tissue growth factor expression in fibroblasts, 3468

Lupus. *See* Cutaneous lupus erythematosus; Systemic lupus erythematosus (SLE)

Lupus in Minorities, Nature versus Nurture study (LUMINA study)
 accelerated damage accrual in men, 622
 thrombocytopenia and SLE prognosis, 614, 2811

Lupus nephritis. *See also* Glomerulonephritis
 autoimmune, protection in MyD88-deficient mice, 1618
 CD1d and NKT cells in, mouse studies, 1219
 CD8+ T cells in periglomerular infiltrates, 2362
 experimental immune, urinary mediators in, 949
 hemostasis factor polymorphisms and glomerular microthrombosis risk, 1608
 proliferative, azathioprine plus methylprednisolone for, case against, 702
 proliferative, cyclophosphamide vs. azathioprine plus methylprednisolone for, 924
 proliferative, rituximab/cyclophosphamide combination treatment for, 1263
 somatic B cell gene vaccination for, with anti-DNA IgG, renal protection in mice, 1945
 TLR-9 in development of tubulointerstitial injury, 1569
 urinary lipocalin-2 and renal disease activity, 1894

Lyme arthritis
 antibiotic-refractory, chemokines and cytokines in synovial fluid and tissue, 1325
 antibody responses to *Borrelia burgdorferi* in, 4216

Lymph nodes, MRI and microfocus CT assessments of volume in inflammatory arthritis, 4024

Lymphoid tissue
 CXCR5- and CCR7-dependent lymphoid neogenesis in antigen-induced arthritis, mouse study, 3271
 IL-7 signaling pathway in RA synovial tissues with lymphoid neogenesis, 2492

Lymphoma, risk with MTX and anti-TNF therapy for RA, 1433

Lyn kinase, altered regulation in SLE B lymphocyte signaling domains, 291

M

Macroglossia, AL amyloidosis in, 3858

Macrophage activation syndrome
 in hyperimmunoglobulinemia D with periodic fever syndrome, case study, 658
 in systemic JIA, gene expression profiling predicting, 3793
 in systemic JIA, sDC163 and sIL-2R α significance in diagnosis of, 965, 3877

Macrophage inhibitory cytokine 1 (MIC-1), serum, as joint destruction marker in RA, 753

Macrophages
 DNA vaccine targeting migration inhibitory factor in collagen-induced arthritis, 521
 OA, synovial, role in MMP-3-mediated cartilage destruction, 147
 SS, infiltration and expression of IL-18 and IL-12 in salivary gland lesions, 3977
 synovial sublining, as biomarker for RA, 3869

Magnetic resonance imaging (MRI)
 anatomic basis for joint disease localization, polymyalgia rheumatica vs. RA, 3496
 delayed enhanced, myocardial fibrosis in SSc, 3827
 functional, assessment of cognitive function in childhood-onset SLE, 4151
 for inflammatory arthritis assessment in mice, 4024
 knee OA, delayed gadolinium-enhanced imaging of meniscus, 1507
 MTX alone vs. combination with infliximab or methylprednisolone for early RA treatment, 3919
 OA knee pain and bone marrow lesion development, 2986
 RA, bone erosion and bone marrow edema, 1118
 SSc, angiographic assessment of hand vascular abnormalities, 2747

Majed syndrome, *LPIN2* mutations in, 960

Major histocompatibility complex (MHC), MHC-typed FLS as antigen-presenting cells to T cells, 1497

MAPK
 activation by fractalkine/FLS signaling in RA, 2512
 RA, angiopoietin 1 stimulation in joint destruction, 2170
 SSc, in hepatocyte growth factor regulation of collagen and connective tissue growth factor in lung fibroblasts, 3468
 in synergistic stimulation of prostaglandin biosynthesis in osteoblasts, 910

Mast cells
 synovial, PAR-2 mediation of proinflammatory effects in mice, 3532
 targeted silencing protecting against joint destruction and angiogenesis, mouse study, 1806

Matrix metalloproteinases (MMPs)
 activity and cartilage blood exposure, in vitro study, 199
 cartilage degradation and imbalance with TIMP-3 in mice, 905
 expression in hepatitis C virus-associated mixed cryoglobulinemia vasculitis, 1315
 OA, C60 fullerene inhibition of, preventing cartilage degeneration in rabbits
 RA, LIGHT up-regulation mediating cellular adhesion and metalloproteinase production by synoviocytes, 1106

Matrix metalloproteinase 1 (MMP-1)
 OA, apoptotic and matrix-degrading genes in articular cartilage and meniscus, rabbit study, 1529
 RA, protein isoprenylation regulating secretion from synovial fibroblasts, 2840

Matrix metalloproteinase 2 (MMP-2)
 glutamate receptor modulation of expression in FLS, 2523
 RA, differential regulation of MMP-2 and MMP-9 by activated protein C, 2864

Matrix metalloproteinase 3 (MMP-3)
 AS, as predictor of cartilage damage progression, 1846
 gene expression regulation by LG268 retinoid X receptor, 892
 increased expression in Frzb^{-/-} mice, 4095
 OA, and macrophage role in cartilage destruction, 147

- Matrix metalloproteinase 3 (MMP-3) (*cont'd*)
 RA, angiopoietin 1 stimulation in joint destruction, 2170
 RA, as predictor of radiographic progression, 3236
- Matrix metalloproteinase 9 (MMP-9)
 differential regulation of MMP-2 and MMP-9 by activated protein C in RA, 2864
 NGAL-MMP-9 complex in OA, 3326
- Matrix metalloproteinase 13 (MMP-13)
 discoidin domain receptor 2 and expression in knee cartilage damage, 3685
 gene expression regulation by LG268 retinoid X receptor, 892
 MBL gene, and pneumonia risk in SLE, 2679
- MCP. *See* metacarpophalangeal (MCP) joints
- MCP-1. *See* monocyte chemoattractant protein 1 (MCP-1)
- Measurement instruments
 Sharp/van der Heijde radiographic scoring system adapted for JIA, 3087
 SS Disease Damage Index and SS Disease Activity Index, scoring of, 2223
 validity of 2004 BILAG index for SLE disease activity assessment, 4113
 validity of "lupus headache" in SLEDAI, 2812
- Mechanotransduction, of superficial zone protein in bovine cartilage by TGF β signaling, 3706
- Medical Expenditures Panel Survey, arthritis-related health care expenditures and earnings loss, 2003 vs. 1997, 1397
- MEFV gene
 mutations in ACPA-negative palindromic rheumatism, 2784
 mutations and inflammation in familial Mediterranean fever, 345
 mutations and risk of renal amyloidosis in familial Mediterranean fever, 1706, 3879
- MEK/ERK pathway, in mouse model of RA, 3347
- Melanoma inhibitory activity, HLA-DR-restricted presentation in RA joint inflammation, 2150
- Men
 gonadal evaluation in SLE, 2352
 gout and coffee intake, 2049
 SLE, accelerated damage accrual, LUMINA study, 622
- Menarche, reproductive and menopausal risk factors in SLE, 1251
- Meningococcal C vaccinations, safety and efficacy in JIA, 639
- Meniscus
 inhibition of IL-1 and TNF α and integrative repair, in vitro, 3033
 OA, apoptotic and matrix-degrading genes in, rabbit study, 1529
 OA, damage and knee pain, 4048
 OA, delayed gadolinium-enhanced knee MRI, 1507
- Menopause
 hormone replacement therapy in SLE, 3070
 risk factors in SLE, 1251
- Mercury, in skin-lightening creams, as SLE risk, 1721
- Mesenchymal stem cells
 OA, 3-dimensional cartilage tissue engineering, 177
 for regenerative medicine, 714
 SSC, impairment of endothelial cell differentiation, 1994
- Metacarpophalangeal (MCP) joints, coincident hereditary hemochromatosis with RA, clinical image, 1463
- Metastasis, TNF α blockers and, 695
- Metastasis-inducing proteins, S100A4 up-regulation in RA, 779
- Methionine aminopeptidase type 2 inhibitors, PPI-2458, suppression of inflammation and structural damage in experimental arthritis, 850
- Methotrexate (MTX)
 antiinflammatory mechanisms and ecto-5'-nucleotidase conversion of AMP to adenosine, 1440
 for chronic calcium pyrophosphate deposition disease, 688, 3172
 GCA, adjunctive treatment with corticosteroids, 2789
 polyarticular JRA, combination therapy with infliximab, 3096
 RA, 34C>T variant in *AMPD1* gene and clinical response to, 694
- Methotrexate (MTX) (*cont'd*)
 RA, bacterial infection risk vs. TNF α antagonists, 1125
 RA, as biomarker predicting radiographic progression, 3236
 RA, early disease activity predicting treatment response, 3226
 RA, efficacy for probable RA, 1424
 RA, etanercept/MTX combination therapy and disease remission, 3-year outcome in TEMPO study, 3928
 RA, infliximab with, for early disease, 2129
 RA, lymphoma risk and, 1433
 RA, pharmacogenetic model for predicting efficacy, 1765
 RA, as solo treatment vs. combination with infliximab or methylprednisolone, MRI study, 3919
 RA, TNF α antagonist exposure and drug-specific and time-dependent risks of infection, 4226
- Methylprednisolone
 with azathioprine, for proliferative lupus nephritis, case against, 702
 with azathioprine, for proliferative lupus nephritis, cyclophosphamide vs., 924
 RA, combination therapy with MTX, MRI study, 3919
- MHC. *See* major histocompatibility complex (MHC)
- Microarray analysis
 altered gene expression in mice with SLE treated with Edr tide, 2371
 C-type lectin-like receptor genes in RA susceptibility, 2620
 gene expression profiles in synovium, SLE vs. RA and OA, 1579
 IL-7 localization in RA synovial tissues with lymphoid neogenesis, 2492
 markers for articular chondrocytes with enhanced in vitro chondrogenic capacity, 586
 OA, microsomal PGES-1 in articular cartilage, 4084
- Microcirculation, hand, MR angiography for abnormalities in SSC, 2747
- Microdissection, laser-mediated, synovial vascular gene expression, RA vs. OA, 1094
- Microparticles, stimulation of PGE₂ synthesis in fibroblasts, 3564
- MicroRNA, epigenetics and, 3523
- Microscopic polyangiitis
 antineutrophil cytoplasmic antibodies in, 2455
 as "pulmonary-muscle" syndrome, 2065
- Mitochondrial depolarization, calcium signaling and chondrocyte death, 2322
- Mixed cryoglobulinemia vasculitis, hepatitis C virus-associated antiviral therapy for, 2810
 molecular mechanisms in, 1315
- ML120B, inhibition of NF- κ B in RA, 117
- MMPs. *See* matrix metalloproteinases (MMPs)
- Monoclonal antibodies. *See also specific antibody names*
 anti-TNF α , bone destruction inhibition in collagen-induced arthritis, vs. WP9QY cyclic peptide, 1164
 aPL, recognizing SE of β_2 -glycoprotein I and serine proteases in APS, 1638
 B3, arginine mutation and altered antibody binding to SLE- and APS-linked antigens, 2392
 β_2 -glycoprotein I, regulating thrombin in factor XI activation, 605
 binding of TRAPS-associated TNFRSF1A mutations, 2765
 MC-21 targeting of CCR2+ monocytes in collagen-induced arthritis, mouse study, 2975
 PsA, long-term use of adalimumab, 476
 RA, ENMD-1068 and PAR-2 expression in synovial tissue, 765
- Monocyte chemoattractant protein 1 (MCP-1), IL-18 up-regulation in synovial fibroblasts, 1787
- Monocytes. *See also* Peripheral blood mononuclear cells
 AS, anti- β_2 -glycoprotein I antibodies and release of TNF α and tissue factor via lipid rafts, 2687
 AS, p38 MAPK dysregulation in HLA-B27-expressing, 2652
 human peripheral, TNF α downregulation of heme oxygenase 1 in inflammation, 464

Monocytes. *See also* Peripheral blood mononuclear cells (*cont'd*)

- MC-21 targeting of Gr-1+,CCR2+ in collagen-induced arthritis, mouse study, 2975
- TRAPS and elevated CD16 expression by, 4182
- Monosodium urate monohydrate, inflammasome and IL-1 β release in gout, 3183
- Mortality. *See also* Outcomes
 - cutaneous changes in nephrogenic systemic fibrosis predicting, 3433
 - PsA, improved survival, 30 year prospective study, 2708
 - RA, HLA-DRB1 SE genotypes and, 1408
 - RA, serum TNFR levels as predictor of, 3940
 - RA mortality vs. general population, 3583
 - SSc, skin thickness progression rate and disease outcome in patients with anti-topoisomerase I antibody, 2740
 - system autoimmune diseases, occupational exposures and, 3189
- Mouse studies
 - abatacept effects on chronic tuberculosis infection, 2557
 - aggrecan degradation in human articular cartilage explants, mediation by ADAMTS-4 and ADAMTS-5, 575
 - aging and increased collagen and aggrecan degradation in mouse joints, TIMP-3 deficiency and, 905
 - aquaporin 5 expression and distribution in submandibular glands, 2566
 - autoimmune depression in mice, induction by anti-ribosomal P antibodies, 938
 - bone destruction inhibition in collagen-induced arthritis, 1164
 - CD73 deficiency and MTX conversion of AMP to adenosine, 1440
 - complement C3 induction of autoantibody-mediated arthritis, 2968
 - CXCR5- and CCR7-dependent lymphoid neogenesis in antigen-induced arthritis, 3271
 - Daf1 expression on CD4+ T cells in autoimmunity, 1934
 - decoy receptor 3 overexpression causing SLE-like syndrome, 3748
 - differential tissue targeting by Y RNAs in TLR activation, 1589
 - DNA vaccine targeting macrophage migration inhibitory factor in collagen-induced arthritis, 521
 - gender in RA mouse model vs. human disease, 1
 - Gr-1+,CCR2+ monocyte targeting in collagen-induced arthritis, 2975
 - heme oxygenase 1 induction reducing inflammatory arthritis, 2585
 - HLA-DR4-transgenic mice mimicking sex bias of human RA, 69
 - IFN γ receptor deficiency and Freund's complete adjuvant induction of collagen-induced arthritis, 2595
 - IFN γ suppression of IL-17 in collagen-induced arthritis, 1145
 - IL-4 suppression of immune response in proteoglycan-induced arthritis, 861
 - IL-17 as molecular target in immune-mediated arthritis, 89
 - immune nephritis, excreted urinary mediators in, 949
 - inflammatory arthritis, FoxP3-dependent Treg cells in K/BxN mice, 509
 - inflammatory arthritis, MRI and microfocal CT assessments, 4024
 - lupus nephritis, CD1d and NKT cells in, 1219
 - MEK/ERK pathway in collagen-induced arthritis, 3347
 - mesenchymal stem cells preventing tissue damage in collagen-induced arthritis, 1175
 - μ -opioid receptor induction for TMJ pain prevention, 2038
 - NF- κ B deficiency in DC and antigen-specific suppression of established arthritis, 2255
 - NKT cell activation by SGL-S23, 1836
 - OA, calcineurin modulation of chondrocytes and disease progression, 2299
 - OA, disease progression in double-knockout ADAMTS-4/ADAMTS-5 mice, 3670
 - OA, lubricin degradation and joint wear, 3662
 - OA, macrophage role in MMP-3-mediated cartilage destruction, 147
 - OA, matrix remodeling and lipid metabolism, 2999
 - OA, osteoprotegerin preventing cartilage destruction with, 3358

Mouse studies (*cont'd*)

- OA, type II collagen catabolism biomarkers, 3336
- OS, *FRZB* deletion affecting articular cartilage and biomechanical properties of long bones, 4095
- PAR-2 activation in arthritis, 101, 3510
- PGE₂ exacerbating collagen-induced arthritis via IL-23/IL-17 axis, 2608
- PM, C protein-induced myositis as model, 1304
- protection against autoimmune nephritis in MyD88-deficient mice, 1618
- protective effects of IFN γ in antigen-induced arthritis, 2244
- RA, IKK-2 kinase inhibition of NF- κ B, molecular imaging, 117
- RA, IL-21 blockade in, 1152
- RA, K/BxN murine model, 2823
- RA, liver X receptor as therapeutic target in collagen-induced arthritis, 1365
- RA, losartan for, 441
- raloxifene for postmenopausal polyarthritis and osteoporosis, 3261
- SLE, COX-2 autoimmune response and inhibitor diet therapy, 4132
- SLE, Edratide treatment and altered gene expression, 2371
- SLE, pathogenesis and IFN-I signaling in IFN-I receptor-deficiency, 3770
- SLE, seliciclib effects on glomerulonephritis and life span, 1629
- SLE, TLR-9 in tubulointerstitial injury, 1569
- SpA, uncoupling of inflammation and joint remodeling in, 489
- SS, HCG for prevention of SS-like exocrinopathy, 2211
- SSc, postnatal induction of TGF β signaling in dermal fibroblasts, 334
- T cell epitopes of La/SSB autoantigen in mice expressing HLA-DRB*0301/DQB1*0201, 3387
- tenosynovitis and osteoclast formation in inflammatory arthritis, 79
- TGF β and BMP-2 in osteophyte formation in experimental arthritis, 4065
- TGF β signaling impairment and inflammatory disorders, 1798
- TLR-4 inhibition in autoimmune destructive arthritis, 2957
- Treg transfer enhancement by elevated Foxp3 expression in collagen-induced arthritis, 2947
- trichostatin A preventing extracellular matrix accumulation in skin fibrosis, 2755
- urocortin effects on inflammatory and Th1 responses and Treg cell induction in collagen-induced arthritis, 531
- VCAM-1/very late activation antigen 4 role in endothelial progenitor cell recruitment to RA synovium, 1817
- MRI. *See* Magnetic resonance imaging (MRI)
- mRNA
 - HLA-B27, up-regulation in unfolded protein response, 215
 - IL-1 β expression and cartilage damage in antigen-induced arthritis, 108
 - MEFV* gene, reduced expression and inflammation in familial Mediterranean fever, 345
 - salivary biomarkers for primary SS, 3588
 - SSc, fibronectin I, imatinib mesylate inhibition of, 311
 - TGF α suppression of articular chondrocyte phenotype and *Sox9* expression in rats, 3693
 - TLRs in human articular chondrocytes, 1880
- MTX. *See* Methotrexate (MTX)
- Muckle-Wells syndrome
 - CIAS1* mutations and, 1273
 - IL-1 β secretion and *CIAS1* mutations, 3138
- Multicenter Osteoarthritis Study, meniscal damage and knee pain, 4048
- Multiple sclerosis, late-onset TRAPS in, 2774
- Muscles
 - IL-1R interlocalization in sarcolemma and nuclei, in idiopathic inflammatory myopathy, 674
 - juvenile DM, plasmacytoid DC in inflamed tissue, 1658
 - restricted T cell receptor BV gene usage in idiopathic myositis, 372

Musculoskeletal abnormalities

- AL amyloidosis manifestations in, 3858
 - JRA, of tibia, 984
 - severe regional musculoskeletal pain, risk factors for, 1355
- ## Mutations
- aPL binding to discontinuous epitopes on domain I of β_2 -glycoprotein I, 280
 - arginine, and altered antibody binding to SLE- and APS-linked antigens, 2392
 - CARD15*, in Blau syndrome with interstitial pneumonitis, 1292
 - CIAS1*, and cryopyrinopathies, 1273
 - CIAS1*, and IL-1 β secretion in CINCA and Muckle-Wells syndrome, 3138
 - in cryopyrin, 2817
 - Foxp3* dysfunction in K/BxN mice and inflammatory arthritis development, 509
 - late-onset TRAPS in multiple sclerosis with *TNFRSF1A* R92Q mutation, 2774
 - LPIN2*, in Majeed syndrome, 960
 - MEFV*, in ACPA-negative palindromic rheumatism, 2784
 - MEFV* gene, and renal amyloidosis risk in familial Mediterranean fever, 1706, 3879
 - MEFV* gene, in familial Mediterranean fever, 345
 - NOD2*, in pediatric granulomatous arthritis, 3805
 - TRAPS-associated, and *TNFRSF1A* structural alterations, 2765
 - V_H genes in AL amyloidosis, 3858
- ## MyD88 pathway
- in autoimmune nephritis, 1618
- ## Myocardial fibrosis
- pattern and distribution in SSC, 3827
- ## Myocardial infarction
- incidence in RA, anti-TNF therapy vs. DMARDs, 2905
- ## Myofibroblasts
- stomach, in SSC, 3442
- ## Myositis
- See also Dermatomyositis (DM); Idiopathic inflammatory myopathies; Polymyositis (PM)
 - anti-asparaginyl-transfer RNA synthetase autoantibodies in, 1295
 - anti-Jo-1 antibody levels and, 3125
 - endogenous activation of IFN α in, 3112
 - histidyl-tRNA synthetase conformation in lung, 2729
 - IFN-I gene expression in DM and PM, 3784
 - inclusion body, T cell receptor BV gene usage in, 372
- ## Myositis ossificans
- of upper extremity, clinical image, 2454

N

- N-3 polyunsaturated fatty acids, inhibition of TNFR expression on neutrophils, 799
- ## Nailfold capillaroscopy
- iloprost-induced vascular remodeling, clinical image, 2243
 - Raynaud's phenomenon transition, 2102
- ## Nanogold
- and collagen-induced arthritis in rats, 544
- ## National Data Bank for Rheumatic Diseases
- lymphoma risk with MTX and anti-TNF therapy for RA, 1433
- ## Natural killer T cells (NKT cells)
- in families of SLE patients, 303
 - in lupus nephritis, mouse study, 1219
 - SGL-S23 activation of, mouse study, 1836
- ## Near-infrared fluorescence
- protease-activated, for NF- κ B activity, 117
- ## Neonatal-onset multisystem inflammatory disease (NOMID)
- CIAS1* mutations and, 1273
 - treatment response, 2099
- ## Neovascularization
- See Angiogenesis
- ## Nephritis
- See Glomerulonephritis; Lupus nephritis
- ## Nephrogenic systemic fibrosis
- cutaneous changes predicting early mortality, 3433
 - gadolinium exposure and, 3173, 3433
- ## Neurodegenerative disorders
- mesenchymal stem cells for, 714
- ## Neuropsychiatric systemic lupus erythematosus
- autoimmune depression in mice, induction by anti-ribosomal P antibodies, 938
- ## Neuropsychiatric systemic lupus erythematosus (cont'd)
- ELISA specificity for IgG anti-NR2 glutamate receptor antibodies in, 386, 2813
 - events and diagnosis of, 265
 - IL-6 and chemokines in CSF, 1242, 3509
 - immunoproteomic characterization of brain antigenic targets in, 3420
- ## Neutrophil gelatinase-associated lipocalin (NGAL)
- NGAL-MMP-9 complex in OA, 3326
- ## Neutrophils
- heat exposure and ANCA activation of, 3149
 - n-3 polyunsaturated fatty acid inhibition of arachidonic acid-induced expression of TNFR, 799
 - RA, TNF α activation of BAFF release by, 1776
- ## NF- κ B
- activin A regulation by, 3715
 - biomechanical signals inhibiting IKK in NF- κ B transcription, 3284
 - deficiency in DC and antigen-specific suppression of established arthritis in mice, 2255
 - OA, protein kinase C ζ and IL-1 β induction of signaling in chondrocytes, 4074
 - RA, molecular imaging IKK-2 kinase inhibition of, 117
- ## Nitric oxide synthase (NOS)
- protein kinase C ζ regulation of NOS-2 via NF- κ B signaling, 4074
- ## NKT cells
- See Natural killer T cells (NKT cells)
- ## *NOD2* gene
- in pediatric granulomatous arthritis, 3805
- ## NOMID
- See Neonatal-onset multisystem inflammatory disease (NOMID)
- ## Nonsteroidal antiinflammatory drugs (NSAIDs)
- dosage and cardiovascular risk, 384
 - for PsA, 1051
- ## Nucleosomes
- apoptosis-induced acetylation in SLE, 1921
- ## Nucleus pulposus
- sciatica and secretion of proinflammatory substances, 3887

O

OA. See Osteoarthritis (OA)

Occupational exposure

- carpal tunnel syndrome and keyboard use, 3620
- regional musculoskeletal pain, risk factors, 1355
- systemic autoimmune disease mortality and, 3189

Older adults

- hip conditions and varus foot alignment, 2993
- OA of hip, Wnt signaling antagonists as biomarkers for radiographic progression in women, 3319
- RA, anti-TNF therapy and bacterial infection risk, 1754
- total knee replacement and procedure volume, patient-centered outcomes, 568

Onercept, TNF blockade and cardiovascular risk in PsA, 831

- Opioid receptors, intraarticular induction of μ -receptor, for TMJ pain prevention, 2038

Orthotic devices, wedged insole for knee OA, 1198

- Osteitis, bone erosion and bone marrow edema in RA, MRI identifying, 1118

Osteoarthritis (OA)

- antiresorptive agents for, 2469
- apoptotic and matrix-degrading genes in articular cartilage and meniscus, rabbit study, 1529
- BNIP-3 protein regulation of apoptosis in FLS, 2854
- C60 fullerene preventing cartilage degeneration in rabbits, 3307
- calcineurin modulation of chondrocytes and disease progression in mice, 2299
- comparative proteomic profiles in normal and OA cartilage, 3675
- decoy receptor 3 expression in FLS and Fas-induced apoptosis, 1067
- diacerein efficacy in knee pain after discontinuation of treatment, 4055
- discoidin domain receptor 2 expression in articular cartilage, 2663

Osteoarthritis (OA) (cont'd)

- disease progression in double-knockout ADAMTS-4/ADAMTS-5 mice, 3670
- failure of chondroprotective agents, 1378, 3873
- FoxO inhibition in synovial tissue, 2180
- FRZB deletion and articular cartilage and long bone properties in mice, 4095
- galactin 9 expression in synovium and induction of FLS apoptosis, 3968
- gene expression profiles in synovium, 1579
- global analysis of gene expression, rat study, 1854
- glucosamine hydrochloride effects on subchondral bone, rabbit study, 1537
- glucosamine sulfate efficacy and conflict of interest in clinical trials, 2105
- hip, active shape model of morphologic bone changes in radiographic disease progression, 3634
- hip, and varus foot alignment in older adults, 2993
- hip, Wnt signaling antagonists as biomarkers for radiographic disease progression, 3319
- hip OA, steroid injections for, randomized controlled trial, 2278
- histone deacetylase/acetylase activity in synovial tissue, 1087
- hypoxia-inducible factor 1 α and up-regulation of microsomal PGES-1 in articular cartilage, 4084
- inflammation/exercise interactions in, 3176
- knee, alignment not predicting incident OA, 1212
- knee, biomarkers as surrogates for imaging, 4038
- knee, correlation between serum and synovial fluid concentrations of estrogen, 698
- knee, delayed gadolinium-enhanced MRI of meniscus, 1507
- knee, discoidin domain receptor 2 expression and cartilage damage, 3685
- knee, fixed-flexion radiography detecting joint space loss, 1512
- knee, glucosamine sulfate vs. acetaminophen for, 555
- knee, intraarticular hylan vs. hyaluronic acids for, 3610
- knee, meniscal damage and pain, 4048
- knee, PET scan of brain areas in pain processing, 1345
- knee, sex and ethnic differences in genetic susceptibility, 137
- knee, smoking/family history interactions in cartilage loss and defects, 1521
- knee, urinary THINE concentrations and joint space narrowing in doxycycline treatment, 3644
- knee, varus and valgus malalignment in disease progression, 1044, 1204, 3872
- knee, vastus medialis muscle changes, 3626
- knee, vitamin D deficiency and worsening of, 129
- knee, wedged insole for, randomized crossover trial, 1198
- knee pain and bone marrow lesions, 2986
- lubricin degradation and joint wear, mouse study, 3662
- macrophages in MMP-3-mediated cartilage destruction, 147
- matrix remodeling and lipid metabolism in STR/Ort mice, 2999
- MMP/TIMP-3 imbalance and increased collagen and aggrecan degradation in mouse joints, 905
- molecular analysis of disease progression, 2474
- NGAL-MMP-9 complex in, 3326
- pioglitazone reducing cartilage lesion development in dogs, 2288
- prevention of cartilage destruction with osteoprotegerin in mice, 3358
- protein kinase C ζ regulation of ADAMTS-4 and NOS-2 via NF- κ B signaling, 4074
- restoration of cartilage extracellular matrix by overexpression of SOX9 transcription factor, 158
- stem cell therapy for, 714
- structure-modifying treatments for, 1378, 3873
- subchondral bone role in guinea pigs, 336f
- synovial vascular gene expression, laser-mediated microdissection, vs. RA, 1094

Osteoarthritis (OA) (cont'd)

- synovio-entheseal complex and synovitis in, 3601
- T cells in pathogenesis, 409
- TGF α suppression of articular chondrocyte phenotype and Sox9 expression in rats, 3693
- transdermal fentanyl for, 696
- type II collagen catabolism biomarkers in mice, 3336
- Osteoblasts, cytokine-induced prostaglandin biosynthesis in, 910
- Osteoclasts
 - preclinical changes in inflammatory arthritis in mice, 79
 - Treg cells and formation of, 4104
- Osteophytes, TGF β vs. BMP-2 role in formation, mouse study, 4065
- Osteoporosis
 - GC-induced, pathogenesis and bisphosphonate treatment of, 3518
 - in juvenile SLE, 1966, 4228
 - raloxifene for, mouse menopausal model, 3261
- Osteoprotegerin, RANKL:osteoprotegerin ratio and BMD in juvenile DM, 977
- Outcome Measures in Rheumatology Clinical Trials (OMERACT), joint disease localization, polymyalgia rheumatica vs. RA, 3496
- Outcomes
 - OA, diacerein efficacy in knee pain after discontinuation of treatment, 4055
 - patient-centered, total knee replacement and procedure volume in older adults, 568
 - RA, early disease activity as predictor of treatment response, 3226
 - RA, etanercept/MTX combination therapy and disease remission, 3-year outcome in TEMPO study, 3928
 - RA, prediction rule for undifferentiated arthritis outcome, 433
 - RA, safety and efficacy of repeat courses of rituximab, 3896
 - rituximab for juvenile DM, 3107
 - skin score changes and dSSc outcome, 2422
 - SSc, skin thickness progression rate and disease outcome in patients with anti-topoisomerase I antibody, 2740
 - Takayasu arteritis, limitations of therapy, 1000
 - thrombocytopenia and SLE prognosis, LUMINA study, 614, 2811
 - uveitis in JIA, 647
- Ovariectomy, calcitonin effects on cartilage degradation and surface erosion in ovariectomized rats, 2674
- Oxidative stress
 - antimyceloperoxidase antibodies and, 2455
 - fluvastatin and vascular dysfunction in antigen-induced arthritis, rat study, 1827
 - OA, C60 fullerene vs. sodium hyaluronate for cartilage degeneration in rabbits, 3307
- Oxidative stress-derived molecules, in hepatitis C virus-associated mixed cryoglobulinemia vasculitis, 1315

P

- P38 MAPK, dysregulation in HLA-B27-expressing monocytes in AS, 2652
- p53 gene, in OA articular cartilage and meniscus, rabbit study, 1529
- PAD (peptidyl arginine deiminase), PAD-2 and PAD-4 expression in RA synovium in tissue inflammation, 3541
- PAD14 gene, CCP association with, in early RA, 1454
- Pain
 - circadian rhythm and, 399
 - knee OA, diacerein efficacy for after discontinuation of treatment, 4055
 - knee OA, meniscal damage and, 4048
 - knee OA, PET brain scan of processing areas, 1345
 - regional musculoskeletal, risk factors for, 1355
 - TMJ, intraarticular induction of μ -opioid receptor for, 2038
- Palindromic rheumatism, ACPA-negative, MEFV mutations in, 2784
- Pannus tissue, ex vivo cellular model, 2875
- PAR-2. See Protease-activated receptor 2 (PAR-2)
- Patient satisfaction, and resistance to changing RA therapies, 2135

- PD184352, anti-inflammatory effects in collagen-induced arthritis, 3347
- Pediatric granulomatous arthritis, *NOD2* gene-associated, 3805
- Pediatric rheumatology, future of, 2815
- PEGylated recombinant mammalian urate oxidase (PEG-uricase), for refractory gout, 1021
- Peptides, disease-specific short peptides in SSc sera, 2018
- Peptidyl arginine deiminase (PAD), PAD-2 and PAD-4 expression in RA synovium in tissue inflammation, 3541
- Perforin deficiency, and primary CNS vasculitis in child, 995
- Peripheral blood mononuclear cells
- apoptosis and reactive oxygen/nitrogen intermediates and complement levels in SLE, 3738
 - gene expression in, predicting macrophage activation syndrome in systemic JIA, 3793
 - gene expression in systemic JIA, 1954
 - IFN- γ gene expression in DM and PM, 3784
 - RA, B cell response to rituximab, 3909
 - Siglec-1 expression in SSc, induced by IFN α and TLR agonists, 1010
- Peripheral quantitative computed tomography, for tibial abnormalities in JRA, 984
- Peroxisome proliferator-activated receptor α genes, in OA progression, 2999
- PET. *See* Positron emission tomography (PET)
- PGE₂. *See* Prostaglandin E₂ (PGE₂)
- PGES. *See* Prostaglandin E synthases (PGES)
- Phosphatidylinositol (PI) 3-kinase/Akt pathway
- heat exposure inhibition of ANCA-induced neutrophil activation, 3149
 - RA, angiopoietin 1 stimulation in joint destruction, 2170
- Phospholipids, surface-active, in articular cartilage boundary lubrication, 882
- Photosensitivity, in subacute CLE, 255
- Pilocarpine, salivary peptides and proteins in SS and, 2216
- Plasminogen activator inhibitor 1, polymorphisms and glomerular microthrombosis risk in lupus nephritis, 1608
- PM. *See* Polymyositis (PM)
- Pneumonia
- interstitial, in Blau syndrome with *CARD15* mutation, 1292
 - SLE, risk factors for, 2679
 - SSc, CCL18 as biomarker for idiopathic interstitial pneumonias and lung disease, 1685
- Polyarthritis, raloxifene for, in mice, 3261
- Polymerase chain reaction
- RA, *HO-1* promoter polymorphism, 3953
 - TLR7 gene copy number variations, SLE patients vs. healthy controls, 3375
- Polymorphisms. *See also* Single nucleotide polymorphism
- AMPD1* gene, 34C>T variant, effects on clinical response to MTX in RA, 694
 - glutathione S-transferase, and proximity to hazardous waste sites in SLE diagnosis, 244
 - glycoprotein IIIa PIA1/A2 polymorphism and risk of cranial ischemic complications in GCA, 3502
 - hemostasis factors and glomerular microthrombosis risk in lupus nephritis, 1608
 - HLA and RA subclassification, 1728
 - human platelet antigen 6b, and thrombocytopenia risk in SLE, 2803
 - IRF5* T allele and primary SS, 3989
 - JIA, lack of evidence for genetic association with *IRF-1*, 972
 - OA, *FRZB* gene, effects on articular cartilage and biomechanical properties of long bones in mice, 4095
 - RA, CCP antibody association with *PADI4* haplotypes in early RA and with SE alleles in late RA, 1454
 - RA, Fc γ receptor IIIa genotype and TNF α blocker response, 448
 - RA, peptidyl arginine deiminase isotypes in synovial tissue inflammation, 3541
- Polymorphisms. *See also* Single nucleotide polymorphism (*cont'd*)
- RA, pharmacogenetic model for predicting MTX efficacy, 1765
 - sex and ethnic differences in genetic susceptibility to knee OA, 137
 - SLE, CD24 allele and susceptibility to, 3080, 3871
 - SLE, pneumonia risk in, 2679
 - TNFA*, and radiographic progression of RA, 1032
- Polymorphous light eruption, in subacute CLE, 255
- Polymyalgia rheumatica, anatomic basis for joint disease localization compared with RA, 3496
- Polymyositis (PM)
- C protein-induced myositis as model for, 1304
 - endogenous activation of IFN α in, 3112
 - IFN- γ gene expression in, 3784
 - IL-1R interlocalization in muscle fibers, 674
 - T cell receptor BV gene usage in, 372
 - vasculitis and, clinical image, 3270
- Polymyositis-scleroderma overlap syndrome, CID as autoantibody target in, 2449
- Polyunsaturated fatty acids, *n*-3, inhibition of TNFR expression on neutrophils, 799
- Popliteal artery, pseudoaneurysm following arthroscopic synovectomy, clinical image, 3432
- Positron emission tomography (PET)
- knee OA, brain areas in pain processing, 1345
 - Takayasu arteritis diagnosis, clinical image, 2466
- PPI-2458, suppression of inflammation and structural damage in experimental arthritis, 850
- Pre-B cell colony-enhancing factor, proinflammatory activities in RA, 2829
- Predictors
- ACPAs and radiologic damage in inflammatory polyarthritis, 2929
 - AS, MMP-3 and radiographic progression, 1846
 - autoantibodies as, 1736
 - cutaneous changes in nephrogenic systemic fibrosis and early mortality, 3433
 - hip OA, active shape model of morphologic bone changes, 3634
 - inflammatory rheumatic disease and smoking in aortic inflammation, 2072
 - macrophage activation syndrome in systemic JIA, 3793
 - RA, anti-TNF therapy response, 2160
 - RA, early disease activity and treatment response, 3226
 - RA, pharmacogenetic model of MTX efficacy, 1765
 - RA, serum RNFR levels and mortality, 3940
 - RA, undifferentiated arthritis outcome, 433
 - SLE, accelerated damage accrual in men, LUMINA study, 622
 - SLE, thrombocytopenia and prognosis, LUMINA study, 614, 2811
 - SSc, bronchoalveolar lavage profiles in ILD not predictive of disease progression, 2005
- Prednisolone, risenedronate with, preventing GC-induced changes in bone, 3726
- PRKCH* gene SNP encoding protein kinase isozyme in Japanese population with RA, 30
- Probable Rheumatoid Arthritis: Methotrexate versus Placebo Treatment (PROMPT) study, MTX efficacy in undifferentiated arthritis, 1424
- Procedure volumes, total knee replacement, and patient-centered outcomes in older adults, 568
- Progressive multifocal leukoencephalopathy, clinical and pathologic patterns, 2116
- Proinflammatory mediators, reversal of CD4⁺.CD25⁺ Treg-mediated suppression in RA, 732, 3874
- Proliferator-activated receptor γ agonists, reducing cartilage lesion development in dogs, 2288
- Prostaglandin E synthases (PGES)
- hypoxia-inducible factor 1 α and up-regulation of microsomal PGES-1 in articular cartilage, 4084
 - microparticles inducing synthesis of, 3564

- Prostaglandin E₂ (PGE₂)
 exacerbating collagen-induced arthritis via IL-23/IL-17 axis, mouse study, 2608
 microparticle stimulation of synthesis in fibroblasts, 3564
- Prostaglandins, bradykinin receptors and interactions of IL-1 and TNF α in biosynthesis, 910
- Protease-activated receptor 2 (PAR-2)
 activation in mouse models of arthritis, 101, 3510
 in joint inflammation, 3514
 RA, expression and proinflammatory role in synovial tissue, 76
 synovial mast cells and mediation of proinflammatory response in mice, 3532
- Protein C, activated, differential regulation of MMP-2 and MMP-9 in RA, 2864
- Protein folding
 AS, p38 MAPK dysregulation in HLA-B27-expressing monocytes, 2652
 TRAPS-associated TNFRSF1A mutations and structural alterations, 2765
- Protein isoprenylation, regulating MMP-1 secretion by synovial fibroblasts, 2840
- Protein kinase C ζ , regulation of ADAMTS-4 and NOS-2 via NF- κ B signaling, 4074
- Proteins, salivary, pilocarpine effects in SS, 2216
- Proteoglycan 4 (lubricin)
 in articular cartilage boundary lubrication, 882
 cartilage damage in antigen-induced arthritis, 108
 differential regulation by TGF β /BMP in articular chondrocytes and synoviocytes, 2312
 friction and cartilage damage in joints lacking, mouse study, 3662
 tribiology of, 3511
- Proteoglycan-induced arthritis, IL-4 suppression of immune response in, 861
- Proteoglycans
 ex vivo protection against degradation in double-knockout ADAMTS-4/ADAMTS-5 mice, 3670
 synthesis and cartilage blood exposure, in vitro study, 199
- Proteomics
 characterization of neuropsychiatric SLE brain antigenic targets, 3420
 OA, comparative profiles of normal and OA cartilage, 3675
 salivary biomarkers for primary SS, 3588
 urine, for glomerulonephritis diagnosis, 705
- PsA. *See* Psoriatic arthritis (PsA)
- P-selectin
 N673S polymorphism as childhood-onset SLE susceptibility gene, 4164
 urinary excretion in experimental immune nephritis, 949
- Pseudogout, misdiagnosis of chylous cyst as chest wall gouty tophus, 3854
- Psoriasis, development after B cell depletion with rituximab, 2715
- Psoriatic arthritis (PsA)
 adalimumab for long-term treatment of, 476
 CASPAR criteria, critique of, 699
 disease activity and clinical damage effects on physical function, HAQ score, 840
 improved survival, 30 year prospective study, 2708
 infliximab inhibiting radiographic damage progression, 2698
 juvenile, classification of, 1368
 pathogenesis-oriented therapy for, 1051
 rituximab B cell depletion and development of, 2715
 synovio-entheseal complex in joint inflammation and damage, 2482
 TNF blockade and cardiovascular risk factors in, 831
 TNF polymorphisms in, 2056
- PSORS1 allele, TNF polymorphisms independent from, in PsA risk, 2056
- Psychosocial factors, in chronic widespread pain, 360
- Pulmonary artery, CENP-B binding to vascular smooth muscle cells, 3814
- Pulmonary fibrosis
 endothelin 1 mediation of TGF β effects, 4189
 microscopic polyangitis as "pulmonary-muscle" syndrome, 2065
 SSc, CCL18 as biomarker for idiopathic interstitial pneumonias and lung disease, 1685
 treatment in SSc, 9
- ## Q
- Quinapril, for vascular damage in SSc and Raynaud's phenomenon, 3837
- ## R
- RA. *See* Rheumatoid arthritis (RA)
- Rabbit studies
 OA, apoptotic and matrix-degrading genes in articular cartilage and meniscus, 1529
 OA, C60 fullerene preventing cartilage degeneration, 3307
 OA, glucosamine hydrochloride effects on subchondral bone changes, 1537
- Radiation synovectomy, for knee arthritis, efficacy of, 385, 386
- Radiography. *See also* Clinical images
 ACR annual slide competition, 2006 winners, 1029
 AS, MMP-3 as predictor of progression, 1846
 JIA, Sharp/van der Heijde scoring system for disease progression assessment, 3087
 myositis ossificans of upper extremity, clinical image, 2454
 OA, fixed-flexion radiography of knee for detection of joint space loss, 1512
 OA, hip, active shape model of morphologic bone changes, 3634
 OA, knee, varus and valgus malalignment, 1204, 3872
 PsA, infliximab inhibiting radiographic damage progression, 2698
 RA, antibody status and association of IL-6 and IL-10 genotypes with radiographic damage, 2549
 RA, biomarkers predicting radiographic progression in early disease, 3236
 RA, joint damage and BMI, 3575
- RAGE (receptor for advanced glycation end products), in Kawasaki disease, 4174
- Raloxifene, for postmenopausal polyarthritis and osteoporosis, mouse model, 3261
- Randomized controlled trials. *See* Clinical trials
- RANKL
 APRIL expression of, in RA FLS, 3554
 juvenile DM, RANKL:osteoprotegerin ratio and BMD in, 977
 in synergistic stimulation of prostaglandin biosynthesis in osteoblasts, 910
- RANTES, interactions with IL-8 in SSc susceptibility, 2443
- Rat studies
 calcitonin effects on cartilage degradation and surface erosion in ovariectomy, 2674
 control of C5a and terminal complement complex by anti-C5 single-chain Fv, 1187
 fluvastatin and vascular dysfunction in antigen-induced arthritis, 1827
 HLA-B27 up-regulation and unfolded protein response, 215
 Hsp65-IgG-expressing B cells protecting against adjuvant-induced arthritis, 1490
 IL-13 gene therapy inhibition of angiogenesis, 2535
 lubricin expression and proteolytic susceptibility in cartilage damage in antigen-induced arthritis, 108
 nanogold effects on collagen-induced arthritis, 544
 PPI-2458 suppression of inflammation and structural damage in experimental arthritis, 850
 RA, IL-21R blockade in, 1152

Rat studies (*cont'd*)

- SpA, immunologic synapse formation between DC and CD4+ T cells in HLA-B27 transgenic rats, 1478
- tenocyte responses to mechanical loading in vivo, 871
- Raynaud's phenomenon
 - iloprost-induced vascular remodeling, clinical image, 2243
 - naifold videocapillaroscopy identifying transition from primary to secondary disease, 2102
 - quinapril for prevention of vascular damage, 3837
- Reactive arthritis, "Reiter's syndrome" condemned as term for, 693
- Reactive nitrogen species, apoptosis of peripheral blood mononuclear cells in SLE and, 3738
- Reactive oxygen species, apoptosis of peripheral blood mononuclear cells in SLE and, 3738
- Receptor activation of NF- κ B ligand. *See* RANKL
- Receptor for advanced glycation end products (RAGE), in Kawasaki disease, 4174
- Remission
 - RA, etanercept/MTX combination therapy, 3-year outcome in TEMPO study, 3928
 - Takayasu arteritis and, 1000
- Retinoic acid orphan receptors, ROR γ t expression in CD4+ T cell regulation of IL-17, 2936
- Retinoid receptor X ligands, LG268, MMP-3 and MMP-13 gene expression regulation by, 892
- Revascularization, iloprost-induced vascular remodeling, clinical image, 2243
- Reverse transcriptase-polymerase chain reaction (RT-PCR)
 - ADAMTS-4 and ADAMTS-5 inhibition and aggrecan degradation in human articular cartilage explants, 575
 - allograft inflammatory factor 1 in T cell migration and profibrotic cytokine production in fibroblasts, 3478
 - altered gene expression in mice with SLE treated with Edrative, 2371
 - aquaporin 5 expression and distribution in submandibular glands of mice with autoimmune exocrinopathy, 2566
 - gene expression profiles in synovium, SLE vs. RA and OA, 1579
 - IFN-I stimulated genes in mice, 3770
 - IL-7 localization in RA synovial tissues with lymphoid neogenesis, 2492
 - NF- κ B activity in antibody-induced arthritis, 117
 - OA, microsomal PGES-1 in articular cartilage, 4084
 - RA, microparticle expression of proinflammatory phenotype in synovial fibroblasts, 3564
 - RA, peptidyl arginine deiminase expression in synovium, 3541
 - SS, androgen response elements in DHEA and cysteine-rich secretory protein 3, 2575
 - type IV collagen α -chain composition in normal and RA synovial lining, 3959
- RF. *See* Rheumatoid factor (RF)
- Rheumatoid arthritis (RA). *See also* Juvenile rheumatoid arthritis
 - ACPAs predicting severity of radiologic damage in inflammatory polyarthritis, 2929
 - anatomic basis for joint disease localization compared with polymyalgia rheumatica, 3496
 - angiopoietin 1 signaling and joint destruction in, 2170
 - angiotensin II type 1 receptor as therapeutic target for, 441
 - antibody status and association of IL-6 and IL-10 genotypes with radiographic damage, 2549
 - anti-CCP, combined SE gene-environmental effects in, 1446
 - anti-TNF agents, outcomes from switching, 13
 - anti-TNF therapy, analgesic effects, 4015
 - anti-TNF therapy and bacterial infection risk in elderly, 1754
 - asymmetric dimethyl-L-arginine in endothelial progenitor cell depletion and carotid atherosclerosis, 809
 - B cell depletion therapy with rituximab vs. alternative anti-TNF agents, 1417

Rheumatoid arthritis (RA). *See also* Juvenile rheumatoid arthritis (*cont'd*)

- B cell subset responses to rituximab, 3909
- bacterial infection risk, TNF α antagonists vs. MTX, 1125
- 11 β -hydroxysteroid dehydrogenases, altered expression of in synovial cells, 1720
- biologic therapy and risk of malignancy, 2886
- biomarkers predicting radiographic progression in early disease, 3236
- bone erosion and bone marrow edema, MRI identifying, 1118
- cancer incidence and survival in inflammatory polyarthritis, 790
- CCP antibody association with *PADI4* haplotypes in early RA and with SE alleles in late RA, 1454
- CD56-expressing T cells with features of senescence in, 43
- circadian rhythms in, 399
- circulating levels of TNFR and mortality, 3940
- coincident hereditary hemochromatosis with, in MCP joints, clinical image, 1463
- control of BAFF synthesis by FLS, 3202
- 34C>T variant in *AMPD1* gene and clinical response to MTX, 694
- C-type lectin-like receptor genes in susceptibility, 2620
- decoy receptor 3 expression in FLS as protection against Fas-induced apoptosis, 1067
- design problems in clinical trials, 3884
- differential regulation of MMP-2 and MMP-9 by activated protein C, 2864
- DRB1 SE genotypes and early mortality, 1408
- drug-specific and time-dependent risks of bacterial infection in exposure to TNF α antagonists, 4226
- early disease activity as predictor of treatment response, 3226
- early treatment, MTX alone vs. combination with infliximab or methylprednisolone, MRI study, 3919
- epigenetics and, 3523
- ex vivo cellular model, 2875
- Fc γ receptor IIIA genotype and TNF α blocker response, 448
- FCRL3* polymorphisms and differential risk in white and East Asian patients, 3168
- FLS expression of BCMA and stimulation by APRIL, 3554
- FoxO transcription factor inhibition in synovial tissue, 2180
- fractalkine as chemoattractant for FLS, 2512
- fractalkine mediation of T cell-dependent synovial fibroblast proliferation, 3215
- galactin 9 expression in synovium and induction of FLS apoptosis, 3968
- gender and, mouse model vs. human disease, 1
- gene expression in synovium, SLE vs., 1579
- glucocorticoids and cardiovascular events in, 820
- glutamate receptor modulation of IL-6 and MMP-2 expression in FLS, 2523
- heterogeneity, linkage analysis of quantitative traits, 58
- histone deacetylase/acetylase activity in synovial tissue, vs. OA, 1087
- HLA-DR-restricted presentation of human cartilage gp39 and melanoma inhibitory activity in inflamed joint, 2150
- HLA-DR4-transgenic mice mimicking sex bias of human RA, 69
- HO-1* promoter polymorphism in, 3953
- IKK ϵ and IRF3 in antiviral gene expression, 743
- IL-13 gene therapy and angiogenesis in rats, 2535
- IL-17, cellular source in, 2111
- IL-18 up-regulation of angiogenic factors in synovial fibroblasts, 1787
- infection risk following anti-TNF therapy, 2896
- infliximab and MTX for early disease, 2129
- interleukin-17 as molecular target for therapy, 89
- IRF5* and *Tyk2* SNPs in, 2202
- liver X receptor as therapeutic target in collagen-induced arthritis, 1365
- lymphoid neogenesis and IL-7 signaling in synovial tissues, 2492

Rheumatoid arthritis (RA). *See also* Juvenile rheumatoid arthritis (*cont'd*)

- mannose-binding lectin and agalactosyl IgA serum levels in ischemic heart disease, 21, 2097
 - mast cell silencing as protection against joint destruction and angiogenesis, mouse study, 1806
 - MEK/ERK pathway in mouse model, 3347
 - microparticle stimulation of PGE₂ synthesis in fibroblasts, 3564
 - mortality and occupational exposures, 3189
 - mortality trends and, 3583
 - MTX efficacy in undifferentiated arthritis, 1424
 - mutated and citrullinated vimentin as biomarker for, 2503
 - myocardial infarction incidence, anti-TNF therapy vs. DMARDs, 2905
 - PAR-2 expression and proinflammatory role in synovial tissue, 765
 - PAR-2 mediation of synovial mast cells in mice, 3532
 - patient resistance to changing therapies, 2135
 - peptidyl arginine deiminase isotype expression in tissue inflammation, 3541
 - pharmacogenetic model for predicting MTX efficacy, 1765
 - pre-B cell colony-enhancing factor proinflammatory activities in, 2829
 - preclinical changes in mouse model of inflammatory arthritis, 79
 - prediction rule for undifferentiated arthritis outcome, 433
 - PRKCH gene encoding protein kinase C isozyme in Japanese population, 30
 - proinflammatory mediator reversal of Treg-mediated suppression in, 732, 3874
 - protein isoprenylation regulating MMP-1 secretion from synovial fibroblasts, 2840
 - radiographic joint damage and BMI, 3575
 - regulation of apoptosis in FLS by BNIP-3 protein, 2854
 - repeat courses of rituximab, safety and efficacy, 3896
 - rheumatoid nodules in synovium, clinical image, 2104
 - risk of leflunomide-related ILD in Korean patients, 2094
 - rituximab effects on synovial cell infiltrates, 772
 - SI100A4 up-regulation in, 779
 - SE alleles and specificity of ACPA response, 3949
 - serum MIC-1 as joint destruction marker, 753
 - smoking and ACPA response in absence of HLA-DRB1 SE alleles, 2913
 - smoking and HLA-DRB1 SE subtypes in predisposition to anti-CCP antibodies, 425
 - smoking/HLA-DR SE allele interactions in anti-CCP formation, 1745
 - stromal cell-derived factor 1 up-regulation in FLS, 1076
 - subclassification and risk factors, 1728
 - swollen shoulder in, clinical image, 3948
 - synovial T cell vaccination in, 453
 - synovial vascular gene expression, analysis by laser-mediated microdissection, vs. OA, 1094
 - systemic humoral autoimmunity with joint-specific inflammation, 2823
 - TLR mediation of macrophage activation in, 2192
 - TNF α activation of BAFF release by neutrophils, 1776
 - Treg cell defects in, 710
 - Treg cells, biology and therapeutic use, 395
 - type II collagen biomarkers and response to biologic therapy, 2919
 - VCAM-1/very late activation antigen 4 role in endothelial progenitor cell recruitment to RA synovium, mouse study, 1817
 - vitamin D and, 1719
- Rheumatoid factor (RF)
- IgM-RF, linkage analysis in RA heterogeneity, 58
 - predictive value of, 1736
 - rituximab effects on production of, 3909
- Rheumatology
- ACR response to workforce study, 730

Rheumatology (*cont'd*)

- mentors and heroes (ACR presidential address), 1037
 - pediatric, future of, 2815
 - US workforce, supply and demand 2005–2025, 722, 3509
- Ribosomal P proteins, induction of autoimmune depression in mice, 938
- Risedronate, preventing GC-induced changes in bone properties, 3726
- Risk factors
- cancer and RA biologic therapy, 2886
 - cardiovascular, COX-2 inhibitors or NSAIDs and, 384
 - carpal tunnel syndrome and keyboard use at work, 3620
 - coffee intake and gout in men, 2049
 - common symptoms in childhood and chronic widespread pain in adulthood, 1669
 - country and renal amyloidosis in familial Mediterranean fever, 1706, 3879
 - fractures, with intermittent high-dose GC therapy, 208
 - gadolinium exposure and nephrogenic systemic fibrosis, 3433
 - glomerular microthrombosis risk and hemostasis factor polymorphisms, 1608
 - glycoprotein IIIa PIA1/A2 polymorphism and cranial ischemic complications in GCA, 3502
 - HLA-DRB4 in Churg-Strauss syndrome, 3159
 - inflammatory bowel disease with AS, in Icelandic families, 2633
 - inflammatory rheumatic disease and smoking in atherosclerosis, 2072
 - JIA, ethnicity as, 1974
 - leflunomide-associated ILD in Korean RA patients, 2094
 - low BMD in juvenile SLE, 1966, 4228
 - psychosocial, chronic widespread pain and HPA axis dysfunction, 360
 - RA, anti-TNF therapy and bacterial infection in elderly, 1754
 - RA, bacterial infection risk and exposure to TNF α antagonists vs. MTX, 1125
 - RA, BMI and joint damage, 3575
 - RA, glucocorticoids and cardiovascular events, 820
 - RA, infection risk following anti-TNF therapy, 2896
 - RA, MTX or anti-TNF therapy and lymphoma risk, 1433
 - RA, prediction rule for undifferentiated arthritis outcome, 433
 - RA, subclassification and patterns of, 1728
 - RA, TNF α antagonist exposure and drug-specific and time-dependent risks of infection, 4226
 - regional musculoskeletal pain, 1355
 - SLE, accelerated damage accrual in men, LUMINA study, 622
 - SLE, atherosclerosis in, 3412
 - SLE, human platelet antigen 6b polymorphism and thrombocytopenia risk, 2803
 - SLE, IFN-I as risk factor for endothelial progenitor cell depletion and endothelial dysfunction, 3759
 - SLE, IRF5 structural insertion/deletion variation associated with risk haplotype, 1234
 - SLE, premature atherosclerotic cardiovascular disease in, 1384, 3878
 - SLE, reproductive and menopausal risk factors, 1251
 - SLE, skin-lightening creams as exposure risk, 1721
 - TNF blockade and cardiovascular risk in PsA, 831
 - uveitis in JIA, 647
- Rituximab
- for juvenile DM, 3107
 - progressive multifocal leukodystrophy risk and, 2116
 - proliferative lupus nephritis, combination treatment with cyclophosphamide for, 1263
 - psoriasis development following treatment with, 2715
 - RA, B cell depletion efficacy vs. alternate anti-TNF agents, 1417
 - RA, effects on synovial cell infiltrates in, 772
 - SLE, delayed memory B cell recovery after B cell depletion therapy with, 3044

Rituximab (cont'd)

- SS, B cell depletion therapy with, 1371
- SS, BAFF-modulated repopulation of B cells following treatment with, 1464

RNA

- differential tissue targeting by Y RNAs in TLR activation, 1589
- small interfering, ADAMTS-4 and ADAMTS-5 inhibition and aggrecan degradation in human articular cartilage explants, 575
- U1, adjuvant activity in SLE, 3379
- RNA helicase A autoantibodies, in early SLE, 596
- RNA synthase, asparaginyl-transfer, autoantibodies in myositis, 1295
- RT-PCR. *See* Reverse transcriptase-polymerase chain reaction (RT-PCR)

S

- Sacroiliac inflammation, adalimumab efficacy for, 4005
- Saliva
 - biomarkers for primary SS, 3588
 - pilocarpine and salivary peptide and proteins in SS, 2216
- Salivary glands
 - SS, aberrant B cell expression of BAFF in, 1134
 - SS, HCG for prevention of SS-like exocrinopathy in mice, 2211
 - SS, macrophage and DC infiltration and expression of IL-18 and IL-12 in minor gland, 3977
 - submandibular, aquaporin 5 expression and distribution in mice with autoimmune exocrinopathy, 2566
- Sarcoidosis, early-onset, with Blau syndrome, *NOD2* gene mutations in, 3805
- Sarcolemma, IL-1R interlocalization in muscle fibers, 674
- Sciatica, TNF α blockade for treatment of, review, 3887
- Scleroderma. *See* Systemic sclerosis (SSc)
- Scleroderma Lung Study, cyclophosphamide impact on health-related quality of life, 1676
- Selicielib, effects on glomerulonephritis and life span in mice with SLE, 1629
- Serine proteases, aPL recognizing SE with β_2 -glycoprotein I, in APS, 1638
- Sex factors. *See also* Gender
 - TGF β signaling impairment and inflammatory disorders in female mice, 1798
- Sex hormone binding globulin, TNF blockade and cardiovascular risk in PsA, 831
- SGL-S23, NKT cell activation in autoantibody-induced arthritis, mouse study, 1836
- Shared epitope (SE). *See also* HLA-DRB1 shared epitope genes
 - aPL recognizing, with β_2 -glycoprotein I and serine proteases, in APS, 1638
 - CCP antibody association with, in late RA, 1454
 - combined SE gene-environmental effects in anti-CCP RA, 1446
 - HLA-DR, interaction with smoking in anti-CCP formation in RA, 1745
 - RA, smoking and ACPA response in absence of HLA-DRB1 SE alleles, 2913
- Shoes, wedged insole for knee OA, 1198
- Shoulder, swelling in RA, clinical image, 3948
- Sialadenitis, B cell activation in primary SS, 1371
- Sialoglycoproteins, Siglec-1 expression in SSc, 1010
- Signal transduction
 - anti- β_2 -glycoprotein I antibodies and monocyte release of TNF α and tissue factor in AS, 2687
 - calcium, in mitochondrial depolarization and equine chondrocyte death, 2322
 - IFN-I and SLE pathogenesis in IFNAR-deficient mice, 3770
 - IL-1 β impairment of TGF β 1 signaling in human chondrocytes, 3020
 - IL-7, in RA synovium with ectopic lymphoid structures, 2492
 - lipid raft-associated, in SLE B lymphocytes, 291
 - MyD88 pathway in autoimmune nephritis, 1618

Signal transduction (cont'd)

- RA, angiopoietin 1 stimulation of ERK/MAPK and PI 3-kinase/Akt pathways, 2170
- RA, IL-18 up-regulation of angiogenic factors in synovial fibroblasts, 1787
- SLE, β 1 integrin activation of T cells, 1559
- SSc, c-Ski/SnoN complex formation in impaired negative feedback regulation of TGF β signaling, 1694
- TGF β , impairment in salivary glands and inflammatory disorders in female mice, 1798
- TGF β , in mechanotransduction of superficial zone protein in bovine cartilage, 3706
- TGF β , postnatal induction in mouse fibroblasts, SSc, 334
- WNT pathway and *FRZB* gene, 3881
- Single-chain Fv antibodies, anti-C5, therapeutic control of C5a and terminal complement complex, 1187
- Single-nucleotide polymorphisms (SNP)
 - AS, previously unrecognized predisposing factors in HLA-B27 extended haplotypes, 2640
 - childhood-onset SLE, identification of susceptibility genes using novel microarray platform, 4164
 - HLA-DRB4 in Churg-Strauss syndrome, 3159
 - IL-8/RANTES interactions in SSc susceptibility, 2443
 - JIA, systemic onset, susceptibility and *SLC262A* polymorphisms, 1286
 - knee OA, sex and ethnic differences in susceptibility to, 137
 - PsA, *TNF* polymorphisms, 2056
 - RA, antibody status and association of IL-6 and IL-10 genotypes with radiographic damage, 2549
 - RA, C-type lectin-like receptor genes in susceptibility, rat study, 2620
 - RA, Fc γ receptor IIIA genotype and TNF α blocker response, 448
 - RA, *FCRL3* polymorphisms and differential risk in white and East Asian patients, 3168
 - RA, *HO-1* promoter polymorphism, 3953
 - RA, *IRF5* and *Tyk2* genes in, 2202
 - RA, *PRKCH* gene encoding protein kinase C isozyme in Japanese population, 30
 - SLE, *IRF5* structural insertion/deletion variation associated with risk haplotype, 1234
- Sjögren's syndrome (SS)
 - aberrant B cell expression of BAFF in salivary glands, 1134
 - androgen insufficiency in targeted salivary tissues, 2575
 - aquaporin 5 expression and distribution in submandibular glands of mice with autoimmune exocrinopathy, 2566
 - B cell infiltration in ILD, 3167
 - BAFF-modulated repopulation of B lymphocytes in rituximab-treated patients, 1464
 - Disease Damage Index and Disease Activity Index, scoring of, 2223
 - etanercept-augmented production of IFN α in, 3995
 - HCG for prevention of SS-like exocrinopathy in mice, 2211
 - IRF5* gene functional polymorphism in, 3989
 - macrophage and DC infiltration and expression of IL-18 and IL-12 in salivary gland lesions, 3977
 - pilocarpine and salivary peptides and proteins in, 2216
 - primary, salivary proteomic and genomic biomarkers for, 3588
 - T cells and loss of immune tolerance in, 3180
 - targeting B cells in, 1371
- Skin
 - cancer, RA biologic therapy and risk of, 2886
 - change in skin score and dcSSc disease outcome, 2422
 - SSc, CD4+CD8+ double-positive T cells in lesions, 3459
 - SSc, skin thickness progression rate in patients with anti-topoisomerase I antibody, 2740
 - SSc, trichostatin A preventing extracellular matrix accumulation in fibrosis, mouse study, 2755
 - Treg cells in CLE skin lesions, 1910

- SLC2624* gene, susceptibility and SNP for systemic-onset JIA, 1286
- SLE. *See* Systemic lupus erythematosus (SLE)
- SLEDAI. *See* Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
- Smad3 protein, c-Ski/SnoN complex formation in impaired negative feedback regulation of TGF β signaling, 1694
- Smad7 protein, up-regulation in IL-1 β impairment of TGF β 1 signaling in human chondrocytes, 3020
- Small ubiquitin-like modifier 1 (SUMO-1) activating enzyme, autoantibodies in DM, 3132
- Smoking
- OA, interaction with family history in knee cartilage loss and defects, 1521
 - predicting aortic inflammation, 2072
 - RA, association with ACPA response in absence of HLA-DRB1 SE alleles, 2913
 - RA, HLA-DRB1 SE alleles and association with anti-CCP antibodies, 425
 - RA, interaction with HLA-DR SE alleles in anti-CCP formation, 1745
- SNP. *See* Single-nucleotide polymorphisms (SNP)
- Sodium hyaluronate, C60 fullerene vs., in preventing cartilage degeneration in rabbits, 3307
- SOX9*
- hypoxia-inducible factor 2 α mediation in cartilage gene expression, 3297
 - overexpression and restoration of extracellular matrix in OA articular cartilage, 158
 - TGF α suppression of in rat OA model, 3693
- Sperm, evaluation of testicular function in SLE, 2352
- Spine, adalimumab efficacy for inflammation in AS, 4005
- Spondylarthritis (SpA)
- HLA-B27 in arthritogenic peptide hypothesis, 4
 - HLA-B27-associated, microdamage and altered vascularity at enthesis-bone interface, 224
 - HLA-B27 up-regulation and unfolded protein response, 215
 - immunologic synapse formation between DC and CD4 $^{+}$ T cells in HLA-B27 transgenic rats, 1478
 - intracellular trafficking of different HLA-B27 alleles, 2232
 - synovio-enthesal complex and synovitis in, 3601
 - uncoupling of inflammation and joint remodeling, mouse model, 489
- SS. *See* Sjögren's syndrome (SS)
- SSA/Ro autoantibodies
- hypoxia and production in congenital heart block, 4120
 - in subacute CLE, 255
- SSB antigens
- T cell epitopes of, in mice expressing HLA-DRB*0301/DOBI*0201, 3387
- SSc. *See* Systemic sclerosis (SSc)
- Statins, effects on MMP-1 secretion in synovial fibroblasts, 2840
- Stem cells. *See also* Hematopoietic stem cell transplantation; Mesenchymal stem cells
- asymmetric dimethyl-L-arginine in endothelial progenitor cell depletion and carotid atherosclerosis in RA, 809
 - mesenchymal stem cell mediation of Treg cells in collagen-induced arthritis, 1175
 - musculoskeletal, in regenerative medicine, 714
 - three-dimensional cartilage tissue engineering using adult stem cells, in OA, 177
- Stomach, SSc fibrotic process and expression of fibrogenic cytokines in gastric wall, 3442
- Stromal cell-derived factor 1
- IL-17/CD40 interactions and up-regulation in rheumatoid synovial fibroblasts, 1076
 - RA, IL-18 up-regulation in synovial fibroblasts, signaling pathways, 1787
- Subchondral bone, in OA development in guinea pigs, 3366
- SUMO-1 protein autoantibodies, in DM, 3132
- Superficial zone protein, mechanotransduction in bovine cartilage by TGF β , 3706
- Suprachiasmatic nucleus, circadian rhythm and, 399
- Susceptibility, genetic
- AS, HLA-B*2709 subtype in, 2805
 - AS, previously unrecognized predisposing factors in HLA-B27 extended haplotypes, 2640
 - HLA-DRB4 in Churg-Strauss syndrome, 3159
 - JIA, systemic onset and *SLC2624* polymorphisms, 1286
 - MEFV* mutations in ACPA-negative palindromic rheumatism, 2784
 - OA, knee, sex and ethnic differences, 137
 - pneumonia in SLE, 2679
 - RA, C-type lectin-like receptor genes, 2620
 - RA, *HO-1* promoter polymorphism, 3953
 - SLE, CD24 polymorphism, 3080, 3871
 - SLE, childhood-onset, gene identification with novel microarray platform, 4164
 - SLE, *Sle1*-induced humoral autoimmunity and CD19 overexpression, 3057
 - SS, *IRF5* functional polymorphism and, 3989
 - SSc, IL-8/RANTES interactions in, 2443
- Synovectomy
- arthroscopic, popliteal artery pseudoaneurysm following, clinical image, 3432
 - radiation, for knee arthritis, efficacy of, 385, 386
- Synovial fibroblasts. *See* Fibroblasts
- Synovial fluid
- constituent roles in articular cartilage boundary lubrication, 882
 - correlation between serum and synovial fluid estrogen concentrations in knee OA, 698
 - Lyme arthritis, chemokines and cytokines in, 1325
 - OA, lubricin deficiency and joint friction and damage, mouse study, 3662
 - RA, HLA-DR-restricted presentation of human cartilage gp39 and melanoma inhibitory activity in inflamed joint, 2150
 - RA, proinflammatory mediator reversal of CD4 $^{+}$, CD25 $^{+}$ Treg-mediated suppression in, 732
 - RA, TLR-2 and TLR-4 mediation of macrophage activation in, 2192
 - Tropheryma whipplei* cultivation from, in Whipple's arthritis, 1713
- Synovial macrophages, in MMP-3-mediated cartilage destruction in OA, 147
- Synoviocytes
- differential regulation of lubricin/superficial zone protein by TGF β and BMP, 2312
 - RA, altered 11 β -hydroxysteroid dehydrogenase expression, 1720
- Synoviocytes, fibroblast-like (FLS)
- antiviral gene expression in, 743
 - control of BAFF synthesis, 3202
 - decoy receptor 3 expression protecting against Fas-induced apoptosis, 1067
 - fractalkine as chemoattractant for, 2512
 - fractalkine mediation of T-cell dependent proliferation, 3215
 - galactin 9 induction of apoptosis, RA vs. OA, 3968
 - glutamate receptor modulation of IL-6 and MMP-2 expression, 2523
 - LIGHT up-regulation mediating cellular adhesion and metalloproteinase production by, 1106
 - MHC-typed, as antigen-presenting cells in joint inflammation, 1497
 - RA, expression of BCMA and stimulation by APRIL, 3554
 - regulation of apoptosis by BNIP-3 protein, 2854
 - stromal cell-derived factor 1 up-regulation through interactions with IL-17 and CD40, 1076
- Synovio-enthesal complex
- in joint inflammation and PsA damage, 2482
 - synovitis in OA and SpA and, 3601

Synovitis

- anatomic basis for joint disease localization, polymyalgia rheumatica vs. RA, 3496
- enthesitis and, 2482
- inflammatory, losartan for, 441
- MTX alone vs. combination with infliximab or methylprednisolone for, MRI study, 3919
- in OA and SpA, synovio-enthesal complex in, 3601

Synovium

- bovine, chondrogenic differentiation of, 1869
- ex vivo cellular model of pannus, development of, 2875
- FoxO transcription factor inhibition in RA and OA, 2180
- galactin 9 expression in and induction of FLS apoptosis, RA vs. OA, 3968
- gene expression profiles in SLE, vs. RA and OA, 1579
- histone deacetylase/acetylase activity in, RA vs. OA, 1087
- inflammatory arthritis, MRI and microfocus CT assessments of synovial tissue volume, 4024
- inner surface, visualization with three-dimensional ultrasonography, 214
- Lyme arthritis, chemokines and cytokines in, 1325
- mast cells and PAR-2 mediation of proinflammatory response in mice, 3532
- RA, B cell response to rituximab, 3909
- RA, IL-18 up-regulation of angiogenic factors in, signaling pathways, 1787
- RA, lymphoid neogenesis and IL-7 signaling in, 2492
- RA, PAR-2 expression and proinflammatory role in, 765
- RA, peptidyl arginine deiminase expression in tissue inflammation, 3541
- RA, rheumatoid nodules in, clinical image, 2104
- RA, S100A4 up-regulation in, 779
- RA, sublining macrophages as biomarker for, 3869
- RA, type IV collagen α -chain composition in, 3959
- RA, VCAM-1/very late activation antigen 4 in endothelial progenitor cell recruitment, mouse study, 1817

- Systemic lupus erythematosus (SLE). *See also* Cutaneous lupus erythematosus; Juvenile systemic lupus erythematosus; Lupus nephritis; Neuropsychiatric systemic lupus erythematosus
- abdominal vasculitis in, clinical image, 1009
- accelerated damage accrual in men, LUMINA study, 622
- altered coronary vasomotor function in young women, 1904
- apoptosis-induced acetylation of histones in, 1921
- apoptosis of peripheral blood mononuclear cells and reactive oxygen/nitrogen intermediates and complement levels in, 3738
- arginine mutation and B3 monoclonal antibody binding to SLE-linked antigens, 2392
- atacept for, 4142
- atherosclerosis, premature in, 1384, 3878
- atherosclerosis progression in, 3412
- autoantibodies to RNA helicase A as marker for, 596
- β 1 integrins in T cell activation, 1559
- CD1d and NKT cells in nephritis development, mouse studies, 1219
- CD8+ T cells in periglomerular infiltrates, 2362
- CD19 hyperexpression and B cell hyperactivity in, 3057
- CD24 polymorphism with susceptibility to, 3080, 3871
- CD45 tyrosine phosphatase in B lymphocytes, 291
- childhood-onset, functional MRI assessment of cognitive function, 4151
- childhood-onset, identification of susceptibility genes, 4164
- clinical and genetic risk factors for pneumonia in, 2679
- corticosteroids preventing, 2098
- COX-2 hyperexpression and effects of inhibitor diet therapy, mouse study, 4132
- delayed memory B cell recovery after B cell depletion therapy, 3044
- Edratide treatment of and altered gene expression in mice, 2371
- epigenetics and, 1035, 3523

Systemic lupus erythematosus (SLE). *See also* Cutaneous lupus erythematosus; Juvenile systemic lupus erythematosus; Lupus nephritis; Neuropsychiatric systemic lupus erythematosus (*cont'd*)

- estrogen exposure and, 1048
- ficolin 3 in clearance of late apoptotic cells, 1598
- gene expression profiles in synovium, vs. RA and OA, 1579
- glutathione S-transferase polymorphisms and proximity to hazardous waste sites in diagnosis of, 244
- hormone replacement therapy in, 3070
- IFN-I as risk factor for endothelial progenitor cell depletion and endothelial dysfunction, 3759
- infliximab therapy and autoantibodies in, 274
- IRF5 structural insertion/deletion variation associated with risk haplotype, 1234
- mortality and occupational exposures, 3189
- NKT cells in families of patients with, 303
- opsonization of apoptotic cells by autoantibodies, 3399
- pathogenesis and IFN-I signaling in receptor-deficient mice, 3770
- polymorphism in human platelet antigen 6b and thrombocytopenia risk, 2803
- prediagnostic onset of autoantibodies and clinical criteria for, 2344
- prevalence in California and Pennsylvania in 2000, 2092
- reproductive and menopausal risk factors in women, 1251
- seliciclib effects on glomerulonephritis and life span in mice, 1629
- skin-lightening creams as exposure risk for, 1721
- SLE-like syndrome in mice overexpressing decoy receptor 3, 3748
- somatic B cell vaccination with anti-DNA IgG, renal protection in mice, 1945
- T cell epitopes of LA/SSB autoantigen in mice expressing HLA-DRB*0301/DQB1*0201, 3387
- T cells and loss of immune tolerance in, 3180
- testicular evaluation in males, 2352
- thrombocytopenia and prognosis, LUMINA study, 614, 2811
- TLR7 gene copy number variations in, 3375
- TLR-9 in development of tubulointerstitial injury in nephritis, 1569
- U1 RNA adjuvant activity in vivo in, 3379
- validity of BILAG-2004 index for disease activity assessment, 4113
- validity of "lupus headache" in, SLEDAI, 2812
- Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
- coronary vasomotor function impairment in young women, 1904
- corticosteroids preventing SLE flares, 2098
- 2000 update and validity of BILAG-2004 index for disease activity, 4113
- urinary lipocalcin-2 as renal disease marker, 1894
- validity of "lupus headache" in, 2812
- Systemic sclerosis (SSc). *See also* Diffuse cutaneous systemic sclerosis (dcSSc)
- allograft inflammatory factor 1 in T cell migration and profibrotic cytokines production in vitro, 3478
- angiogenesis inhibitors in, 3448
- bosentan for vascular endothelial function in, 1985
- bronchoalveolar lavage profiles in ILD not predictive of disease progression, 2005
- CID as autoantibody target in PM-scleroderma overlap syndrome, 2449
- CCL18 as biomarker for idiopathic interstitial pneumonias and lung disease, 1685
- CD4+CD8+ double-positive T cells in skin lesions, 3459
- CENP-B binding to vascular smooth muscle cells in, 3814
- chemokine gene interactions in susceptibility to, 2443
- chronic intestinal pseudoobstruction and "hide-bound" bowel sign, clinical image, 1724
- dermal hypoxia-induced extracellular matrix proteins in, 4203
- disease-specific short peptides in sera, 2018
- epigenetics and, 3523
- familial, clinical, immunologic, and genetic features, 2031
- fibrosis and fibrogenic factors in gastric wall, 3442

Systemic sclerosis (SSc). *See also* Diffuse cutaneous systemic sclerosis (dcSSc) (*cont'd*)

- hepatocyte growth factor effects on collagen and connective tissue growth factor expression in lung fibroblasts, 3468
- hepatocyte growth factor impairment in lung fibroblasts of African Americans, 2432
- with ILD, bronchoalveolar lavage findings following cyclophosphamide treatment, 4195
- imatinib mesylate preventing development of dermal fibrosis in, 311
- impairment of endothelial cell differentiation from mesenchymal stem cells in, 1994
- localized scleroderma in children, laser Doppler flowmetry for assessing, 3489
- with lung disease, cyclophosphamide impact on health-related quality of life, 1676
- mortality and occupational exposures, 3189
- MR angiography for assessment of hand vascular abnormalities, 2747
- myocardial fibrosis, pattern and distribution in, 3827
- normal serum amyloid P component concentration in, 2013, 4229
- pulmonary fibrosis treatment in, 9
- quinapril for prevention of vascular damage, 3837
- Siglec-1 marker for, induced by IFN α and TLR agonists, 1010
- skin thickness progression rate and disease outcome in patients with anti-topoisomerase I antibody, 2740
- TGF β signaling in mouse fibroblasts, postnatal induction of, 334
- trichostatin A in skin fibrosis, mouse study, 2755

T

T cells. *See also* Treg cells

- CD8 in periglomerular infiltrates, lupus nephritis prognosis and, 2362
- CD56-expressing, senescence in RA, 43
- epitopes of LA/SSB autoantigen in mice expressing HLA-DRB*0301/DQB1*0201, 3387
- γ/δ , reactivity to Hsp60 and cytotoxicity in Takayasu arteritis, 2798
- IL-17 regulation in human helper cells, 2936
- intracellular antigen 1, infliximab effects on gene expression levels in RA, 2160
- loss of immune tolerance in SS and SLE and, 3180
- MHC-typed FLS as antigen-presenting cells, 1497
- OA, role in pathogenesis, 409
- RA, vaccination with synovial T cells, 453
- receptor usage of BV genes in idiopathic myositis, 372
- SLE, activation by U1 RNA, 3379
- SLE, β 1 integrin activation of, 1559
- SSc, allograft inflammatory factor 1 effects on migration, 3478
- WG, alterations and lymphoid neogenesis in autoimmunity, 1725
- Takayasu arteritis
 - diagnosis with PET, clinical image, 2466
 - limitations of therapy and prognosis in American cohort, 1000
 - reactivity and cytotoxicity of γ/δ T cells to Hsp60 in, 2798
- TEMPO study
 - authors' response to questions, 1031
 - RA, etanercept/MTX combination therapy and disease remission, 3-year outcome, 3928
- Temporomandibular joint (TMJ), intraarticular induction of μ -opioid receptor for pain prevention, 2038
- Tendinosis, tenocyte responses to mechanical loading in rats, insulin-like growth factor 1 and, 871
- Tenosynovitis, preclinical changes in mouse model, 79
- Terminal complement complex (C5b-9), therapeutic control by anti-C5 single-chain Fv, 1187
- Testicular function, evaluation in SLE, 2352
- TGFA, TGFA suppression of articular chondrocyte phenotype and Sox9 expression in rat model, 3693
- Th1 cells, urocortin down-regulation of, 531

- Thermography, infrared, vs. laser Doppler flowmetry for assessing localized scleroderma in children, 3489
- Thrombin, binding by β_2 -glycoprotein I, 605
- Thrombocytopenia
 - SLE, human platelet antigen 6b polymorphism and risk of, 2803
 - SLE prognosis and, LUMINA study, 614, 2811
- Thrombosis
 - aspirin for prevention in APS, 2382
 - cardiac, in APS, clinical image, 1036
- THNE, urinary concentrations and joint space narrowing in knee OA, 3644
- Tissue engineering
 - articular cartilage, isolation and chondroinduction of DIAS cells, 168
 - stem cells and, 714
 - three-dimensional cartilage, using adult stem cells from OA patients, 177
- Tissue factor, anti- β_2 -glycoprotein I antibodies and monocyte release of, in AS, 2687
- Tissue inhibitor of metalloproteinases 3 (TIMP-3), cartilage degradation and imbalance with MMPs in mice, 905
- TNAP gene, haplotype association with AS, 234
- TNF genes
 - pneumonia risk in SLE, 2679
 - polymorphisms and RA radiographic progression, 1032
 - SNPs in PsA, 2056
- TNF receptor (TNFR)
 - decoy receptor 3 in synovial fibroblasts as protection against Fas-induced apoptosis, 1067
 - n-3 polyunsaturated fatty acid inhibition of arachidonic acid-induced expression of, 799
 - RA, serum levels as mortality predictor, 3940
 - urinary excretion in experimental immune nephritis, 949
- TNFR-associated periodic syndrome (TRAPS)
 - elevated CD16+ expression by monocytes in, 4182
 - late-onset, in multiple sclerosis, 2774
 - mutations and TNFRSF1A structural alterations, 2765
- Toll-like receptors (TLR)
 - differential tissue targeting by Y RNAs, 1589
 - in human articular cartilage and chondrocytes, 1880
 - IL-1 signaling pathway and, 3183
 - negative regulation of BAFF synthesis by rheumatoid synoviocytes, 3202
 - OA, innate immune system activation, 409
 - RA, TLR-2 and TLR-4 mediation of synovial macrophage activation in, 2192
 - SLE, TLR-9 in tubulointerstitial injury, 1569
 - SSc, Siglec-1 induction by agonists of, 1010
 - TLR-4 inhibition in autoimmune destructive arthritis, mouse study, 2957
- Topoisomerase I, anti-DNA, predictive value of, 1736
- TRAIL receptor 3, expression on eosinophils in Churg-Strauss syndrome, 662
- Transcription factors
 - FoxO, inhibition in rheumatoid synovial tissue, 2180
 - OA, SOX9 overexpression and restoration of extracellular matrix in articular cartilage, 158
- Transforming growth factor α (TGFA), suppression of chondrocyte phenotype and Sox9 expression in rat OA model, 3693
- Transforming growth factor β (TGF β)
 - chondrogenic differentiation of bovine synovium with TGF β 1, vs. BMPs, 1869
 - dcSSc, anti-TGF β therapy for, 323
 - differential regulation of lubricin/superficial zone protein in articular chondrocytes and synoviocytes, 2312
 - endothelin 1 mediation of TGF β effects in lung fibroblasts, 4189

Transforming growth factor β (TGF β) (*cont'd*)

- experimental arthritis, TGF β vs. BMP-2 role in osteophyte formation, mouse study, 4065
- IL-1 β impairment of TGF β 1 signaling in human chondrocytes, 3020
- signaling impairment and inflammatory disorders in female mice, 1798
- signaling and mechanotransduction of superficial zone protein in bovine cartilage, 3706
- SSc, c-Ski/SnoN complex formation in impaired negative regulation of signaling in fibroblasts, 1694
- SSc, signaling in mouse fibroblasts, postnatal induction of, 334
- Treg cells
 - in CLE skin lesions, 1910
 - enhanced efficacy of transfer by elevated Foxp3 expression in collagen-induced arthritis, mouse study, 2947
 - FoxP3-dependent, 509, 710
 - JIA, differential recognition of HSP dnaJ-derived epitopes by effector and Treg cells in inflammation, 1648
 - mesenchymal stem cell mediation in collagen-induced arthritis, 1175
 - in osteoclast formation, 4104
 - RA, cell biology and therapeutic use in, 395
 - RA, defects in, 710
 - RA, proinflammatory mediator reversal of suppression by, 732, 3874
 - RA, T cell vaccination and induction in, 453
 - urocortin induction of, in collagen-induced arthritis, 531
 - WG, functional defects in remission, 2080
 - WG, regulation of autoimmunity, 1725
- Tribology, in joint failure, 3511
- Trichostatin A, preventing extracellular matrix accumulation in skin fibrosis, mouse study, 2755
- Triglycerides, in pediatric SLE, longitudinal study, 631
- Tristetraprolin
 - infliximab effects on gene expression levels in RA, 2160
- Tropheryma whippelii*, cultured from synovial fluid in Whipple's arthritis, 1713
- Tryptase, synovial mast cell release and PAR-2 inflammatory mediation, 3532
- Tuberculosis, abatacept effects on chronic infection in mice, 2557
- Tumor necrosis factor (TNF)
 - bradykinin receptors and interaction with IL-1 in osteoblasts, 910
 - circadian rhythm and, 399
 - inflammatory arthritis, preclinical changes in mouse model, 79
 - inhibition not affecting joint remodeling in mouse model of SpA, 489
 - inhibitors and uveitis, 3248
 - PsA, TNF blockade and cardiovascular risk factors in, 831
 - RA, early disease activity as predictor of treatment response, 3226
 - RA, LIGHT up-regulation in TNF superfamily, mediating cellular adhesion and metalloproteinase production by synoviocytes, 1106
 - SLE autoantibodies and short-term infliximab blockade of, 274
- Tumor necrosis factor α (TNF α)
 - APRIL expression of, in RA FLS, 3554
 - AS, anti- β_2 -glycoprotein I antibodies and monocyte release of TNF α and tissue factor via lipid rafts, 2687
 - blockade for treatment of sciatica, review, 3887
 - blockers and metastases, 695
 - down-regulation of heme oxygenase 1 in human peripheral monocytes, 464
 - inhibition of, and integrative repair of porcine meniscus in vitro, 3033
 - negative regulation of BAFF synthesis by rheumatoid synoviocytes, 3202
 - PsA pathophysiology and, 1051
 - RA, activation of BAFF release by neutrophils, 1776
 - RA, bacterial infection risk, anti-TNF vs. MTX, 1125
 - RA, infliximab effects on gene expression levels in, 2160
 - RA, polymorphisms and radiographic progression, 1032

Tumor necrosis factor α (TNF α) (*cont'd*)

- RA, TNF α antagonist exposure and drug-specific and time-dependent risks of bacterial infection, 4226
- triggering osteoclastogenesis in Freund's complete adjuvant induction of arthritis in IFN γ receptor deficient mice, 2595
- Tyk2 gene, SNPs in RA, 2202

U

- U1 RNA, adjuvant activity in SLE, 3379
- Ultrasonography, three-dimensional, of inner synovial surface, 214
- Unfolded protein response, HLA-B27 up-regulation and, 215
- Urate oxidase, PEGylated recombinant mammalian, for gout, 1021
- Urine, proteomics for glomerulonephritis diagnosis, 705
- Urocortin, effects on inflammatory and Th1 responses and Treg cell induction in collagen-induced arthritis, 531
- Uveitis
 - prevalence, risk factors, and outcome in JIA, 647
 - TNF inhibitors and, 3248

V

Vaccination

- DNA vaccine targeting macrophage migration inhibitory factor in collagen-induced arthritis, 521
- meningococcal C, safety and efficacy in JIA, 639
- T cell, in RA, 453

Vascular cell adhesion molecule 1 (VCAM-1)

- RA synovium, role in endothelial progenitor cell recruitment to, mouse study, 1817
- urinary excretion in experimental immune nephritis, 949

Vascular endothelial growth factor (VEGF)

- gene expression, RA vs. OA, analysis by laser-mediated microdissection, 1094
- nanogold binding in human RA synovial fluid and amelioration of collagen-induced arthritis in rats, 544
- RA, IL-18 up-regulation in synovial fibroblasts, signaling pathways, 1787
- SSc, impairment of endothelial cell differentiation from mesenchymal stem cells, 1994

Vascular endothelium

- antigen-induced arthritis, fluvastatin and dysfunction of, in rats, 1827
- SSc, bosentan improving function of, 1985

Vascular smooth muscle cells, CENP-B binding to, 3814

Vasculitis

- abdominal, in juvenile SLE, clinical image, 1009
- ANCA-associated, circulating CD34+ hematologic and endothelial progenitor cells in endothelial repair, 3847
- antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis, comment on article, 2810
- heat effects on ANCA-induced neutrophil activation, 3149
- hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy, molecular mechanisms in, 1315
- inflammatory rheumatic disease and smoking as predictors of aortic inflammation, 2072
- microscopic polyangiitis as "pulmonary-muscle" syndrome, 2065
- polymyositis and, clinical image, 3270
- primary CNS, in child, perforin deficiency causing, 995
- Vastus medialis muscle, morphologic changes in knee OA, 3626
- Vaughan, John Heath, In Memoriam, 701
- VCAM-1. *See* Vascular cell adhesion molecule 1 (VCAM-1)
- VEGF. *See* Vascular endothelial growth factor (VEGF)
- Videocapillaroscopy, for diagnosing Raynaud's phenomenon transition, 2102
- Vimentin, mutated and citrullinated, as RA biomarker, 2503
- Vitamin D
 - in juvenile SLE, 4228

Vitamin D (*cont'd*)
in knee OA, 129
in RA, 1719
serum metabolites and disease activity in early inflammatory polyarthritis, 2143

W

Wegener's granulomatosis (WG)
CD4⁺ Treg cells in remission of, 2080
T cell alterations and lymphoid neogenesis in, 1725
Western Ontario and McMaster Universities OA Index (WOMAC)
OA, diacerein efficacy in knee pain after discontinuation of treatment, 4055
steroid injections for hip OA, pain improvement score, 2278
Whipple's arthritis, cultivation of *Tropheryma whippelii* from synovial fluid, 1713
Wnt signaling
antagonists as biomarkers for radiographic progression in hip OA, 3319
FRZB gene in, 3881
OS, cartilage damage in *Frzb*^{-/-} mice and, 4095

Women

hormone replacement therapy in SLE, 3070
SLE, altered coronary vasomotor function, 1904
SLE and estrogen exposure, 1048
SLE, reproductive and menopausal risk factors, 1251
Wnt signaling antagonists as biomarkers for radiographic progression in hip OA, 3319

Workforce

rheumatology, US, ACR response to supply and demand study, 730
rheumatology, US, supply and demand 2005–2025, 722, 3509
WP9QY cyclic peptide, vs. anti-TNF α monoclonal antibody for bone destruction inhibition in collagen-induced arthritis, 1164

Y

Yttrium-90, efficacy in radiation synovectomy for knee arthritis, 385, 386

Z

Zymosan-induced arthritis (ZIA), PAR-2 activation in, 101, 3510